

ENVELOPE

DEC 15 2008 Form 990-PF

POSTMARK DATE Department of the Treasury Internal Revenue Service (77)

Return of Private Foundation or Section 4947(a)(1) Nonexempt Charitable Trust Treated as a Private Foundation

OMB No 1545-0052

2007

Note: The foundation may be able to use a copy of this return to satisfy state reporting requirements.

For calendar year 2007, or tax year beginning JUL 1, 2007, and ending JUN 30, 2008

G Check all that apply: Initial return Final return Amended return Address change Name change

SCANNED JAN 21 2009 Use the IRS label. Otherwise, print or type. See Specific Instructions.

Name of foundation: NUCLEAR THREAT INITIATIVE, INC. Employer identification number: 52-2289435. Telephone number: (202) 296-4810. City or town, state, and ZIP code: WASHINGTON, DC 20006. Section 501(c)(3) exempt private foundation. Accounting method: Accrual. Fair market value of all assets at end of year: \$14,293,667.

Table with 5 columns: (a) Revenue and expenses per books, (b) Net investment income, (c) Adjusted net income, (d) Disbursements for charitable purposes. Rows include Revenue (1-12), Operating and Administrative Expenses (13-26), and Summary (27-29).

LHA For Privacy Act and Paperwork Reduction Act Notice, see the instructions.

Form 990-PF (2007)

723501 02-20-08

9-23

Part II Balance Sheets		Attached schedules and amounts in the description column should be for end-of-year amounts only		
		Beginning of year	End of year	
		(a) Book Value	(b) Book Value	(c) Fair Market Value
Assets	1 Cash - non-interest-bearing	3,028.	11,684.	11,684.
	2 Savings and temporary cash investments	7,485,012.	7,490,890.	7,490,890.
	3 Accounts receivable ▶ 8,312.			
	Less: allowance for doubtful accounts ▶	2,826.	8,312.	8,312.
	4 Pledges receivable ▶			
	Less: allowance for doubtful accounts ▶			
	5 Grants receivable			
	6 Receivables due from officers, directors, trustees, and other disqualified persons			
	7 Other notes and loans receivable ▶			
	Less: allowance for doubtful accounts ▶			
	8 Inventories for sale or use			
	9 Prepaid expenses and deferred charges	215,517.	287,529.	287,529.
	10a Investments - U S and state government obligations			
	b Investments - corporate stock STMT 9	6,487,400.	6,354,784.	6,354,784.
	c Investments - corporate bonds			
Liabilities	11 Investments - land, buildings, and equipment: basis ▶			
	Less: accumulated depreciation ▶			
	12 Investments - mortgage loans			
	13 Investments - other			
	14 Land, buildings, and equipment: basis ▶ STMT 15 822,252.			
	Less: accumulated depreciation ▶ 681,784.	178,015.	140,468.	140,468.
	15 Other assets (describe ▶)			
	16 Total assets (to be completed by all filers)	14,371,798.	14,293,667.	14,293,667.
	17 Accounts payable and accrued expenses	291,275.	779,566.	
	18 Grants payable	1,400,414.	661,645.	
19 Deferred revenue				
20 Loans from officers, directors, trustees, and other disqualified persons				
21 Mortgages and other notes payable				
22 Other liabilities (describe ▶ DEFERRED RENT)	145,331.	96,872.		
23 Total liabilities (add lines 17 through 22)	1,837,020.	1,538,083.		
Net Assets or Fund Balances	Foundations that follow SFAS 117, check here and complete lines 24 through 26 and lines 30 and 31. <input checked="" type="checkbox"/>			
	24 Unrestricted	12,016,716.	9,180,890.	
	25 Temporarily restricted	518,062.	3,574,694.	
	26 Permanently restricted			
	Foundations that do not follow SFAS 117, check here and complete lines 27 through 31. <input type="checkbox"/>			
	27 Capital stock, trust principal, or current funds			
	28 Paid-in or capital surplus, or land, bldg., and equipment fund			
29 Retained earnings, accumulated income, endowment, or other funds				
30 Total net assets or fund balances	12,534,778.	12,755,584.		
31 Total liabilities and net assets/fund balances	14,371,798.	14,293,667.		

Part III Analysis of Changes in Net Assets or Fund Balances

1 Total net assets or fund balances at beginning of year - Part II, column (a), line 30 (must agree with end-of-year figure reported on prior year's return)	1	12,534,778.
2 Enter amount from Part I, line 27a	2	245,292.
3 Other increases not included in line 2 (itemize) ▶	3	0.
4 Add lines 1, 2, and 3	4	12,780,070.
5 Decreases not included in line 2 (itemize) ▶ UNREALIZED LOSS ON INVESTMENTS	5	24,486.
6 Total net assets or fund balances at end of year (line 4 minus line 5) - Part II, column (b), line 30	6	12,755,584.

**Part IV Capital Gains and Losses for Tax on Investment Income**

(a) List and describe the kind(s) of property sold (e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co)		(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
<b>1a PUBLICLY TRADED SECURITIES</b>				
b				
c				
d				
e				
(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)	
a 4,421,556.		17,052.	4,404,504.	
b				
c				
d				
e				
Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(i) Gains (Col (h) gain minus col (k), but not less than -0-) or Losses (from col (h))	
(j) F.M.V. as of 12/31/69	(l) Adjusted basis as of 12/31/69	(k) Excess of col. (l) over col. (j), if any		
a			4,404,504.	
b				
c				
d				
e				
2 Capital gain net income or (net capital loss) ( If gain, also enter in Part I, line 7 If (loss), enter -0- in Part I, line 7 )		2	4,404,504.	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c) If (loss), enter -0- in Part I, line 8		3	0.	

**Part V Qualification Under Section 4940(e) for Reduced Tax on Net Investment Income**

(For optional use by domestic private foundations subject to the section 4940(a) tax on net investment income.)

If section 4940(d)(2) applies, leave this part blank.

Was the foundation liable for the section 4942 tax on the distributable amount of any year in the base period?  Yes  No  
 If "Yes," the foundation does not qualify under section 4940(e). Do not complete this part.

1 Enter the appropriate amount in each column for each year; see instructions before making any entries.

(a) Base period years Calendar year (or tax year beginning in)	(b) Adjusted qualifying distributions	(c) Net value of noncharitable-use assets	(d) Distribution ratio (col. (b) divided by col. (c))
2006	17,370,638.	5,701,131.	3.046876
2005	20,706,924.	5,450,333.	3.799203
2004	25,672,160.	13,047,293.	1.967623
2003	15,981,703.	15,936,071.	1.002863
2002	27,036,811.	<5,577,492.>	.000000
2 Total of line 1, column (d)		2	9.816565
3 Average distribution ratio for the 5-year base period - divide the total on line 2 by 5, or by the number of years the foundation has been in existence if less than 5 years.		3	1.963313
4 Enter the net value of noncharitable-use assets for 2007 from Part X, line 5		4	4,416,659.
5 Multiply line 4 by line 3		5	8,671,284.
6 Enter 1% of net investment income (1% of Part I, line 27b)		6	46,063.
7 Add lines 5 and 6		7	8,717,347.
8 Enter qualifying distributions from Part XII, line 4 If line 8 is equal to or greater than line 7, check the box in Part VI, line 1b, and complete that part using a 1% tax rate. See the Part VI instructions.		8	25,848,683.

Part VI Excise Tax Based on Investment Income (Section 4940(a), 4940(b), 4940(e), or 4948 - see instructions)

Table with 11 rows for excise tax calculations. Line 1: 46,063. Line 2: 0. Line 3: 46,063. Line 4: 0. Line 5: 46,063. Line 7: 0. Line 9: 46,063. Line 11: Refunded.

Part VII-A Statements Regarding Activities

Table with 10 rows for activity statements. 1a: X. 1b: X. 1c: X. 2: X. 3: X. 4a: X. 4b: N/A. 5: X. 6: X. 7: X. 8a: SEE STATEMENT 10. 8b: X. 9: X. 10: X.

Part VII-A Statements Regarding Activities (continued)

11a	At any time during the year, did the foundation, directly or indirectly, own a controlled entity within the meaning of section 512(b)(13)? If "Yes," attach schedule. (see instructions)	11a		X
b	If "Yes," did the foundation have a binding written contract in effect on August 17, 2006, covering the interest, rents, royalties, and annuities described in the attachment for line 11a?	N/A	11b	
12	Did the foundation acquire a direct or indirect interest in any applicable insurance contract?	12		X
13	Did the foundation comply with the public inspection requirements for its annual returns and exemption application? Website address ► WWW.NTI.ORG	13	X	
14	The books are in care of ► CHARLOTTE S. ATKINSON Telephone no ► 202.454.7736 Located at ► 1747 PENNSYLVANIA AVE, NW STE 700, WASHINGTON, DC ZIP+4 ► 20006			
15	Section 4947(a)(1) nonexempt charitable trusts filing Form 990-PF in lieu of Form 1041 - Check here and enter the amount of tax-exempt interest received or accrued during the year	15		N/A

Part VII-B Statements Regarding Activities for Which Form 4720 May Be Required

File Form 4720 if any item is checked in the "Yes" column, unless an exception applies.

	Yes	No
1a During the year did the foundation (either directly or indirectly):		
(1) Engage in the sale or exchange, or leasing of property with a disqualified person? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
(2) Borrow money from, lend money to, or otherwise extend credit to (or accept it from) a disqualified person? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
(3) Furnish goods, services, or facilities to (or accept them from) a disqualified person? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
(4) Pay compensation to, or pay or reimburse the expenses of, a disqualified person? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
(5) Transfer any income or assets to a disqualified person (or make any of either available for the benefit or use of a disqualified person)? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
(6) Agree to pay money or property to a government official? (Exception. Check "No" if the foundation agreed to make a grant to or to employ the official for a period after termination of government service, if terminating within 90 days.) <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
b If any answer is "Yes" to 1a(1)-(6), did any of the acts fall to qualify under the exceptions described in Regulations section 53.4941(d)-3 or in a current notice regarding disaster assistance (see page 22 of the instructions)? Organizations relying on a current notice regarding disaster assistance check here <input type="checkbox"/>	1b	X
c Did the foundation engage in a prior year in any of the acts described in 1a, other than excepted acts, that were not corrected before the first day of the tax year beginning in 2007?	1c	X
2 Taxes on failure to distribute income (section 4942) (does not apply for years the foundation was a private operating foundation defined in section 4942(j)(3) or 4942(j)(5)):		
a At the end of tax year 2007, did the foundation have any undistributed income (lines 6d and 6e, Part XIII) for tax year(s) beginning before 2007? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No If "Yes," list the years ►		
b Are there any years listed in 2a for which the foundation is not applying the provisions of section 4942(a)(2) (relating to incorrect valuation of assets) to the year's undistributed income? (If applying section 4942(a)(2) to all years listed, answer "No" and attach statement - see instructions.) N/A	2b	
c If the provisions of section 4942(a)(2) are being applied to any of the years listed in 2a, list the years here. ►		
3a Did the foundation hold more than a 2% direct or indirect interest in any business enterprise at any time during the year? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
b If "Yes," did it have excess business holdings in 2007 as a result of (1) any purchase by the foundation or disqualified persons after May 26, 1969, (2) the lapse of the 5-year period (or longer period approved by the Commissioner under section 4943(c)(7)) to dispose of holdings acquired by gift or bequest; or (3) the lapse of the 10-, 15-, or 20-year first phase holding period? (Use Schedule C, Form 4720, to determine if the foundation had excess business holdings in 2007.) N/A	3b	
4a Did the foundation invest during the year any amount in a manner that would jeopardize its charitable purposes?	4a	X
b Did the foundation make any investment in a prior year (but after December 31, 1969) that could jeopardize its charitable purpose that had not been removed from jeopardy before the first day of the tax year beginning in 2007?	4b	X

Form 990-PF (2007)

**Part VII-B Statements Regarding Activities for Which Form 4720 May Be Required (continued)**

- 5a During the year did the foundation pay or incur any amount to:
- (1) Carry on propaganda, or otherwise attempt to influence legislation (section 4945(e))?  Yes  No
  - (2) Influence the outcome of any specific public election (see section 4955); or to carry on, directly or indirectly, any voter registration drive?  Yes  No
  - (3) Provide a grant to an individual for travel, study, or other similar purposes?  Yes  No
  - (4) Provide a grant to an organization other than a charitable, etc., organization described in section 509(a)(1), (2), or (3), or section 4940(d)(2)?  Yes  No
  - (5) Provide for any purpose other than religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals?  Yes  No
- b If any answer is "Yes" to 5a(1)-(5), did any of the transactions fail to qualify under the exceptions described in Regulations section 53.4945 or in a current notice regarding disaster assistance (see instructions)?  Yes  No  
 Organizations relying on a current notice regarding disaster assistance check here
- c If the answer is "Yes" to question 5a(4), does the foundation claim exemption from the tax because it maintained expenditure responsibility for the grant? **SMNT 25**  Yes  No  
 If "Yes," attach the statement required by Regulations section 53.4945-5(d).
- 6a Did the foundation, during the year, receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?  Yes  No
- b Did the foundation, during the year, pay premiums, directly or indirectly, on a personal benefit contract?  Yes  No  
 If you answered "Yes" to 6b, also file Form 8870.
- 7a At any time during the tax year, was the foundation a party to a prohibited tax shelter transaction?  Yes  No
- b If yes, did the foundation receive any proceeds or have any net income attributable to the transaction?  Yes  No  N/A

5b		X
6b		X
7b		

**Part VIII Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid Employees, and Contractors**

**1 List all officers, directors, trustees, foundation managers and their compensation.**

(a) Name and address	(b) Title, and average hours per week devoted to position	(c) Compensation (If not paid, enter -0-)	(d) Contributions to employee benefit plans and deferred compensation	(e) Expense account, other allowances
SEE STATEMENT 16				
	0.00	1,655,002.	300038.	0.
R.E. TURNER III 214 HAMRICK LAMONT, FL 32336	CO-CHAIRMAN 5.00	0.	0.	0.

**2 Compensation of five highest-paid employees (other than those included on line 1). If none, enter "NONE,"**

(a) Name and address of each employee paid more than \$50,000	(b) Title and average hours per week devoted to position	(c) Compensation	(d) Contributions to employee benefit plans and deferred compensation	(e) Expense account, other allowances
SEE STATEMENT 17				
	0.00	728,229.	216549.	

Total number of other employees paid over \$50,000

14

**Part VIII** Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid Employees, and Contractors *(continued)*

**3** Five highest-paid independent contractors for professional services. If none, enter "NONE."

(a) Name and address of each person paid more than \$50,000	(b) Type of service	(c) Compensation
SEE STATEMENT 18	PROGRAM SUPPORT	2,037,414.
Total number of others receiving over \$50,000 for professional services		10

**Part IX-A** Summary of Direct Charitable Activities

List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc.	Expenses
1 RUSSIA/NEW INDEPENDENT STATES (NIS) PROGRAMS - SEE STATEMENTS 22 & 23	2,038,137.
2 GLOBAL HEALTH AND SECURITY INITIATIVE - SEE STATEMENTS 22 & 23	1,950,068.
3 COMMUNICATIONS PROGRAMS - SEE STATEMENTS 22 & 23	2,513,634.
4 INTERNATIONAL PROGRAMS - SEE STATEMENTS 22 & 23	2,041,995.

**Part IX-B** Summary of Program-Related Investments

Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2.	Amount
1 N/A	
2	
All other program-related investments See instructions.	
3	
Total. Add lines 1 through 3	0.

**Part X** Minimum Investment Return (All domestic foundations must complete this part. Foreign foundations, see instructions.)

1 Fair market value of assets not used (or held for use) directly in carrying out charitable, etc., purposes:			
a	Average monthly fair market value of securities	1a	9,845,135.
b	Average of monthly cash balances	1b	6,247,905.
c	Fair market value of all other assets	1c	
d	Total (add lines 1a, b, and c)	1d	16,093,040.
e	Reduction claimed for blockage or other factors reported on lines 1a and 1c (attach detailed explanation)	1e	0.
2	Acquisition indebtedness applicable to line 1 assets	2	0.
3	Subtract line 2 from line 1d	3	16,093,040.
4	Cash deemed held for charitable activities. Enter 1 1/2% of line 3 (for greater amount, see instructions) <i>5000000</i>	4	11,676,381.
5	Net value of noncharitable-use assets. Subtract line 4 from line 3. Enter here and on Part V, line 4	5	4,416,659.
6	Minimum investment return. Enter 5% of line 5	6	220,833.

**Part XI** Distributable Amount (see instructions) (Section 4942(j)(3) and (j)(5) private operating foundations and certain foreign organizations check here  and do not complete this part)

1	Minimum investment return from Part X, line 6	1	
2a	Tax on investment income for 2007 from Part VI, line 5	2a	
b	Income tax for 2007. (This does not include the tax from Part VI)	2b	
c	Add lines 2a and 2b	2c	
3	Distributable amount before adjustments Subtract line 2c from line 1	3	
4	Recoveries of amounts treated as qualifying distributions	4	
5	Add lines 3 and 4	5	
6	Deduction from distributable amount (see instructions)	6	
7	Distributable amount as adjusted. Subtract line 6 from line 5 Enter here and on Part XIII, line 1	7	

**Part XII** Qualifying Distributions (see instructions)

1 Amounts paid (including administrative expenses) to accomplish charitable, etc., purposes:			
a	Expenses, contributions, gifts, etc. - total from Part I, column (d), line 26	1a	13,529,527.
b	Program-related investments - total from Part IX-B	1b	0.
2	Amounts paid to acquire assets used (or held for use) directly in carrying out charitable, etc., purposes	2	44,088.
3 Amounts set aside for specific charitable projects that satisfy the:			
a	Suitability test (prior IRS approval required)	3a	
b	Cash distribution test (attach the required schedule) <i>5000000</i>	3b	12,275,068.
4	Qualifying distributions. Add lines 1a through 3b. Enter here and on Part V, line 8, and Part XIII, line 4	4	25,848,683.
5	Foundations that qualify under section 4940(e) for the reduced rate of tax on net investment income. Enter 1% of Part I, line 27b	5	46,063.
6	Adjusted qualifying distributions. Subtract line 5 from line 4	6	25,802,620.

Note: The amount on line 6 will be used in Part V, column (b), in subsequent years when calculating whether the foundation qualifies for the section 4940(e) reduction of tax in those years.

Form 990-PF (2007)



**Part XIII** Undistributed Income (see instructions)

	(a) Corpus	(b) Years prior to 2006	(c) 2006	(d) 2007
1 Distributable amount for 2007 from Part XI, line 7				0.
2 Undistributed income, if any, as of the end of 2006:				
a Enter amount for 2006 only			0.	
b Total for prior years:		0.		
3 Excess distributions carryover, if any, to 2007:				
a From 2002				
b From 2003				
c From 2004				
d From 2005				
e From 2006				
f Total of lines 3a through e	0.			
4 Qualifying distributions for 2007 from Part XII, line 4. $\blacktriangleright$ \$ <u>N/A</u>				
a Applied to 2006, but not more than line 2a			0.	
b Applied to undistributed income of prior years (Election required - see instructions)		0.		
c Treated as distributions out of corpus (Election required - see instructions)	0.			
d Applied to 2007 distributable amount				0.
e Remaining amount distributed out of corpus	0.			0.
5 Excess distributions carryover applied to 2007 (If an amount appears in column (d), the same amount must be shown in column (a).)	0.			0.
6 Enter the net total of each column as indicated below:				
a Corpus. Add lines 3f, 4c, and 4e. Subtract line 5	0.			
b Prior years' undistributed income. Subtract line 4b from line 2b		0.		
c Enter the amount of prior years' undistributed income for which a notice of deficiency has been issued, or on which the section 4942(a) tax has been previously assessed		0.		
d Subtract line 6c from line 6b. Taxable amount - see instructions		0.		
e Undistributed income for 2006. Subtract line 4a from line 2a. Taxable amount - see instr.			0.	
f Undistributed income for 2007. Subtract lines 4d and 5 from line 1. This amount must be distributed in 2008				0.
7 Amounts treated as distributions out of corpus to satisfy requirements imposed by section 170(b)(1)(F) or 4942(g)(3)	0.			
8 Excess distributions carryover from 2002 not applied on line 5 or line 7	0.			
9 Excess distributions carryover to 2008. Subtract lines 7 and 8 from line 6a	0.			
10 Analysis of line 9:				
a Excess from 2003				
b Excess from 2004				
c Excess from 2005				
d Excess from 2006				
e Excess from 2007				

**Part XIV Private Operating Foundations** (see instructions and Part VII-A, question 9)

1 a If the foundation has received a ruling or determination letter that it is a private operating foundation, and the ruling is effective for 2007, enter the date of the ruling **09/28/01**  
 b Check box to indicate whether the foundation is a private operating foundation described in section  4942(j)(3) or  4942(j)(5)

	Tax year		Prior 3 years		(e) Total
	(a) 2007	(b) 2006	(c) 2005	(d) 2004	
2 a Enter the lesser of the adjusted net income from Part I or the minimum investment return from Part X for each year listed	201,790.	285,057.	272,517.	539,319.	1,298,683.
b 85% of line 2a	171,522.	242,298.	231,639.	458,421.	1,103,881.
c Qualifying distributions from Part XII, line 4 for each year listed	25848683.	17376153.	20712903.	25672168.	89609907.
d Amounts included in line 2c not used directly for active conduct of exempt activities	0.	0.	0.	0.	0.
e Qualifying distributions made directly for active conduct of exempt activities					
Subtract line 2d from line 2c	25848683.	17376153.	20712903.	25672168.	89609907.
3 Complete 3a, b, or c for the alternative test relied upon:					
a "Assets" alternative test - enter:					
(1) Value of all assets					0.
(2) Value of assets qualifying under section 4942(j)(3)(B)(i)					0.
b "Endowment" alternative test - enter 2/3 of minimum investment return shown in Part X, line 6 for each year listed	147,222.	190,038.	181,678.	434,910.	953,848.
c "Support" alternative test - enter:					
(1) Total support other than gross investment income (interest, dividends, rents, payments on securities loans (section 512(a)(5)), or royalties)					0.
(2) Support from general public and 5 or more exempt organizations as provided in section 4942(j)(3)(B)(iii)					0.
(3) Largest amount of support from an exempt organization					0.
(4) Gross investment income					0.

**Part XV Supplementary Information** (Complete this part only if the foundation had \$5,000 or more in assets at any time during the year-see the instructions.)

1 Information Regarding Foundation Managers:  
 a List any managers of the foundation who have contributed more than 2% of the total contributions received by the foundation before the close of any tax year (but only if they have contributed more than \$5,000). (See section 507(d)(2))

**R.E. TURNER III**

b List any managers of the foundation who own 10% or more of the stock of a corporation (or an equally large portion of the ownership of a partnership or other entity) of which the foundation has a 10% or greater interest.

**NONE**

2 Information Regarding Contribution, Grant, Gift, Loan, Scholarship, etc., Programs:  
 Check here  if the foundation only makes contributions to preselected charitable organizations and does not accept unsolicited requests for funds if the foundation makes gifts, grants, etc. (see instructions) to individuals or organizations under other conditions, complete items 2a, b, c, and d.

a The name, address, and telephone number of the person to whom applications should be addressed:

b The form in which applications should be submitted and information and materials they should include.

c Any submission deadlines:

d Any restrictions or limitations on awards, such as by geographical areas, charitable fields, kinds of institutions, or other factors:

**Part XV** Supplementary Information (continued)

<b>3 Grants and Contributions Paid During the Year or Approved for Future Payment</b>				
Recipient	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
Name and address (home or business)				
<b>a Paid during the year</b>				
SEE STATEMENT 21				3141947.
<b>Total</b>				<b>3141947.</b>
<b>b Approved for future payment</b>				
SEE STATEMENT 21				661,645.
<b>Total</b>				<b>661,645.</b>

Part XVI-A Analysis of Income-Producing Activities

Table with 5 main columns: (a) Business code, (b) Amount, (c) Exclusion code, (d) Amount, (e) Related or exempt function income. Rows include: 1 Program service revenue (a-f, g Fees and contracts from government agencies), 2 Membership dues and assessments, 3 Interest on savings and temporary cash investments (14, 84,020), 4 Dividends and interest from securities (14, 117,770), 5 Net rental income or (loss) from real estate (a Debt-financed property, b Not debt-financed property), 6 Net rental income or (loss) from personal property, 7 Other investment income, 8 Gain or (loss) from sales of assets other than inventory (18, 752,785), 9 Net income or (loss) from special events, 10 Gross profit or (loss) from sales of inventory, 11 Other revenue (a-e), 12 Subtotal. Add columns (b), (d), and (e) (0, 954,575, 0), 13 Total. Add line 12, columns (b), (d), and (e) (13, 954,575).

(See worksheet in line 13 instructions to verify calculations.)

Part XVI-B Relationship of Activities to the Accomplishment of Exempt Purposes

Table with 2 columns: Line No., Explain below how each activity for which income is reported in column (e) of Part XVI-A contributed importantly to the accomplishment of the foundation's exempt purposes (other than by providing funds for such purposes).

Part XVII Information Regarding Transfers To and Transactions and Relationships With Noncharitable Exempt Organizations

1 Did the organization directly or indirectly engage in any of the following with any other organization described in section 501(c) of the Code (other than section 501(c)(3) organizations) or in section 527, relating to political organizations?
a Transfers from the reporting foundation to a noncharitable exempt organization of:
(1) Cash
(2) Other assets
b Other transactions:
(1) Sales of assets to a noncharitable exempt organization
(2) Purchases of assets from a noncharitable exempt organization
(3) Rental of facilities, equipment, or other assets
(4) Reimbursement arrangements
(5) Loans or loan guarantees
(6) Performance of services or membership or fundraising solicitations
c Sharing of facilities, equipment, mailing lists, other assets, or paid employees
d If the answer to any of the above is "Yes," complete the following schedule. Column (b) should always show the fair market value of the goods, other assets, or services given by the reporting foundation. If the foundation received less than fair market value in any transaction or sharing arrangement, show in column (d) the value of the goods, other assets, or services received.

Table with 4 columns: (a) Line no, (b) Amount involved, (c) Name of noncharitable exempt organization, (d) Description of transfers, transactions, and sharing arrangements. Row 1 contains 'N/A' in column (c).

2a Is the foundation directly or indirectly affiliated with, or related to, one or more tax-exempt organizations described in section 501(c) of the Code (other than section 501(c)(3)) or in section 527? Yes No

b If "Yes," complete the following schedule. Table with 3 columns: (a) Name of organization, (b) Type of organization, (c) Description of relationship. Row 1 contains 'N/A' in column (a).

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than taxpayer or fiduciary) is based on all information provided to the preparer.

Sign Here: Signature of officer or trustee, Preparer's signature, Firm's name (or yours if self-employed), address, and ZIP code: AVALON FINANCIAL ADVISOR, 133 LUCKIE STREET, ATLANTA, GA 30303

**Schedule B**

(Form 990, 990-EZ, or 990-PF)

Department of the Treasury  
Internal Revenue Service

**Schedule of Contributors**

Supplementary information for  
line 1 of Form 990, 990-EZ, and 990-PF (see instructions)

OMB No 1545-0047

**2007**

Name of organization

NUCLEAR THREAT INITIATIVE, INC.

Employer identification number

52-2289435

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)( ) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule. (Note: Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule-see instructions.)

**General Rule-**

For organizations filing Form 990, 990-EZ, or 990-PF that received, during the year, \$5,000 or more (in money or property) from any one contributor. (Complete Parts I and II.)

**Special Rules-**

For a section 501(c)(3) organization filing Form 990, or Form 990-EZ, that met the 33 1/3% support test of the regulations under sections 509(a)(1)/170(b)(1)(A)(vi), and received from any one contributor, during the year, a contribution of the greater of \$5,000 or 2% of the amount on line 1 of these forms. (Complete Parts I and II.)

For a section 501(c)(7), (8), or (10) organization filing Form 990, or Form 990-EZ, that received from any one contributor, during the year, aggregate contributions or bequests of more than \$1,000 for use *exclusively* for religious, charitable, scientific, literary, or educational purposes, or the prevention of cruelty to children or animals. (Complete Parts I, II, and III.)

For a section 501(c)(7), (8), or (10) organization filing Form 990, or Form 990-EZ, that received from any one contributor, during the year, some contributions for use *exclusively* for religious, charitable, etc., purposes, but these contributions did not aggregate to more than \$1,000. (If this box is checked, enter here the total contributions that were received during the year for an *exclusively* religious, charitable, etc., purpose. Do not complete any of the Parts unless the General Rule applies to this organization because it received nonexclusively religious, charitable, etc., contributions of \$5,000 or more during the year.) ... .. ▶ \$ \_\_\_\_\_

**Caution:** Organizations that are not covered by the General Rule and/or the Special Rules do not file Schedule B (Form 990, 990-EZ, or 990-PF), but they must check the box in the heading of their Form 990, Form 990-EZ, or on line 2 of their Form 990-PF, to certify that they do not meet the filing requirements of Schedule B (Form 990, 990-EZ, or 990-PF).

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990, Form 990-EZ, and Form 990-PF.

Schedule B (Form 990, 990-EZ, or 990-PF) (2007)

Name of organization: **NUCLEAR THREAT INITIATIVE, INC.**  
 Employer identification number: **52-2289435**

**Part I Contributors** (See Specific Instructions.)

(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
1	THE SUSAN THOMPSON BUFFETT FOUNDATION 222 KIEWIT PLAZA OMAHA, NE 68131	\$ 3,545,392.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input checked="" type="checkbox"/> (Complete Part II if there is a noncash contribution.)
2	TURNER CHARITABLE REMAINDER UNITRUST #4 214 HAMRICK LAMONT, FL 32336	\$ 2,204,913.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
3	GOOGLE FOUNDATION 1600 AMPHITHEATRE PARKWAY MOUNTAIN VIEW, CA 94043	\$ 1,500,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
4	JOHN D. & CATHERINE T. MACARTHUR FOUNDATION 140 S. DEARBORN, SUITE 1100 CHICAGO, IL 60603	\$ 1,150,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
5	THE RUSSELL FAMILY FOUNDATION PO BOX 2567 GIG HARBOR, WA 98335	\$ 1,000,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
6	NORWEGIAN ROYAL MINISTRY OF FOREIGN AFFAIRS PO BOX 8114 DEP NO-0032 OSLO, NORWAY	\$ 797,346.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)

Name of organization

Employer identification number

NUCLEAR THREAT INITIATIVE, INC.

52-2289435

**Part I** Contributors (See Specific Instructions.)

(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
7	THE CARNEGIE CORPORATION OF NEW YORK 437 MADISON AVENUE NEW YORK, NY 10022	\$ 500,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> <small>(Complete Part II if there is a noncash contribution.)</small>
8	THE BILL AND MELINDA GATES FOUNDATION PO BOX 23350 SEATTLE, WA 98102	\$ 500,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> <small>(Complete Part II if there is a noncash contribution.)</small>
9	THE WORLD BANK 1800 H ST NW WASHINGTON, DC 20006	\$ 300,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> <small>(Complete Part II if there is a noncash contribution.)</small>
10	FRED ISEMAN 500 PARK AVENUE, 8TH FLOOR NEW YORK, NY 10022	\$ 159,500.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> <small>(Complete Part II if there is a noncash contribution.)</small>
11	THE ROCKEFELLER FOUNDATION 420 FIFTH AVENUE NEW YORK, NY 10018	\$ 112,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> <small>(Complete Part II if there is a noncash contribution.)</small>
12	STEPHAN STRANAHAN 132 WEST SECOND ST, SUITE B PERRYBURG, OH 43551	\$ 102,500.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> <small>(Complete Part II if there is a noncash contribution.)</small>



Name of organization

Employer identification number

NUCLEAR THREAT INITIATIVE, INC.

52-2289435

**Part I Contributors** (See Specific Instructions.)

(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
13	SAGA FOUNDATION 985 LAKEVIEW WAY REDWOOD CITY, CA 94062	\$ 100,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
14	STATENS KARNKRAFTINSPEKTION SE-106 5B STOCKHOLM, SWEDEN	\$ 100,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
15	UNITED KINGDOM FOREIGN & COMMONWEALTH OFFICE KING CHARLES STREET LONDON, SW1A 2AH, UK	\$ 78,860.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
16	TOLEDO COMMUNITY FOUNDATION (DICK & FRAN ANDERSON) 608 MADISON AVE #1540 TOLEDO, OH 43604	\$ 25,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
17	LYOR COHEN C/O TAG ASSOC LLC, 75 ROCKEFELLER PLAZA, 9TH FL NEW YORK, NY 10019	\$ 25,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
18	NATHANIEL ROTHSCHILD C/O ATTICUS CAPITAL, 152 W 57TH ST, 45 FL NEW YORK, NY 10049	\$ 25,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)

Name of organization

Employer identification number

NUCLEAR THREAT INITIATIVE, INC.

52-2289435

**Part I** Contributors (See Specific Instructions.)

(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
19	THE DANIEL M. NEIDICH AND BROOKE GARBER FOUNDATION  100 WALL ST, 11FL  NEW YORK, NY 10005	\$ 25,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> <small>(Complete Part II if there is a noncash contribution.)</small>
20	LEHMAN BROTHERS  745 SEVENTH AVENUE  NEW YORK, NY 10005	\$ 25,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> <small>(Complete Part II if there is a noncash contribution.)</small>
21	THE SCHAFFNER FAMILY FOUNDATION  252 SEVENTH AVE, APT 17M  NEW YORK, NY 10001	\$ 20,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> <small>(Complete Part II if there is a noncash contribution.)</small>
22	RUSSELL & ANNE FULLER  2499 BUTTERNUT DRIVE  HILLSBOROUGH, CA 94010	\$ 20,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> <small>(Complete Part II if there is a noncash contribution.)</small>
23	ANTHONY PENNOCK  3320 CEDAR FARMS COURT  ALPHARETTA, GA 30004	\$ 15,249.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input checked="" type="checkbox"/> <small>(Complete Part II if there is a noncash contribution.)</small>
24	AON FOUNDATION  200 EAST RANDOLPH STREET  CHICAGO, IL 60601	\$ 11,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> <small>(Complete Part II if there is a noncash contribution.)</small>

Name of organization

Employer identification number

NUCLEAR THREAT INITIATIVE, INC.

52-2289435

**Part I** Contributors (See Specific Instructions.)

(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
25	EDLOW INTERNATIONAL 1666 CONNECTICUT AVE, NW, STE 201 WASHINGTON, DC 20009	\$ 10,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
26	PATRICK WOLF 740 ULLOA STREET SAN FRANCISCO, CA 94127	\$ 10,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
27	THE BODMAN FAMILY FOUNDATION 1185 IMMOKALEE RD, STE 110 NAPLES, FL 34110	\$ 10,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
28	WILLIAM HOWARD FLOWER, JR. FOUNDATION PO BOX 6100 THOMASVILLE, GA 31758	\$ 10,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
29	THE SCHWAB FUND FOR CHARITABLE GIVING (MR. & MRS. WILLIAM H. DRAPER III) 101 MONTGOMERY ST SAN FRANCISCO, CA 94104	\$ 10,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
30	DANIEL & JOANNA S. ROSE FUND, INC. 200 MADISON AVENUE NEW YORK, NY 10016	\$ 10,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)

Name of organization <b>NUCLEAR THREAT INITIATIVE, INC.</b>	Employer identification number <b>52-2289435</b>
--	---

**Part I Contributors** (See Specific Instructions.)

(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
31	MORGAN STANLEY 1585 BROADWAY, 36TH FL NEW YORK, NY 10036	\$ 10,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
32	RHR INTERNATIONAL COMPANY 220 GERRY DRIVE WOOD DALE, IL 60191	\$ 10,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
33	FIDELITY CHARITABLE GIFT FUND (ANONYMOUS) PO BOX 55158 BOSTON, MA 02205	\$ 6,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
34	PAUL MATTEUCCI C/O US VENTURE PARTNERS, 729 CONCORD WAY BURLINGAME, CA 94010	\$ 5,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
35	DAVID & ANITA MASSENGILL 5653 EAST HAMPTON RD OAKLAND GARDENS, NY 11364	\$ 5,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
36	LEIDY FOUNDATION PO BOX 1709 HAILEY, ID 83333	\$ 5,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)

Name of organization

Employer identification number

NUCLEAR THREAT INITIATIVE, INC.

52-2289435

**Part I Contributors** (See Specific Instructions.)

(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
37	JF MADDOX FOUNDATION PO BOX 2588 HOBBS, NM 88241	\$ 5,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
38	THE WHITEHEAD FOUNDATION 65 EAST 55TH ST NEW YORK, NY 10022	\$ 5,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
39	CYNTHIA R. HELMS 4649 GARFIELD ST, NW WASHINGTON, DC 20007	\$ 5,000.	Person <input checked="" type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
		\$	Person <input type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
		\$	Person <input type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)
		\$	Person <input type="checkbox"/> Payroll <input type="checkbox"/> Noncash <input type="checkbox"/> (Complete Part II if there is a noncash contribution.)

Name of organization

Employer identification number

NUCLEAR THREAT INITIATIVE, INC.

52-2289435

**Part II Noncash Property** (See Specific Instructions.)

(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
1	BERKSHIRE HATHAWAY CLASS B SHARES (PUBLICLY TRADED SECURITIES)	\$ 3,545,392.	10/12/07
23	ENERGY TRANSFER PARTNERS STOCK (PUBLICLY TRADED SECURITIES)	\$ 15,249.	08/20/07

FORM 990-PF GAIN OR (LOSS) FROM SALE OF ASSETS STATEMENT 1

(A) DESCRIPTION OF PROPERTY	MANNER ACQUIRED	DATE ACQUIRED	DATE SOLD
PUBLICLY TRADED SECURITIES			
(B) GROSS SALES PRICE	(C) COST OR OTHER BASIS	(D) EXPENSE OF SALE	(E) (F) DEPREC. GAIN OR LOSS
4,421,556.	3,668,771.	0.	0. 752,785.
CAPITAL GAINS DIVIDENDS FROM PART IV			0.
TOTAL TO FORM 990-PF, PART I, LINE 6A			752,785.

FORM 990-PF INTEREST ON SAVINGS AND TEMPORARY CASH INVESTMENTS STATEMENT 2

SOURCE	AMOUNT
INTEREST INCOME	84,020.
TOTAL TO FORM 990-PF, PART I, LINE 3, COLUMN A	84,020.

FORM 990-PF DIVIDENDS AND INTEREST FROM SECURITIES STATEMENT 3

SOURCE	GROSS AMOUNT	CAPITAL GAINS DIVIDENDS	COLUMN (A) AMOUNT
DIVIDEND INCOME	117,770.	0.	117,770.
TOTAL TO FM 990-PF, PART I, LN 4	117,770.	0.	117,770.

FORM 990-PF	LEGAL FEES			STATEMENT 4
DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
LEGAL FEES - SEE STMT 13	39,684.	0.	0.	44,912.
TO FM 990-PF, PG 1, LN 16A	39,684.	0.	0.	44,912.

FORM 990-PF	ACCOUNTING FEES			STATEMENT 5
DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
ACCOUNTING FEES - SEE STMT 13	190,255.	0.	0.	195,255.
TO FORM 990-PF, PG 1, LN 16B	190,255.	0.	0.	195,255.

FORM 990-PF	OTHER PROFESSIONAL FEES			STATEMENT 6
DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
OTHER PROF FEES - SEE STMT 13	295,001.	0.	0.	300,201.
TO FORM 990-PF, PG 1, LN 16C	295,001.	0.	0.	300,201.

FORM 990-PF	TAXES			STATEMENT 7
DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
TAXES - SEE STMT 12	366.	0.	0.	366.
TO FORM 990-PF, PG 1, LN 18	366.	0.	0.	366.



FORM 990-PF OTHER EXPENSES STATEMENT 8

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
OTHER EXP - SEE STMT 12	3,725,489.	0.	0.	3,201,440.
TO FORM 990-PF, PG 1, LN 23	3,725,489.	0.	0.	3,201,440.

FORM 990-PF CORPORATE STOCK STATEMENT 9

DESCRIPTION	BOOK VALUE	FAIR MARKET VALUE
CORPORATE STOCK - SEE STMT 14	6,354,784.	6,354,784.
TOTAL TO FORM 990-PF, PART II, LINE 10B	6,354,784.	6,354,784.

FORM 990-PF LIST OF STATES RECEIVING COPY OF RETURN STATEMENT 10

STATES

AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, IL, KS, LA, ME, MD, MA, MI, MN, MS, MO, NH, NJ, NM, NY  
NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, UT, VA, WA, WV, WI, KY

FORM 990-PF LIST OF SUBSTANTIAL CONTRIBUTORS PART VII-A, LINE 10 STATEMENT 11

NAME OF CONTRIBUTOR	ADDRESS
GOOGLE FOUNDATION	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW, CA 94043
JOHN D & CATHERINE T. MACARTHUR FOUNDATION	140 S. DEARBORN ST., CHICAGO, IL 60603

Nuclear Threat Initiative, Inc.  
 EIN: 52-2289435  
 Form 990 PF (FY08)  
 Part I

Statement 12

Lines 11, 18, 19 and 23 - Taxes, Depreciation and Depletion, Other Expenses

	(a) Revenue and expenses per books	(b) Net Investment Income	(c) Adjusted net Income	(d) Disbursements for Charitable purposes
<b>Line 18 - Taxes</b>				
Property Tax on leased equipment	366	-	-	366
	<u>366</u>	<u>-</u>	<u>-</u>	<u>366</u>
<b>Line 19 - Depreciation &amp; Depletion</b>				
Depreciation of Office Furniture & Equipment	33,258	-	-	N/A
Amortization of Developed Software	43,429	-	-	N/A
Amortization of Leasehold Improvements	4,946	-	-	N/A
	<u>81,633</u>	<u>-</u>	<u>-</u>	<u>-</u>
<b>Line 23 - Other Expenses</b>				
International Program contracts & professional services	875,086			597,035
Global Health & Security contracts and professional services	438,871			310,159
Russia/ NIS Program contracts and professional services	437,952			236,509
Communications Program contracts and professional services	495,544			496,576
Website Content - Global Security Newswire	915,083			991,583
Telecommunications	283,032			286,867
Insurance	60,499			66,102
Supplies	54,450			54,804
Postage & Shipping	48,608			51,003
Equipment rental & maintenance	32,510			26,693
Foreign Exchange loss	29,782			29,782
Advertising	866			866
Miscellaneous expenses	53,206			53,461
	<u>3,725,489</u>	<u>-</u>	<u>-</u>	<u>3,201,440</u>

## Nuclear Threat Initiative, Inc.

Statement 13

EIN: 52-2289435

Form 990 PF (FY08)

## Part I

## Lines 16 a, b, c - Accounting Fees, Legal Fees, Other Professional Fees

	(a) Revenue and expenses per books	(b) Net Investment Income	(c) Adjusted net Income	(d) Disbursement for Charitable purposes
<b>Line 16a - Legal Fees</b>				
Program Implementation	\$ 3,806			\$ 3,806
Fundraising	959			959
Organization & Governance Activities	34,919			40,147
<b>Total Legal Fees</b>	<b>39,684</b>	<b>\$ -</b>	<b>\$ -</b>	<b>44,912</b>
<b>Line 16b - Accounting Fees</b>				
Annual Audit	23,962			23,962
Outsourced Accounting Services	156,075			161,075
Payroll Services	\$ 10,218			\$ 10,218
<b>Total Accounting Fees</b>	<b>190,255</b>	<b>\$ -</b>	<b>\$ -</b>	<b>195,255</b>
<b>Line 16c - Other Professional Fees</b>				
401(k) Plan recordkeeping	3,663			3,663
FSA recordkeeping	1,865			1,865
Outsourced IT function	92,648			97,848
Recruitment Fees	45,473			45,473
Export Control Services	15,600			15,600
Fundraising	50,970			50,970
Business Continuity	19,274			19,274
Advisory Services	15,000			15,000
Temporary Help	32,428			32,428
Website Development	18,080			18,080
<b>Total Other Professional Fees</b>	<b>295,001</b>	<b>\$ -</b>	<b>\$ -</b>	<b>300,201</b>

**Nuclear Threat Initiative, Inc.**

**Statement 14**

**EIN: 52-2289435**

**Form 990 PF (FY08)**

**Part II**

**Line 10b - Investments - Corporate Stock**

Berkshire Hathaway Class A	\$	2,415,000
Berkshire Hathaway Class B		<u>3,939,784</u>
Total	\$	<u><u>6,354,784</u></u>

**Nuclear Threat Initiative, Inc.**  
**EIN: 52-2289435**  
**Form 990 PF (FY08)**  
**Part II**  
**Line 14 - Land, Buildings and Equipment**

**Statement 15**

Office Furniture and Equipment	\$ 572,546
Leased Equipment	229,922
Leasehold Improvements	<u>19,784</u>
 Total Cost	 <u>822,252</u>
 Accumulated Depreciation, Office Furniture and Equipment	 (502,580)
Accumulated Depreciation, Leased Equipment	(164,777)
Accumulated Amortization, Leasehold Improvements	<u>(14,427)</u>
 Total Accumulated Depreciation and Amortization	 <u>(681,784)</u>
 Total Fixed Asset Net Book Value	 <u><u>\$ 140,468</u></u>

OFFICERS AND DIRECTORS

All officers and directors can be contacted at 1747 Pennsylvania Avenue, NW, 7th Floor, Washington, D.C. 20006

NTI Officers

Name & Address	Title	Estimated Hours Per Week Devoted to Position	July 1, 2007 - June 30, 2008 Compensation	Contributions to employee benefit plans and deferred compensation	Expense Account, other allowances
Honorable Sam Nunn Atlanta, GA	Co-Chairman & Chief Executive Officer	35	\$ 315,000	\$ 31,142	None
Mr Charles B. Curtis Washington, DC	President & Chief Operating Officer	45	289,308	45,065	None
Mr J Rutherford Seydel, II Atlanta, GA	Secretary	2-5	None	None	None
Ms Joan B. Rohlfing Washington, DC	Senior Vice President for Programs & Operations	45	218,171	49,497	None
Mr Terence Taylor Washington, DC	Vice President for Global Health & Security	40	149,651	34,461	None
Ms Brooke Anderson Washington, DC	Vice President for Communications	45	211,560	37,591	None
Ms Laura Holgate Washington, DC	Vice President for Russia/ New Independent States Programs	45	206,050	44,621	None
Mr Kraig Butrum Washington, DC	Vice President for Development	45	193,485	43,531	None
Ms. Melissa Sarver Washington, DC	Treasurer	* 40	9,854	2,291	None
Ms. Charlotte S. Atkinson Washington, DC	Treasurer	** 40	61,923	11,839	None
<b>Total Officers</b>			<b>\$ 1,655,002</b>	<b>\$ 300,038</b>	<b>\$ -</b>

\* July 1 to July 31, 2007

\*\* February 4, 2008 to present

NTI Directors

Mr R.E. (Ted) Turner	Class I Director & Board Co-Chairman	5	None	None	None
Honorable Sam Nunn	Class I Director & Board Co-Chairman	35	See Above	See Above	See Above
Dr. Alexei Arbatov	Class I Director	2-5	None	None	None
Mr Charles B. Curtis	Class I Director	45	See Above	See Above	See Above
Senator Pete V. Domenici	Class I Director	2-5	None	None	None
Ms. Susan Eisenhower	Class I Director	2-5	None	None	None
Ambassador Rolf Ekous	Class I Director	2-5	None	None	None
Gen. Eugene E. Habiger (USAF Ret.)	Class I Director	2-5	None	None	None
Mr Pierre Lehouche	Class I Director	2-5	None	None	None
Senator Richard G. Lugar	Class I Director	2-5	None	None	None
Dr. Jessica Tuchman Mathews	Class I Director	2-5	None	None	None
Judge Hisash Owada	Class I Director	2-5	None	None	None
Dr. William J. Perry	Class I Director	2-5	None	None	None
Dr. Nafis Sadik	Class I Director	2-5	None	None	None
Professor Amartya K. Sen	Class I Director	2-5	None	None	None
HRH Prince El Hassan bin Talal	Class I Director	2-5	None	None	None

**Nuclear Threat Initiative, Inc.**  
**EIN: 52-2289435**  
**Form 990 PF (FY08)**  
**Part VIII**  
**Line 2**

Statement 17

**Five Highest Paid Employees (other than those included on line 1)**

All employees can be contacted at 1747 Pennsylvania Avenue, NW, 7th Floor, Washington, D.C 20006

<u>Name &amp; Address</u>	<u>Position</u>	<u>Estimated Hours Per Week Devoted to Position</u>	<u>July 1, 2007 - June 30, 2008 Compensation</u>	<u>Contributions to employee benefit plans and deferred compensation</u>	<u>Expense Account, other allowances</u>
Robert E. Berls, Jr Washington, DC	Senior Advisor for Russia/ New Independent States Programs, Director of Moscow Office	45	185,437	52,785	None
Lisa Cutler Washington, DC	Director of Programs and Outreach	45	158,981	47,075	None
Diane Hauslein Washington, DC	Director of Administration	45	146,400	38,515	None
Cathy Gwin Washington, DC	Director of Communications	36	127,661	43,341	None
Corey Hinderstein Washington, DC	Director International Program	45	109,750	34,833	None
<b>Total Employees</b>			<u>\$ 728,229</u>	<u>\$ 216,549</u>	<u>\$ -</u>

Total number of other employees paid over \$50,000 ... .. 14

Nuclear Threat Initiative, Inc.  
EIN: 52-2289435  
Form 990 PF (FY08)  
Part VIII  
Line 3

Schedule 18

Five Highest Paid Independent Contractors for Professional Services

<u>(a) Name and Address</u>	<u>(b) Type of Service</u>	<u>(c) Compensation</u>
1) National Journal Group 600 New Hampshire Avenue, NW Washington, DC 20037	Communications Program Support	915,083
2) Goddard Clausen Strategic Advocacy 3001 Douglas Blvd. Ste 225 Roseville, CA 95661	Communications Program Support	444,857
3) The RAND Corporation 1776 Main Street Santa Monica, CA 90401	Global Health & Security Initiative Program Support	351,584
4) West Wing Writers 1150 Connecticut Avenue, NW, Ste 505 Washington, DC 20036	Communications Program Support	182,500
5) International Nuclear Consultants, Inc. 5670 Millwick Drive Alpharetta, GA 30005	Russia/NIS Program Support	143,390

2,037,414

Total number of other independent contractors paid over \$50,000.....10



**Nuclear Threat Initiative, Inc.**  
**EIN: 52-2289435**  
**Form 990 PF (FY08)**  
**Part X**  
**Minimum Investment Return, Line 4**

**Statement 19**

The Nuclear Threat Initiative has included \$11,676,381 as cash deemed to be held for charitable activities. This amount represents more than the normal 1.5% of cash deemed held for charitable activities, due to the Board of the organization approving \$11,676,381 & \$3,313,674 to be paid in fiscal years 2009 and 2010 for charitable program activities - see Statement 20.

Nuclear Threat Initiative, Inc.  
EIN: 52-2289435  
Form 990 PF (FY08)  
Part XII  
Line 3b

Statement 20

Amounts set aside for Treatment as Qualifying Distributions - (cash distribution test)

Awards approved for payment in future years

FY09	11,676,381	
FY10	<u>3,313,674</u>	
	14,990,055	See Statement 24
Less: Discount (per FASB 116)	<u>(151,038)</u>	
Awards approved for payment in future years	\$ 14,839,017	
Reversal of prior year amount	<u>(2,563,949)</u>	
Net awards approved for payment in future years	<u>\$ 12,275,068</u>	

## Nuclear Threat Initiative, Inc.

EIN: 52-2289435

Form 990 PF (FY08)

## Part XV

## Lines 3(a) and 3 (b) - Grants and Contributions Paid During the Year

Statement 21

Recipient Name	Recipient Address		Foundation status of recipient	Purpose of grant or contribution	Paid during the Year	Approved for Future Payment
Sarov Labs	Variamovskoye Shosse 23/16	Sarov, Nizhegorodskaya Russia 607 190	Non- US Organization	To assist Sarov Labs in becoming a self-sustaining, commercial contract research organization that employs former weapons scientists by contributing to the cost of project management and marketing support.	(5,915)	
Center for Policy Studies in Russia	Suite 025, Bldg. 1, 11/13, Trekhpudny Per.	Moscow, 123001, Russia	Public	Promoting Multilateral Approaches to the Nuclear Fuel Cycle in Russia	227,100	
Fdn for Russian American Co-operation	2601 Fourth Avenue Ste 310	Seattle, WA 98121	Public	Support for the Strategic Catalyst Fund to help reverse the bilateral strained relations between the US and Russia	25,000	
<b>Total Russia/ New Independent States Program</b>					<b>246,185</b>	<b>-</b>
The American Association for the Advancement of Science	1200 New York Avenue, NW	Washington, D.C. 20005	Public	To support biomedical/public health experts to work on national security issues in US government through one-year fellowship programs	92,995	101,625
Search for Common Ground	1601 Connecticut Avenue, NW Ste. 200	Washington, D.C. 2009-1035	Public	Providing Internm Secretariat function to project improving regional capacity for infectious disease surveillance in the Middle East by developing a food-borne and water-borne disease surveillance system uniting Israel, the Palestine Authority, Jordan, and Egypt.	57,200	5,000
Newly Formed Corporation of Former Employees of State Research Center for Applied Microbiology (SRCAM), Obolensk, Moscow Region	2, Kurchatov Square	Moscow, 123182 Russia	Non- US Organization	To support the establishment of a laboratory for the production of enzymes used in the diagnosis of endemic infectious disease threats. The laboratory will employ former biowapons scientists who are in imminent risk of unemployment owing to proposed closure of the State Research Center for Applied Microbiology (SRCAM) at Obolensk, Moscow Region	185,000	
The Academy of Scientific Research and Technology	101 Kasr El Ainy Street	Cairo, Egypt	Non- US Organization	To support a workshop in Egypt that will raise awareness of the threat of bioterrorism and the need for safe and secure handling of dangerous biological materials in bioscience facilities		11,532
State Research Center of Virology and Biotechnology (VECTOR)	SRC VB Vecot	Koltsova, 630559 Russia	Non- US Organization	To create a regional reference clinical immunological laboratory for diagnosis of Viral Hepatitis leveraging the restructuring of FSU Biodefense Institute	175,000	
Al-Quds University	P O. Box 51000, Abdel Hamad Shoman Street	Beit Hanina	Non- US Organization	Middle East Consortium on Infectious Disease Surveillance, (MECIDS), country support. To improve early disease detection and response to pandemic influenza and other food and water borne diseases within MECIDS countries	44,987	93,313
Jordanian Ministry of Health	P O. Box 86, Jabal Al-Hussein	Amman, Jordan, 11118	Non- US Organization	Middle East Consortium on Infectious Disease Surveillance, (MECIDS), country support. To improve early disease detection and response to pandemic influenza and other food and water borne diseases within MECIDS countries.	72,451	65,850

## Nuclear Threat Initiative, Inc.

EIN: 52-2289435

Form 990 PF (FY08)

Part XV

Statement 21

## Lines 3(a) and 3 (b) - Grants and Contributions Paid During the Year

Recipient Name	Recipient Address	Foundation status of recipient	Purpose of grant or contribution	Paid during the Year	Approved for Future Payment
Tel Aviv University	Ramat Avrv Tel Aviv, 69978, Israel	Non- US Organization	Middle East Consortium on Infectious Disease Surveillance, (MECIDS), country support. To improve early disease detection and response to pandemic influenza and other food and water borne diseases within MECIDS countries.	38,090	100,211
Mekong Basin Disease Surveillance Network	Rajprachasamasai Building (No 8), 4th floor, Tiwanond Road Nonthabun 11000 Thailand	Non- US Organization	To assist in the deployment of Rapid Response Teams to post-cyclone Myanmar	30,000	
International Council for the Life Sciences	1747 Pennsylvania Ave, NW, Ste 700 Washington, DC 20009	Public	To support ICLS in working cooperatively to build global networks to help reduce biological risks	396,612	31,614
<b>Total Global Health &amp; Security Initiative</b>				<b>1,092,335</b>	<b>409,145</b>
The Monterey Institute for International Studies, Center for Nonproliferation Studies	425 Van Buren Street Monterey, CA 93940	Public	To develop and maintain for the NTI website a comprehensive research library with information, analysis and educational materials about the threats from nuclear, biological and chemical weapons. The library builds on the most comprehensive open-source nonproliferation databases in the world and brings together a range of expert opinion and analysis on these issues.	812,500	162,500
Harvard University, JFK School of Government	1350 Massachusetts Avenue Cambridge, MA 02138-3800	Public	To track the progress and budgets of U.S. - Russian cooperative nuclear security programs with an annual report and website and make recommendations for accelerating the pace and effectiveness of this threat reduction work.	147,061	
Harvard University, JFK School of Government	1350 Massachusetts Avenue Cambridge, MA 02138-3800	Public	Support of conference, "Overcoming Nuclear Danger"	75,000	
<b>Total Communications Program</b>				<b>1,034,561</b>	<b>162,500</b>
New Delhi Policy Group	246 Vasant Enclave, New Delhi New Delhi, 110057 India	Non- US Organization	To promote responsible government policies and practices related to the safety and security of nuclear weapons and materials in India, by developing educational materials for policy makers and by facilitating meetings between nuclear experts in India and other nations.	75,200	
Institute of Peace and Conflict Studies	C 1/4 Vasant Vihar New Delhi, 110057 India	Non- US Organization	To continue a WMD module on the Institute of Peace and Conflict Studies website, that draws from South Asian, Chinese and Central Asian sources and provides comprehensive news analysis and reference materials relating to nuclear, chemical and biological weapons and to support research workshops and publications on nonproliferation, and nuclear biological and chemical threats.	92,000	

Nuclear Threat Initiative, Inc.

EIN: 52-2289435

Form 990 PF (FY08)

Part XV

Lines 3(a) and 3 (b) - Grants and Contributions Paid During the Year

Statement 21

Recipient Name	Recipient Address	Foundation status of recipient	Purpose of grant or contribution	Paid during the Year	Approved for Future Payment
International Atomic Energy Agency	Wagramer Strasse 5 A-1400 Vienna, Austria	Public	To support IAEA project "Developing Research Reactor Coalitions and Regional Centres of Excellence" striving to develop a much broader "incentive package" to help convince facilities to convert to LEU while also making it possible for some facilities after shutdown to have available capabilities in other countries which its researchers can utilize	195,000	
Carnegie Endowment for International Peace	1779 Massachusetts Avenue, NW Washington, DC 20036	Public	Carnegie International Nonproliferation Conference "Tomorrows Solutions" (June 25-27, 2007)	50,000	
World Security Institute	1779 Massachusetts Avenue, NW, # 615 Washington, DC 20036	Public	Nuclear Modelling Project	45,000	
CSIS	1800 K St, NW Washington, DC 20006	Public	To expand international dialogue, education and action towards a global consensus for reversing the reliance on nuclear weapons	196,166	
World Security Institute	1779 Massachusetts Avenue, NW, # 615 Washington, DC 20036	Public	Nuclear Modelling Project	100,000	90,000
National Defense University Foundation	P.O. Box 71386 Washington, DC 20024	Public	American Patriot Award sponsorship	10,000	
U.S. Kazakhstan Business Association	1200 G. Street, NW, Suite 827 Washington, DC 20005	501(c)(6)	Event sponsorship	5,000	
The Joshua Lederberg Fund	Rockefeller University, 1230 York Avenue, New York, NY 10065	Public	Contribution in memory of Joshua Lederberg	500	
<b>Total International Program</b>				<b>768,866</b>	<b>90,000</b>
<b>TOTAL</b>				<b>3,141,947</b>	<b>661,645</b>
Less: Discount to present value per FASB 116					
<b>TOTAL</b>				<b>3,141,947</b>	<b>661,645</b>

NUCLEAR THREAT INITIATIVE, INC  
 EIN 52-2289435  
 990-PF (FY08)  
 Part IX-A

Statement 22

STATEMENT OF FUNCTIONAL EXPENSES  
 for the year ended June 30, 2008  
 (with summarized information for the year ended June 30, 2007)

Expense Type	Russia/NIS	Global Health & Security	Communications	International	Total Programs	Management & Governance	Fundraising	2008 Total Expense	2007 Total Expense
Employee costs	933,606	828,318	728,407	499,362	2,989,693	914,006	500,370	4,404,069	4,430,636
Contracts	425,945	366,584	959,596	642,569	2,394,714	-	-	2,394,714	1,780,575
Grants, contributions and gifts	101,084	1,007,811	652,410	469,124	2,230,429	-	-	2,230,429	5,288,064
Professional services	44,547	100,281	419,278	322,165	886,271	377,818	68,858	1,332,947	1,055,239
Travel, conferences & meetings	254,739	432,959	62,202	445,976	1,195,876	266,633	33,290	1,495,799	944,221
Occupancy	250,937	116,414	69,013	37,929	494,293	110,658	44,399	649,350	685,365
Telecommunications	30,477	19,379	176,658	18,084	245,098	17,118	20,816	283,032	276,114
Printing and publications	12,878	17,538	38,751	21,481	90,648	2,119	30,556	123,323	142,403
Depreciation and amortization	10,689	21,517	12,756	10,707	55,669	18,529	7,435	81,633	99,593
Insurance	7,004	15,178	11,420	7,618	41,220	14,225	5,054	60,499	72,915
Supplies	11,819	12,246	12,779	6,000	42,844	12,657	3,819	59,320	67,059
Postage and shipping	3,268	3,485	11,817	3,004	21,574	5,437	21,547	48,608	68,067
Equipment rental & maintenance	4,388	8,472	5,022	4,216	22,098	7,482	2,930	32,510	31,583
Foreign Exchange Loss	29,782	-	-	-	29,782	-	-	29,782	13,004
Advertising	-	200	-	667	867	-	-	867	2,092
Miscellaneous	18,038	6,997	5,935	2,217	33,187	18,724	1,661	53,572	46,240
<b>Total expenses per Financial Statements</b>	<b>2,139,221</b>	<b>2,957,879</b>	<b>3,166,044</b>	<b>2,511,119</b>	<b>10,774,263</b>	<b>1,765,456</b>	<b>740,735</b>	<b>11,280,454</b>	<b>15,001,170</b>
Reconciliation, Audited Financial Statements to 990-PF									
Less Grants, contributions & gifts	(101,084)	(1,007,811)	(652,410)	(469,124)	(2,230,429)			(2,230,429)	(5,288,064)
Less in-kind professional services. (Avalon Financial)						(38,400)		(38,400)	(36,800)
Less in-kind supplies (Coca cola)						(4,870)		(4,870)	(4,339)
Misc.						(1,785)		(1,785)	5,926
<b>Expenses per Form 990-PF</b>	<b>2,038,137</b>	<b>1,950,068</b>	<b>2,513,634</b>	<b>2,041,995</b>	<b>8,543,834</b>	<b>1,765,456</b>	<b>740,735</b>	<b>11,004,970</b>	<b>9,679,893</b>

**NUCLEAR THREAT INITIATIVE**

**EIN: 52-2289435**

**Form 990-PF (FY08)**

**Part IX-A**

**Projects Approved or Ongoing in Fiscal Year 2008**

**Russia/New Independent States Programs**

**Accelerating Russian HEU Blend-down, Phase II**

To build on a previous project to analyze options for accelerating the elimination through blend-down of excess Russian highly enriched uranium. This allows for additional analysis to optimize the options, promote the accelerated blend-down concept in the United States, Russia and Europe, as well as prepare additional data necessary for Russian government decision making.

*Facilities and Institutes of Russian Ministry of Atomic Energy  
Moscow, Russia and others*

**Removing HEU from Serbia**

To contribute to the removal of poorly secured HEU from the Vinca Institute of Nuclear Sciences by supporting the decommissioning of its research reactor and management of remaining spent nuclear fuel.

*International Atomic Energy Agency  
Vienna, Austria*

**Supporting Conversion for Alatau Nuclear Research Reactor**

To provide the equipment and incentives for the research reactor at the Institute of Nuclear Physics at Alatau to be converted to use low-enriched uranium fuel by providing a new reactor control and protection system that will improve reactor safety.

*Institute for Nuclear Physics  
Alatau, Kazakhstan*

**Planning to Secure and Remove HEU from Soviet-Supplied Research Reactors to Improve Safety and Reduce Proliferation Risks**

To evaluate security, safety, regulatory, transportation and cost issues associated with removing fresh and spent HEU fuel from 24 poorly secured research reactors in 17 countries and to develop a comprehensive plan to achieve it.

*International Atomic Energy Agency  
Vienna, Austria*

**Development of Conversion Companies**

To contribute \$1 million to the Fund for Development of Conversion Companies, an existing Russian revolving loan fund, established to create permanent, commercially viable civilian businesses in the closed nuclear city of Sarov and provide sustainable employment for former weapons personnel.

*Fund for Development of Conversion Companies*

*Sarov, Russia*

**Building Capacity at SarovLabs**

To assist SarovLabs in becoming a self sustaining, commercial contract research organization that employs former weapons scientists by providing project management and marketing support.

*SarovLabs*

*Sarov, Russia*

**Strategic Planning for Snezhinsk**

To engage local and institute leaders from the closed nuclear city of Snezhinsk in strategic planning to support two key missions of the city over the next five years: downsizing the nuclear weapons facility and staff and securing the remaining nuclear materials at the site.

*The Eisenhower Institute*

*Washington, DC, USA*

**Development of Open Technopark**

To support project and infrastructure development in the new Open Technopark, located just outside the closed nuclear city of Sarov and in an area that provides free access to non-Russian companies and investors but still within an easy commute for former weapons scientists and engineers from Sarov. This project will contribute to the creation of new jobs not related to nuclear weapons and accelerate the transition to a smaller, more stable and more secure Russian nuclear weapons complex.

*Center for Technologies Transfer "Sistema-Sarov"*

*Sarov, Russia*

**Strengthening the Global Partnership**

To develop a constituency among and beyond the Group of Eight (G8) leading industrial nations for nuclear, biological and chemical threat reduction programs through partnerships with 21 security organizations from 16 nations. This project promotes the effective and timely implementation of the G8 Global Partnership Against the Spread of Weapons and Materials of Mass Destruction's commitment to devote \$20 billion to support nonproliferation projects, initially in Russia, over the next decade.

*Center for Strategic and International Studies*

*Washington, DC, USA*



**Supporting Russian Chemical Weapons Destruction**

To provide \$1 million, matched by a minimum of \$2 million from other sources, for high-priority infrastructure development for the Shchuch'ye Chemical Weapons Destruction Facility.

*Global Partnership Program*

*Canada Department of Foreign Affairs and International Trade*

*Ottawa, Canada*

**Strategic Master Plan for Russian Research Reactors**

To build on a previous successful project to define, at an aggregate level, the challenges associated with the continued use of highly enriched uranium (HEU) fuel at research reactors and related facilities in Russia. This project will create a strategic master plan on the basis of a facility-by-facility survey to consider security requirements, HEU removal, spent fuel management, and reactor conversion opportunities for civilian research reactors in Russia. The resulting recommendations will provide necessary input to a comprehensive approach to phasing out HEU use in Russian civilian research facilities.

*Foundation for Atomic Energy in the 21st Century*

*Moscow, Russia*

**Concept Development Grant for Low Enriched Uranium (LEU) Fuel Reserve to be Owned and Managed by the International Atomic Energy Agency**

To promote the creation of a low enriched uranium (LEU) fuel reserve, owned and managed by the International Atomic Energy Agency (IAEA), to limit the spread of fuel cycle technology. Should NTI win the necessary support for this concept, up to \$50 million will be put toward the initial establishment of such a reserve, to include the first three years of storage costs, the IAEA's management and oversight costs, and the purchase of the initial LEU deposit. An LEU fuel reserve that is buffered from politically motivated disruptions of nuclear fuel supply will add a unique tool to current national and international efforts to significantly reduce the need for new enrichment facilities.

*NTI and others*

*Washington, DC, USA*

**Ballistic Missile Defense and Nuclear Stability in Asia**

To assess the impact of ballistic missile defense on the strategic interactions and strategic interactions and stability among India, Pakistan, China and Taiwan.

*Center for International Security and Cooperation, Stanford University*

*Palo Alto, CA, USA*

**Nuclear Nonproliferation Workshop**

To support a joint NTI – Russian Academy of Sciences Nuclear Nonproliferation Workshop in Moscow in the fall of 2008.

*NTI and Russian Academy of Sciences*

*Washington, DC, USA and Moscow, Russia*

**US-Russian Civilian Nuclear Cooperation Agreement Study**

To conduct a study of the implications and potential benefits of a completed United States-Russian civilian nuclear cooperation agreement.

*Center for Strategic and International Studies*

*Washington, DC, USA*

**Promoting Multilateral Approaches to the Nuclear Fuel Cycle in Russia**

To promote the NTI fuel bank initiative and related subjects, including the Russian Angarsk international enrichment center project, by initiating a discussion among Russian governmental and non-governmental experts and the media on the future of nuclear energy and the future role of international nuclear fuel cycle initiatives.

*PIR Center – Center for Policy Studies in Russia*

*Moscow, Russia*

**Bio Security Projects**

**Educating and Training the International Life Sciences Community on Dual-Use Dangers**

To assess the best methods for educating and training life scientists about the risks of dual-use technologies and research and to cultivate a project for curriculum development in this area.

*NTI*

*Washington, DC, USA*

**International Council for the Life Sciences**

To support and sustain an organization to promote best practices and standards for biosafety and biosecurity among the life sciences community to reduce potential proliferation of dangerous pathogens and the misuse of technical information.

*International Council for the Life Sciences*

*Washington, DC, USA*

**AAAS-NTI Fellowship in Global Security**

To strengthen scientific expertise in national security policymaking and encourage scientists to pursue careers in this arena, by supporting biomedical/public health experts to work on national security issues in the U.S. government through a one-year fellowship.

*American Association for the Advancement of Science*

*Washington, DC, USA*

**Regional Reference Laboratory for Viral Hepatitis**

To set up a reference laboratory at the facilities of the Federal State Research Initiation-State Research Center of Virology and Biotechnology (VECTOR) that will meet all national and international requirements and regulations for diagnostic work involving the use of molecular biological methods.

*VECTOR*

*Koltsovo, Novosibirsk Oblast, Russia*

**Brucellosis Vaccine Research**

To develop a new vaccine, employing former Soviet bioweapons scientists, to contribute to the management of this disease that threatens domestic and wild animal populations around the world.

*All-Russian Research Veterinary Institute, Kazan, Russia*

*International Science and Technology Center, Moscow, Russia*

*(in conjunction with the U.S. Department of State)*

**Strengthening National Health Preparedness**

To assess preparedness for biological and chemical attacks in several nations by establishing and testing a set of international guidelines for preparedness, comparing them against existing public health capabilities that states have in place and making recommendations for improving those capabilities.

*World Health Organization*

*Geneva, Switzerland*

**Employing Former Bioweapons Scientists in Russia to Manufacture Diagnostic Enzymes for Endemic Infectious Disease Threats**

To redirect former bioscientists who were at risk of unemployment due to ongoing bankruptcy procedures at the State Research Center for Applied Microbiology and Biotechnology (SCRAM), Obolensk, by providing them with alternative, long-term employment relevant to their scientific expertise.

*SRAM*

*Obolensk, Moscow Region, Russia*

**Developing Diagnostic Kits for Select Biological Agents**

To develop rapid diagnostic tests for select biological agents of most significance to Russia, to introduce them to health-care practices and to organize manufacturing of such tests. Once developed, these tests could help fill a critical global need for better diagnostic tests for the detection of infectious diseases.

*Moscow State Central Research Institute for Epidemiology of the*

*Health Ministry of Russia*

*Moscow, Russia*

**Rapid Outbreak Response Revolving Fund**

To create within the World Health Organization an account dedicated to supporting rapid emergency response to infectious disease outbreaks.

*World Health Organization*

*Geneva, Switzerland*

**Middle East Consortium on Infectious Disease Surveillance (MECIDS)**

To improve regional capacity for infectious disease surveillance in the Middle East by developing a food-borne and water-borne disease surveillance system among Israel, the Palestine Authority and Jordan, and by designing an infectious disease epidemiology course to build regional rapid response capabilities in the event of disease outbreaks.

*NTI and others*

*Washington, DC, USA and others*

**Biological Weapons Threat Reduction: Expanding Outbreak Reporting and Education in the New Independent States**

To reduce the threat of biological weapons and other emerging infectious diseases in the new independent states, the International Society for Infectious Diseases will expand the scope of a Russian language-based electronic network (PROMED) that rapidly disseminates information about outbreaks of infectious diseases, including potential biological weapons attacks, to include more physicians, scientists and public health officials throughout the new independent states.

*International Society for Infectious Diseases*

*Brookline, MA, USA*

**Creating a Regional Disease Surveillance System in South Asia**

This project builds on NTI's experience developing a regional disease surveillance network in the Middle East with Jordan, Israel, Egypt and the Palestinian Authority, to create a regional disease surveillance network that would initially bring together India, Pakistan and Bangladesh.

*NTI*

*Washington, DC, USA*

**Pandemic Influenza Simulation Exercises in Southeast Asia**

To strengthen national and sub-regional disease surveillance capacity in the Mekong Basin area (Thailand, Vietnam, Cambodia, Laos, Myanmar, and China- Yunnan province), and develop a system that operates across borders, responds quickly to regional disease threats, and works to create equity in the national capacities to detect and respond to local outbreaks, and, hence, prevent regional or even global emergencies.

*NTI and others*

*Washington, DC, USA and others*

**Mekong Basin Disease Surveillance (MBDS) Network**

To combat infectious disease by focusing on laboratory capacity and training to enhance early detection and identification of disease outbreaks.

*NTI and others*

*Washington, DC, USA and others*

**Regional Training Centers for Biological Safety and Security**

To develop a comprehensive strategy for establishing regional training centers for biological safety and security in the Middle East/Gulf/North Africa region and eventually in the South and South East Asia. The centers will offer life scientists and laboratory staff on-site technical training in the highest biosafety and biosecurity standards and practices, tailored specifically to their work and regional concerns.

*NTI and others*

*Washington, DC, USA and others*

**MBDS Rapid Response**

To assist MBDS in the deployment of Rapid Response Teams to Myanmar in order to provide humanitarian support by helping reduce the spread and impact of infectious disease outbreaks following the cyclone.

*MBDS*

*Thailand*

**Joint Training on Laboratory Biosecurity and Biosafety in Egypt**

This project supports a workshop that will raise awareness of the threat of bioterrorism and the need for safe and secure handling of dangerous biological materials in bioscience facilities. NTI's ultimate plan is to build relationships through this process and to identify an appropriate Egyptian laboratory needing biosecurity upgrades.

*Academy of Scientific Research and Technology*

*Cairo, Egypt*

**Control of Drug Resistant Tuberculosis in the Democratic People's Republic of Korea (North Korea)**

To initiate a professional exchange with North Korea to develop a national TB laboratory that has potential to address this emerging health crisis for northeast Asia, while also opening new perspectives in health policy and inter-governmental cooperation.

*NTI and members of the Bay Area Consortium*

*Washington, DC and San Francisco, CA, USA*

**Improving Biological Threat Detection and Surveillance in Russia**

To engage experts from the animal health and human health systems in Russia to determine a comprehensive strategy for upgrading and integrating their infectious disease surveillance systems.

*NTI*

*Washington, DC, USA*

**"Network of networks" Conference**

To bring together representatives from infectious disease surveillance networks in Africa, the Americas, Europe and the Middle East, experts in infectious disease surveillance from the WHO, the business sector and private foundations, to share best practices and lessons learned.

*NTI*

*Washington, DC, USA*

**Communications Programs**

**Global Security Newswire**

To support a daily news service – available exclusively on the NTI website – with original reporting and a comprehensive snapshot of the day’s global news on nuclear, biological and chemical weapons, terrorism and missile issues.

*National Journal Group, Inc.  
Washington, DC, USA*

**Online Research Center and Library**

To build, expand and update a comprehensive online research library with information, analysis and educational materials about the threats from nuclear, biological and chemical weapons. The library builds on the most comprehensive open-source nonproliferation databases in the world and brings together a range of expert opinion and analysis on these issues.

*Monterey Institute of International Studies  
Center for Nonproliferation Studies  
Monterey, CA, USA*

**Securing the Bomb**

To track the progress and budgets of global nuclear security programs with an annual report and website and make recommendations for accelerating the pace and effectiveness of this threat reduction work.

*Project on Managing the Atom,  
Belfer Center for Science and International Affairs  
John F. Kennedy School of Government  
Harvard University  
Cambridge, MA, USA*

**Public Opinion Project**

To conduct public opinion research on the threats from weapons of mass destruction.

*NTI  
Washington, DC, USA*

***Last Best Chance—Public Education on Nuclear Threats***

To produce and distribute a fact-based fictional film that illustrates the threat of nuclear terrorism. The film highlights the threats and what should be done to address them, and reminds viewers of the real human, political and economic costs of a nuclear terrorism incident.

*NTI (in conjunction with the Carnegie Corporation of New York and  
The John D. and Catherine T. MacArthur Foundation)  
Washington, DC, USA*

**Safer World Action Network**

To engage and expand the network of individuals interested in efforts to reduce the threats from nuclear, biological and chemical weapons and materials with the goal of inspiring individuals to become personally involved in efforts to expand and accelerate the pace of work to reduce these threats.

*NTI*

*Washington, DC, USA*

**Research and Analysis**

To conduct research and analysis to support NTI projects and activities.

*Monterey Institute of International Studies*

*Center for Nonproliferation Studies*

*Monterey, CA, USA*

**Public Education Project: Turning the “D” into an “A”**

To support NTI and Families of September 11 in raising public awareness about nuclear dangers throughout the United States. Activities include screenings and discussions about the film *Last Best Chance*, television public service announcements, and distributing educational materials that can be used in university courses by professors across the country.

*NTI*

*Washington, DC, USA*

**South Asian Security and WMD Website Module**

To continue a weapons of mass destruction module on the Institute of Peace and Conflict Studies website that draws from South Asian, Chinese and Central Asian sources and provides comprehensive news analysis and reference materials relating to nuclear, chemical and biological weapons and to support research, workshops and publications on nonproliferation and nuclear, biological and chemical threats.

*Institute of Peace and Conflict Studies*

*New Delhi, India*

**Global Health and Security Outreach**

To develop and implement outreach activities to advance the agenda and activities of NTI's Global Health and Security Initiative.

*NTI*

*Washington, DC, USA*

**Nuclear Security Documentary**

To develop a short documentary film about the visions and steps for a nuclear weapons free world.

*NTI*

*Washington, DC, USA*

### **International Programs**

#### **Promoting Responsible Nuclear Stewardship in India**

To promote responsible government policies and practices related to the safety and security of nuclear weapons and materials in India by developing educational materials for policymakers and facilitating meetings among nuclear experts in India and other nations.

*Delhi Policy Group  
New Delhi, India*

#### **Cooperative Threat Reduction in East Asia**

This project aims to build political support for cooperative threat reduction on the Korean peninsula, promote contacts between national technical communities likely to be involved in such programs, provide support for developing specific CTR activities, and use regional expertise to adapt existing CTR approaches to the Korean peninsula.

*Center for Strategic and International Studies  
Washington, DC, USA*

#### **Developing Nuclear Security Guidelines**

The IAEA has been working since 9/11 to strengthen its capacity to support better security of nuclear materials around the globe. This project enables the IAEA to draft, publish and disseminate for the first time in its history, nuclear security guidelines or “standards” for all countries to use as a basis for securing their nuclear materials. Creation of these guidelines/standards will fill a critical gap in the IAEA’s framework for strengthening global nuclear materials security.

*International Atomic Energy Agency  
Vienna, Austria*

#### **Developing Research Reactor Coalitions and Regional Centers of Excellence**

To develop research reactor coalitions and regional centers of excellence in order to help secure under-utilized research reactors, and incentivize reactor operators to convert from highly enriched uranium (HEU) fuel to low enriched uranium (LEU) fuel.

*International Atomic Energy Agency  
Vienna, Austria*

#### **The World Institute for Nuclear Security: Developing a Concept for a New Entity to Collect and Promulgate Best Practices for Nuclear Material Security**

To gather international input and develop a concept to create a new international organization that would improve nuclear material security worldwide through the collection and dissemination of best practices in physical protection and nuclear material control and accountancy.

*NTI  
Washington, DC, USA*



**The World Institute for Nuclear Security: Founding Grant**

To support the launch of the World Institute for Nuclear Security (WINS), a new independent, international institution to facilitate the collection and sharing of best practices in nuclear material security.

*WINS*

*Vienna, Austria*

**U.S.-Russian Nonproliferation Working Group Project**

To support the U.S.-Russian Nonproliferation Working Group of the Belfer Center to improve critical U.S.-Russian collaboration.

*Belfer Center for Science and International Security*

*Harvard University*

*Boston, MA, USA*

**Nuclear Modeling Project**

To fully develop a research project that considers the strategic impact of increasing the warning and decision time that would result from the US and Russia de-alerting their nuclear arsenals.

*World Security Institute*

*Washington, DC, USA*

**Nuclear Security Project: toward a Vision and Steps for a Nuclear Free World**

The Nuclear Security Project seeks to galvanize global action to reduce urgent nuclear dangers and to build support for reducing reliance on nuclear weapons, ultimately ending them as a threat to the world.

*NTI and others*

*Washington, DC, USA*

**Weapons of Mass Destruction Project**

To support the conduct of several WMD projects, specifically a project to build awareness and support for Indian engagement in a Fissile Material Cutoff Treaty and another to help catalyze greater Indian participation in mechanisms for nuclear materials security, and finally to support the continuation of the Institute's highly successful web module on WMD issues which reaches a wide South Asian audience.

*Institute of Peace and Conflict Studies*

*New Delhi, India*

Line 3b - Awards Approved for Payment in Future Years

	Award Amount	Award Commitments at 6/30/2007	Additions FY08	Payments FY08	Adjustments FY08	Award Commitments at 6/30/2008
<b>Global Health and Security Initiative</b>						
Educating and Training the International Life Sciences Community on Dual Use Dangers (Gates)	50,000	18,524		16,990		1,534
Creating a Regional Disease Surveillance System in South Asia	275,000	246,136		10,575		235,561
Pandemic Influenza Simulation Exercises in Southeast Asia (R)	610,000	371,605		89,573		282,032
Improving Biological Threat Detection and Surveillance in Regional Training Centers for Biological Safety and Security	75,000	68,993		18,634		50,359
Middle East Consortium on Infectious Disease Surveillance (International Council of the Life Sciences)	120,000		120,000	15,371		104,629
AAAS	300,000	176,171		646,025		(469,854)
Vector (IFTI)	397,150	171,034		151,272		19,763
Research Center for Applied Microbiology (SRCAM), Obolensk, Moscow Region	1,131,538	194,620		92,995		101,625
Joint Training on Laboratory Biosecurity and Biosafety in Egypt	350,000	175,000		175,000		-
MECIDS - World Bank	400,000	185,000		185,000		-
SE Asia (Google)	70,000	11,532		-		11,532
Bellagio	976,899		976,899	304,589		672,310
Control of Drug Resistant Tuberculosis	2,500,000		2,500,000	195,411		2,304,589
Total for GHSI Program	120,000		120,000	93,770		26,230
	300,000		300,000	642		299,358
	7,675,587	1,618,615	4,016,899	1,995,847	-	3,639,667
<b>Communications Program</b>						
Website (Starpoint) Summary 2001/2002/2003	960,000	67,183		29,377		37,806
Public Opinion Project (Reduced Grant -\$339,500)	339,500	28,500		-	28,500	
Last Best Chance	1,625,000	7,314		(15,502)		22,816
NTI's Safer World Action Network	500,000	300,954		46,792		254,162
Global Health and Security Initiative Outreach	75,000	73,775		4,893		68,882
Public Education Project: Turning the "D" into an "A"	631,816	245,792		85,844		159,948
Goddard Claussen	800,000			(349,102)		349,102
National Journal Group FY2008-FY2009	918,000	918,000		918,000		-
National Journal Group FY2007-FY2008	883,000	73,583		73,583		-
MIIS (WMD Research Ctr. & Lib) FY2008-FY2009	650,509	650,509		488,009		162,500
MIIS (WMD Research Ctr. & Lib) FY2007-FY2008	650,000	325,000		325,000		-
Securing the Bomb (Harvard)	650,000	147,060		147,060		-
National Journal Group FY2009 - FY2010	955,000		955,000	153,000		802,000
MIIS (WMD Research Ctr & Lib) FY2009 - FY2010	649,000		649,000	-		649,000
Securing the Bomb (Harvard) 2008 - 2009	351,105		351,105	-		351,105
Total for Communications Program	10,637,930	2,837,670	1,955,105	1,906,953	28,500	2,857,322

Nuclear Threat Initiative, Inc.  
 EIN: 52-2289435  
 Form 990 PF (FY08)  
 Part XII

Statement 24

Line 3b - Awards Approved for Payment in Future Years

	Award Amount	Award Commitments at 6/30/2007	Additions FY08	Payments FY08	Adjustments FY08	Award Commitments at 6/30/2008
<b>International Program</b>						
The Delhi Policy Group	230,000	75,200		75,200		-
WINS	500,000	426,303		124,611		301,692
Cooperative Threat Reduction in East Asia - CSIS	85,000	14,498		10,607		3,891
International Atomic Energy Agency (IAEA)	390,000	195,000		195,000		-
ISKRAN	2,000		2,000	-		2,000
Nuclear Security Project	3,000,000		3,000,000	1,099,962		1,900,038
Institute of Peace and Conflict Studies	184,000	92,000		92,000		-
Carnegie Endowment for International Peace	50,000	50,000		50,000		-
WINS Founding Grant	3,000,000		3,000,000	-		3,000,000
US-Russian Nonproliferation Working Group (Belfer Center)	250,000		250,000	-		250,000
<b>Total for International Program</b>	<b>7,691,000</b>	<b>853,001</b>	<b>6,252,000</b>	<b>1,647,381</b>	<b>-</b>	<b>5,457,620</b>
<b>Russia/NIS Program</b>						
Preparing to Double the Blend down Rate of HEU in Russia	2,000,000	84,571		-	(22,201)	106,772
down	1,000,000	303,467		204,502		98,965
Consolidating and Blending Down HEU in Kazakhstan	2,000,000	210,453		13,385		197,068
Supporting Conversion of the Alatau Research Reactor	1,600,000	1,595,726		71,046		1,524,680
Project Development for Russian Research Reactor Strategic	32,000	10,796		7,925		2,871
Sarov Labs	450,000	11,430		(6,004)		17,434
Bochvar All-Russia Research Institute	500,000	500,000		-	500,000	-
Russian Research Reactor Master Plan	1,000,000	996,642		318,714		677,928
PIR Center	227,100	227,100		227,100		-
Nuclear Nonproliferation Workshop	150,000		150,000	-		150,000
<b>Total for Russia/NIS Program</b>	<b>8,959,100</b>	<b>3,940,185</b>	<b>150,000</b>	<b>836,668</b>	<b>477,799</b>	<b>2,775,718</b>
<b>Board of Directors Meetings</b>						
FY 07 (July 1, 2006 - June 30, 2007)	230,000	31,770		-	31,770	-
FY 08 (July 1, 2007 - June 30, 2008)	250,000	250,000		240,271		9,729
FY09 (July 1, 2008 - June 30, 2009)	250,000		250,000	-		250,000
<b>Total for Board of Directors Meetings</b>	<b>730,000</b>	<b>281,770</b>	<b>250,000</b>	<b>240,271</b>	<b>31,770</b>	<b>259,729</b>
<b>Total Award Cash Commitments</b>	<b>35,693,617</b>	<b>9,531,241</b>	<b>12,624,004</b>	<b>6,627,120</b>	<b>538,069</b>	<b>14,990,055</b>

Nuclear Threat Initiative, Inc.  
990 PF (FY08)  
Part VII-B

Statement 25

Line 5 (c) - Grants where Expenditure Responsibility Exists

Name and Address of Grantee	Date of Grant	Amount	Purpose of Grant	Amounts Expended	Diversion of Funds?	Date latest Report Received	Date and Results of Verification
Sarov Labs Varlamovskoye Shosse 23/16, Sarov, Nizhegorodskaya Russia 607 190	4/1/2005	\$ 424,731	To assist Sarov Labs in becoming a self-sustaining, commercial contract research organization that employs former weapons scientists by contributing to the cost of project management and marketing support.	418,816	No	5/29/08 (Final report)	6/4/2008 Satisfactory
Newly Formed Corporation of Former Employees of State Research Center for Applied Microbiology (SRCAM) 2, Kurchatov Square Moscow, 123182 Russia	3/24/2006	\$ 400,000	To support the establishment of a laboratory for the production of enzymes used in the diagnosis of endemic infectious disease threats. The laboratory will employ former bioweapons scientists who are in imminent risk of unemployment owing to proposed closure of the State Research Center for Applied Microbiology (SRCAM) at Obolensk, Moscow Region	400,000	No	8/31/2008	6/4/2008 Satisfactory
The Academy of Scientific Research and Technology 101 Kasr El Ainy Street Cairo, Egypt	3/8/2007	\$ 69,192	To create a regional reference clinical immunological laboratory for diagnosis of Viral Hepatitis leveraging the restructuring of FSU Biodefense Institute.	57,660	No	9/18/2007	n/a
State Research Center of Virology and Biotechnology (VECTOR) SRC VB Vecot Koltsova, 630559 Russia	2/16/2007	\$ 350,000	To create a regional reference clinical immunological laboratory for diagnosis of Viral Hepatitis leveraging the restructuring of FSU Biodefense Institute.	350,000	No	6/30/2008	6/4/2008 Satisfactory
Al-Quds University P.O. Box 51000, Abdel Hamad Shoman Street Beit Hanina	7/20/2007	\$ 138,300	Middle East Consortium on Infectious Disease Surveillance, (MECIDS), country support. To improve early disease detection and response to pandemic influenza and other food and water borne diseases within MECIDS countries.	44,987	No	10/23/2007 (Note: Grant is paid primarily on basis on invoices and supporting documentation)	5/3/2008 Satisfactory
Jordanian Ministry of Health P O Box 86, Jabal Al- Hussein Amman, Jordan, 11118	7/20/2007	\$ 138,300	Middle East Consortium on Infectious Disease Surveillance, (MECIDS), country support. To improve early disease detection and response to pandemic influenza and other food and water borne diseases within MECIDS countries.	72,450	No	5/7/2008 (Note: Grant is paid primarily on basis on invoices and supporting documentation)	5/3/2008 Satisfactory
Tel Aviv University Ramat Aviv Tel Aviv, 69978, Israel	7/20/2007	\$ 138,300	Middle East Consortium on Infectious Disease Surveillance, (MECIDS), country support. To improve early disease detection and response to pandemic influenza and other food and water borne diseases within MECIDS countries.	38,089	No	Outstanding (Note: Grant is paid primarily on basis on invoices and supporting documentation)	5/3/2008 Satisfactory
Mekong Basin Disease Surveillance Network Rajprachasamasai Building (No 8), 4th floor, Tiwanond Road Nonthaburi 11000 Thailand	5/15/2008	\$ 30,000	To assist in the deployment of Rapid Response Teams to post-cyclone Myanmar	30,000	No	Outstanding	6/11/08 Satisfactory
New Delhi Policy Group 246 Vasant Enclave, New Delhi New Delhi, 110057 India	9/30/2003	\$ 230,000	To promote responsible government policies and practices related to the safety and security of nuclear weapons and materials in India, by developing educational materials for policy makers and by facilitating meetings between nuclear experts in India and other nations.	230,000	No	10/2007	3/24/2008 Satisfactory
Institute of Peace and Conflict Studies C 1/4 Vasant Vihar New Delhi, 110057 India	2/2/2007	\$ 184,000	To continue a WMD module on the Institute of Peace and Conflict Studies website, that draws from South Asian, Chinese and Central Asian sources and provides comprehensive news analysis and reference materials relating to nuclear, chemical and biological weapons and to support research, workshops and publications on nonproliferation, and nuclear, biological and chemical threats	184,000	No	3/31/2008	3/24/2008 Satisfactory




**IFTI**

**ANNEX I Part I**  
**to the AGREEMENT**  
between  
the International Foundation of Technology  
and Investment (IFTI)  
and the Nuclear Threat Initiative, Inc.  
№ RU/55229907/00012  
of December, 31, 2002  
and as amended December 31, 2005

**Working Schedule of the Project**

**“Establishing a regional reference laboratory for PCR diagnostics of  
viral Hepatitis at the facilities of FSRI SRC VB VECTOR”**

**THE PROJECT № 00012/00049**

On behalf of the Performer/Grantee	Director General		/I.G. Drozdov /
"Is authorized" On behalf of the Foundation	Director		/Y. Cherches/
"Is approved" On behalf of the Partner	President & COO		/Charles B. Curtis/



## SUMMARY PROJECT INFORMATION

## 1. Project title

<b>Full Title: Establishing a regional reference laboratory for PCR diagnostics of viral Hepatitis at the facilities of FSRI SRC VB VECTOR</b>
--

## 2. Project Manager

Name, first name, patronymic: Netesov, Sergei Victorovich		
Address:	Building, street: n/a	City: Koltsovo
Region: Novosibirsk	State: Russia	Zip code: 630559
Phone: +7-(383)-336-73-27	Fax: +7-(383)-336-74-09	E-mail: netesov@vector.nsc.ru

## 3. Participating Organizations

Name: Federal State Research Institution - State Research Center of Virology and Biotechnology VECTOR		
Address:	Building, street: n/a	City: Koltsovo
Region: Novosibirsk	Zip code: 630559	Website: www.vector.nsc.ru
Full Name of the Head of Organization: Drozdov Ilyia Guennadicvich		
Phone: +7-(383)-336-60-10	Fax: +7-(383)-336-74-09	E-mail: drozdov@vector.nsc.ru
Ministry (Department): Federal Service for Surveillance on Consumer Rights Protection and Human Well-being (a.k.a. Rospotrebnadzor), Ministry of Health and Social Development		

## 4. Project Duration

Project duration (months): 24
-------------------------------

## 5. Project Budget

## 5.1 Budget Costs of the Project

Estimated total cost of the project (US\$)	\$325,500.00
Including:	
Payments to Individual Participants	\$99,500.00
Equipment	\$110,500.00
Materials	\$60,500.00
Other Direct Costs	\$21,500.00
Travel	\$23,500.00
Overhead	\$10,000.00

## 6. Project Summary

As a result of the Project, a reference laboratory will be set up at the facilities of FSRI SRC VB VECTOR that will meet all national and international requirements and regulations for diagnostic work involving the use of molecular biological methods. Namely, it will have an optimum layout, necessary equipment, and highly skilled and trained personnel. The major requirement to the establishment of such a laboratory is strict adherence to GLP (Good Laboratory Practises) principles and rules in setting up diagnostic activities. The reference laboratory will, first of all, perform diagnostic and monitoring functions. In the long run, the reference laboratory will also be capable of assuming the role of an educational and training center for personnel at medical institutions in Siberia involved in molecular diagnostics activities.

According to the declared functions, the reference laboratory will fulfill the following tasks: conduct of on-line accurate and valid polymerase chain reaction diagnostics, including detection, typing and epidemiology studies of agents causing viral hepatitis A, B, C, D, E, G (HAV, HBV, HCV, HDV, HEV, HGV), and in the future other infections as well, in samples from patients at medical institutions, volunteers, and blood donors in Novosibirsk and in other locations in Siberia; if necessary, confirmation of the validity of results obtained in other laboratories of the Siberian Federal District; promotion, to the extent possible, of professional development and optimization of diagnostic activities in other similar laboratories in Siberia; and expansion of the introduction of molecular diagnostics techniques into current medical practice.

## PROJECT DESCRIPTION

## 1. Project Title

<b>Full Title:</b> Establishing a regional reference laboratory for PCR diagnostics of viral Hepatitis at the facilities of FSRI SRC VB VECTOR ("VECTOR")
---

## 2. Project Manager

Name, first name, patronymic: Netesov Sergei Victorovich		
Address:	Building, street: n/a	City: Koltsovo
Region: Novosibirsk	State: Russia	Zip code: 630559
Phone: +7-(383)-336-73-27	Fax: +7-(383)-336-74-09	E-mail: netesov@vector.nsc.ru

## 3. Participating Organizations

Name: Federal State Research Institution - State Research Center of Virology and Biotechnology VECTOR		
Address:	Building, street: n/a	City: Koltsovo
Region: Novosibirsk	Zip code: 630559	Website: www.vector.nsc.ru
Full Name of the Head of Organization: Drozdov Ilyia Guennadievich		
Phone: +7-(383)-336-60-10	Fax: +7-(383)-336-74-09	E-mail: drozdov@vector.nsc.ru
Ministry (Department): Federal Service for Surveillance on Consumer Rights Protection and Human Well-being (a.k.a. Rospotrebnadzor), Ministry of Health and Social Development		

## 4. Project Duration

Project duration (months): 24
-------------------------------

## 5. Technical description of Project stages

## 5.1. Stage 1. Logistical Support for Work Conducted by Reference Laboratory

Molecular biological work under the Project will be carried out at the facilities of an existing, specialized laboratory ("Existing Laboratory") of the Department of Molecular Virology of Flaviviruses and Viral Hepatitides, located on the 3<sup>rd</sup> floor of Building I at VECTOR. Architectural design and engineering facilities available at the Existing Laboratory meet the pathogenic biological BSL2-BSL3 agents work requirements as well as molecular diagnostics requirements, such as the principle of physical separation of activities (see paragraph 14.3.). The Existing Laboratory also has necessary research tools for diagnostic polymerase chain reaction ("PCR") analysis, including biosafety class II and III cabinets, amplifiers, bench-top and floor standing centrifuges (including refrigerated centrifuges), deep-freeze and household refrigerators, a gel electrophoresis video documenting system, an automatic DNA analyzer (sequencing machine), a fluorescence detector of amplification products, and other equipment used in molecular biology work, including means of decontamination. It should be noted, however, that the range of application of the Existing Laboratory's resources remains, for a number of reasons, limited. First, said equipment and facilities are used almost entirely for scientific research purposes, and, as a result, they do not allow processing of significant quantities of diagnostic samples. It is determined by not only the overcomplexity (and, thus, a maintenance burden) of equipment currently used for routine diagnostics, which it is not intended for, but also the fact that a significant amount of this equipment (including engineering equipment) was manufactured more than 10 years ago. Thus, it has significantly exhausted its service life. Moreover, given the current setup of the Existing Laboratory, some of the diagnostic assays currently in demand are difficult to accomplish, for instance, a precise quantitative determination of pathogen concentrations in a specimen under study. In addition, we are forced to use some of the Existing Laboratory facilities for different types of activities simultaneously, which is unacceptable in terms of PCR diagnostics.

It is also worth noting that providing the Existing Laboratory with costly disposable materials and reagents for diagnostic studies currently occurs through centralized supply to VECTOR divisions or by concluding contract research agreements with third-party organizations. This leads, as a rule, to insufficient provision of the Existing Laboratory's needs, which contributes significantly to an increased cost and time of conducting analysis for individual patients.

A significant part of the current logistical problems (materials and reagents) is resolved by using universal, commercially-available diagnostic kits. This approach, provided the satisfactory quality of these kits and their mandatory certification, allows one to facilitate and significantly reduce the price of PCR analysis procedures. In addition, professional application of standardized kits allows for reliably ensuring a

high degree of validity of the diagnostic results. At the moment, the use of licensed test kits in the Existing Laboratory is quite limited, basically because of logistical difficulties in organizing centralized supply of large batches of said products.

Given the above, it appears appropriate to conduct the following activities as a first step of the Project:

1. Purchase and installation of new specialized equipment for diagnostic purposes (see paragraph 9);
2. Refurbishment and engineering reequipment of additional specialized laboratory areas at the VECTOR facilities, namely facilities for electrophoresis detection and DNA sequencing as well as rooms for primary treatment, classification, and storage of samples;
3. Conclusion of service contracts with specialized organizations on all Existing Laboratory equipment, including maintenance/repair and upgrades of devices currently available;
4. Conclusion of a contract with a licensed manufacturer for the supply of a large batch of diagnostic PCR test kits on a long-term basis; and
5. Purchase of disposable materials and reagents required for diagnostic work and normal operation of the Existing Laboratory.

#### 5.2. Stage 2. Efficient Management of Diagnostic Activities

The productive performance of the reference laboratory to be established ("Reference Laboratory"), consisting in rapid and efficient analysis of a flow of diagnostic samples and delivery of valid and reproducible results, can be achieved only by strict adherence to GLP regulations and requirements, which involves (in this particular case) mandatory implementation of the following measures:

1. Development of standard operating procedures ("SOPs") for each stage of all kinds of PCR tests conducted by the Reference Laboratory as well as SOPs regulating the execution of the working and reporting documentation, with the follow-up monitoring of the Reference Laboratory staff's compliance with the SOP-prescribed procedures;
2. Continuous professional development of the Reference Laboratory personnel by training the staff at specialized courses in infectious disease diagnostics with the help of molecular biological methods and also having them trained at foreign organizations;
3. Periodic (at least once a year) participation of the Reference Laboratory in the available Russian and international programs of external quality control (EQC) of diagnostic laboratories;
4. Standardization and certification of available and newly acquired laboratory equipment with the involvement of licensed metrological service organizations.

An important requirement of the successful work under the Project is that management and staff of medical organizations in the Novosibirsk area and in other regions of Siberia become interested in what the Reference Laboratory is going to offer. With a view to involve public health workers in collaboration activities, it seems reasonable to arrange information events for physicians, such a series of seminars and site meetings with medical workers as well as thematic information news postings to persons concerned. In the future, this kind of work, if managed efficiently, will pave the way for creating a full-fledged training center at the Reference Laboratory's facilities that will perform educational functions.

### 6. Technical Schedule and Accountable Materials

Stage №	Stage start (Year, Month)	Stage finish (Year, Month)	Description of accountable materials	
1. Logistical Support for Work Conducted by Reference Laboratory:	Quarter 1	Quarter 8	Annual and quarterly reports, Final Report	
	• Equipment procurement	Quarter 1		Quarter 6
	• Conclusion of agreements on after-sales service of equipment	Quarter 1		Quarter 6
	• Refurbishment of rooms designated for electrophoretic detection and sequencing as well as rooms used for initial treatment, sorting and storage of samples	Quarter 1		Quarter 4
	• Purchase of disposable materials and reagents	Quarter 1		Quarter 8
	• Purchase of diagnostic PCR test kits	Quarter 1		Quarter 8
	Quarter 4	Quarter 8		



<ul style="list-style-type: none"> <li>Conduct of PCR diagnostics of clinical samples</li> </ul>			
<b>2 Efficient Management of Diagnostic Activities:</b> <ul style="list-style-type: none"> <li>Development of SOPs</li> <li>Training of staff through education courses in infectious disease diagnostics</li> <li>Internship training at foreign institutions</li> <li>Participation in EQC programs</li> <li>Standardization and certification of equipment</li> <li>Conduct of information and education support for medical workers in Novosibirsk</li> </ul>	Quarter 1 Quarter 1 Quarter 3  Quarter 3 Quarter 3 Quarter 3 Quarter 4	Quarter 8 Quarter 2 Quarter 6  Quarter 6 Quarter 8 Quarter 8 Quarter 8	Annual and quarterly reports, Final Report

### 7. Description of techniques in operation

<ol style="list-style-type: none"> <li>Extraction of nucleic acids by phenol extraction of lysate and/or selective reversible sorption on glass, in high-salt solutions.</li> <li>Reverse transcriptase.</li> <li>Polymerase chain reaction (including nested PCR).</li> <li>Real-time PCR.</li> <li>End-point analysis of amplification product.</li> <li>Electrophoresis in agarose and polyacrylamide gels (analytical and preparative).</li> <li>Extraction of specific amplification product by passive and electro-elution with subsequent purification by phenol extraction and/ or glass sorption.</li> <li>Identification of nucleotide DNA sequence with the help of modified Sanger's method, using an automated sequencing machine.</li> <li>Analysis of determined nucleotides sequences for the purpose of genotyping, identification of genetic relation to previously identified isolates, discovery of clinically and epidemiologically relevant mutations in genomes of pathogenic microorganisms.</li> </ol>
---

### 8. Project budget

Payments to Individual Participants	\$99,500.00
Equipment	\$110,500.00
Materials	\$61,000.00
Other Direct Costs	\$21,500.00
Travel	\$23,500.00*
Overhead	\$10,000.00
<b>Total</b>	<b>\$325,500.00</b>

\*In case additional funding is available for United States ("US") lab-based training for Vector experts, up to \$10,000.00 out of \$23,500.00 might be spent by Partner's personnel for one or two trips to related US labs to establish such a training program.

### 9. Equipment

#### Equipment for Leading Organization

Name	Cost, US\$	Delivery Time, Quarter №
1. Biosafety Class II Cabinet (SterilGARD III Advance, Baker Co.)	\$13,000.00	Quarter 1-8
2. Amplifier capable of real-time detection of specific amplification product (RotorGene, Corbett Research)	\$51,000.00	Quarter 1-8
3. Multi-block amplifier (Eppendorf ep)	\$16,000.00	Quarter 1-8
4. Low-temperature freezer (-80°C) (Sanyo)	\$16,500.00	Quarter 1-8
5. Household refrigerators (2-8°C and -20°C)	\$1,800.00	Quarter 1-8
6. Electrophoretic detection system	\$4,000.00	Quarter 1-8
7. Office equipment	\$5,200.00	Quarter 1-8
8. Furniture	\$3,000.00	Quarter 1-8

## 10. Materials

Name	Amount	Cost, US\$	Delivery Time, Quarter №
1. Reagents for nucleic acid purification		\$4,000.00	Quarter 1-8
2. Reagents for reverse transcriptase and PCR		\$3,500.00	Quarter 1-8
3. Reagents for electrophoretic DNA detection		\$1,500.00	Quarter 1-8
4. Reagents for identification of nucleotide DNA sequence		\$10,500.00	Quarter 1-8
5. Kits for PCR diagnostics of infectious agents (AmpliSense, Central Research Institute of Epidemiology, Moscow)		\$21,500.00	Quarter 1-8
6. Biological sampling tools		\$3,000.00	Quarter 1-8
7. Laboratory plasticware (0.2-ml, 0.5-ml and 1.5-ml plastic tubes, tips for 10-ml, 200-ml and 1000-ml tubes with and without aerosol barriers)		\$4,000.00	Quarter 1-8
8. Work clothes and personal protection equipment		\$3,000.00	Quarter 1-8
9. Workplace support equipment (mini-centrifuges, bench-top constant-temperature cabinets, vortexes, pumps, automatic pipettes)		\$7,500.00	Quarter 1-8
10. Disinfectants		\$1,000.00	Quarter 1-8
11. Office supplies		\$1,500.00	Quarter 1-8

## 11. Personnel Participation in the Project Commitments ("Individual Participants")

Name	Birth year	Position	Function	Daily rate (US\$)	Total days	Total grants (US\$)
1. Akulov Andrei Aleksandrovich	1963		Car Driver	\$20.00	100	\$2,000.00
2. Bayandin Roman Borisovich	1978		Diagnostics	\$25.00	80	\$2,000.00
3. Bogryantseva Marina Polikarpovna	1947		Quality Control	\$30.00	30	\$900.00
4. Bondarenko Tatiana Yurievna	1962		Diagnostics	\$25.00	100	\$2,500.00
5. Gorbunov Yuri Anatolievich	1954	PhD	Oligonucleotides Synthesis	\$25.00	40	\$1,000.00
6. Grazhdantseva Antonina Anatolievna	1958	PhD	SOPs and Reports Development	\$30.00	75	\$2,250.00
7. Drozdov Ilya Gennadievich	1953	Dr. of Medicine, Prof.	Scientific Consultant	\$35.00	100	\$3,500.00
8. Ivanova Alla Vladimirovna	1961		Sequencing Assistance	\$20.00	60	\$1,200.00
9. Kaverina Galina Borisovna	1971		Laboratory Assistant	\$20.00	150	\$3,000.00
10. Karpysheva Natalia Nikolayevna	1952		Accountant	\$25.00	80	\$2,000.00
11. Kartseva Lyudmila Aleksandrovna	1958		Supplier	\$20.00	100	\$2,000.00
12. Kisurina Maria Ivanovna	1953		Science Studies Coordinator	\$30.00	70	\$2,100.00
13. Kichapin Victor Ivanovich	1955		Supplier	\$25.00	70	\$1,750.00
14. Kochneva Galina Vadimovna	1957	PhD	SOPs and Reports Development	\$30.00	110	\$3,300.00
15. Kurcheiko Lyudmila Ivanovna	1950		Laboratory Assistant	\$20.00	100	\$2,000.00
16. Larkina Lyudmila	1956		Supplier	\$20.00	30	\$600.00

Aleksandrovna						
17. Loktev Valeriy Borisovich	1952	Dr. of Science, Prof	Bioethical Coordinator	\$30.00	50	\$1,500.00
18. Manuilov Victor Aleksandrovich	1980		Deputy Manager, Diagnostics	\$30.00	300	\$9,000.00
19. Netesov Sergei Victorovich	1953	Dr. of Science, Prof.	Project Manager	\$35.00	300	\$10,500.00
20. Netesova Irina Grigorievna	1956	PhD	SOPs and Reports Development, Quality Control	\$30.00	100	\$3,000.00
21. Plyasunova Irina Victorovna	1975		Diagnostics	\$25.00	240	\$6,000.00
22. Pokhodniya Svetlana Alekseyevna	1967		Laboratory Assistant	\$20.00	220	\$4,400.00
23. Sivolobova Galina Filippovna	1947	PhD	SOPs and Reports Development	\$30.00	75	\$2,250.00
24. Stavskiy Evgeniy Aleksandrovich	1952		Biological Security	\$30.00	30	\$900.00
25. Temovoy Vladimir Aleksandrovich	1961	PhD	Diagnostics	\$30.00	300	\$9,000.00
26. Chausov Evgeniy Vladimirovich	1983		Sequencing	\$25.00	240	\$6,000.00
27. Chertkova Tatiana Fedorovna	1954		Custom Coordinator	\$25.00	70	\$1,750.00
28. Ryabenko Vladimir Victorovich	1970		Translator	\$30.00	70	\$2,100.00
29. Chub Elena Vladimirovna	1976		Diagnostics	\$30.00	300	\$9,000.00
Support personnel	-	-	-	\$20.00	100	\$2,000.00
					<b>Total:</b>	<b>\$99,500.00</b>

## 12. Intellectual Property

### 12.1. The objects of intellectual property, know-how included, utilized in the Project.

In the course of the Project implementation, the following objects of intellectual property ("Intellectual Property") will be involved, newly developed or utilized: composition of reagents included in commercially available or newly developed (by the Project Team) diagnostics kits and other test and reagent kits; nucleotide sequences of oligonucleotides (primers and fluorescent probes) described in professional literature and protected in accordance with the legislation of the Russian Federation (hereinafter referred to as "Russia" or "RF"); procedures of management of various types of activities conducted by the Reference Laboratory; SOPs ) for different stages of analysis performed; model reporting; and working documentation.

Any training and/or educational programs developed by the Project Team, including a series of lectures, education and laboratory training programs, or printed or electronic information, will be subject to copyright protection if these are utilized in the course of or upon completion of the Project. In using educational and other materials provided by a third party, Grantee guarantees that the use of such materials will be strictly for non-commercial purposes in compliance with copyright belonging to such third parties.

If Grantee participates in developing an EQC program as well as approaches to verify results produced by diagnostic laboratories as part of this Project, the copyright to said programs and relevant documentation shall vest in Grantee.

### 12.2. Legal relationships

The rights to the Intellectual Property, arising in the course of the Project implementation, are regulated by the laws of the RF. Notwithstanding the foregoing, Grantee represents that it will hold the copyright to, and will otherwise own, all materials resulting from the Project. It is understood and agreed that Partner does not wish to receive from Grantee any confidential or sensitive information or State,

commercial or trade secrets (the "Confidential Information") of the RF, Grantee or of any third party, Grantee represents and warrants that any information provided to Foundation, Partner or any third party (other than authorized Russian representatives, agents, agencies or instrumentalities) in the course of entering into this Agreement or performing any activities hereunder, including, without limitation, such information as shall be contained in the reports to be delivered under this Agreement, shall not contain or constitute Confidential Information. All Confidential Information received, gathered or generated by or on behalf of Grantee in connection with the Project shall in all instances be treated as strictly confidential by Grantee, and Grantee shall neither use nor disclose to third parties any Confidential Information whatsoever, except as necessary to authorized Russian representatives, agents, agencies or instrumentalities in order to perform activities under this Agreement. Grantee shall be responsible for ensuring the strict compliance of Grantee's employees, personnel, representatives, agents, contractors, subcontractors and any Individual Participants (collectively, the "IP") with the terms of this Section 12.2.

### 13. Monitoring and Auditing

Grantee will provide the Foundation and Partner the right of access to carry out monitoring on the Project site and audit of all activities of the Project.

### 14. Scientific and Engineering Content of the Project

#### 14.1 Rationale for Establishing Reference Laboratory

According to one estimate, more than 170 million people in the world are chronically infected with HCV and twice as many -- with HBV [3]. It is four times more than the total number of HIV-infected individuals. Viral hepatitis are one of the challenges to modern public health in the FSU countries, especially in the Asian part of Russia and in the Central Asia CIS countries. National monitoring data on all kinds of hepatitis in Asian Russia and in the Central Asia Republics shows that the number of cases varies from 110 up to 256 per 100000 [4]. An insufficient level of the study of the etiology and certain risk factors of transmission of these diseases limit the use of available data for development and evaluation of prevention measures.

Modern approaches to studying the prevalence and frequency of occurrence of viral hepatitis as well as genotypes variety came into use in Russia just several years ago. Therefore, there are only a small number of publications describing virus isolates in the European and Central Asian part of Russia. According to data presented in these publications, the prevalence of HCV markers in the blood of clinically healthy individuals in European Russia and those in the Central Asia Republics of the former Soviet Union varies from 1.2 % in Moscow up to 5.3 % in Ashkhabad (Turkmenistan) [5, 6]. As to the level of incidence of acute hepatitis B and C in Russia, it is 3 to 5 times higher than in the USA, making 35 to 40 cases per 100,000 for hepatitis B and a bit less for hepatitis C [7, 8].

During its history, Russia has gathered rich experience in combating infectious diseases. However, during the last fifteen years it has been experiencing slow economic revival accompanied by a difficult economic situation in the country. One of the consequences of this period is the recession in the field of research and development, reduction in the financing of the public health system, and an increase in the incidence of most of infectious diseases. All this is aggravated by "brain drain" whereas the most talented researchers have been emigrating to abroad. As a result, the monitoring of the infectious disease situation has weakened.

In spite of the fact that the Soviet medical educational system brought up many talented researchers, in local hospitals and at laboratories at blood transfusion centers there is a serious lack of specially trained professionals. In areas far from Moscow, there is almost no such thing as quality control of laboratory studies and, hence, the quality of diagnostic activities is quite low. A recent study of the main ways of transmission of parenteral viral hepatitis in Russia [1] has demonstrated that blood transfusion still remains one of the main causes of infection with parenteral hepatitis, along with intravenous drug abuse.

Currently in Russia, serology methods (EIA, immunoblot assay) are used for viral hepatitis diagnostics, according to the adopted regulations. These techniques, although relatively inexpensive and simple in use in terms of analysis, have a number of flaws such as the impossibility of detection of infection during the so-called "serologic window", i.e. during the period from the moment of infection contraction and until the first serological markers appear (which is of special importance in HCV infection characterized by a lengthy "serologic window"), which significantly complicates an early diagnosis of disease. Moreover, using EIA it is often difficult to recognize the etiology of disease, such as in diagnosing acute hepatitis. Therefore, etiotropic therapy has to be replaced by treatment for symptoms. It should also be noted that serology methods are indirect, i.e., as a rule, they do not allow seeing directly whether an

infectious agent is present in a sample under study (e.g. in HBV the degree of viremia is not directly connected with HbsAg levels in the blood).

Use of molecular biology techniques and, first of all, PCR for viral hepatitis diagnostics allows one to effectively solve the problems mentioned above. Moreover, various modifications of these methods can significantly increase the information value of the diagnostic test. In particular, the use of molecular biological methods allows one to quantitatively (real-time PCR) or semi-quantitatively measure viral loads, and to determine the nucleotide sequence of genomic fragments of a causative agent, which is of great importance for virus genotyping (with HCV, the belonging to one or another genotype is an important prognostic factor in a way that it determines the choice of a treatment strategy), discovery of mutations responsible for drug resistance, and studying epidemiological aspects of disease, such as study of virus transmission pathways, investigation of epidemiological history of outbreaks and infections, etc. Moreover, as is known, the PCR method displays a significantly higher diagnostic (and analytical) sensitivity and specificity, in comparison to conventional methods. Today, the molecular biological diagnostic methods are able to successfully supplement the generally accepted EIA methods, and, in increasing frequency, to assume the role of laboratory analytical methods of choice, in spite of their relatively high cost.

In spite of all the advantages of PCR diagnostics, it has not yet been widely adopted in the current system of public health in Russia. Molecular methods of diagnostics, with rare exception, find limited use in hospitals, polyclinics, or in laboratories located at blood transfusion stations (this situation is typical of not only viral hepatitis but also in case of diagnostics of other pathogens). There are several reasons for this, including without limitation: the considerable cost of equipment required; absence of skilled specialists (the agenda of laboratory doctor training at most Russian medical higher education establishments does not envisage hands-on experience training in molecular biology methods); the need for the allocation of a separate suite for a PCR laboratory; insufficient financing of public health institutions; and also the relative complexity and high cost (until recently) of testing (patients are cannot always afford to pay the tests). In addition, the domestic public health system prefers conventional proven methods to more advanced new techniques. All of these factors, against the background of unsatisfactory information distribution to physicians and insufficient regulatory framework for the operation of PCR laboratories, leads to merely incidental use of molecular biology methods in modern medical practice in Russia to date. Some laboratories, which are part of medical institutions and which use PCR for diagnostic purposes, often hire experts from the doctor staff who frequently do not have special training in molecular biology, nor have they the necessary skills, which results in a wrong work site arrangement, and, ultimately, in the generation of a lot of false results. Moreover, the procedure of biological samples collection and treatment at diagnostic laboratories at medical institutions is not strictly regulated and so sometimes it results in the cross-contamination of samples, which causes false-positive results (in case of a PCR laboratory this situation is sometimes considerably aggravated by the fact that inadequate preprocessing of samples and contamination of research samples by amplification products represent the main challenges to molecular diagnostics). In addition, the low efficiency of diagnostics at some of these laboratories usually remains unnoticed for a long time since the system of external quality control of PCR laboratory operations in Russia is just coming into being. All of the aforesaid have prompted the development of the Project proposal on the establishment of the Reference Laboratory at VECTOR. The Reference Laboratory will be capable of not only effectively applying molecular methods in viral hepatitis diagnostics (and diagnostics of other infectious diseases) but also, if necessary, verifying results produced by other laboratories (including verification of EIA results by means of molecular methods), which in turn will advance the ultimate goal of enhancing the overall quality of diagnostic studies performed in the Siberian region.

#### 14.2 Objectives of the Project:

1. Establishment of the Reference Laboratory meeting all necessary requirements and being capable of as much effective diagnostics of agents causing viral hepatitis, with the help of molecular biology method, as possible;
2. Ensuring the Reference Laboratory's preparedness for diagnostic work on other infectious diseases;
3. Involvement of VECTOR researchers in solving practical public health problems of current importance; and
4. Contributing, to the extent possible, to introducing molecular diagnostics methods into routine medical practice at public health institutions in Novosibirsk.

#### 14.3 Capabilities of VECTOR

During the past several years, VECTOR has been purposefully reshaping its activity portfolio,

combining scientific research with implementing practical tasks for the needs of public health. In its heyday from 1985 to 1990, it was one of the largest research and biotechnology centers of the USSR, employing more than 4500 scientific, technical, and administrative personnel. In spite of the fact that the field of science, which VECTOR is involved in, remains so far underfunded by the government and almost not supported by private foundations, VECTOR has continued pursuing high quality scientific research in such areas as research on viral hemorrhagic fevers, development of antivirals, diagnostic products, and vaccines, and research on the next generation vaccines. In the 1990s, VECTOR launched research activities in the field of molecular epidemiology of virus infections (viral hepatitises, measles, mumps, hemorrhagic fever with renal syndrome, etc ) and tuberculosis that are significantly supported through international grants.

More than twelve (12) years ago, VECTOR commenced research in the field of viral hepatitises, which for the time being has led to numerous publications in the leading national and international journals and to development of a vaccine against hepatitis A and production technologies of diagnostic test kits for the markers of viral hepatitises A, B, C, D, and E. As a result, on the basis of these achievements, two large private Novosibirsk-based companies launched the manufacture and distribution of test kits. Currently these companies are in the list of the five top sellers on the Russian market. For developing these test kits, several scientists and experts of Russian scientific research institutes, including seven (7) representatives of VECTOR and its spin-offs, were awarded the Russian Government Prize in 1998. Manufacture of hepatitis A vaccine organized at VECTOR on the basis of technology developed in collaboration with M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitis, Russian Academy of Medical Science, is a unique enterprise in Russia, and it has been expanding from year to year.

About ten years ago, VECTOR (among which workers were the manager and most of the Applicant Team members) initiated a study of HCV and HBV isolates collected in various hospitals and blood transfusion stations in Novosibirsk. This research was partially financed by the Russian Ministry of Science and Technologies (currently, Ministry of Education and Science). Additional financing came from international science foundations, such as the Soros Foundation (ISF Grants NR-9000 and NR-9300 funded in 1994-1995), the International Science and Technology Center (NAS Project #883-97 and DHHS/BTEP Project #1637p), and from Sandia National Laboratories (via the US Civilian Research and Development Foundation, Grant Award # #RB0-893).

During the past seven (7) years, several national and international research projects in the field of viral hepatitises have been carried out at VECTOR in collaboration with the Division for Viral Hepatitis of the National Center for Infectious Diseases, Centers for Disease Control and Prevention ("CDC"), Yale University Medical School, North Carolina Medical School, and Sandia National Laboratories of the US Department of Energy. The largest of them is DHHS/BTEP-funded Project # 1637p that has been successfully completed. The objective of this project was studying the prevalence, etiology, risk factors, routes of infection and genotype diversity of viral hepatitises A, B, C, D, E, and G in the territories of three regions in the Asian part of the Russian Federation. The VECTOR researchers were implementing this project in collaboration with two Novosibirsk-based, one Irkutsk-based, and one Barnaul-based infectious disease clinics, and also together with the Regional Centers of Sanitary and Epidemiological Surveillance in those three regions. The project employed modern diagnostic and epidemiological methods, including the most advanced modifications of RT-PCR and sequencing. This became possible thanks to intense teamwork of the Collaborators at CDC and the research team at VECTOR. In 1997 and 2003, the collaborators from the United States visited VECTOR and provided valuable comments regarding technical re-equipment of the laboratory facilities at VECTOR, training of several VECTOR scientists in state-of-the-art molecular biological and epidemiological techniques, and since then they have continued providing advice to VECTOR scientists on similar research activities pursued by VECTOR.

On repeated occasions, our research results were presented to regional and national authorities. They were considered as one of the major arguments for implementing a regional program of immunization of health workers and teenagers against hepatitis B.

The main results in the field of viral hepatitis research obtained by VECTOR scientists during the last ten (10) years (in cooperation with other institutions, including foreign organizations) have been published in twenty-one (21) articles in Russian and international journals and presented in thirty-six (36) abstracts at national and international conferences.

The aforesaid demonstrates the expertise available at VECTOR in issues dealing with research on viral hepatitises. On a separate note, it is necessary to comment on VECTOR's preparedness for activities to be conducted under the Project.

The molecular biology part of work under the Project will be mainly conducted at the facilities located on the 3<sup>rd</sup> floor of Laboratory Building 1 at VECTOR (rooms 301, 304, 305, 306, 307, 308, 310,

311, 346, 347, 200). This building is one of VECTOR's major research facilities. Building 1 represents a six-storied facility designed as a BSL-2 - BSL-3 laboratory with some elements of BSL-4. The building is intended for conducting research on viruses of BSL-2 - BSL-4 risk groups, according to international classification (or risk groups I to III, according to Russian national classification). By design, the building is divided into two zones isolated from each other: a so-called "hot" (high containment) zone, in which facilities research on infectious material is conducted, and a "cold" zone (non-containment) intended for other types of work.

The Existing laboratory, which is currently operating at VECTOR and involved in PCR diagnostics of viral hepatitis (hereinafter referred to as Laboratory), organizationally relates to the Department of Molecular Virology of Flaviviruses and Viral Hepatitis. It has minimum required equipment allowing all stages of PCR analysis (purification of nucleic acids, amplification, and detection). The Existing Laboratory has an automatic high-throughput sequencing machine to determine nucleotide DNA sequences.

The Existing Laboratory has gained extensive experience in diagnostic studies. The Existing Laboratory's practices and operations are arranged in a way that allows minimizing the risk of cross-contamination (by material under diagnostics) samples under study, as much as possible. The Existing Laboratory has gathered a systematized collection of blood samples obtained from patients with different viral hepatitis. Standard operating and reporting procedures have been developed. The Existing Laboratory's diagnostic operations undergo regular internal quality control/ assurance audits. Such facilities and equipment of this VECTOR unit are going to be involved in the Project activities. Some features of the Existing Laboratory's activities and suggestions on how to improve its efficacy as a result of the Project are described below.

Operations management at a PCR diagnostics laboratory should, on the one hand, comply with current biosafety requirements (because the work is done on material which is considered to be potentially contagious). On the other hand, the specificity of molecular biological procedures imposes its own limitations on the Existing Laboratory's activities (due to the risk of contamination of samples, reagents, and work surfaces with amplification products). The Existing Laboratory's facilities at VECTOR and the diagnostic and material flow procedures are in full compliance with the above requirements. For instance, the principle of physical separation of work is efficiently organized (i.e. low-copy DNA procedures are conducted separately from high-copy DNA procedures). To implement this principle, the Existing Laboratory's areas were divided into so-called pre-PCR rooms, i.e. areas where primary treatment of incoming material is performed as well as isolation of nucleic acids and conducting of reverse transcriptase reactions (in case of RNA viruses) and PCR, and post-PCR rooms where amplification products detection is carried out as well as procedures dealing with DNA sequence identification. The pre-PCR and post-PCR rooms are totally isolated from each other. Equipment, disposables, reagents, and working clothes are assigned to their respective pre-PCR or post-PCR rooms and are not removed from these.

The work with infectious material and nucleic acids extracted (before the amplification stage) is conducted in the Existing Laboratory's specially equipped BSL-3 facilities located in the "hot" zone (according to Russian biosafety regulations, HCV is classified in Russia as a BSL-3 risk pathogen, and HBV, HAV, HEV are BSL-2 pathogens). These areas are hermetically sealed from other rooms of the building and from the outer environment. The air supply and exhaust ventilation available in these facilities provides inside pressure which is negative in comparison to the atmospheric pressure. This area of the Existing Laboratory has equipment dedicated to the initial stages of PCR analysis, such as two Biosafety Class II Cabinets (the one is Gelair ET-124 dedicated to sorting and initial treatment of infectious material; the other is Baker SterilGARD III Advance dedicated to the extraction of nucleic acids and conducting of the reverse transcriptase reaction), a Holton PCR cabinet (a mini biosafety class III cabinet dedicated to mixing the PCR composition), an Eppendorf Mastercycler gradient amplifier, an Eppendorf 5415D microcentrifuge, a refrigerated Beckman J2-21 centrifuge with a rotor for Eppendorf 1.5-ml tubes, vortexes, membrane pumps, constant-temperature cabinets, individual kits of automatic pipettes for each work place, holders, tanks for collection and disposal of infectious and non-infectious material, etc. These facilities are also housing refrigerators for 2-8°C (for storage of reagents), and for (-20)°C and (-80)°C (for storage of samples and nucleic acids extracted). It should be noted, however, that much of said equipment has been operated for quite a while, i.e. it is not new. Thus, it requires either repair or replacement of component parts. The lack of funding results in the lack of regular servicing. Due to expired service life or hardware constraints, many of the devices cannot be certified for use in diagnostic operations. Moreover, currently almost all equipment available at the Existing Laboratory is used for scientific research purposes and so, functionally, it is not intended for diagnostic activities that are, as a rule, associated with an increased workload on such research equipment.

In areas designated for work with purified nucleic acids, a separate set of working clothes and personal protection equipment, which must not be removed from the "hot" zone, is used. All the procedures are conducted using disposable laboratory plasticware (tubes), aerosol barrier pipette tips, and rubber gloves (all of this is used only one time, i.e. never reused). The facilities are equipped with both fixed-site and portable UV-irradiators. The staff involved in the above stages of PCR analysis have no contact with material containing amplification products, i.e. they are not doing electrophoretic detection.

To be able to conduct high quality quantitative diagnostic studies using real-time PCR in the available pre-PCR rooms of the Existing Laboratory, the Project will involve installation of appropriate equipment (RotorGene, Corbett Research) connected to the institutional local area network. Use of quantitative diagnostic techniques in routine infectious disease diagnostics will make it possible to significantly improve patients surveillance, in particular, to measure single viral loads and to conduct therapy response monitoring at certain time intervals (which is of special importance in case of HBV and HCV).

In implementing the Project, the pre-PCR rooms designated for initial treatment (sorting, serum separation, and packaging) of blood samples and other biological materials will be equipped as appropriate. These rooms (where no work is being done at the moment) will be refurbished and they receive equipment necessary for implementing the above tasks, such as a biosafety class II cabinet, a microcentrifuge, a centrifuge for Vacutainers (i.e. 11-14-ml tubes), refrigerators for (2-8)<sup>o</sup>C and for (-20)<sup>o</sup>C (for reagents storage), laboratory benches, and chairs. It is also necessary to equip a separate room in the "hot" area for keeping newly arrived specimens and maintaining a repository of research samples. This room will be refurbished, too, and it will receive a low-temperature freezer exclusively dedicated to temporary archival storage of samples. This approach will make it possible to conduct verification of previously obtained findings, in arguable cases. Using a computer in this room connected with other workstations in the Existing Laboratory via a local area network will contribute to efficient samples accounting, analytical data processing, and issuing diagnostic findings reports to patients. The facility renovation, including equipment upgrades, to be accomplished under the Project will allow implementation of not only Russian sanitary requirements but also of some of GLP requirements, which will advance the level of research quality at the Reference Laboratory to standards accepted in the developed countries of the world.

Detection of amplification products is carried out in the non-containment areas. These areas are equipped with an independent ventilation system separate from that installed in the high containment areas. The non-containment areas are separated from the high containment areas by a system of sealed doors (submarine-like doors) and airlocks, which precludes any exchange of air between these areas. Electrophoretic detection of the amplification products is performed by a dedicated worker (a laboratory assistant) who has no access to the high containment areas. Tubes with the amplicate are opened only in these rooms dedicated to detection work. For the purpose of electrophoresis and documentation of the findings, the Laboratory has chambers for vertical polyacrylamide gel electrophoresis, electrical power sources, a transilluminator (Vilber Lourmat TCP-20-MC), and a video documenting system (Gel Imager) connected to a computer via the local area network (therefore, no direct contact with the amplicate-containing gel is necessary to access the results of a diagnostic test), a separate automatic pipette kit, and laboratory plastic ware for preparing process solutions. A portable UV-irradiator is also available in this area.

As part of the Project activities, it is proposed to equip a new area for electrophoresis by relocating this PCR analysis stage from the 3<sup>rd</sup> floor to another area in the building (basement floor). This will allow avoiding contact between personnel involved in amplification products detection and those dealing with the initial treatment of samples and extraction of nucleic acids, which will even further reduce the risk of cross-contamination of the diagnostic samples. To this end, the replacement room will be renovated, fitted out with an independent ventilation system and necessary equipment (a transilluminator, a video documenting system, and electrophoresis chambers). It will also be connected to the institutional local area network.

Procedures dealing with nucleotide DNA sequencing are currently performed in a separate room in the non-containment area by a skilled professional in molecular biology. To carry out these tasks, the Existing Laboratory is equipped with an automated DNA analyzer (sequencer), Beckman CEQ2000 XL, an amplifier, Applied Biosystems GeneAmp 9700, a refrigerated centrifuge, Hermle Z233 MK-2, biosafety class III cabinet, refrigerators for (2-8)<sup>o</sup>C and (-20)<sup>o</sup>C, and a set of automatic pipettes.

The flow of diagnostic material within the Existing Laboratory is arranged in a way that clinical samples and materials containing amplification products never cross.

By now, fifteen (15) SOPs regulating various steps of PCR analysis for viral hepatitis have been developed and have now mandatory use at the Existing Laboratory. However, it is necessary to develop and



implement updated SOPs since the ones currently in use were developed about three years ago and intended mainly for governing research practices (e.g. some of the SOPs involve the use of quite complex molecular biological analysis procedures that are not routinely used).

To diagnose pathogens causing viral hepatitis (and other infectious agents), the Existing Laboratory is using commercially available test kits (reagent kits), AmpliSense Series, manufactured by FSRI Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow), employing the PCR technique. These kits are in compliance with all sine qua non requirements to PCR-based test kits. They have good ratings (high sensitivity and specificity) and are licensed for use in the RF, which is confirmed by appropriate registration certificates issued by the RF Ministry of Health and Social Development and the certificates of manufacture issued by L. A. Tarasevich State Institute of Standardization and Control on each test kit. The test kit is comprised of reagents embracing every PCR step: extraction of DNA/ RNA from different types of samples; conducting reverse transcriptase (for diagnostics of RNA viruses) to obtain cDNA; amplification of DNA or cDNA of an infectious agent in PCR, using pairs of specific primers; detection of amplification products by electrophoresis in polyacrylamide or agarose gel. DNA amplification with these test kits is conducted in one round, which significantly reduces the risk of research samples contamination. All test kits of the AmpliSense Series are provided with control samples (a positive, a negative, and an internal one) and detailed user's instructions. This provides the necessary level of standardization of all the procedures and, as a result, high confidence in diagnostic results. It is also worth noting the availability of this series of test kits designed for real-time PCR use. The AmpliSense test kits, though relatively inexpensive, have proved to be good in routine diagnostics of infectious diseases (including viral hepatitis) conducted at PCR laboratories at VECTOR and at other institutions. They will be used to support the diagnostics tasks of the Reference Laboratory that will be established as a result of the Project.

The Existing Laboratory's staff involved in the Project activities have higher university education in medicine, biology, chemistry, or specialized secondary education (laboratory assistants). They have great expertise in virology and molecular biology research on pathogens causing hepatitis and other diseases (with 4 to 20 years of experience). The staff involved in the diagnostic studies under this Project have the necessary, duly executed medical and competency permits to do work on material that may potentially contain BLS-2 or BSL-3 grade pathogens. Some of the employees have had hands-on research experience at foreign research institutions. Two team members possess state certificates of having taken courses in modern PCR diagnostics of infectious diseases conducted by FSRI Central Research Institute of Epidemiology in Moscow.

In spite of the available high professional level of specialists involved in the Project, their significant expertise in diagnostics work, and broad research skills, this Work Plan envisages further professional development for the Reference Laboratory staff, including rapid advances in molecular biology methods and technology and continuous development and introduction of increasingly novel diagnostic methods and tools into the world diagnostic practice, which determine the strictest training requirements to different types of personnel. To provide professional development of staff and exchange of experience with specialists of third-party institutions, the Project has a budget for:

- a) Three training trips of up to one month duration to foreign medical or scientific research institutions (in particular, Massachusetts General Hospital, USA);
- b) Training for an additional three (3) Project team members at the PCR diagnostics courses at FSRI Central Research Institute of Epidemiology;
- c) Participation in at least three (3) national level conferences in Russia.

On the whole, the level of capabilities and professional skill currently available at the Existing Laboratory is already high enough to permit it to perform the functions and tasks of the Reference Laboratory, which is confirmed by previously accomplished work dealing with viral hepatitis diagnostics (although it was more focused on scientific research than on practical healthcare needs). At the same time, a set of measures need to be taken to boost the performance of the Existing Laboratory. First, it must be technically re-equipped, and its equipment must be standardized. For instance, currently it is not possible to simultaneously conduct several tests for different infections due to the lack of work places (there is only one work place for each PCR analysis step). It seems reasonable, therefore, that at least one more work place be equipped to permit the extraction of nucleic acids, which is the longest, man-operated step of PCR analysis). In addition, it is necessary to purchase a multi-block amplifier in which each block operates independently because this will significantly accelerate the process of amplification in case different thermocycling programs are to be used for different infections. All this will significantly enhance the Existing Laboratory's ability to process diagnostic samples coming in.

#### 14.4 Involvement of Public Health Institutions

To permit more efficient performance of the Reference Laboratory, it is proposed to conduct the main diagnostic activities on a contractual basis with public health institutions in Novosibirsk and those in other cities and regions in Siberia rather than involve individuals (patients) interested in having an accurate diagnosis. This approach will allow:

- a) a desired volume of studies;
- b) an improvement in the quality of medical examination and treatment services at a number of hospitals and polyclinics in the Siberian region (i.e. this will be a direct practical outcome of the Reference Laboratory's work);
- c) gradual implementation of molecular diagnostics methods in day-to-day medical practice; and
- d) development of relationships between scientific research and medical institutions in Siberia.

VECTOR has extensive experience in providing contractual services (including diagnostic service) to health care institutions in the Siberian region (e.g., Municipal Infectious Diseases Clinical Hospital # 1 in Novosibirsk, Medical and Sanitary Unit # 163 in the Novosibirsk area, Novosibirsk Region AIDS Center, City Clinical Hospital # 5 in Barnaul, Municipal Infectious Diseases Clinical Hospital of Irkutsk City, Novosibirsk Branch of Sheining Plough, and several other organizations). Using Project funds to conclude agreements with said and other health care institutions on preferential terms will make the use of molecular diagnostics methods attractive to medical professionals and, in the long run, it will contribute to increased popularity of these techniques with the health care community. In addition, physicians directly involved in collaboration with the Reference Laboratory will gain a good understanding of the capabilities of molecular methods for the diagnosis of viral hepatitis (and other diseases), which will not only contribute to the overall professional improvement of medical workers but also lead to other important practical results, such as standardization of methods of collection and storage of samples for diagnostic studies.

Moreover, the involvement of medical workers in the project-related activities seems rational for the following reasons. Until now, collaborations between scientific research and medical institutions in Novosibirsk (although both kinds of institutions are quite numerous as compared to their numbers in the rest of the Siberian region) are lacking overall, despite positive recent in this area. Unfortunately, the local public health and sanitary-epidemiological surveillance communities have not been fully receptive to most of the medically oriented research conducted at scientific research institutions (including VECTOR). On the one hand, a collaborative long-term project, involving both scientists and medical workers, will make it possible to engage the VECTOR scientists in developing solutions to practical health problems. On the other hand, it will smooth the way for the future close collaborations between scientific research and medical institutions in the Novosibirsk area.

The aforesaid, in spite of obvious importance, emphasizes the main idea of a regional Reference Laboratory based upon the need for providing accurate diagnosis of patients undergoing medical examination or treatment at large medical care institutions in Novosibirsk. Solving this task will be one of the first most important practical results of the Reference Laboratory's activities.

It should be noted that the accomplishment of said objectives is only possible with the immaculate performance of the Reference Laboratory (which can be reached, first of all, by strict adherence to GLP requirements and procedures and by employing highly skilled personnel). As a result, it will help gain higher levels of confidence of medical practitioners and patients in molecular diagnostics methods, and, on the whole, in data generated as a result of PCR laboratory operations. The high quality work conducted by the Reference Laboratory is proposed to be promoted through briefings and seminars with interested medical professionals dedicated to general principles of molecular diagnostics studies and case studies at the example of practical tasks accomplished at the Reference Laboratory. Such seminars may lay the foundation of training and educational courses, including training in molecular biological principles and techniques as they apply to diagnostic studies. Pilot versions of such courses will be developed under this Project and implemented by distance education (by distributing the methods learning materials and questionnaires with subsequent processing of feedback data obtained). In addition, it is proposed to follow up on these activities by implementing programs of on-site quality assessment of diagnostic activities of participating organizations and individual medical workers, using reference sample panels available at the Laboratory's collection. The Project will provide only a portion of funds required for implementing said distance learning courses and programs. The main portion of funds will be earned by providing paid diagnostic services. In the future, experience gathered in implementing the proposed training programs may be used for the establishment of a full-fledged molecular diagnostics training center at the facilities of

## VECTOR.

## 14.5 Expected Results and Their Application

1. As a result of the Project, a state-of-the-art diagnostic Reference Laboratory in all of the Asian part of Russia will be established in Novosibirsk. This Reference Laboratory will be capable of conducting PCR analysis of agents causing viral hepatitis and related research using molecular biology methods, in compliance with all necessary requirements associated with this type of diagnostics work. As part of its activities, the Reference Laboratory will, inter alia, conduct routine diagnostics of hepatitis viruses A, B, C, E in samples obtained from patients at medical care institutions and from blood donors in Novosibirsk as well as from individuals interested in undergoing such analysis.
2. The Reference Laboratory will be able to, in the shortest possible time, reorient its capabilities towards the diagnostics of other pathogens, which is of special importance in the event of outbreaks or epidemics of various infectious diseases among the population of the Siberian Federal District as well as in the event of a suspected bioterrorist attack.
3. In the course of Project implementation, the highly skilled scientists and technicians at VECTOR (including those formerly involved in biodefense research activities) will be able to combine their basic and applied research with practical work in the interests of public health.
4. Implementing this Project will make it possible to heighten the interest of medical professionals in the use of molecular diagnostics methods in medical practice. In addition, the work of the Reference Laboratory, provided it is efficient enough, will promote the idea of PCR diagnostics among medical professionals and patients in Novosibirsk. Ultimately, it will contribute to the overall improvement in the quality of medical service in Novosibirsk and in other Siberian cities.

## 14.6 References

1. Shustov A.V., Kochneva G.V., Sivolobova G.F., Grazhdantseva A.A., Gavrilova I.V., Akinfeeva L.A., Rakova I.G., Aleshina M.V., Bukin V.N., Orlovskiy V.G., Bespalov V.S., Zelicoff A.P., Netesov S.V. The frequency of occurrence, genotype distribution and risk factors of hepatitis C among certain population groups in the Novosibirsk region. Zh. Microbiol. - 2004.- N5.- P.20-25. Russian.
2. Weekly Epidemiological Record. 1999. - V.74.- N49.-P.425. (10 December 1999). WHO.
3. Population Health and Environment. Monthly Informational Bulletin of the State Sanitary and Epidemiological Surveillance, Ministry of Public Health of the Russian Federation. No. 1 (22), 1995; No. 1 (34), 1996; No. 1 (46), 1997; No. 1 (58), 1998; No. 1 (70), 1999; No. 1 (82), 2000; No. 1 (94), 2001; No. 1 (106), 2002; No. 1 (118), 2003.
4. Yashina T.L., Shakhgildyan I.V. et al. Prevalence of viral hepatitis B and delta markers among the populations of regions contrast in terms of morbidity rates. Vopr. Virusol. - 1992.- N4.-P.194-196. Russian.
5. Kruglov I.V., Yashina T.L., Tsvetova G.V. et al. The prevalence of hepatitis B and C markers, the etiological structure of incidence of acute viral hepatitis in the population of Kuzbass and of north-west regions of Kazakhstan. Zh. Microbiol. - 1995.- N6.- P.36-37. Russian.
6. Somova A.V., Golosova T.V., Margolina A.N. et al. Serodiagnosis of viral hepatitis C and B in different population groups. Vopr. Virusol. -1992.- N4.-P.105-107. Russian.
7. Ohba K., Mizokami M., Kato T. et al. Seroprevalence of hepatitis B virus, hepatitis C virus and GB virus-C infections in Siberia.-Epidemiol. Infect.-1999.- V.122.- №1.- P.139-143.

## 15. Additional Information

15.1 Grantee shall be responsible for coordinating the work of, and ensuring the full and complete performance of and strict compliance with the terms and obligations of, this Agreement by the IP.

15.2 Technical documents, programs, processes and information created or developed within the framework of the present Project will neither be used for creation of WMD nor for any military purposes whatsoever.

15.3 Grantee shall observe and conform to, and cause its employees, agents, contractors and subcontractors, if any, and the IP to so observe and conform to, in all material respects, all laws, rules, regulations, orders and requirements of governmental authorities (including, without limitation, all applicable local, national and international laws and regulations) relating to the Project or to any materials, reports, technical documents or information created within the framework of the present Project and acknowledges that, when applicable, Grantee has the responsibility to obtain any licenses, or other authority as may be required, with respect to activities undertaken in connection with the Project.

15.4 It is anticipated that no materials, reports, programs, processes, or technical documents or information created, developed or compiled within the framework of the present Project, which are provided to Partner or Foundation, will be subject to any Russian customs and export laws, rules, regulations, orders or requirements, including, without limitation, the Russian law "On export control procedures" (collectively, "Russian Customs Requirements"). However, to the extent that any such Russian Customs Requirements may be deemed applicable, Grantee represents and warrants that all materials, reports, programs, processes, technical documents and information created within the framework of the present Project, which is provided to Partner or Foundation, will comply in all respects with all Russian Customs Requirements, and that compliance therewith will in no way diminish the contents or substance of the contemplated technical reports, information, programs, processes and materials. Grantee shall be liable for all legal and factual activities necessary to represent and warrant the aforementioned obligation.

15.5 Grantee agrees that it shall not involve as participants in the Project or otherwise use any Project funds to enter into transactions with entities listed pursuant to the U.S. Foreign Assets Control Regulations (31 Code of Federal Regulations Parts 500-599) as ineligible to participate in transactions, directly or indirectly, with U.S. organizations and persons. Partner calls Grantee's attention to the list of entities published in the Weapons of Mass Destruction Trade Control Regulations (31 Code of Federal Regulations 539; current list provided as Exhibit "A"). Grantee understands that the list may change from time to time. Prohibited transactions with the parties listed pursuant to the Weapons of Mass Destruction Trade Control Regulations and subject to this limitation include, without limitation: (i) procuring any goods, technology or services, or entering into any agreement for the procurement of any goods, technology or services from listed organizations; (ii) providing any assistance to or obligating funds for such purpose with listed organizations; or (iii) importing into the U.S. any goods, technology, or services produced or provided by listed organizations, any of the entities described in the above regulations or executive order. For entities listed pursuant to certain other Parts of the Foreign Assets Control Regulations (e.g., listed Foreign Terrorist Organizations) the prohibition covers all business transactions and funds transfers of any kind. The aforementioned prohibitions hereto apply to all forms of cooperation with organizations mentioned in the list attached hereto as Exhibit "A" and with organizations affiliated with said organizations.

15.6 Grantee agrees to immediately notify Partner, in writing, if Grantee has reason to believe that the Project funding cannot be or continue to be used for the specific purposes of the Project or in accordance with this Agreement.

15.7 All tasks to be performed by Grantee and IP in connection with the Project shall be performed and prepared in a timely, workmanlike manner and with professional diligence and skill in accordance with any and all safety requirements that may be applicable under Russian and international standards.

15.8 Grantee agrees that whenever travel must be undertaken by Grantee or IP in connection with the Project using any part of the funding provided by Partner hereunder, such travel shall be undertaken on an "economy" or "coach" basis and not include luxury, first class or business class travel or lodging costs.

15.9 In the case of any violation by Grantee of any of the provisions or conditions of this Agreement, Partner reserves the right in its absolute discretion to terminate this Agreement and pursue any remedies provided for in this Agreement or otherwise permitted by law for default. Partner's determination shall be final and shall be binding and conclusive upon Grantee and IP. Upon termination of this Agreement for any reason, Partner shall withhold any further Project funding and all unexpended funding and any portion of the funding, which was not spent for the Project (including, without limitation, Foundation management fees) shall be immediately returned to Partner.

15.10 The Parties hereto each acknowledge and agree that Partner has had no control over, has not supervised or participated in any aspect of the Project, and shall not supervise or participate in any aspect of the Project, including, without limitation, the planning, implementation, inspection or evaluation of the Project. Partner's role in connection with the Project and the planning thereof has been, is and shall at all times remain strictly to provide enabling funds. Any monitoring or periodic progress reviews conducted by or on behalf of Partner are only for the internal interests of Partner and to facilitate disbursement of the Project funding. Partner and its employees, agents and representatives/contractors shall not have, and shall not be deemed to have, any control over the actions of Grantee or IP, including, without limitation, any actions relating to the Project. Partner shall not be liable for any negligence or omission of Grantee or IP, any independent contractors or others or any condition or occurrence which Partner or its employee, agents or representatives/contractors may discover as a result of progress review or any other monitoring activities. Grantee acknowledges and agrees that Grantee and IP shall each independently conduct and rely upon their own planning, monitoring, inspections and safety regulation with respect to the Project and shall not be entitled to rely in any way on any advice or input from Partner or its employees, agents or representatives/contractors regarding the Project or otherwise. Notwithstanding anything contained herein to the contrary or in conflict, Grantee acknowledges and agrees that the extent of Partner's obligations and undertakings under this Agreement is solely to provide Project funding pursuant to the provisions and conditions contained in this Agreement, that Partner shall have no liability or obligations whatsoever with respect to the planning, implementation, inspection or evaluation of the Project and that Partner has no control whatsoever, directly or indirectly, over the Project or any aspect thereof.

**15.11 NTI SHALL HAVE NO LIABILITY FOR ANY SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY NATURE WHATSOEVER, HOWEVER CAUSED, EVEN IF NTI HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.**

## Exhibit "A"

## Selected Entities Subject to 31 Code of Federal Regulations Part 539 "WMD Trade Control Regulations" and Executive Order 13382

AEROSPACE INDUSTRIES ORGANIZATION (a.k.a. SAZMANE SANAYE HAVA FAZA, a.k.a. "AIO"), Langare Street, Nobonyad Square, Tehran, Iran [NPWMD]

ATOMIC ENERGY ORGANIZATION OF IRAN (a.k.a. SAZEMAN-E ENERGY ATOMI), P.O. Box 14144-1339, End of North Karegar Avenue, Tehran, Iran [NPWMD]

BANK SEPAH, Imam Khomeini Square P.O. Box 11364-9569, Tehran, Iran, all offices worldwide [NPWMD]

BANK SEPAH INTERNATIONAL PLC, 5-7 Eastcheap, London EC3M 1JT, United Kingdom [NPWMD]

BALTIC STATE TECHNICAL UNIVERSITY, wherever located, including 1/21, 1- ya Krasnoarmeiskaya Ul., 198005 St. Petersburg, Russia [63 FR 42089, July 30, 1998]

BEIJING ALITE TECHNOLOGIES CO., LTD. (a.k.a. ALCO; a.k.a. BEIJING HAILI LIANHE KEJI YOUXIAN GONGSI), 12A Beisanhuan Zhong Road, P.O. Box 3042, Beijing, China; and all other locations worldwide [NPWMD]

CHINA GREAT WALL INDUSTRY CORPORATION (a.k.a. CGWIC; a.k.a. ZHONGGUO CHANGCHENG GONGYE ZONGGONGSI), No. 30 Haidian Nanlu, Beijing, China; Moscow, Russia; and all other locations worldwide [NPWMD]

CHINA NEW ERA GROUP (a.k.a. China Xinshidai Company; a.k.a. New Era Group; a.k.a. XSD; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]

CHINA NATIONAL PRECISION MACHINERY IMPORT/EXPORT CORPORATION (a.k.a. CHINA NATIONAL PRECISION MACHINERY I/E CORP.; a.k.a. CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION; a.k.a. CPMIEC; a.k.a. ZHONGGUO JINGMI JIXIE JINCHUKOU ZONGGONGSI), No. 30 Haidian Nanlu, Beijing, China; and all other locations worldwide [NPWMD]

CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION (a.k.a. CPMIEC), wherever located [July 30, 2003]

CHINA XINSHIDAI COMPANY (a.k.a. China New Era Group; a.k.a. New Era Group; a.k.a. XSD; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]

CPMIEC (a.k.a. CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION), wherever located [July 30, 2003]

D. MENDELEYEV UNIVERSITY OF CHEMICAL TECHNOLOGY OF RUSSIA, wherever located, including 9 Miusskaya Sq., Moscow 125047, Russia [64 FR 2935, January 8, 1999]

DERAKHSHANDEH, AHMAD, c/o BANK SEPAH, No. 33 Hormozan Building, Pirozan St., Sharak Ghods, Tehran, Iran; DOB 11 Aug 1956; POB Iran (individual) [NPWMD]

ELECTRONICS INSTITUTE, P.O. Box 4470, Damascus, Syria [NPWMD]

FEDERAL RESEARCH AND PRODUCTION COMPLEX ALTAY, Russia [69 FR 67617-18, November 18, 2004]

G.W. AEROSPACE, INC. (a.k.a. GREAT WALL AEROSPACE, INC.), 21515 Hawthorne Blvd., Suite 670, Torrance, CA 90503; California Corporate Number C1458237 (United States) [NPWMD]

GLAVKOSMOS, wherever located, including 9 Krasnoiproletarskaya St., 103030 Moscow, Russia [63 FR 42089, July 30, 1998]

HESONG TRADING CORPORATION, Pyongyang, Korea, North [NPWMD]

HIGHER INSTITUTE OF APPLIED SCIENCE AND TECHNOLOGY (a.k.a. IIAST; a.k.a. INSTITUT DES SCIENCES APPLIQUEES ET DE TECHNOLOGIE; a.k.a. INSTITUT SUPERIEUR DES SCIENCES APPLIQUEES ET DE TECHNOLOGIE; a.k.a. ISAT; a.k.a. ISSAT), P.O. Box 31983, Barzeh, Damascus, Syria [NPWMD]

KOHAS AG, Route des Arsenaux 15, Fribourg, FR 1700, Switzerland; C.R. No. CH-217.0.135.719-4 (Switzerland) [NPWMD]

KOREA COMPLEX EQUIPMENT IMPORT CORPORATION, Rakwondong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA INTERNATIONAL CHEMICAL JOINT VENTURE COMPANY (a.k.a. CHOSUN INTERNATIONAL CHEMICALS JOINT OPERATION COMPANY; a.k.a. CHOSUN INTERNATIONAL CHEMICALS JOINT OPERATION COMPANY; a.k.a. INTERNATIONAL CHEMICAL JOINT VENTURE CORPORATION), Hamhung, South Hamgyong Province, Korea, North; Man gyongdae-kuyok, Pyongyang, Korea, North; Mangyungdae-gu, Pyongyang, Korea, North [NPWMD]

KOREA KWANGSONG TRADING CORPORATION, Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA MINING DEVELOPMENT TRADING CORPORATION (a.k.a. CHANGGWANG SINYONG CORPORATION; a.k.a. EXTERNAL TECHNOLOGY GENERAL CORPORATION; a.k.a. NORTH KOREAN MINING DEVELOPMENT TRADING CORPORATION; a.k.a. "KOMID"), Central District, Pyongyang, Korea, North [NPWMD]

KOREA PUGANG TRADING CORPORATION, Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONBONG GENERAL CORPORATION (a.k.a. KOREA YONBONG GENERAL CORPORATION; f.k.a. LYONGAKSAN GENERAL TRADING CORPORATION), Pot'onggang District, Pyongyang, Korea, North; Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONGWANG TRADING CORPORATION (a.k.a. KOREA RYENGWANG TRADING CORPORATION), Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONHA MACHINERY JOINT VENTURE CORPORATION (a.k.a. CHOSUN YUNHA MACHINERY JOINT OPERATION COMPANY; a.k.a. KOREA RYENHA MACHINERY J/V CORPORATION; a.k.a. RYONHA MACHINERY JOINT VENTURE CORPORATION), Central District, Pyongyang, Korea, North; Mangungdae-gu, Pyongyang, Korea, North; Mangyongdae District, Pyongyang, Korea, North [NPWMD]

LIMMT ECONOMIC AND TRADE COMPANY, LTD. (a.k.a. LIMMT (DALIAN FTZ) METALLURGY AND MINERALS CO., LTD.; a.k.a. LIMMT (DALIAN FTZ) MINMETALS AND METALLURGY CO., LTD.; a.k.a. LIMMT (DALIAN) METALLURGY AND MINERALS CO.,

LTD.), 2501-2508 Yuexiu Mansion, No. 82 Xinkai Road, Dalian, Liaoning 116011, China; and all other locations worldwide [NPWMD]

MAI (a.k.a. MOSCOW AVIATION INSTITUTE), wherever located, including 4 Volokolamskoye Shosse, Moscow 125871, Russia [64 FR 2935, January 8, 1999]

MESBAH ENERGY COMPANY (a.k.a. "MEC"), 77 Armaghan Gharbi Street, Valiasr Blve, Tehran, Iran [NPWMD]

MOSCOW AVIATION INSTITUTE (a.k.a. MAI), wherever located, including 4 Volokolamskoye Shosse, Moscow 125871, Russia [64 FR 2935, January 8, 1999]

NATIONAL STANDARDS AND CALIBRATION LABORATORY (a.k.a. NATIONAL CALIBRATION CENTRE; a.k.a. NSCL), P.O. Box 4470, Damascus, Syria [NPWMD]

NEW ERA GROUP (a.k.a. China New Era Group; a.k.a. China Xinshidai Company; a.k.a. Xinshidai; a.k.a. XSD) [69 FR 56260, September 20, 2004]

NOVIN ENERGY COMPANY (a.k.a. Energy Novin; a.k.a. Noveen Energy Company), End of North Karegar Avenue, Tehran, Iran [NPWMD]

SANAM INDUSTRIAL GROUP (a.k.a. Sanam Industries Group) Pasdaran Road 15, Tehran, Iran

SCIENTIFIC STUDIES AND RESEARCH CENTER (a.k.a. CENTRE D'ETUDES ET RECHERCHES; a.k.a. "SSRC"), P.O. Box 4470, Damascus, Syria [NPWMD]

SHAHID BAKERI INDUSTRIAL GROUP (a.k.a. "SBIG"), Tehran, Iran [NPWMD]

SHAHID HEMMAT INDUSTRIAL GROUP (a.k.a. "SHIG"), Damavand Tehran Highway, Tehran, Iran [NPWMD]

STEIGER, Jakob, c/o KOHAS AG, Fribourg, FR, Switzerland; DOB 27 Apr 1941; POB Altstatten, SG, Switzerland (individual) [NPWMD]

TANCHON COMMERCIAL BANK (f.k.a. CHANGGWANG CREDIT BANK; f.k.a. KOREA CHANGGWANG CREDIT BANK), Saemul 1-Dong Pyongchon District, Pyongyang, Korea, North [NPWMD]

TOSONG TECHNOLOGY TRADING CORPORATION, Pyongyang, Korea [NPWMD]

XINSHIDAI (a.k.a. China New Era Group; a.k.a. China Xinshidai Company; a.k.a. New Era Group; a.k.a. XSD) [69 FR 56260, September 20, 2004]

XSD (a.k.a. China New Era Group; a.k.a. China Xinshidai Company a.k.a. New Era Group; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]

YA MAHDI INDUSTRIES GROUP (a.k.a. Ya Mahdi Industrial Research Complex; a.k.a. Ya Mahdi Industrial Complex; a.k.a. "YMA") PO Box 19395-4797, Tehran, Iran



**IFTI**

Приложение №1 Часть I  
к Соглашению № RU/  
55229907/00012  
от "31" декабря 2002 г.  
между Международным Фондом  
Технологий и Инвестиций (МФТИ)  
и Nuclear Threat Initiative, Inc.  
с изменениями  
от «31» декабря 2005 года

**РАБОЧИЙ ПЛАН ПО ПРОЕКТУ**

**«Создание региональной референс-лаборатории для ПЦР-диагностики  
вирусных гепатитов»**  
№ 00012/00049

От Исполнителя Генеральный директор

Утверждено:  
от Фонда

Директор

Одобрено:  
От Партнера

Президент

  
И.Г. Дроздов/  
Ю.И. Черчес/  
Дарльз Кертис/

## СВОДНЫЕ ДАННЫЕ ПО ПРОЕКТУ

### 1. Название проекта

Полное название: Создание региональной референс-лаборатории для ПЦР-диагностики вирусных гепатитов на базе ФГУН ГНЦ ВБ «Вектор»
---

### 2. Руководитель проекта

Фамилия, имя, отчество: Нетесов Сергей Викторович		
Адрес:	Дом, улица: ФГУН ГНЦ ВБ «Вектор»	Город, р.п: Кольцово
Область: Новосибирская	Государство: Россия	Почтовый индекс: 630559
Телефон: 7-(383)-336-73-27	Факс: 7-(383)-336-74-09	Эл. почта: netesov@vector.nsc.ru

### 3. Организации участники

#### 3.1. Исполнитель

Название организации: Федеральное Государственное Учреждение Науки «Государственный Научный Центр Вирусологии и Биотехнологии «Вектор»		
Адрес:	Дом, улица: ФГУН ГНЦ ВБ «Вектор»	Город: р.п. Кольцово
Область: Новосибирская	Почтовый индекс: 630559	Website: www.vector.nsc.ru
ФИО руководителя организации: Дроздов Илья Геннадьевич		
Телефон: 7-(383)-336-73-27	Факс: 7-(383)-336-74-09	Эл. почта: drozdov@vector.nsc.ru
Министерство (ведомство): Министерство Здравоохранения и Социального Развития; Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека (Роспотребнадзор)		

### 4. Продолжительность Проекта

Продолжительность проекта (мес.): 24
--------------------------------------

### 5. Сводный бюджет Проекта

5.1 Сметная стоимость Проекта (долларов США)	\$325,500
В том числе:	
Выплаты индивидуальным участникам	\$99,500
Оборудование	\$110,500
Материалы	\$60,500
Прочие прямые расходы	\$21,500
Расходы на командировки	\$23,500
Накладные расходы	\$10,000

### 6. Аннотация

В ходе выполнения Проекта на базе ФГУН ГНЦ ВБ «Вектор» будет создана лаборатория, отвечающая всем отечественным и международным требованиям и нормам проведения диагностических работ с использованием молекулярно-биологических методов, а именно: имеющая оптимальную планировку помещений, необходимое оборудование, а также высококвалифицированный и обученный персонал. Важнейшим условием создания такой лаборатории является неукоснительное соблюдение принципов и правил GLP при организации диагностической деятельности. Референс-лаборатория будет обладать, в первую очередь, диагностической и контролирующей функциями. В долгосрочной перспективе референс-лаборатория также будет способна взять на себя роль образовательного и тренингового центра для работников медицинских учреждений Сибири, привлекаемых к молекулярной диагностике.

В соответствии с заявленными функциями референс-лаборатория будет выполнять следующие задачи: осуществлять оперативную, точную и достоверную ПЦР-диагностику, включающую обнаружение, титрование и изучение эпидемиологии возбудителей вирусных

гепатитов А, В, С, D, E, G (ВГА, ВГВ, ВГС, ВГD, ВГЕ, ВГG), а в перспективе – и других инфекций, в пробах от пациентов медицинских учреждений, добровольцев и доноров г. Новосибирска и других населенных пунктов Сибири; при необходимости подтверждать валидность результатов, полученных в других лабораториях Сибирского Федерального Округа; способствовать, по мере возможности, повышению профессионального уровня и оптимизации диагностической деятельности в других аналогичных лабораториях Сибири; расширять внедрение в сложившуюся медицинскую практику применение методов молекулярной диагностики.

## ОПИСАНИЕ ПРОЕКТА

## 1. Название проекта

Полное название: Создание региональной референс-лаборатории для ПЦР-диагностики вирусных гепатитов на базе ФГУН ГНЦ ВБ «Вектор»
---

## 2. Руководитель проекта

Фамилия, имя, отчество: Нетесов Сергей Викторович		
Адрес:	Дом, улица: ФГУН ГНЦ ВБ «Вектор»	Город: р.п. Кольцово
Область: Новосибирская	Государство: Россия	Почтовый индекс: 630559
Телефон: 7-(383)-336-73-27	Факс: 7-(383)-336-74-09	Эл. почта: netesov@vector.nsc.ru

## 3. Организации участники

Название организации: Федеральное Государственное Учреждение Науки «Государственный Научный Центр Вирусологии и Биотехнологии «Вектор»		
Адрес:	Дом, улица: ФГУН ГНЦ ВБ «Вектор»	Город: р.п. Кольцово
Область: Новосибирская	Почтовый индекс: 630559	Website: www.vector.nsc.ru
ФИО руководителя организации: Дроздов Илья Геннадьевич		
Телефон: 7-(383)-336-73-27	Факс: 7-(383)-336-74-09	Эл. почта: drozdov@vector.nsc.ru
Министерство (ведомство): Министерство Здравоохранения и Социального Развития; Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека (Роспотребнадзор)		

## 4. Продолжительность Проекта

Продолжительность проекта (мес.): 24
--------------------------------------

## 5. Техническое описание этапов

## 5.1. Этап I. Материально-техническое обеспечение работы референс-лаборатории

Молекулярно-биологические работы в рамках Проекта будут выполняться на базе специализированной лаборатории Отдела молекулярной вирусологии флавивирусов и вирусных гепатитов, расположенном на 3-м этаже корпуса №1 ФГУН ГНЦ ВБ «Вектор». Архитектурная планировка и инженерное оснащение помещений лаборатории соответствуют требованиям, предъявляемым при работе с патогенными биологическими агентами II-III групп, а также накладываемым спецификой молекулярно-диагностической деятельности, в частности, принципу физического разделения работ (см. п. 14.3). Лаборатория также располагает необходимым научно-исследовательским инструментарием для осуществления диагностических ПЦР-анализов: биокабинетами II и III класса биологической безопасности, амплификаторами, настольными и стационарными центрифугами (в том числе и с охлаждением), низкотемпературными и бытовыми холодильниками, системой видеодокументирования электрофорезных гелей, автоматическим ДНК-анализатором (секвенатором), флуоресцентным детектором продуктов амплификации и другим оборудованием, используемым при проведении молекулярно-биологических работ, включая технические средства дезинфекции. В то же время следует отметить, что область применения имеющихся ресурсов лаборатории в силу ряда причин остается достаточно ограниченной. В первую очередь, это связано с тем, что указанные оборудование и помещения используются почти исключительно в научных целях, и, как следствие, не способны обеспечить обработку значительного потока диагностических образцов. Это объясняется не только избыточной сложностью (и, соответственно, трудоемкостью в эксплуатации) используемых приборов, не предназначенных для рутинной диагностики, но и тем обстоятельством, что значительная часть оборудования (включая инженерное) была выпущена более 10 лет назад и в значительной степени исчерпала свой ресурс. Более того, в существующих условиях лаборатории трудноосуществимы некоторые востребованные виды диагностических анализов, в частности, точное количественное определение концентрации патогена в исследуемой пробе. К тому же

<p>Немаловажным условием успешной работы в рамках Проекта является также занятость руководителей и сотрудников медицинских организаций Новосибирской области.</p> <p>4. Проведение мероприятий по стандартизации и сертификации имеющегося и вновь приобретаемого лабораторного оборудования с привлечением лицензированных метрологических служб.</p> <p>3. Проведение мероприятий по стандартизации и сертификации имеющегося и вновь приобретаемого лабораторного оборудования (не реже одного раза в год) участвия лабораторий в существующих российских и зарубежных программах внешнего контроля качества (ВКК) деятельности лабораторий;</p> <p>2. Постоянное повышение квалификации персонала лабораторий путем обучения сотрудников на специализированных курсах по диагностике инфекционных заболеваний с применением молекулярно-биологических методов и направленных на стажировку в зарубежных организациях;</p> <p>1. Разработка стандартных операционных процедур (СОП) на каждый этап всех видов ПЦР-анализов, осуществленных в референс-лаборатории, а также СОП на оформление рабочей и отчетной документации с последующим постоянным контролем за соблюдением регламентов СОПами действующими лабораториями;</p> <p>5.2. Этап 2. Эффективная организация диагностической деятельности</p>	<p>некоторые лабораторные помещения выжигаются в настоящее время одновременно для разных видов работ, что недопустимо с точки зрения ПЦР-диагностики.</p> <p>Следует отметить и то обстоятельство, что обеспечение лабораторий дорогостоящими расходными материалами и реактивами, необходимыми для диагностических исследований, в настоящее время происходит либо путем централизованного снабжения подразделениями «Бекора», либо через заключение договоров на выполнение работ со сторонними организациями. Такая ситуация приводит, как правило, к недостаточному обеспечению потребностей лабораторий, что служит причиной заметного увеличения стоимости и времени выполнения анализов для отдельных пациентов.</p> <p>Значительная часть существующих проблем, связанных с трудными материалами и реактивами, решается путем использования унифицированных коммерческих диагностических наборов. Такой подход, при условии необходимого качества этих наборов и их обязательной сертификации, позволяет упростить и существенно удешевить процедуру ПЦР-анализа. Кроме того, квалификация персонала и применение стандартных наборов позволяет с очень высокой степенью достоверности гарантировать истинность диагностического результата. В настоящее время используются лицензированные тест-системы в лабораториях носит ограниченный характер, из-за сложности с организацией централизованных поставок крупных партий. Все вышеописанное позволяет констатировать целесообразность выполнения на первом этапе Проекта следующих действий:</p> <p>1. Приобретение и установка нового специализированного оборудования, предназначенного для решения диагностических задач (см. п. 5.1);</p> <p>2. Косметического ремонта и инженерного оснащения дополнительных специализированных лабораторных помещений на базе существующих площадей «Бекора», а именно помещений для электрофлуоресцентной детекции и секвенирования ДНК, а также помещений для первичной обработки, сортировки и хранения образцов;</p> <p>3. Заключение договоров с организациями соответствующего профиля на сервисное обслуживание всего оборудования лабораторий, включающего ремонт и модернизацию уже имеющихся приборов;</p> <p>4. Заключение с лицензированным производителем договора на поставку крупной партии диагностических ПЦР-тест-систем в условиях длительного сотрудничества с поставщиком;</p> <p>5. Закупки расходных материалов и реактивов, необходимых для проведения диагностических работ и нормального функционирования лабораторий.</p>
---	--

области и других регионов Сибири в деятельности референс-лаборатории. В целях привлечения к сотрудничеству работников учреждений здравоохранения, целесообразным представляется проведение мероприятий по информационному обеспечению врачей, в частности, организация серии семинаров и выездных встреч с медработниками, а также тематических информационных рассылок для заинтересованных лиц. Подобная работа, при правильной ее организации, в дальнейшем может положить основу для создания на базе референс-лаборатории полноценного тренингового центра, выполняющего образовательные функции.

#### 6. Календарный план и подотчетные материалы

№ этапа	Начало этапа	Окончание этапа	Описание подотчетных материалов
1. Материально-техническое обеспечение работы референс-лаборатории:	1-й квартал	8-й квартал	Годовые и квартальные отчеты, финальный отчет
• Закупка оборудования	1-й квартал	6-й квартал	
• Заключение договоров на сервисное обслуживание оборудования	1-й квартал	6-й квартал	
• Ремонт помещения для электрофоретической детекции и секвенирования и помещений для первичной обработки, сортировки и хранения образцов	1-й квартал	4-й квартал	
• Закупка расходных материалов и реактивов	1-й квартал	8-й квартал	
• Закупка диагностических ПЦР-тест-систем	1-й квартал	8-й квартал	
• Проведение ПЦР-диагностики клинических образцов	4-й квартал	8-й квартал	
2. Эффективная организация диагностической деятельности:	1-й квартал	8-й квартал	Годовые и квартальные отчеты, финальный отчет.
• Разработка СОП'ов	1-й квартал	2-й квартал	
• Обучение сотрудников на образовательных курсах по диагностике инфекционных заболеваний	3-й квартал	6-й квартал	
• Стажировка в зарубежных организациях	3-й квартал	6-й квартал	
• Участие в программах ВКК	3-й квартал	8-й квартал	
• Стандартизация и сертификация оборудования	3-й квартал	8-й квартал	
• Работа по информационному и образовательному обеспечению медицинских работников г. Новосибирска	4-й квартал	8-й квартал	

#### 7. Описание применяемых методик

1. Выделение нуклеиновых кислот методами фенольной экстракции лизата и/или избирательной обратной сорбции на стекле в высокосолевых растворах;
2. Обратная транскрипция;
3. Полимеразная цепная реакция (включая вложенную (nested) ПЦР);
4. ПЦР с детекцией накопления специфического продукта амплификации в режиме реального времени (Real-time PCR);
5. Детекция специфического продукта амплификации по конечной точке (End-point Analysis);
6. Электрофорез в агарозном и полиакриламидном (ПААГ) гелях (аналитический и препаративный);
7. Выделение специфического продукта амплификации методами пассивной и электроосмотической с последующей очисткой при помощи фенольной экстракции и/или сорбции на стекле;
8. Определение нуклеотидной последовательности ДНК при помощи модифицированного метода Сэнгера с использованием автоматического секвенатора;
9. Анализ полученных нуклеотидных последовательностей с целью генотипирования, выявления генетического родства с ранее выявленными изолятами, обнаружения клинически

и эпидемиологически значимых мутаций в геноме патогенных микроорганизмов.

## 8. Бюджет Проекта

Бюджет Исполнителя	
Выплаты индивидуальным участникам	\$99,500
Оборудование, программное обеспечение	\$110,500
Материалы	\$60,500
Прочие расходы	\$21,500
Расходы на командировки	\$23,500*
Накладные расходы	\$10,000
Итого по проекту	\$325,500

\*В случае если будет выделена дополнительная сумма на проведение лабораторного тренинга на базе какой-либо лаборатории в США для специалистов «Вектора», сумма вплоть до 10,000 USD из 23,500 USD может быть использована на 1 или 2 поездки сотрудников NPI в соответствующие лаборатории США для организации такого тренинга.

## 9. Оборудование

Оборудование для Исполнителя		
Наименование	Стоимость USD	Срок поставки, квартал №
1. Биокабинет второго класса биологической безопасности (SterilGARD III Advance, Baker Co.)	\$13,000	1-8-й квартал
2. Амплификатор с детекцией накопления специфического продукта амплификации в режиме реального времени (RotorGene 3000, Corbett Research)	\$51,000	1-8-й квартал
3. Многоблочный амплификатор (Eppendorf ep)	\$16,000	1-8-й квартал
4. Низкотемпературный холодильник (-80°C) (Sanyo)	\$16,500	1-8-й квартал
5. Бытовые холодильники (2-8°C и -20°C)	\$1,800	1-8-й квартал
6. Система электрофоретической детекции	\$4,000	1-8-й квартал
7. Оргтехника	\$5,200	1-8-й квартал
8. Мебель	\$3,000	1-8-й квартал

## 10. Материалы

Наименование	Стоимость USD	Срок поставки, квартал №
1. Реактивы, используемые для очистки нуклеиновых кислот	\$4,000	1-8 кварталы
2. Реактивы, используемые для проведения реакции обратной транскрипции и полимеразной цепной реакции	\$3,500	1-8 кварталы
3. Реактивы, используемые для электрофоретической детекции ДНК	\$1,500	1-8 кварталы
4. Реактивы, используемые для определения нуклеотидной последовательности ДНК	\$10,500	1-8 кварталы
5. Наборы для ПЦР-диагностики инфекционных агентов	\$21,000	1-8 кварталы

(«АмплиСенс», ЦНИИ Эпидемиологии, г. Москва)		кварталы
6. Средства забора биологических образцов	\$3,000	1-8 кварталы
7. Лабораторный пластик (пластиковые пробирки на 0.2, 0.5 и 1.5 мл., носики для пипеток на 10, 200 и 1000 мкл. с аэрозольными барьерами и без)	\$4,000	1-8 кварталы
8. Спецодежда и средства защиты	\$3,000	1-8 кварталы
9. Вспомогательное оборудование рабочего места (миницентрифуги, настольные термостаты, портексы, насосы, автоматические пипетки)	\$7,500	1-8 кварталы
10. Дезинфектанты	\$1,000	1-8 кварталы
11. Канцелярские товары	\$1,500	1-8 кварталы

### 11. Участие персонала в Проекте (Индивидуальные участники)

Исполнитель							
№	ФИО	Год рождения	Звание	Роль	Дневная ставка (USD)	Всего дней	Общие выплаты по грантам
1.	Акулов Андрей Александрович	1963		Водитель	20	100	\$2,000
2.	Баяндин Роман Борисович	1978		Лабораторная диагностика	25	80	\$2,000
3.	Богрянцева Марина Поликарповна	1947		Контроль качества	30	30	\$900
4.	Бондаренко Татьяна Юрьевна	1962		Лабораторная диагностика	25	100	\$2,500
5.	Горбунов Юрий Анатольевич	1954	к.б.н.	Синтез олигонуклеотидов	25	40	\$1,000
6.	Гражданцева Антонина Анатольевна	1958	к.б.н.	Разработка СОП и отчетных материалов	30	75	\$2,250
7.	Дроздов Илья Геннадьевич	1953	д.м.н., проф.	Научный консультант	35	100	\$3,500
8.	Иванова Алла Владимировна	1961		Секвенирование	20	60	\$1,200
9.	Каверина Галина Борисовна	1971		Лаборант	20	150	\$3,000
10.	Карпышева Наталья Николаевна	1952		Бухгалтер	25	80	\$2,000
11.	Карцева Людмила Александровна	1958		Снабжение	20	100	\$2,000
12.	Кисурин Мария Ивановна	1953		Координатор по НИР	30	70	\$2,100
13.	Кичапин Виктор Иванович	1955		Снабжение	25	70	\$1,750
14.	Кочнева Галина Вадимовна	1957	к.б.н.	Разработка СОП и отчетных материалов	30	110	\$3,300
15.	Курчейко Людмила Ивановна	1950		Лаборант	20	100	\$2,000
16.	Ларкина Людмила	1956		Снабжение	20	30	\$600



	Александровна						
17.	Локтев Валерий Борисович	1952	д.б.н., проф	Специалист по биоэтике	30	50	\$1,500
18	Мануйлов Виктор Александрович	1980		Заместитель руководителя Проекта, диагностика	30	300	\$9,000
19.	Нетесов Сергей Викторович	1953	д.б.н., проф.	Руководитель Проекта	35	300	\$10,500
20.	Нетесова Ирина Григорьевна	1956	к.б.н	Разработка СОП и отчетных материалов	30	100	\$3,000
21.	Плясунова Ирина Викторовна	1975		Лабораторная диагностика	25	240	\$6,000
22.	Походня Светлана Алексеевна	1967		Лаборант	20	220	\$4,400
23.	Сиволобова Галина Филипповна	1947	к б н	Разработка СОП и отчетных материалов	30	75	\$2,250
24.	Ставский Евгений Александрович	1952		Специалист по биобезопасности	30	90	\$900
25.	Терновой Владимир Александрович	1961	к.б.н	Лабораторная диагностика	30	300	\$9,000
26.	Чаусов Евгений Владимирович	1983		Секвенирование	25	240	\$6,000
27.	Черткова Татьяна Федоровна	1954		Работа с таможенной	25	70	\$1,750
28.	Рябенко Владимир Викторович	1970		Переводчик	30	70	\$2,100
29.	Чуб Елена Владимировна	1976		Лабораторная диагностика	30	300	\$9,000
	Вспомогательный персонал	-	-	-	20	100	\$2,000
<b>TOTAL</b>							<b>\$99,500</b>

## 12. Интеллектуальная собственность

### 12.1. Объекты интеллектуальной собственности, включая ноу-хау, используемые в проекте

В ходе выполнения Проекта будут привлечены, вновь разработаны или использованы в работе следующие объекты интеллектуальной собственности: состав реактивов, входящих в комплектацию коммерческих или разработанных Исполнителем диагностических и иных тест-систем и наборов реагентов; нуклеотидные последовательности олигонуклеотидов (праймеров и флуоресцентных зондов), описанные в научной литературе и защищенные в соответствии с законодательством Российской Федерации (далее именуемой «Россия» или «РФ»), а также разработанные Исполнителем; методики и технологии, защищенные патентами или иными формами авторских прав.

Также к объектам интеллектуальной собственности будут отнесены разработанные в рамках данного Проекта технические документы: инструкции по организации различных видов деятельности, осуществляемых в референс-лаборатории, стандартные операционные процедуры (СОП'ы) на различные этапы проводимых анализов, образцы отчетной и рабочей документации.

Любые образовательные материалы, разработанные участниками Проекта, включая лекционные курсы, программы обучения и лабораторных тренингов, информационные печатные и электронные документы, будут защищены авторскими правами в случае их использования в ходе выполнения или после завершения Проекта. При использовании обучающих или иных материалов, предоставленных третьей стороной, Исполнитель гарантирует их исключительно некоммерческое применение с соблюдением авторских прав соответствующих лиц.

В случае участия Исполнителя в разработке программ внешней оценки качества деятельности, а также систем верификации результатов диагностических лабораторий в рамках настоящего Проекта, авторские права на указанные программы и соответствующую документацию остаются за Исполнителем.

#### 12.2. Правовые отношения

Права интеллектуальной собственности, возникающие в ходе выполнения Проекта, регулируются в соответствии с законодательством РФ. Исполнитель сохраняет права интеллектуальной собственности на результаты Проекта и права собственности на материалы, возникшие в ходе выполнения Проекта. Стороны признают, что Партнер не желает получать от Исполнителя конфиденциальную информацию, составляющую государственную, коммерческую, торговую тайну (далее – «Конфиденциальная информация») в РФ в отношении Исполнителя или третьих лиц. Исполнитель гарантирует, что любая информация, предоставленная Фонду, Партнеру, третьим лицам (кроме уполномоченных представителей, агентов, должностных лиц РФ) в ходе выполнения условий Соглашения, включая без ограничения любые отчеты, предоставляемые в рамках Соглашения, не будет содержать Конфиденциальную информацию. Любая конфиденциальная информация, полученная, собранная или созданная Исполнителем лично, или от его имени, в связи с Проектом, будет рассматриваться Исполнителем как Конфиденциальная, и Исполнитель обязуется не использовать и не раскрывать ее третьим лицам за исключением уполномоченных представителей, агентов, должностных лиц РФ. Исполнитель возлагает на себя ответственность за соблюдение ВТК условий ст. 12.2 Приложения.

### 13. Проверки и ревизии

Исполнители Проекта предоставят Фонду и Партнеру право доступа к месту выполнения Проекта для осуществления проверки и ревизии всей деятельности по проекту.

### 14. Научно-техническое содержание проекта

#### 14.1. Обоснование необходимости создания референс-лаборатории

Согласно одному из подсчетов, более чем 170 миллионов людей в мире хронически инфицировано ВГС и вдвое больше – ВГВ [3]. Это в четыре раза больше общего числа ВИЧ-инфицированных. Вирусные гепатиты являются одной из главных проблем современного здравоохранения в странах бывшего Советского Союза, в особенности в Азиатской части России и Центрально-Азиатских странах СНГ. Национальные данные по наблюдению за всеми видами гепатитов в Азиатской части России и Центрально-Азиатских республиках свидетельствуют о том, что число случаев заболеваемости варьирует от 110 до 256 на 100000 человек [4]. Недостаточная изученность этиологии и некоторых факторов риска передачи этих заболеваний ограничивают использование имеющихся данных для разработки и оценки превентивных мер.

Современные подходы по изучению распространенности и частоты встречаемости вирусных гепатитов, так же как и изучение разнообразия генотипов начали применяться в России только несколько лет назад. В связи с этим имеется лишь небольшое число публикаций по описанию вирусных изолятов Европейской части и Центрально-Азиатской части России. Согласно данным этих публикаций, распространенность маркеров ВГС в крови клинически здоровых людей из Европейской части России и Центрально-Азиатских странах бывшего Советского Союза колеблется от 1,2% в Москве до 5,3% в Ашхабаде (Туркмения) [5,6]. Что касается уровня заболеваемости острыми гепатитами В и С, то в России он в 3-5 раз выше, чем в США и составляет 35-40 человек на каждые 100000 для гепатита В и немногим меньше для гепатита С [7].

За плечами у России большой опыт борьбы с инфекционными заболеваниями. Однако последние пятнадцать лет она находится в состоянии медленного экономического становления, сопровождаемого тяжелой экономической ситуацией в стране. Одним из следствий этого периода является спад в области исследовательской работы, снижение финансирования системы общественного здравоохранения и рост заболеваемости для большинства инфекционных болезней. Все это дополнительно усугубляется «утечкой мозгов», то есть отъездом за границу наиболее талантливых исследователей. Следствием всего этого является ослабление контроля над ситуацией с инфекционными заболеваниями.

Несмотря на то, что советская медицинская образовательная система подготовила немало талантливых исследователей, в обычных больницах и лабораториях центров переливания крови ощущается острая нехватка специально подготовленных профессионалов. В удаленных от Москвы регионах контроль качества лабораторных исследований практически отсутствует и, следовательно, качество проведенной диагностической работы является достаточно низким. Недавно проведенные исследования основных путей передачи парентеральных вирусных гепатитов в России [1] показали, что переливание крови все еще остается одной из главных причин заражения парентеральными гепатитами, вслед за внутривенным употреблением наркотических средств.

В настоящий момент в России для диагностики вирусных гепатитов в соответствии с принятыми нормами используются серологические методы (ИФА, иммуноблот). Эти методы, при относительной дешевизне и простоте выполнения анализа, обладают рядом недостатков, в частности, невозможностью обнаружения инфекции в период так называемого «серологического окна», то есть в период, проходящий от момента заражения до появления первых серологических маркеров (что особенно актуально в случае инфекции ВГС, характеризующейся большой продолжительностью «серологического окна»), что существенно затрудняет раннюю диагностику заболевания. Кроме того, при помощи ИФА зачастую сложно распознать этиологию заболевания в случае диагноза «острый гепатит», вследствие чего этиотропная терапия вынужденно заменяется симптоматической. Следует отметить также, что серологические методы являются непрямыми, то есть, как правило, не позволяют показать непосредственное присутствие инфекционного агента в исследуемом материале (для ВГВ, например, степень виремии не связана напрямую с уровнем HBsAg в крови).

Использование для диагностики вирусных гепатитов методов молекулярной биологии, и, прежде всего, ПЦР, позволяет эффективно решать описанные проблемы. Более того, эти методы в различных модификациях существенно повышают информативность диагностического теста. В частности, применение молекулярно-биологических методов позволяет количественно (с использованием технологии Real-Time PCR) или полуколичественно измерять вирусную нагрузку, а также определять нуклеотидную последовательность фрагментов генома возбудителя, что имеет большое значение для генотипирования вируса (для ВГС принадлежность к тому или иному генотипу является важным прогностическим фактором и определяет выбор тактики лечения), поиска мутаций лекарственной устойчивости и изучения эпидемиологических аспектов заболевания: исследования пути передачи вируса, расследования эпидемиологической истории вспышек и заражений и т. д. Более того, показано, что метод ПЦР демонстрирует существенно более высокую диагностическую (и аналитическую) чувствительность и специфичность по сравнению с традиционными методами. В настоящее время молекулярно-биологические методы диагностики способны успешно дополнять принятые методы ИФА, и все чаще выполняют роль предпочтительных методов лабораторного анализа, несмотря на их относительно высокую стоимость.

Несмотря на все преимущества ПЦР-диагностики, до сих пор она не находила широкого применения в условиях российского здравоохранения. Молекулярные методы диагностики, за редким исключением, мало используются и в больницах, и в поликлиниках, и в лабораториях станций переливания крови (эта ситуация типична не только в случае вирусных гепатитов, но и является обычной в случае диагностики других патогенов). Связано это, в первую очередь, с немалой стоимостью необходимого оборудования, отсутствием квалифицированных специалистов (курс обучения врачей-лаборантов в большинстве российских медицинских ВУЗ'ов не предусматривает практического изучения методов молекулярной биологии), необходимостью выделения комплекса отдельных помещений для ПЦР-лаборатории, недостаточным финансированием учреждений здравоохранения, а также относительной сложностью и высокой стоимостью (до недавних пор) проведения теста (пациенты не всегда способны оплатить анализ). Не последней причиной является также инерционность отечественной системы здравоохранения, предпочитающей традиционные проверенные методы более совершенным новым. Все это, на фоне неудовлетворительного информационного обеспечения врачей и недостаточности нормативной базы, регулирующей деятельность ПЦР-лабораторий, приводит к пока что эпизодическому использованию методов молекулярной биологии в современной российской медицинской практике. Те же лаборатории, которые входят в состав медицинских учреждений и применяют метод ПЦР в диагностических целях, обычно используют специалистов из числа врачей, часто не обладающих специальным молекулярно-биологическим образованием и не

имеющих необходимой квалификации, что приводит к неправильной организации работы, и, в конечном итоге, к получению большого количества ложных результатов. Кроме того, порядок отбора и обработки биологических образцов в диагностических лабораториях медицинских учреждений не является строго регламентированным и приводит иногда к кросс-контаминации проб, что дает ошибочные положительные результаты (в случае ПЦР-лабораторий ситуация значительно усугубляется тем, что неправильная первичная обработка образцов и контаминация исследуемых проб продуктами амплификации являются первоочередными проблемами молекулярной диагностики). Более того, обычно низкая эффективность диагностики в некоторых таких лабораториях остается незамеченной в течение длительного времени, так как в России только начинается становление системы внешнего контроля качества деятельности ПЦР-лабораторий. Все вышесказанное побудило нас разработать и предложить проект по созданию на базе ФГУН ГНЦ ВБ «Вектор» областной/окружной референс-лаборатории, способной не только эффективно применять молекулярные методы в диагностике вирусных гепатитов (и других инфекционных заболеваний), но и при необходимости верифицировать результаты иных лабораторий (в том числе при помощи молекулярных методов уточнять результаты ИФА), преследуя, таким образом, цели повышения общего качества диагностических исследований в Сибирском регионе.

#### 14.2. Цели Проекта:

1. Создать отвечающую всем необходимым требованиям референс-лабораторию, способную максимально эффективно выполнять диагностику возбудителей вирусных гепатитов с использованием методов молекулярной биологии;
2. Обеспечить готовность созданной лаборатории к осуществлению диагностической деятельности в отношении других инфекционных заболеваний;
3. Привлечь научных сотрудников ФГУН ГНЦ ВБ «Вектор» к решению актуальных задач практического здравоохранения;
4. По мере возможностей обеспечить внедрение методов молекулярной диагностики в повседневную медицинскую практику учреждений здравоохранения г. Новосибирска.

#### 14.3. Возможности ФГУН ГНЦ ВБ «Вектор»

ФГУН Государственный Научный Центр Вирусологии и Биотехнологии «Вектор», расположенный в наукограде Кольцово Новосибирской области, в течение ряда лет направленно изменяет характер своей деятельности, совмещая научные исследования с выполнением практических задач в интересах здравоохранения. В момент своего наибольшего расцвета в 1985-90 гг. это был один из самых больших научно-исследовательских и биотехнологических центров СССР, в его стенах работало более 4500 научных, технических и административных работников. Несмотря на то, что область науки, в которой задействован Центр, пока что слабо поддерживается государством и практически не поддерживается частными фондами, «Вектор» до сих пор проводит высокочастотные научные исследования в таких областях, как изучение вирусных геморрагических лихорадок, разработка противовирусных лекарств, диагностикумов и вакцин, исследования по разработке новых противовирусных вакцин. В 1990-х годах Центр начал исследовательскую работу в области молекулярной эпидемиологии вирусных инфекций (вирусные гепатиты, корь, эпидемический паротит, ГЛПС и т.д.) и туберкулеза, которая в значительной степени проводится на средства международных грантов.

Более 12 лет назад Центр начал исследования в области вирусных гепатитов, которые за это время уже привели к многочисленным публикациям в ведущих отечественных и зарубежных журналах, а также к разработке вакцины против гепатита А и технологий производства диагностических тест-систем на маркеры вирусных гепатитов А, В, С, D, Е. В результате на базе данных разработок организовано производство и распространение тест-систем двумя крупными частными компаниями Новосибирска, по числу продаж находящихся в настоящий момент в пятерке лидеров на российском рынке. За разработку этих тест-систем ряд ученых и специалистов российских НИИ, 7 из которых представляли ГНЦ ВБ «Вектор» и отделившиеся от него фирмы, в 1998 году были удостоены Премии Правительства России. Производство вакцины против гепатита А, также организованное в «Векторе» на основе технологии, разработанной им совместно с Институтом Полиомиелита и Вирусных Энцефалитов РАМН им. М.П.Чумакова, является

уникальным для России и расширяется год от года.

Около десяти лет назад «Вектор» (среди работников которого - Руководитель Проекта и большая часть предполагаемых участников Проекта) стал инициатором изучения изолятов ВГС и ВГВ, собранных в различных Новосибирских больницах и станциях переливания крови. Эти исследования частично финансировались Российским Министерством Науки и Технологий (в настоящий момент - Министерство Образования и Науки). Дополнительное финансирование было получено от международных научных фондов - Фонда Сороса (ISF Grants №№ NR-9000 и NR-9300 в течение 1994-1995 гг.), от Международного Научно-Технического Центра (NAS Project №883-97 и DHHS/BTER Project #1637-p) и от Сандийских Национальных Лабораторий (через Американский Фонд Гражданских Исследований и Развития, грант №RB0-893).

Несколько национальных и международных научно-исследовательских проектов в области вирусных гепатитов выполнялись в «Векторе» в последние 7 лет в сотрудничестве с Отделением вирусных гепатитов Центров по контролю и предотвращению распространения инфекционных заболеваний (CDC), Медицинской Школой Йельского Университета, Медицинской Школой Университета Северной Каролины и Сандийскими Национальными Лабораториями Министерства Энергетики, США. Самым крупным из них является успешно завершённый проект DHHS/BTER №1637p, целью которого являлось изучение распространённости, этиологии, факторов риска, путей заражения при заболевании вирусными гепатитами А, В, С, Е и G, генотипического разнообразия вирусных гепатитов А, В, С, Е и G на территории трёх областей Азиатской Части Российской Федерации. Научные сотрудники «Вектора» осуществляли этот проект совместно с двумя Новосибирскими, одной Иркутской и одной Барнаульской инфекционными клиниками, а также совместно с областными Центрами санитарно-эпидемиологического надзора этих трёх регионов. В проекте использовались современные диагностические и эпидемиологические методы, включая наиболее современные варианты техники ОТ-ПЦР и секвенирования. Это стало возможным в результате активной совместной работы коллабораторов из CDC и ученых «Вектора». В 1997 и 2003 годах американские коллабораторы посетили Центр и дали ценные комментарии по поводу переоснащения лабораторных помещений «Вектора», обучению нескольких сотрудников Центра современным молекулярно-биологическим и эпидемиологическим методам и с тех пор регулярно консультируют ученых «Вектора» по аналогичным работам.

Наши результаты неоднократно были представлены региональной и национальной администрациям, они были приняты в качестве одного из важных оснований для проведения региональной программы вакцинации против гепатита В среди работников здравоохранения и подростков.

Основные результаты в области изучения вирусных гепатитов, полученные учеными «Вектора» за последние 10 лет (в сотрудничестве с другими, в том числе и зарубежными, организациями), опубликованы в виде 21 статьи в российских и иностранных журналах, а также представлены 36 тезисами на конференциях национального и международного уровня.

Вышесказанное демонстрирует компетентность ФГУН ГНЦ ВБ «Вектор» в вопросах, посвященных исследованию вирусных гепатитов. Отдельно следует отметить готовность Центра к выполнению работ в ходе выполнения предлагаемого Проекта.

Молекулярно-биологическая работа в рамках Проекта будет проводиться в основном в помещениях 3 этажа лабораторного корпуса №1 ФГУН ГНЦ ВБ «Вектор» (комнаты 301, 304, 305, 306, 307, 308, 310, 311, 346, 347, 200). Это здание является одним из основных исследовательских помещений Центра. Корпус №1 представляет собой шестиэтажное здание, оснащенное как BSL-2.-BSL-3 лаборатория с элементами лаборатории BSL-4. Здание предназначено для проведения исследовательской работы с вирусами II-IV патогенных групп согласно международной классификации (I-III групп по российской национальной классификации). Инженерно здание разделено на две изолированные друг от друга зоны - так называемую «грязную», в помещениях которой ведутся работы с инфекционным материалом, и «чистую», предназначенную для иной работы.

Существующая в настоящее время специализированная лаборатория Центра, занимающаяся ПЦР-диагностикой вирусных гепатитов (далее - Лаборатория), административно относится к отделу молекулярной вирусологии флавивирусов и вирусных гепатитов. Она оснащена минимально необходимым оборудованием, позволяющим проводить все этапы ПЦР-анализа (очистку нуклеиновых кислот, амплификацию и детекцию); для решения задач, связанных с определением нуклеотидной последовательности ДНК, Лаборатория располагает автоматическим

секвенатором высокой производительности.

В Лаборатории накоплен значительный опыт проведения диагностических исследований, работа организована таким образом, чтобы максимально снизить риск кросс-контаминации (перекрестного загрязнения диагностируемым материалом) исследуемых образцов, накопленна большая систематизированная коллекция образцов крови от пациентов с различными вирусными гепатитами, разработаны стандартные образцы рабочей и отчетной документации. Регулярно проводятся мероприятия, связанные с внутренним контролем качества диагностической работы. Именно с использованием площадей и оборудования данного подразделения «Вектора» планируется осуществлять работы в рамках настоящего Проекта. Особенности функционирования Лаборатории с предложениями по повышению эффективности ее деятельности в ходе выполнения Проекта изложены ниже.

Организация работ в диагностической ПЦР-лаборатории должна соответствовать с одной стороны, существующим требованиям биобезопасности (поскольку работа ведется с предположительно инфекционным материалом), с другой стороны, специфика молекулярно-биологических процедур накладывает свои ограничения на деятельность лаборатории (вследствие опасности контаминации образцов, реактивов и рабочих поверхностей специфическими продуктами амплификации). Помещения Лаборатории «Вектора», организация диагностических работ и схема движения материала полностью соответствуют выдвигаемым требованиям. В частности, эффективно реализован принцип физического разделения работ (процедуры с ДНК низкой копийности проводятся изолированно от процедур с ДНК высокой копийности – амплификатом). Для выполнения этого принципа помещения Лаборатории разделены на так называемые пре-ПЦР-помещения, в которых осуществляется первичная обработка материала, выделение нуклеиновых кислот, постановка реакций обратной транскрипции (в случае РНК-содержащих вирусов) и ПЦР, и пост-ПЦР-помещения, в которых производится детекция продуктов амплификации, а также процедуры, связанные с определением нуклеотидной последовательности ДНК. Пре- и пост-ПЦР-помещения полностью изолированы друг от друга. Соответствующие оборудование, расходные материалы, реактивы и спецодежда закреплены за пре- и пост-ПЦР-помещениями и не выносятся из них.

Работы с инфекционным материалом и выделенными нуклеиновыми кислотами (до стадии амплификации) выполняются в специально оборудованных BSL-3 помещениях Лаборатории, располагающихся в «грязной зоне» (согласно российским правилам биобезопасности, ВГС является инфекционным агентом II группы патогенности; ВГВ, ВГА, ВГЕ относятся к III группе). Этих помещения герметично изолированы от других помещений здания и окружающей среды. Принудительная приточно-вытяжная вентиляция этих помещений обеспечивает пониженное относительно атмосферного давление. Данная часть Лаборатории оснащена оборудованием, предназначенным для проведения первых этапов ПЦР-анализа: имеются два биокабинета II класса биологической защиты (один из них – «Gelair ET-124» – предназначен для сортировки и первичной обработки инфекционного материала, второй – «Baker SterilGARD III Advance» – для выделения нуклеиновых кислот и постановки реакции обратной транскрипции), ПЦР-бокс «Holton» (мини-биокабинет III класса биологической защиты, предназначенный для смешивания реакционной смеси ПЦР), амплификатор «Eppendorf Mastercycler gradient», микроцентрифуга «Eppendorf 5415D», центрифуга с охлаждением «Beckman J2-21» с ротором под пробирки типа «Eppendorf» на 1,5 мл, вортексы, мембранные насосы, твердотельные термостаты, отдельные наборы автоматических пипеток для каждого рабочего места, штативы, емкости для сброса и утилизации инфекционного и неинфекционного материала и т. д. В этих помещениях также имеются холодильники на 2-8°C (для хранения реактивов), -20°C и -80°C (для хранения образцов и выделенных нуклеиновых кислот). Следует отметить, что указанное оборудование в значительной своей части не является новым, требует ремонта или замены комплектующих. Недостаток финансирования приводит к отсутствию регулярного сервисного обслуживания приборов; многие из них не могут в силу выработки ресурса или аппаратной ограниченности быть сертифицированы для диагностической деятельности. Кроме того, в настоящий момент практически все оборудование Лаборатории используется в научных целях и функционально не предназначено для диагностических работ, связанных, как правило, с повышенными нагрузками на исследовательскую аппаратуру.

В помещениях, предназначенных для работы с очищенными нуклеиновыми кислотами, используется отдельный комплект рабочей одежды и средств индивидуальной защиты, не предназначенный для выноса из «грязной зоны». Все процедуры выполняются с использованием

одноразовой пластиковой посуды (пробирок), окончательников для пипеток с воздушными барьерами и резинových перчаток (все используется одноразово). Помещение оборудовано стационарными и мобильными УФ-излучателями. Сотрудниками, выполняющие указанные этапы, занимаются электрофторорганической (леткинии).

Для осуществления высококачественных количественных исследований с применением метода Real-Time PCR в существующих пре-PCR-помещениях лаборатории в ходе выполнения проекта планируется установка соответствующего прибора (RotorGene 3000, Corbett Research), подключение компьютерной сети интернета. Использование количественных диагностических методов в повседневной диагностике инфекционных заболеваний позволит существенно улучшить качество обследования пациентов, в частности, измерять разовую вирусную нагрузку и проводить мониторинг ответа на терапию во времени (что особенно актуально в случае ВТВ и ВГС).

В ходе выполнения проекта будут оборудованы пре-PCR-помещения, предназначенные для первичной обработки (сортировки, отлеживания сыпорокки и фазовки) образцов крови и других биологических материалов. В данных помещениях (в которых в настоящий момент работы не ведутся) будет проведен косметический ремонт, а также установлено оборудование, необходимое для выполнения указанных задач, а именно: биокabinet II класса биологической безопасности, микроцентрифуга, центрифуга для вакуумированных пробирок на 1-14 мл), холодильники на 2-8°C и -20°C (для хранения реактивов), рабочие столы, стулья. Также необходимо оснащение отдельных комнат в «грязной зоне» для хранения вновь поступивших образцов и архивации анализированных проб. В данном помещении также будет проведен косметический ремонт и установлен низкотемпературный холодильный шкаф, предназначенный исключительно для временной архивации образцов (такой подход позволит осуществлять подтверждение полученных ранее результатов в других случаях). Использование в этом помещении компьютерной локальной сети с другими пользователями лаборатории, позволит эффективно решить задачу учета образцов, обработки результатов анализа и выдачи заключений пациентам. Ремонт новых помещений в ходе выполнения проекта позволит обеспечить их не только в соответствии с санитарными требованиями, существующими в России, но и с применением правил GLS (good laboratory system), что приближает уровень создаваемой референс-лаборатории к стандартам, принятым в развитых странах мира.

Леткиния продукция амплификации осуществляется в помещениях «чистой зоны». Данные помещения оборудованы системой вентиляции, независимой от систем вентиляции «грязной зоны». «Чистая» и «грязная» зоны разделены системой гермодверей и переходных шлюзов, что исключает воздухообмен между помещениями этих зон. Электрофторорганическую леткинию продуктов амплификации осуществляет отдельный сотрудник (лаборант), не посещающий помещения «грязной зоны». Пробирки, содержащие амплификат, открываются только в этих помещениях, предназначенных для леткинии. Для проведения электрофореза и документации результатов в лаборатории имеются камеры для вертикального (ПААГ) электрофореза, источники питания, трансформатор «Viber Lomat TCR-20-MC», система видеодомониторинга «Gel Image», подключение к доступному по локальной сети компьютеру (таким образом для получения результатов диагностического теста не требуется непосредственный контакт с тем, содержащим ампликон), отдельным набором автоматических пипеток, посудой для приготовления рабочих растворов. В помещении имеется переносной УФ-излучатель.

В ходе выполнения проекта планируется оборудовать новое помещение для проведения электрофореза, переместив данный этап PCR-анализа с 3 этажа корпуса в другую часть здания (подвал). Это позволит избежать контактов персонала, занимающегося леткинией продуктов амплификации с сотрудниками лаборатории, проводящими первичную обработку проб и выделение нуклеиновых кислот, что еще более снижает риск кросс-контаминации диагностических образцов. С этой целью новое помещение будет отремонтировано, оборудовано независимой системой вентиляции и необходимым оборудованием (трансформатором, системой видеодомониторинга и камерами для электрофореза), будет проведена линия локальной сети интернета.

Процедуры, связанные с определением нуклеотидной последовательности ДНК, в настоящий момент выполняются в отдельном помещении «чистой зоны» квалифицированными специалистами в области молекулярной биологии. Для выполнения этих задач лаборатория оснащена автоматическим анализатором ДНК (секвенатором) «Beckman CEQ2000 XL», амплификатором «Applied Biosystems GeneAmp 9700», центрифугой с охлаждением «Hermle Z233

МК-2», биокрибиетом III класса биологической защиты, холодильниками на 2-8°С и -20°С, набором автоматических пипеток.

Пути доставки диагностического материала в лабораторию организованы таким образом, чтобы потоки клинических образцов и матриц, содержащих продукты амплификации, не пересеклись.

К настоящему моменту в лаборатории разработаны и являются обязательными к исполнению 15 стандартных процедур для различных этапов ПЦР-анализа на вирусные гепатиты А, В, С, Е. В то же время, ведется разработка и внедрение новых COIT-ов, так как используются сейчас были разработаны около трех лет назад и признаны неактуальными в основном, для научных целей (например, в части из них предусматривается достаточное количество схемы молекулярно-биологического анализа, не находящиеся в рутинной диагностике).

Для диагностики возбудителей вирусных гепатитов (и других инфекционных агентов) в лаборатории используются коммерчески доступные тест-системы (наборы реагентов) серии «АмплиСенс» производства ФГУН ЦНИИ Эпидемиологии Роспотребнадзора (Москва), основанные на использовании метода ПЦР. Данные наборы соответствуют всем необходимым требованиям, предъявляемым к тест-системам, основанным на использовании метода ПЦР, обладают хорошими паспортными характеристиками (высокой чувствительностью и специфичностью) и разрешены к применению на территории Российской Федерации, что подтверждено соответствующими регистрационными удостоверениями Минздрава РФ и сертификации производства ГИСК им. И. А. Тарасевича для каждой тест-системы. В комплект тест-систем входят реагенты, предназначенные для выполнения всех этапов ПЦР-анализа: выделения ДНК (РНК) из различных типов образцов; проведение обратной транскрипции (в случае диагностики РНК-содержащих вирусов) с целью получения кДНК; амплификации ДНК или кДНК инфекционного агента при помощи ПЦР с использованием специфических пар праймеров; детекция продуктов амплификации путем электрофореза в ПААГ или агарозном геле.

Амплификация ДНК в данных тест-системах проводится в один разряд, что существенно снижает риск contamination исследуемых образцов. Все тест-системы серии «АмплиСенс» комплектуются контрольными образцами (положительными, отрицательными и внутренними), и подробными инструкциями к применению, что обеспечивает необходимый уровень стандартизации всех процедур, и, как следствие, высокую достоверность диагностического результата. Следует отметить также доступность тест-систем данной серии, предназначенных для проведения ПЦР-анализа в режиме Real-time PCR. Тест-системы серии «АмплиСенс», при относительно невысокой стоимости, хорошо зарекомендовали себя в рутинной диагностике инфекционных заболеваний (в том числе и вирусных гепатитов), проводимой в ПЦР-лабораториях «Вектора» и других организациях, и будут использоваться для осуществления диагностики диагностических задач референс-лаборатории, формируемой в ходе выполнения проекта.

Персонал лаборатории, занятый в работах по проекту имеет высшее медицинское, биологическое или химическое (университетское), либо среднее специальное (для лаборантов) образование. Сотрудники имеют большой опыт в вирусологических и молекулярно-биологических исследованиях, связанных с возбудителями гепатитов и других заболеваний (от 4-х до 20 лет стажа). Для работы с матрицами, предполагающими содержание патогенных II-III групп, сотрудников лаборатории, привлекаемые к диагностической деятельности в ходе выполнения проекта, имеют необходимые медицинские и квалификационные допуски в соответствии с принятыми ведомственными нормами. Часть сотрудников имеет опыт выполнения исследований на базе иностранных научных учреждений. Двое научных сотрудников имеют государственные сертификаты об обучении на курсах по современной ПЦР-диагностике инфекционных заболеваний, проводимых ФГУН ЦНИИ Эпидемиологии.

Несмотря на существующий высокий уровень подготовки занятых в проекте специалистов, их значительный опыт в выполнении диагностических работ и обширные навыки в проведении научных исследований, настоящие планы по проекту предусматривают дальнейшее повышение квалификации сотрудников референс-лаборатории. Это связано, в первую очередь, с быстрым развитием молекулярно-биологических методов и технологий. Постоянная разработка и внедрение в мировую диагностическую практику все новых методов и средств диагностики является высочайшей потребностью специалистов соответствующего профиля. В целях повышения квалификации сотрудников и обмена опытом со специалистами сторонних учреждений, в проекте предусматриваются расходы по организации:

а) трех стажировок сроком до одного месяца в зарубежные медицинские и научных



исследователейских центрах (в частности, в Massachusetts General Hospital, USA);

б) обучения дополнительного трюка сотрудников на курсах по ПЦР-диагностике, проводимых ФГУН ЦНИИ Эпидемиологии;

в) участия минимум в трех российских конференциях национального уровня.

В целом, существующий уровень оснащенности лабораторий и квалификации занятых персоналом уже сейчас являются достаточно высокими для выполнения функций и задач референс-лаборатории, что подтверждается выполненными ранее работами, практическая полностью посвященными диагностике вирусных гепатитов (правда, более в интересах научного исследования, чем практического здравоохранения). В то же время, для более эффективной деятельности лабораторий необходимо принять ряд мер, связанных, в первую очередь, с техническим переснащением и стандартизацией оборудования. В частности, в настоящий момент невозможно параллельное одновременное проведение нескольких тестов на различные инфекции, что связано с недостатком рабочих мест (на каждый этап ПЦР-анализа имеется лишь одно рабочее место). В связи с этим предлагается рассмотреть возможность приобретения оборудования для выполнения процедуры выделения нуклеиновых кислот (это наиболее продолжительный этап ПЦР-анализа, требующий непосредственного участия человека). Также необходимо приобретение многоканального амплификатора с автономной работой каждого блока, так как это существенно ускорит процесс амплификации в случае различных программ термочувствования для разных инфекций. Все это позволит значительно увеличить возможность лаборатории по обработке потока диагностических проб. Кроме того, в связи с недостатком государственного финансирования, Центр в целом и лаборатория в частности, испытывают потребность в тех или иных реактивах и расходных материалах, не имеют возможности проводить регулярное сервисное обслуживание оборудования, участвовать в программах внешней оценки качества и т. д. Для решения всех этих проблем необходимо приобрести средства, полученные из источников альтернативных государственным (в перспективе лаборатория планирует выйти на самостоятельную оплату) за счет увеличения доли коммерческих тестов).

1.4. Привлечение учреждений здравоохранения

Для более эффективной работы референс-лаборатории планируется основную диагностическую деятельность осуществлять не столько с привлечением отдельных лиц (пациентов), заинтересованных в точном диагнозе, сколько в тесном сотрудничестве с учреждениями здравоохранения г. Новосибирска, а также других городов и областей Сибири. Такой подход позволит обеспечить:

а) необходимый объем исследований;

б) повышение качества обследования и лечения в ряде больниц и поликлиник Сибирского региона (непосредственный практический эффект деятельности референс-лаборатории);

в) постепенное внедрение методов молекулярной диагностики в повседневную медицинскую практику;

г) развитие связей между научными и медицинскими учреждениями Сибири.

ФГУН ЦНИИ ВБ «Вектор» имеет большой опыт выполнения работ (в том числе и диагностических) по договорам с медицинскими учреждениями Сибирского региона (в частности, МИКБ №1 г. Новосибирска, МСЧ №63 Новосибирской обл., Новосибирским областными ЦСНД, ТКБ №5г. Барнаул, МИКБ г. Иркутск, Новосибирским отделением компании «Шеринг-Плау» и рядом других организаций). Обеспечение за счет средств проекта льготных условий договоров для этих и других учреждений здравоохранения способно сделать использование методов молекулярной диагностики привлекательным для врачей и, в перспективе, способствовать повышению популярности этих методов в медицинской среде. Кроме того, врачи, непосредственно вовлеченные в сотрудничество с референс-лабораторией, получают хорошее представление о возможностях молекулярных методов в диагностике вирусных гепатитов (и иных заболеваний), что будет способствовать не только повышению общего профессионального уровня медицинских работников, но и приведет к иным важным практическим результатам – в частности, к стандартизации методов отбора и хранения образцов для диагностических исследований. Более того, вовлечение медицинских работников в деятельность, связанную с осуществлением проекта представляется целесообразным, исходя из следующих соображений. До настоящего времени в Новосибирской области практически отсутствует взаимодействие между научными и медицинскими учреждениями (несмотря на большое для российского региона

количество и тех и других), хотя за несколько последних лет наметились некоторые положительные тенденции в этом направлении. Большинство исследований, проводимых в институтах (в том числе и в «Векторе»), и связанных с медицинской тематикой, к сожалению, были не до конца востребованы местной системой здравоохранения и санитарно-эпидемиологического надзора. Совместный длительный проект, включающий как научных, так и медицинских работников, позволил бы, с одной стороны, вовлечь ученых «Вектора» в решение задач практического здравоохранения, а с другой – заложил бы основу для дальнейшего тесного сотрудничества между научными и медицинскими учреждениями Новосибирской области.

Все вышесказанное, несмотря на очевидную важность, только подчеркивает основную идею существования региональной референс-лаборатории, заключающуюся в необходимости установления точных диагнозов для пациентов, находящихся на обследовании и лечении в крупных медицинских учреждениях г. Новосибирска. Решение этой задачи будет являться одним из первых наиболее актуальных практических результатов деятельности референс-лаборатории.

Следует отметить, что реализация означенных целей возможна только при безукоризненной деятельности референс-лаборатории (что достигается, в первую очередь, неукоснительным соблюдением принципов GLP и организации работ, а также высокой квалификацией задействованного персонала), и, как следствие, повышения уровня доверия практикующих врачей и пациентов к методам молекулярной диагностики и, в целом, к результатам, получаемым в ходе работы ПЦР-лаборатории. Демонстрацию необходимого качества работ, выполняемых в референс-лаборатории, планируется осуществлять путем проведения информационных встреч и семинаров с участием заинтересованных врачей, посвященных как общим принципам проведения молекулярно-диагностических исследований, так и примерам практических задач, решаемых в Лаборатории. Подобные семинары могут стать основой для разработки тренинговых и образовательных курсов, включающих обучение молекулярно-биологическим принципам и техникам применительно к диагностическим исследованиям. Пилотные версии таких курсов в ходе выполнения Проекта будут разработаны и осуществлены дистанционно (рассылкой методических материалов и опросников с последующей обработкой полученных результатов), причем планируется сопровождать их проведением локальных программ оценки качества диагностической деятельности участвующих организаций и отдельных медицинских работников с использованием панелей контрольных образцов из коллекций Лаборатории. Средства, требуемые для проведения указанных дистанционных курсов и программ, лишь частично будут получены от финансирующей Проект стороны; основная их часть будет получена за счет выполнения платных диагностических исследований. В дальнейшем опыт, полученный в ходе реализации планируемых обучающих программ, может быть использован для организации на базе ФГУН ГНЦ ВБ «Вектор» полноценного молекулярно-диагностического тренингового центра.

#### 14.5. Ожидаемые результаты и их применение:

1. В результате выполнения Проекта в г. Новосибирске будет создана самая современная на текущий момент в Азиатской части России диагностическая лаборатория, способная осуществлять ПЦР-анализы возбудителей вирусных гепатитов и сопутствующие исследования с привлечением методов молекулярной биологии в соответствии со всеми необходимыми требованиями, предъявляемыми данным видом диагностической деятельности. В ходе своей работы референс-лаборатория будет выполнять, в числе прочего, рутинную диагностику вирусов гепатитов А, В, С, Е в образцах, полученных от пациентов медицинских учреждений и доноров г. Новосибирска, а также отдельных лиц, заинтересованных в выполнении анализов.
2. Указанная лаборатория будет способна в кратчайшие сроки перевести свои мощности на диагностику других патогенов, что особенно актуально в случаях возникновения вспышек или эпидемий различных инфекционных заболеваний среди населения Сибирского Федерального Округа, а также при подозрении на возможность совершения акта биологического терроризма.
3. В ходе выполнения Проекта квалифицированные ученые и технический персонал ФГУН ГНЦ ВБ «Вектор» (в том числе и занятые ранее в разработке защиты от биологического оружия) смогут совмещать фундаментальные и прикладные научные исследования с выполнением практической работы в интересах здравоохранения.

4. Осуществление Проекта позволит повысить интерес медицинских работников к использованию молекулярно-диагностических методов в лечебной практике. Кроме того, работа референс-лаборатории, при условии ее достаточной эффективности, популяризирует идею ПЦР-диагностики среди врачей и пациентов г. Новосибирска, повысит уровень конкуренции на рынке предоставляемых (зачастую некачественных) диагностических услуг, и, в конечном итоге, будет способствовать общему улучшению качества медицинского обслуживания в г. Новосибирске и других городах Сибири.

#### 14.6. Литература:

1. Шустов А.В., Кочнева Г.В., Сиволобова Г.Ф., Гражданцева А.А., Гаврилова И.В., Акинфеева Л.А., Ракова И.Г., Алешина М.В., Букин В.Н., Орловский В.Г., Беспалов В.С., Zelicoff A.P., Нетесов С.В. Частота встречаемости, распределение генотипов и факторы риска вирусного гепатита С среди некоторых групп населения Новосибирской области. // Журн. микробиол.- 2004.- №5.- С.20-25.
2. Weekly Epidemiological Record.1999. – V.74.- №49.-P.425. (10 December, 1999).WHO.
3. Population Health and Environment. Monthly Informational Bulletin of the State Sanitary and Epidemiological Surveillance, Ministry of Public Health of the Russian Federation. No. 1 (22), 1995; No. 1 (34), 1996; No. 1 (46), 1997; No. 1 (58), 1998; No. 1 (70), 1999; No. 1 (82), 2000; No. 1 (94), 2001; No. 1 (106), 2002; No. 1 (118), 2003.
4. Яшина Т.Л., Шахгильдян И.В., и др. Распространение маркеров вирусных гепатитов В и дельта среди населения регионов, контрастных по уровню заболеваемости. // Вопр. вирусол.- 1992.- №4.-С.194-196.
5. Круглов И.В., Яшина Т.Л., Цветова Г.В. и др. Распространение маркеров гепатитов В и С и этиологическая структура заболеваемости острыми вирусными гепатитами населения Кузбасса и северо-западного Казахстана// Журн. микробиол. – 1995.- №6.- С.36-37.
6. Сомова А.В., Голосова Т.В., Марголина А.Н. и др. Серодиагностика вирусных гепатитов С и В среди различных групп населения. // Вопр. вирусол.-1992.- №4.-С.105-107.
7. Ohba K., Mizokami M., Kato T. et al. Seroprevalence of hepatitis B virus, hepatitis C virus and GB virus-C infections in Siberia.-Epidemiol. Infect.-1999.- V.122.- №1.- P.139-143.

#### 15. Дополнительная информация

- 15.1. Исполнитель отвечает за координацию работы ВТК и обеспечивает надлежащее выполнение ими своих обязательств и строгое соблюдение условий, оговоренных настоящим Соглашением, как если бы ВТК являлись сотрудниками, агентами и представителями Исполнителя.
- 15.2. Техническая документация и информация, созданная в рамках данного Проекта, не будет использоваться для создания оружия массового уничтожения или для достижения каких бы то ни было военных целей.
- 15.3. Исполнитель соблюдает и подчиняется всем законам, правилам, нормативным актам, приказам и требованиям правительственных органов (в том числе, без ограничений, всем применимым федеральным и международным законам и нормативным актам, а также законам и нормативным актам, принятым органами местного самоуправления), имеющим отношение к Проекту или любым материалам, отчетам, техническим документам или информации, созданной в рамках данного Проекта, и обеспечивает такое соблюдение и подчинение со стороны своих сотрудников, представителей, подрядчиков и субподрядчиков, если таковые имеются, а также ИУ; при этом Исполнитель признает, что, в применимых случаях, Исполнитель несет ответственность за получение любых лицензий или за реализацию иных полномочий, по необходимости, связанных с мероприятиями, проводимыми в связи с реализацией Проекта.
- 15.4. Предполагается, что никакие материалы, отчеты, технические документы или информация, созданная или собранная в рамках настоящего Проекта, представленные на рассмотрение Партнера или Фонда, не подпадают под любые российские таможенные и экспортные законы, правила, нормативы, распоряжения или требования (совместно именуемые "Таможенные требования России"). Однако по поводу той степени, в которой

- такие Таможенные требования России могут считаться применимыми, Исполнитель заявляет и гарантирует, что все материалы, отчеты, техническая документация и информация, созданная в рамках данного Проекта, которую предоставляют Партнеру или Фонду, во всех отношениях соответствуют Таможенным требованиям России, и что такое соответствие ни коим образом не умаляет значимости планируемых технических отчетов по содержанию или по существу
- 15.5. Исполнитель соглашается, что он не будет вовлекать или иным образом использовать средства Проекта на заключение сделок с организациями, прямые или косвенные сделки с которыми со стороны американских организаций и отдельных лиц – граждан или постоянных жителей США, в соответствии с Правилами контроля над активами иностранных компаний (Свод федеральных постановлений США, том 31, разделы 500-598) считаются нежелательными. Партнер обращает внимание Исполнителя на список организаций, включенный в Закон о контроле над торговлей оружием массового уничтожения (Свод федеральных постановлений США, том 31, раздел 539); этот список в его настоящем виде приведен в качестве Приложения Б). Исполнитель понимает, что время от времени в список могут вноситься изменения. Запрещенные сделки со сторонами, перечисленными в Законе о контроле над торговлей оружием массового уничтожения включают, без ограничений (i) поставки любых товаров, технологий или услуг, или заключение любого соглашения на поставки любых товаров, технологий или услуг от организаций, перечисленных в списке; (ii) предоставление помощи или средств на вышеперечисленные цели, связанные с перечисленными в списке организациями; или (iii) импортирование в США любых товаров, технологий или услуг, изготовленных или предоставленных организациями, перечисленными в списке, или любыми организациями, оговоренными в вышеуказанных нормативных актах или приказе исполнительных органов. Если речь идет об организациях, перечисленных в некоторых других разделах Правил контроля над активами иностранных компаний (например, вошедших в список иностранных террористических организаций), запрет распространяется на все сделки и любые перечисления средств.
- 15.6. Исполнитель соглашается немедленно уведомить Партнера в письменном виде, если у Исполнителя есть основания полагать, что средства Проекта не могут быть использованы на предусмотренные Проектом цели или в соответствии с условиями настоящего Соглашения или что целевое использование средств Проекта или их использование в соответствии с условиями настоящего Соглашения не может продолжаться.
- 15.7. Все задачи, которые должны быть выполнены Исполнителем и ВТК в связи с Проектом выполняются и готовятся своевременно и по-деловому, с профессиональной тщательностью и умением в соответствии с любыми и всеми требованиями по технике безопасности, которые могут быть применимы в соответствии с российскими и международными стандартами.
- 15.8. Исполнитель соглашается, что, когда Исполнитель или ИУ в связи с Проектом должен выехать в командировку, предполагающую использование любой части средств, выделенных Партнером по условиям настоящего документа, такая командировка осуществляется по «экономическому» или «третьему» разряду и не предусматривает затрат на роскошные гостиницы и поездки первым классом или бизнес классом.
- 15.9. В случае, если Исполнитель нарушает любое из положений или условий настоящего Соглашения, Партнер оставляет за собой право на свое полное и единоличное усмотрение прекратить действие настоящего Соглашения и применить любые средства судебной защиты, предусмотренные настоящим Соглашением или иным образом предусмотренные законодательством на случай невыполнения обязательств. Решение Партнера является окончательным, а также связывающим и решающим для Исполнителя и ИУ. По прекращении настоящего Соглашения по любой причине Партнер прекращает дальнейшее финансирование Проекта, и все не потраченные средства и любая их часть, не затраченная на реализацию Проекта немедленно возвращаются Партнеру.
- 15.10. Каждая Сторона-участница настоящего Соглашения признает и соглашается, что Партнер ни в прошлом, ни в настоящем, ни в будущем не контролирует, не руководит и не участвует ни в каких аспектах Проекта, включая, без ограничений, планирование, реализацию, инспекцию или оценку Проекта. Роль Партнера в связи с Проектом и аспектами его планирования заключалась, заключается и будет заключаться во все

времена исключительно в предоставлении средств, делающих возможной реализацию Проекта. Любой надзор и периодическое рассмотрение хода работ, проводимые Партнером или от его имени, осуществляются исключительно в целях соблюдения внутренних интересов Партнера, а также для того, чтобы ускорить выплату средств на реализацию Проекта. Партнер и его сотрудники, агенты и представители/подрядчики ни как образом не контролируют действия Исполнителя или ИУ, в том числе, без ограничений, любые действия, связанные с Проектом, и не будут считаться контролирующими такие действия. Партнер не несет ответственности за любую допущенную небрежность или оплошность со стороны Исполнителя или ИУ, любых независимых подрядчиков или других сторон, и не несет ответственности за любое условие или происшествие, которые Партнер или его сотрудники, агенты или представители/подрядчики могут обнаружить в результате рассмотрения хода работ по проекту или любых других мероприятий, связанных с надзором. Исполнитель признает и соглашается, что и Исполнитель, и ИУ в процессе реализации Проекта проводят и опираются на независимые планы, результаты надзора и проведения инспекций, а также нормативы по технике безопасности и ни в коей мере, ни в связи с Проектом, ни по другому поводу, не имеют права полагаться на какой-либо совет или вклад Партнера или его сотрудников, агентов или представителей/подрядчиков. Не взирая на любое положение настоящего документа, которое оговаривает противоречащие или противоположные нижеизложенному условия, Исполнитель признает и соглашается, что степень участия Партнера и его обязательств, установленных в настоящем Соглашении, состоит только в предоставлении средств на реализацию Проекта, в соответствии с положениями и условиями, изложенными в настоящем Соглашении, и что Партнер ни в коей мере не принимает на себя финансовых или иных обязательств в связи с планированием, реализацией, инспекцией или оценкой Проекта и ни прямо, ни косвенно не осуществляет контроль над Проектом или какими-либо его аспектами.

- 15.11. **NTI НЕ НЕСЕТ ОТВЕТСТВЕННОСТИ ЗА ЛЮБЫЕ ОСОБЫЕ, СЛУЧАЙНЫЕ ИЛИ ВЫТЕКАЮЩИЕ ИЗ ОБСТОЯТЕЛЬСТВ СЛУЧАИ НАНЕСЕНИЯ УЩЕРБА ЛЮБОГО РОДА, ВНЕ ЗАВИСИМОСТИ ОТ ИХ ПРИЧИНЫ, ДАЖЕ ЕСЛИ NTI ИНФОРМИРОВАЛИ О ВОЗМОЖНОСТИ ТАКОГО НАНЕСЕНИЯ УЩЕРБА.**

**Приложение "А"**

Список избранных юридических и физических лиц, подпадающих под положения Закона о торговле оружием массового уничтожения, Свод федеральных постановлений США, том 31, глава 539

**Правительственное распоряжение № 13382**

АВИАЦИОННО-КОСМИЧЕСКАЯ ПРОМЫШЛЕННАЯ ОРГАНИЗАЦИЯ (также известная как «САЗМАНЕ САНАЙЕ ХАВА ФАЗА» (SAZMANE SANAYE HAVA FAZA); также известная как "АЮ"), ул. Лангаре, площадь Нобонияд, Тегеран, Иран [Постановление о нераспространении ОМУ].

ИРАНСКАЯ ОРГАНИЗАЦИЯ ПО АТОМНОЙ ЭНЕРГЕТИКЕ (также известная как «САЗЕМАН-Е ЭНЕРДЖИ АТОМИ»), Почтовый ящик 141144-1339, Конец Северного Карегарского проспекта, Тегеран, Иран [Постановление о нераспространении ОМУ].

БАНК «СЕПА», площадь имама Хомейни, почтовый ящик № 11364-9569, Тегеран, Иран; все отделения во всех странах мира [Постановление о нераспространении ОМУ].

БАНК «СЕПА ИНТЕРНШЭНЛ Пи-Эл-Си», 5-7 Истхип, Лондон EC3M 1JT, Великобритания [Постановление о нераспространении ОМУ].

БАЛТИЙСКИЙ ГОСУДАРСТВЕННЫЙ ТЕХНИЧЕСКИЙ УНИВЕРСИТЕТ, независимо от места расположения, в т.ч. по следующему адресу: Россия, 198005 Санкт-Петербург, ул. 1-ая Красноармейская, 1/21 [Свод федеральных постановлений США, т. 63, гл. 42089, 30 июля 1998 г.]

ПЕКИНСКАЯ КОМПАНИЯ «АЛИТЭ ТЕКНОЛОДЖИЗ ЛТД.» (также известная как АЛКО, также известная как ПЕКИН ХАЙЛИ ЛИАТХЕ КЕДЖИ ЮКСИАН ГОНГСИ) Улица Беисанхуан, д. 12А, почтовый ящик № 3042, Пекин, Китай, и все другие адреса во всех странах мира [Постановление о нераспространении ОМУ].

КИТАЙСКАЯ ПРОМЫШЛЕННАЯ КОРПОРАЦИЯ «ВЕЛИКАЯ СТЕНА» (также известная, как CGWIC, также известная, как ZHONGGUO CHANGCHENG CONGYE ZONGGONGSI), Хайдан Налу, № 30, Пекин, Китай; Москва, Россия, и все другие адреса во всех странах мира [Постановление о нераспространении ОМУ].

КИТАЙСКАЯ ГРУППА «НОВАЯ ЭРА» (она же Китайская компания Циншидаи (Xinshidai); она же Группа «Новая Эра»; она же XSD; она же Xinshidai) [Свод федеральных постановлений США, т. 69, гл. 56260, 20 сентября 2004 г.]

КИТАЙСКАЯ НАЦИОНАЛЬНАЯ ИМПОРТНО-ЭКСПОРТНАЯ КОРПОРАЦИЯ ПО ТОЧНОМУ МАШИНОСТРОЕНИЮ (также известная как КИТАЙСКАЯ НАЦИОНАЛЬНАЯ И/Э КОРПОРАЦИЯ ПО ТОЧНОМУ МАШИНОСТРОЕНИЮ; также известная как КИТАЙСКАЯ ИМПОРТНО-ЭКСПОРТНАЯ КОРПОРАЦИЯ ПО ТОЧНОМУ МАШИНОСТРОЕНИЮ, также известная как СРМЕС; также известная как ЖОНГГУО ДЖИНГМИ ДЖИКСИ ДЖИНЧУКОУ ЗОНГТОНГСИ), Хайдан Налу 30, Пекин, Китай, и все другие адреса во всех странах мира [Постановление о нераспространении ОМУ].

КИТАЙСКАЯ ИМПОРТНО-ЭКСПОРТНАЯ КОРПОРАЦИЯ ПО ТОЧНОМУ МАШИНОСТРОЕНИЮ (она же СРМЕС), независимо от места расположения [30 июля 2003 г.]

КИТАЙСКАЯ КОМПАНИЯ ЦИНШИДАИ (XINSHIDAI) (она же Китайская группа «Новая Эра», она же она же Группа «Новая Эра»; она же XSD; она же Xinshidai) [69 FR 56260, 20 сентября 2004 г.]

СРМЕС (она же КИТАЙСКАЯ ИМПОРТНО-ЭКСПОРТНАЯ КОРПОРАЦИЯ ПО ТОЧНОМУ МАШИНОСТРОЕНИЮ), независимо от места расположения [30 июля 2003 г.]

РОССИЙСКИЙ ХИМИКО-ТЕХНОЛОГИЧЕСКИЙ УНИВЕРСИТЕТ ИМ. Д. МЕНДЕЛЕЕВА, независимо от места расположения, в т.ч. по адресу: Россия 125047 г. Москва, Мнусская пл., 9 [Свод федеральных постановлений США, т 64, гл. 2935, 8 января 1999 г.]

ДЕРАХШАДЕ, АХМАД, для вручения по адресу: БАНК «СЕПА», д. 33, здание Хормозан, улица Пирозан, Шарак Ходс, Тегеран, Иран; дата рождения. 11 августа 1956 г., место рождения: Иран (частное лицо) [Постановление о нераспространении ОМУ].

ИНСТИТУТ ЭЛЕКТРОНИКИ, почтовый ящик № 4470, Дамаск, Сирия [Постановление о нераспространении ОМУ]

ФЕДЕРАЛЬНЫЙ НАУЧНО-ПРОИЗВОДСТВЕННЫЙ КОМПЛЕКС «АЛТАЙ», Россия [Свод федеральных постановлений США, т.69, гл. 67617-18, 18 ноября, 2004 г.]

G.W. АЭРОСПЕЙС, ИНК. (также известная как Авиацнонно-космическая корпорация «Великая Стена») Готорн бульвар, № 21515, Офис 670, Торранс, Калифорния 90503. Калифорнийский корпоративный номер C1458237 (Соединенные Штаты) [Постановление о нераспространении ОМУ].

ГЛАВКОСМОС, независимо от места расположения, в т.ч. по адресу: Россия 103030 г. Москва, ул. Краснопролетарская, 9 [Свод федеральных постановлений США, т. 63, гл. 42089, 30 июля 1998 г.]

ТОРГОВАЯ КОРПОРАЦИЯ «ХЕСОНГ», Пхеньян, Северная Корея [Постановление о нераспространении ОМУ].

ИНСТИТУТ ПРИКЛАДНОЙ НАУКИ И ТЕХНОЛОГИИ (HIGHER INSTITUTE OF APPLIED SCIENCE AND TECHNOLOGY) (также известный как HIAST; также известный как INSTITUT DES SCIENCES APPLIQUEES ET DE TECHNOLOGIE; также известный как INSTITUT SUPERIEUR DES SCIENCES APPLIQUEES ET DE TECHNOLOGIE; также известный как ISAT; также известный как ISSAT), почтовый ящик № 31983, Барзе, Дамаск, Сирия [Постановление о нераспространении ОМУ]

КОХАС АГ, улица Арсено, 15, Фрибург, FR 1700, Швейцария; С.Р. # СН-217.0.135.719-4 (Швейцария) [Постановление о нераспространении ОМУ].

КОРЕЙСКАЯ КОМПЛЕКСНАЯ КОРПОРАЦИЯ ПО ИМПОРТУ ОБОРУДОВАНИЯ, Округ Раквондонг Потонггян, Пхеньян, Северная Корея, [Постановление о нераспространении ОМУ].

КОМПАНИЯ «КОРЕЙСКОЕ МЕЖДУНАРОДНОЕ ХИМИЧЕСКОЕ СОВМЕСТНОЕ ПРЕДПРИЯТИЕ» (также известная как КОМПАНИЯ «ШОСОН» ПО СОВМЕСТНОМУ ПРОИЗВОДСТВУ ХИМИКАЛЕЙ, также известная как КОМПАНИЯ «ШОСУН» ПО СОВМЕСТНОМУ ПРОИЗВОДСТВУ ХИМИКАЛЕЙ, также известная как КОРПОРАЦИЯ «МЕЖДУНАРОДНОЕ ХИМИЧЕСКОЕ СОВМЕСТНОЕ ПРЕДПРИЯТИЕ»), Ханхун, Южная провинция Ханьонг, Северная Корея; Ман Гионглае-книок, Пхеньян, Северная Корея, Мангюнглае-гу, Пхеньян, Северная Корея [Постановление о нераспространении ОМУ]

КОРЕЙСКАЯ ТОРГОВАЯ КОРПОРАЦИЯ КВАНСОНГ, Баквон-донг, Округ Потонггян, Пхеньян, Северная Корея [Постановление о нераспространении ОМУ]

КОРЕЙСКАЯ ГОРНОДОБЫВАЮЩАЯ ТОРГОВАЯ КОРПОРАЦИЯ (также известная как КОРПОРАЦИЯ ЧАНГГВАНГ СИНЬОНГ; также известная как ГЕНЕРАЛЬНАЯ КОРПОРАЦИЯ ВНЕШНИХ ТЕХНОЛОГИЙ; также известная как ГОРНОДОБЫВАЮЩАЯ ТОРГОВАЯ КОРПОРАЦИЯ СЕВЕРНОЙ КОРЕИ; также известная как «КОМИД»), Центральный Округ, Пхеньян, Северная Корея [Постановление о нераспространении ОМУ]

КОРЕЙСКАЯ ТОРГОВАЯ КОРПОРАЦИЯ ПУНЪЯНЬ, Раквон-донг, Округ Потонггян, Пхеньян, Северная Корея [Постановление о нераспространении ОМУ]

КОРЕЙСКАЯ КОРПОРАЦИЯ ОБЩЕГО НАЗНАЧЕНИЯ «РИОНБОНГ» (также известная как КОРЕЙСКАЯ КОРПОРАЦИЯ ОБЩЕГО НАЗНАЧЕНИЯ «ЙОНБОНГ», ранее известная как КОРПОРАЦИЯ ОБЩЕГО НАЗНАЧЕНИЯ «ЛИОНГАКСАН», Округ Потонггян, Пхеньян, Северная Корея; Раквон-донг, Округ Потонггян, Пхеньян, Северная Корея [Постановление о нераспространении ОМУ].

КОРЕЙСКАЯ ТОРГОВАЯ КОРПОРАЦИЯ «РИОНГВАНГ» (также известная как КОРЕЙСКАЯ ТОРГОВАЯ КОРПОРАЦИЯ «РИЕНГВАНГ», Раквон-донг, Округ Потонггян, Пхеньян, Северная Корея, [Постановление о нераспространении ОМУ].

КОРПОРАЦИЯ «КОРЕЙСКОЕ СОВМЕСТНОЕ ПРЕДПРИЯТИЕ «РИОНХА» ПО ПРОИЗВОДСТВУ МАШИННОГО ОБОРУДОВАНИЯ» (также известная как СОВМЕСТНО ЭКСПЛУАТИРУЕМАЯ КОМПАНИЯ «ЧОСУН ЮНХА» ПО ПРОИЗВОДСТВУ МАШИННОГО ОБОРУДОВАНИЯ; также известная как КОРПОРАЦИЯ «КОРЕЙСКОЕ СОВМЕСТНОЕ ПРЕДПРИЯТИЕ «РИЕНХА» ПО ПРОИЗВОДСТВУ МАШИННОГО ОБОРУДОВАНИЯ; также известная как КОРПОРАЦИЯ «РИОНХА» ПО ПРОИЗВОДСТВУ МАШИННОГО ОБОРУДОВАНИЯ), Центральный округ, Пхеньян, Северная Корея; Мангунгдае-гу, Пхеньян, Северная Корея; округ Мангйонгдае, Пхеньян, Северная Корея, [Постановление о нераспространении ОМУ].

ЭКОНОМИЧЕСКАЯ И КОММЕРЧЕСКАЯ КОМПАНИЯ С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ ЛММТ (также известная, как ЛММТ (ДАЛИАН, ФТЗ), КОМПАНИЯ С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ ПО ПРОИЗВОДСТВУ МЕТАЛЛУРГИЧЕСКОЙ ПРОДУКЦИИ И МИНЕРАЛОВ, также известная как ЛММТ (ДАЛИАН), КОМПАНИЯ С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ ПО ПРОИЗВОДСТВУ МЕТАЛЛУРГИЧЕСКОЙ ПРОДУКЦИИ И МИНЕРАЛОВ) 2501-1508 Юксиу Мэншэн, № 82, улица Хинкаи, Далиан, Лиаонинг 116011, Китай, а также другие адреса во всех странах мира [Постановление о нераспространении ОМУ].

МАИ (он же МОСКОВСКИЙ АВИАЦИОННЫЙ ИНСТИТУТ), независимо от места расположения, в т.ч. по адресу: Россия 125871 г. Москва, Волоколамское шоссе, 4 [Свод федеральных постановлений США, т. 64, гл. 2935, 8 января 1999 г.]

ЭНЕРГЕТИЧЕСКАЯ КОМПАНИЯ «МЕСБАХ» (также известная как «МЕК»), улица Армагхан Гхарби, Бульвар Валиаср, Тегеран, Иран [Постановление о нераспространении ОМУ].

МОСКОВСКИЙ АВИАЦИОННЫЙ ИНСТИТУТ (он же МАИ), независимо от места расположения, в т.ч. по адресу: Россия 125871 г. Москва, Волоколамское шоссе, 4 [64 FR 2935, 8 января 1999 г.]

НАЦИОНАЛЬНАЯ ЛАБОРАТОРИЯ СТАНДАРТОВ И КАЛИБРОВКИ (также известная как НАЦИОНАЛЬНЫЙ ЦЕНТР КАЛИБРОВКИ; также известная как NSCL), почтовый ящик № 4470, Дамаск, Сирия [Постановление о нераспространении ОМУ]

ГРУППА «НОВАЯ ЭРА» (она же Китайская группа «Новая Эра», она же она же Китайская компания Циншидаи, она же Xinchidai, она же XSD) [69 FR 56260, 20 сентября 2004 г.]

ЭНЕРГЕТИЧЕСКАЯ КОМПАНИЯ «НОВИН» (также известная как Энерджи Новин; также известная как Энергетическая компания «Новин»); конец Северного Карегарского проспекта, Тегеран, Иран [Постановление о нераспространении ОМУ].

ПРОМЫШЛЕННАЯ ГРУППА «САНАМ» (также известная как Группа «Санам Индастриз»), улица Пасдаран 15, Тегеран, Иран.



НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ЦЕНТР (также известный как CENTRE D'ETUDES ET RECHERCHES, также известный как «SSRC»), почтовый ящик № 4470, Дамаск, Сирия [Постановление о нераспространении ОМУ].

ПРОМЫШЛЕННАЯ ГРУППА «ШАХИД БАКЕРИ» (также известная как «СБИГ» ("SBIG")), Тегеран, Иран [Постановление о нераспространении ОМУ]

ПРОМЫШЛЕННАЯ ГРУППА «ШАХИД ХЕММАТ», (также известная как «ШИГ» ("SHIG")), шоссе «Дамавад Тегеран», Тегеран, Иран [Постановление о нераспространении ОМУ].

СТИГЕР, Якоб, для вручения по адресу: КОХАС АГ, Фрибург, FR, Швейцария, родился 27 апреля 1941 года в г. Алстаттен, SG, Швейцария (частное лицо). [Постановление о нераспространении ОМУ].

КОММЕРЧЕСКИЙ БАНК «ТАНЧОН» (ранее известный как КРЕДИТНЫЙ БАНК «ЧАНГВАНГ»; ранее известных как КОРЕЙСКИЙ КРЕДИТНЫЙ БАНК «ЧАНГВАНГ», округ Саемул 1-Донг Пьончон, Пхеньян, Северная Корея [Постановление о нераспространении ОМУ]

ТОРГОВАЯ КОРПОРАЦИЯ «ТОСОНГ ТЕКНОЛОДЖИ», Пхеньян, Корея [Постановление о нераспространении ОМУ].

ЦИНШИДАИ (XINSHIDAI) (она же Китайская группа «Новая Эра», она же Китайская компания Циншидаи (Xinshidai), она же группа «Новая Эра», она же XSD) [Свод федеральных постановлений США, т. 69, гл. 56260, 20 сентября 2004 г.]

XSD (она же Китайская группа «Новая Эра», она же Китайская компания Циншидаи (Xinshidai), она же группа «Новая Эра», она же Xinshidai) [Свод федеральных постановлений США, т. 69, гл. 56260, 20 сентября 2004 г.]

ГРУППА «Я МАХДИ ИНДАСТРИЗ», также известная как Научно-исследовательский промышленный комплекс «Я Махди»; также известная как Промышленный комплекс «Я Махди»; также известная как «УМА»); почтовый ящик 19395-4797, Тегеран, Иран.

<p>Приложение №1. Часть II.          Проект № 00012/00049          к Соглашению № RU/55229907/00012          от «31» Декабря 2002 г.          между Международным Фондом          Технологий и Инвестиций          и Nuclear Threat Initiative, Inc.          и к дополнительному соглашению о продлении          срока действия Соглашения          № RU/55229907/00012          от «31» Декабря 2005 г.</p>	<p>ANNEX I Part II.          THE PROJECT № 00012/00049          to the AGREEMENT between The International          Foundation of Technology and          Investment and          Nuclear Threat Initiative, Inc.          № RU/ 55229907/00012          of December 31, 2002          and Amendment to extend R&amp;D          target financing agreement          № RU/ 55229907/00012          as of December 31, 2005</p>
<p><b>Порядок финансирования          Проекта и предоставления Отчетов.</b></p>	<p><b>Financing Procedures of the Project and          Reports submission.</b></p>
<p>Данное Приложение заключено в Москве «__»          _____ 2007 года между <b>МЕЖДУНАРОДНЫМ          ФОНДОМ ТЕХНОЛОГИЙ И ИНВЕСТИЦИЙ</b>,          именуемым в дальнейшем "Фонд", в лице Директора  <b>Черчеса Юрия Ильича</b>, действующего на основании          Устава, <b>NUCLEAR THREAT INITIATIVE, INC</b>          (Вашингтон, США), именуемым в дальнейшем,          "Партнер", в лице Президента <b>Charles B. Curtis</b>,          действующего на основании Устава и  <b>ФЕДЕРАЛЬНЫМ ГОСУДАРСТВЕННЫМ          УЧРЕЖДЕНИЕМ НАУКИ          «ГОСУДАРСТВЕННЫЙ НАУЧНЫЙ ЦЕНТР          ВИРУСОЛОГИИ И БИОТЕХНОЛОГИИ          «ВЕКТОР»</b>», именуемым в дальнейшем,          "Исполнитель", в лице <b>Дроздова Илья          Геннадьевича</b>, действующего на основании Устава,          совместно именуемыми "Стороны", которые</p>	<p>This Annex is made in Moscow as of this __ day of          _____ 2007 by and between <b>THE          INTERNATIONAL FOUNDATION OF          TECHNOLOGY AND INVESTMENT</b>,          hereinafter referred to as the "Foundation",          represented by Director <b>Yuriy I. Cherches</b> acting in          accordance with the Foundation's Charter,  <b>NUCLEAR THREAT INITIATIVE, INC.</b>          (Washington DC, USA), hereinafter referred to as          the "Partner", represented by President <b>Charles B.          Curtis</b>, acting in accordance with Partner's Articles          of Incorporation, and  <b>FEDERAL STATE RESEARCH          INSTITUTION-STATE RESEARCH CENTER          OF VIROLOGY AND BIOTECHNOLOGY          'VECTOR'</b>, hereinafter referred to as "Grantee",          represented by <b>Drozdoov Ilyia Gennadievich</b>, acting          in accordance with Grantee's Charter (Foundation,          Partner and Grantee hereinafter jointly referred to as          the "Parties").</p>
<p><b>принимая во внимание, что:</b></p> <p>➤ Проект «Создание региональной референс-          лаборатории для ПЦР-диагностики вирусных          гепатитов на базе ФГУН ГНИЦ ВБ «Вектор»», в          дальнейшем именуемый «Проект», подан          Исполнителем в Фонд в виде оформленной заявки на          финансирование, принят Фондом и утвержден          Партнером с момента подписания Приложения №1          Часть I;</p>	<p><b>Understanding:</b></p> <p>➤ The Project "Establishing a regional          reference laboratory for PCR diagnostics of viral          Hepatitis at the facilities of FSRI SRC VB          VECTOR", hereinafter referred as the "Project", is          submitted to the Foundation as an application for          financing, accepted by the Foundation and approved          by the Partner upon signing Annex I Part I;</p> <p>➤ By signing the present Annex, Grantee</p>

<p>➤ Исполнитель, подписавший настоящее Приложение, согласен с положениями указанного Соглашения, будут действовать согласно его установлениям и в соответствии с настоящим Приложением;</p> <p>➤ Проект будет финансироваться от имени Фонда за счет средств, предоставленных Партнером.</p>	<p>agrees to the terms and conditions of the stated Agreement and shall act in compliance with the Agreement and the present Annex, and</p> <p>➤ The Project shall be financed on behalf of the Foundation at the Partner's expense.</p>
<p><i>настоящим договорились о нижеследующем:</i></p> <p><b>1. Предмет Приложения №1 Часть II</b></p> <p>1.1. Предметом Приложения №1 Часть II является определение порядка целевого финансирования Проекта Фондом из средств, предоставляемых Партнером в пользу Фонда и установление порядка предоставления отчетности Исполнителя перед Фондом.</p> <p>Стороны определили, что Исполнителем Проекта является Организация, подавшая заявку на финансирование Проекта в Фонд, далее «Организация» и физические лица, объединившиеся на основе общности целей во временный творческий коллектив и участвующие в Проекте, далее – «ВТК».</p>	<p><i>The Parties hereby agree as follows:</i></p> <p><b>1. Subject of Annex 1 Part II</b></p> <p>1.1. The subject of the Annex 1 Part II shall be the procedure of Project target financing by the Foundation at the Partner's expense in favor of the Foundation and Grantee's submission of reports to the Foundation.</p> <p>The Parties shall consider the Grantee participating in the Project to include an organization, hereinafter referred to as the "Organization", which has submitted the application with a request to finance the Project, and natural persons (individuals), hereinafter referred to as the "Individual Participants," participating in the Project.</p>
<p>1.2. Полномочным и ответственным представителем Исполнителя во взаимоотношениях с Фондом и Партнером с правом подписания научно-технических отчетов, заявок и иных документов, получения оборудования, иных материально-технических средств по Проекту, как от имени Организации, так и – ВТК, является Руководитель проекта <u>Нетесов Сергей Викторович</u> с момента подписания Сторонами настоящего Приложения.</p> <p>1.3. Николенко Татьяна Гордеевна (Руководитель программ), и Роберт Е. Берлз мл. (Старший Советник по программам России/СНГ, руководитель Московского представительства) являются полномочными и ответственными представителями Партнера во взаимоотношениях с</p>	<p>1.2. With regard to participating in legal relations with the Foundation and the Partner, the Grantee shall assign a representative authorized to sign technical reports, applications and to receive equipment / other material and technical means on the Project, hereinafter referred to as the "Project Manager". <u>Netesov Sergei Viktorovich</u> is appointed as the Project Manager and shall act upon signing the present Annex by the Parties on behalf of the Organization and the Individual Participants.</p> <p>1.3. With regard to participating in legal relations with the Foundation and the Grantee, the Partner assigns Tatiana G. Nikolenko (Program Manager, Biological) and Robert E. Berls Jr.</p>

<p>Фондом и Исполните. Названные представители наделяются следующими полномочиями:</p> <p>а) Утверждать лиц, входящих в состав ВТК;</p> <p>б) Утверждать замену членов ВТК новыми лицами в рамках выполнения работ по данному Проекту;</p> <p>в) Утверждать перемещение денежных средств между статьями бюджета Проекта, не меняя условий оплаты;</p> <p>г) Утверждать перемещение денежных средств с изменением условий оплаты</p> <p>д) Утверждать финансовые и научно-технические отчеты;</p> <p>е) Одобрять заявки от Исполнителя;</p> <p>ж) Утверждать изменения в ходе выполнения Проекта.</p>	<p>(Senior Advis for Russia/NIS Programs Director of the Moscow Office) to act as authorized representatives that are empowered to:</p> <p>a) Approve personnel to be a team member;</p> <p>b) Replace personnel in the Project team;</p> <p>c) Move money from one budget item to another without changing terms of payments;</p> <p>d) Move money with changing terms of payments;</p> <p>e) Approve financial and technical reports,</p> <p>f) Approve applications from the Grantee; and</p> <p>g) Approve changes during Project implementation.</p>
<p><b>2. Финансирование Проекта</b></p> <p>2.1. Общая стоимость Проекта определяется Сторонами в 325 500.00 долларов США (<i>Триста Двадцать Пять Тысяч Пятьсот долларов США 00 Центов</i>).</p>	<p><b>2. Financing of the project</b></p> <p>2.1. The total cost of the Project is determined by the Parties to be in the amount of Three Hundred Twenty Five Thousand Five Hundred and No/100 US Dollars (\$325,500.00).</p>
<p>2.2. Стоимость Проекта включает в себя:</p> <p>2.2.1. Денежные средства, перечисляемые Фондом на расчетный счет Организации или указанного ею лица для финансирования сметных материальных расходов по Проекту (расходов на приобретение необходимого оборудования, иных материально-технических средств и накладных расходов по Проекту).</p> <p>2.2.2. Средства, передаваемые Фондом в качестве выплат (грантов) членам ВТК. Фонд выплачивает гранты членам ВТК на сметную сумму и в порядке, устанавливаемом в соответствующем Договоре, заключаемом между Фондом и</p>	<p>2.2. The cost of the Project shall include:</p> <p>2.2.1. Funds transferred by the Foundation to the bank account of Grantee or its designee to reimburse estimated expenses on the Project (expenses on procurement of equipment, other material and technical means and overhead necessary for the Project).</p> <p>2.2.2. Funds transferred by the Foundation as awards (grants) to Individual Participants. The Foundation shall award grants to the Individual Participants in the estimated amount and in compliance with the procedure established in the Contract concluded between the Foundation and the</p>

<p>Руководителем ВТК (руководителем Проекта).</p> <p>Руководитель Проекта вправе подать на рассмотрение Фонда Заявку об увеличении суммы индивидуальных выплат, при условии экономии Исполнителем иных расходов по Проекту.</p>	<p>Head of the Individual Participants (the Project Manager).</p> <p>The Project Manager is entitled to submit an Application with a request to increase the amount of grants to the Individual Participants to the Foundation in the event of saving other expenses on the Project by Grantee.</p>
<p>2.3. Фонд по Заявке Исполнителя может принять на себя обязательства по поставке последнему (финансированию поставки) необходимого для реализации Проекта оборудования, технических средств, материалов и т.п. (далее - оборудование и материалы) в рамках программ безвозмездной технической помощи.</p> <p>В случае принятия Фондом на себя указанных обязательств, Стороны подписывают соглашение о предоставлении безвозмездной технической помощи, в котором Стороны определяют номенклатуру, количество технической помощи и ее общую стоимость. Соглашение о предоставлении технической помощи станет неотъемлемой частью настоящего Соглашения.</p>	<p>2.3. Under Grantee's Application and in the course of the gratuitous technical programs' realization, the Foundation may undertake to make a delivery (or to finance a delivery) of equipment, technical facilities, materials, etc. (hereinafter referred to as "Equipment and Materials) necessary for the implementation of the Project.</p> <p>Should the Foundation undertake the above-mentioned obligations, the Parties shall sign an agreement on providing gratuitous technical assistance, in which the Parties shall specify the nomenclature, amount of technical assistance and the total cost of this assistance. The agreement on providing gratuitous technical assistance shall be an integral part of the present Agreement.</p>
<p><b>3. Порядок финансирования Проекта</b></p> <p>3.1. Полученные от Партнера средства, Фонд аккумулирует на своем расчетном счете.</p> <p>3.2. Фонд начинает финансирование Проекта с момента получения им от Партнера денежных средств и производит платежи Исполнителю в соответствии с установленным планом графиком финансовых выплат по Проекту.</p>	<p><b>3. The project financing procedure</b></p> <p>3.1. The Foundation shall accumulate funds transferred by the Partner on its bank account.</p> <p>3.2. The Foundation shall begin to finance the Project upon receipt of funds from the Partner and shall produce payments to Grantee in compliance with the Financial Schedule of the Project set forth below.</p>

**План график финансовых выплат по Проекту**

Этапы Проекта (календарный план)	Сумма выплат, долл. США		
	Аванс	Текущие Выплаты	Отложенный платеж
1 квартал	140 000,00		

2-7 квартал		163 500,00	
8 квартал			22 000,00
<b>The Financial Schedule of the Project</b>			
Stages of the Project (Scheduling)	Amount of payments		
	Prepayment, USD	Scheduled Payments in USD	Delayed Payments in USD
1 quarter	\$140,000.00		
2-7 quarter		\$163,500.00	
8 quarter			\$22,000.00

<p>3.3. Фонд производит поэтапные платежи Организации в соответствии с поступающими от неё заявками на финансирование Проекта (далее - «Заявка») в течение десяти (10) рабочих дней с момента получения заявки.</p> <p>Заявка должна содержать информацию о назначении платежа и сумму платежа.</p>	<p>3.3. The Foundation shall produce staged payments to the Organization under applications with a request to finance the Project (the Application) submitted by the Organization and within ten (10) business days upon receipt of such Application. The Application shall contain information on the purpose of the payment and on sum of the payment.</p>
<p>3.4. Гранты ВТК выплачиваются Фондом в соответствии с пп.2.2.2. п.2. настоящего Приложения.</p>	<p>3.4. Grants to the Individual Participants shall be awarded in compliance with Article 2.2.2 of the present Annex.</p>
<p>3.5. В случае если денежные средства, переданные Фондом Исполнителю или членам ВТК на реализацию Проекта были использованы не в соответствии с целями Проекта и данного Соглашения, Исполнитель и члены ВТК совместно и в равных долях несут материальную ответственность перед Фондом, а Фонд перед Партнером в объеме использованных нецелевым образом денежных средств. Исполнитель и члены ВТК несут полную ответственность перед Партнером за целевое использование полученных денежных средств.</p>	<p>3.5. In case financial resources for the Project realization are transferred to Grantee or Individual Participants by the Foundation and such funds have not been used in strict compliance with the Project goals and present Agreement, Grantee and Individual Participants shall bear material responsibility and joint and several liability to Foundation, and Foundation to Partner for the amount of such misused funds. Grantee and Individual Participants are each fully responsible to Partner for appropriate use of received funds.</p>

3.6. Исполнитель гарантирует Фонду, Партнеру, их руководителям, должностным лицам, сотрудникам, консультантам, представителям и агентам (при отдельном упоминании «Гарантируемая сторона») возмещение убытков, которые могут возникнуть в результате претензий третьих лиц, долговых обязательств, исковых требований, судебных разбирательств, штрафных санкций, процентов, расходов (далее «Претензии»), включая без ограничения разумные расходы по представительству и ведению бухгалтерского учета, возникшие в результате нарушения Исполнителем предоставленных им гарантий в рамках данного Соглашения или Проекта, либо в результате нарушения условий настоящего Соглашения, либо в результате допущенной небрежности в виде действий или бездействий Исполнителя, его руководителей, должностных лиц, сотрудников, консультантов, представителей, агентов или членов ВТК, связанных с работой по данному Соглашению или Проекту. Помимо вышеизложенного, Исполнитель гарантирует всем Сторонам возмещение убытков, которые могут возникнуть в результате: 1) получения любых необходимых разрешений и лицензий в соответствии с федеральным, региональным и муниципальным законодательством, применимым при оказании соответствующих услуг и оплате дополнительных расходов на такие разрешения и лицензии; 2) оплаты любых таможенных платежей, пошлин и налогов, взимаемых Российской Федерацией с бюджета Проекта либо Партнером, или его сотрудниками, или агентами в связи с выполнением настоящего Соглашения или Проекта; 3) причинения ущерба личности или имуществу в результате виновных или неосторожных действий или бездействий Исполнителя или членов ВТК; 4) каких-либо претензий, предъявленных в результате причинения убытков, телесных повреждений или смерти, возникших в связи с Проектом, с тем, чтобы

3.6. Grantee shall indemnify and hold the Foundation, the Partner, and their respective directors, officers, employees, consultants, representatives and agents (each an "Indemnified Party") harmless from and against all third party claims, liabilities, suits, demands, losses, judgments, fines, penalties, interest, expenses and costs (collectively "Claims"), including, without limitation, reasonable accounting and attorneys' fees and disbursements, which result from any breach of Grantee's representations or warranties made in relation to this Agreement or the Project, or from any breach of the terms of this Agreement, or from any negligent acts or omissions of Grantee, its directors, officers, employees, consultants, representatives, agents or any Individual Participants relating to, or in any way connected with, activities conducted pursuant to this Agreement or the Project. Without limiting the foregoing in any way, Grantee shall indemnify and hold each Indemnified Party harmless with respect to: (i) obtaining any and all necessary licenses and permits, complying with any and all national, regional, local and municipal laws, codes and regulations applicable to the performance of the work and payment of any and all additional costs associated with the foregoing; (ii) payment of any customs, duties or taxes which may be imposed by Russia on Project funds or Partner or its employees or agents in connection with this Agreement or the Project; (iii) all damages to persons or property that occur as a result of Grantee's or Individual Participant's acts, omissions, fault or negligence; (iv) any and all Claims arising from or connected with any alleged and/or actual injury, loss or death, accidental or otherwise, occurring during or related to the Project or performance thereof, to include claims lodged by the estate of the affected party; and (v) all legal, technical and operational aspects of planning, implementing and fully completing the

<p>... честь претензии, заявленной потерпевшей стороной; 5) любых юридических, технических и организационных аспектов планирования, выполнения и полного завершения работ по Проекту.</p>	<p>Project.</p>
<p><b>4. Отчеты о расходах и ходе выполнения Проекта</b></p> <p>4.1. Исполнитель обязуется представлять в Фонд финансовые и научно-технические отчеты по Проекту в соответствии с условиями настоящего Приложения.</p>	<p><b>4. Reports on expenses and on project implementation</b></p> <p>4.1. Grantee shall undertake to submit technical and financial reports on the Project to the Foundation in compliance with the terms of the present Annex.</p>
<p>4.2. Финансовые отчеты Организации.</p> <p>4.2.1. Организация, в случае получения от Фонда денежных средств, оборудования и (или) иных материально-технических средств по Проекту, представляет Фонду текущие отчеты об их целевом использовании поэтапно.</p> <p>4.2.2. Отчеты составляются Организацией в одном экземпляре на бумажном носителе и подписываются руководителем Организации (иным уполномоченным лицом) и главным бухгалтером.</p> <p>4.2.3. Организация представляет Фонду Итоговый финансовый отчет в рамках полученного им имущества и средств по Проекту в течение пяти (5) банковских дней после окончания или прекращения Проекта.</p>	<p><b>4.2. Financial reports of the Organization:</b></p> <p>4.2.1. In the event that the Organization receives funds, equipment or other material and technical means on the Project from the Foundation, the Organization shall undertake to submit routine reports on the use of such assets on a stage basis.</p> <p>4.2.2. The written reports shall be drawn-up by the Organization in one copy and shall be signed by the head of the Organization (other authorized officer) and its Chief Accountant.</p> <p>4.2.3. The Organization shall submit the Final financial report on assets granted to the Organization within the Project to the Foundation within five (5) business days upon accomplishment or termination of the Project.</p>
<p>4.3. Финансовые отчеты от имени ВТК представляются Руководителем ВТК в порядке, на условиях и сроки, устанавливаемые Договором.</p>	<p>4.3. Financial reports on behalf of the Individual Participants shall be submitted by the Head of the Individual Participants in compliance with terms and conditions set forth in the Contract.</p>
<p>4.4. Исполнитель представляет Фонду объединенные научно-технические отчеты (Организация/ВТК) поэтапно.</p>	<p>4.4. Grantee shall submit consolidated technical reports (Organization/Individual Participants) to the Foundation on a stage basis.</p>
<p>4.5. Отчеты Исполнителя считаются принятыми после утверждения Партнером сводных Отчетов Фонда.</p>	<p>4.5. The reports of the Grantee shall be deemed accepted after approval of the combined reports of the Foundation by the Partner.</p>




<p>6. Если указанные в настоящем Уставе, отчеты не представлены Исполнителем своевременно, то Фонд обращается к указанным лицам с письменным запросом. В случае игнорирования запроса, Фонд и Партнер прекращают финансирование Проекта и возмещение понесенных Исполнителем расходов</p>	<p>4.6. Should the Grantee fail to submit reports enumerated in the present Article in proper time, the Foundation shall apply to Grantee with a written request. In the event that such request is ignored, the Foundation and the Partner shall cancel financing of the Project and reimbursement of expenses incurred by Grantee.</p>
<p>4.7. В случае если Партнер принимает решение прекратить дальнейшее финансирование этапов Проекта в результате неполного и (или) несоответствующего выполнения работ Исполнителем, Фонд возвращает Партнеру полученные от него, но не перечисленные Исполнителю средства.</p>	<p>4.7. In the event that the Partner decides to stop further financing of the Project stages resulting from an incomplete and/or a non-consistent performance of Grantee, the Foundation shall pay back funds received from the Partner, but not transferred to Grantee, to the Partner.</p>
<p><b>5. Заключительные положения</b> 5.1. Настоящее Приложение I вступает в силу со дня его подписания надлежащими представителями Сторон и действует до полного исполнения Сторонами своих обязательств в связи с осуществлением данного Проекта.</p>	<p><b>5. Miscellaneous</b> 5.1. The present Annex I shall come into force on the day of its signing by the authorized representatives of the Parties and shall be effective until the Parties fulfill their obligations under the current Project in full measure.</p>
<p>5.2. Изменения и дополнения в Приложение № I Часть II действительны, если они составлены в письменной форме и подписаны надлежащим образом уполномоченными представителями Сторон, если иное не предусмотрено соглашением Сторон.</p> <p><b>В СВИДЕТЕЛЬСТВО ЧЕГО</b> Стороны составили настоящие Соглашение на английском и русском языках в двух подлинных экземплярах в день и год, установленный в Преамбуле.</p>	<p>5.2. All amendments to this Annex I Part II shall only be effective if set forth in writing and signed by duly authorized representatives of the Parties, if there is no contrary agreement between the Parties.</p> <p><b>IN WITNESS WHEREOF</b>, the Parties hereto have caused this Agreement to be executed in Russian and in English in duplicate on the day and year indicated in the Preamble.</p>

Подписи Сторон


Signatures

От Фонда:  
Директор

  
Ю.И. Черков


On behalf of the Foundation:

Director

  
Yury I. Cherkov


От исполнителя:

Генеральный Директор

  
И. Г. Дроздов

On behalf of Grantee:

President

  
Ilya G. Drozdov

От Партнера:  
Президент

  
Charles B. Curtis

On behalf of the Partner:

President

  
Charles B. Curtis

<p>Приложение № 2. Проект № 00012/00049 к Соглашению № RU/55229907/00012 от «31» Декабря 2002 г. между Международным Фондом Технологий и Инвестиций и Nuclear Threat Initiative, Inc. и к дополнительному соглашению о продлении срока действия Соглашения № RU/55229907/00012 от «31» Декабря 2005 г.</p>	<p>ANNEX II THE PROJECT № 00012/00049 to the AGREEMENT between The International Foundation of Technology and Investment and Nuclear Threat Initiative, Inc. № RU/55229907/00012 of December 31, 2002 and Amendment to extend R&amp;D target financing agreement № RU/55229907/00012 as of December 31, 2005.</p>
<p><b>Порядок расчетов между Фондом и Партнером по Проекту № 00012.00048</b></p> <p><b>"Создание региональной референс- лаборатории для ПЦР-диагностики вирусных гепатитов"</b></p>	<p><b>The Procedure of Payments between the Foundation and the Partner The Project # 00012/00048</b></p> <p><b>"Establishing a regional reference laboratory for PCR diagnostics of viral Hepatitis at the facilities of FSRI SRC VB VECTOR"</b></p>
<p>Данное Приложение составлено в Москве «_» _____ 2007 года между <b>МЕЖДУНАРОДНЫМ ФОНДОМ ТЕХНОЛОГИЙ И ИНВЕСТИЦИЙ (Москва, Российская Федерация),</b> именуемым в дальнейшем "Фонд", в лице Директора Черчеса Юрия Ильича, действующего на основании Устава, и <b>NUCLEAR THREAT INITIATIVE, INC (Вашингтон, США),</b> именуемым в дальнейшем, "Партнер", в лице Президента Charles B. Curtis, действующего на основании Устава, совместно именуемыми "Стороны", которые</p>	<p>This Annex is made in Moscow as of this _ day of _____ 2007 by and between <b>THE INTERNATIONAL FOUNDATION OF TECHNOLOGY AND INVESTMENT (Moscow, RF),</b> hereinafter referred to as the "Foundation", represented by Director Yuriy I. Cherches acting in accordance with the Foundation's Charter, and <b>NUCLEAR THREAT INITIATIVE, INC. (Washington DC, USA),</b> hereinafter referred to as the "Partner", represented by President Charles B. Curtis, acting in accordance with the Partner's Articles of Incorporation, jointly referred to as the "Parties."</p>
<p><b>настоящим договорились о нижеследующем:</b></p> <p><b>1. Предмет Приложения № 2</b> Предметом настоящего приложения является определение порядка оплаты Партнером Фонду стоимости Проекта, определение размера возмещения расходов Фонда по Проекту и суммы целевого финансирования собственных проектов Фонда в соответствии с условиями и</p>	<p><b><i>The Parties hereby agree as follows:</i></b></p> <p><b>1. Subject of Annex №II</b> The subject of Annex II shall be the procedure of compensation of the Project cost by the Partner to the Foundation, determination of reimbursement of the Foundation on the Project and defining the amount of financing for the projects of the</p>

<p>сроками установленными ниже.</p>	<p>Foundation in accordance with the terms and conditions set forth below.</p>
<p><b>2. Срок действия</b>          Настоящее Приложение 2 вступает в силу со дня его подписания надлежащими представителями Сторон и действует до полного исполнения Сторонами своих обязательств в связи с осуществлением данного Проекта.</p>	<p><b>2. Term</b>          Annex II shall come into force on the day of its signing by the authorized representatives of the Parties and shall be effective until the Parties fulfill their obligations under the current Project in full measure.</p>
<p><b>3. Оплата.</b>          3.1. Партнер выделяет Фонду средства целевого финансирования на Проект в сумме 325 500.00 долларов США (<i>Триста двадцать пять тысяч пятьсот долларов США 00 центов</i>), согласованной Сторонами в Приложении №1 Часть I, и 24 500.00 долларов США (<i>Двадцать четыре тысячи пятьсот долларов США 00 центов</i>) на компенсацию расходов Фонда в связи с его уставной деятельностью.</p>	<p><b>3. Payment</b>          3.1. The Partner shall transfer to the Foundation financial means for the Project in the sum of Three Hundred Twenty Five Thousand Five Hundred and No/100 US Dollars (\$325,500.00), agreed by the Parties in Annex I Part I, and Twenty Four Thousand Five Hundred and No/100 US Dollars (\$24,500.00) to reimburse Foundation's expenses on the Project maintenance.</p>
<p><b>ИТОГО: 350 000 долларов США.</b></p>	<p><b>TOTAL: 350,000 US dollars</b></p>
<p>Возмещение расходов Фонда, связанных с ведением проекта, составляет 7% от общей суммы, указанной в статье 3.1 настоящего Приложения.</p>	<p>The amount of Partner's reimbursement to the Foundation is equal to 7% of the total sum specified in Article 3.1 of the present Annex.</p>
<p>3.2. Партнер осуществляет целевое финансирование Проекта двумя платежами.</p>	<p>3.2. The Partner shall transfer the financial means for the Project in two payments.</p>
<p>3.3. Порядок платежей Фонду:</p> <ul style="list-style-type: none"> <li>• Платежи по Проекту должны быть осуществлены Партнером не позднее, чем через 30 (тридцать) банковских дней после выставления Фондом соответствующего инвойса.</li> </ul>	<p>3.3. The procedure of payments to the Foundation:</p> <ul style="list-style-type: none"> <li>• Payments under the Project shall be effected by the Partner not later than 30 (thirty) business days after the Foundation appropriately invoices.</li> </ul>
<p>3.4. Переоценка остатка средств по проекту за отчетный период (календарный квартал, год) производится Фондом за счет средств Проекта в соответствии с законодательством России.</p> <p>3.5. Средства, выделенные Партнером на финансирование Проекта и оставшиеся у</p>	<p>3.4. Revaluation of the remainder of funds under the Project for the accountable period (calendar quarter, year) is carried out by the Foundation for the account of the Project funds in accordance with legislation of the Russian Federation.</p>

<p>Фонда после его окончания, направляются Фондом на свои уставные цели. Данное положение распространяется на остаток средств, не превышающий в сумме 100 00 долларов США (<i>Сто долларов США 00 центов</i>).</p> <p>3.6. Фонд, перечисливший денежные средства Организации и/или членам ВТК не несет имущественной ответственности перед Партнером за нецелевое использование полученных ими средств.</p>	<p>3.5. Funds, transmitted by the Partner in order to finance the Project and not used by the Foundation until final completion of the Project, are directed at the goals stipulated in the Foundation charter. The present provision is effective for the remainder of funds that does not exceed the amount of One Hundred and No/100 US Dollars (\$100.00).</p> <p>3.6. Having produced payments to the Grantee and/or the Individual Participant members, the Foundation shall not be liable to the Partner for non-project use of the transferred assets.</p>
<p>3.7. Партнер, одобряя Проект и перечислив средства Фонду, не несет ответственность за осуществление Фондом платежей непосредственно Исполнителю, если только сам не давал Фонду распоряжения о не перечислении средств по Проекту.</p> <p>В случае неисполнения Фондом обязательств по финансированию Проекта, предусмотренных Приложением I после получения средств от Партнера, Фонд обязуется незамедлительно вернуть полученные им в соответствии с п.3. настоящего Приложения суммы по письменному распоряжению Партнера в размере неиспользованных средств.</p>	<p>3.7. Having approved the Project and produced payments to the Foundation, the Partner shall not be liable for payments to the Grantee affected by the Foundation unless the Partner has ordered not to finance the Project.</p> <p>In case the Foundation fails to fulfill its obligations under Annex I after the Partner has transferred Project payments and Foundation's expenses to the Foundation bank account, the Foundation shall promptly, upon the Partner's written request, return to the Partner part of the total sum mentioned in Article 3 of the present Annex II in the amount of the failed financial obligations of the Foundation.</p>
<p><b>4. Изменения.</b></p> <p>Настоящее приложение может быть изменено только с письменного согласия между Фондом и Партнером, если иное не предусмотрено соглашением Сторон.</p>	<p><b>4. Amendments</b></p> <p>The present Annex may only be amended if agreed by the Foundation and the Partner in writing, if there is no contrary agreement between the Parties.</p>
<p><b>5. Прекращение.</b></p>	<p><b>5. Termination of the Annex</b></p>

<p>В случае прекращения финансирования Проекта в соответствии с условиями раздела 9 Соглашения о целом финансировании научно-технического проекта, Исполнитель возвращает Фонду ранее перечисленные денежные средства, а Фонд перечисляет эти средства Партнеру после поступления на счет Фонда, за исключением фактически понесенных и подтвержденных Исполнителем и Фондом расходов.</p>	<p>In the event that the Project is terminated in compliance with Article 9 of the Agreement, Grantee shall return granted funds to the Foundation and the Foundation shall transfer the aforementioned assets to the Partner upon receipt, not including actual and confirmed expenses of the Foundation and Grantee.</p>
<p><b>В СВИДЕТЕЛЬСТВО ЧЕГО</b> Стороны составили настоящее Приложение на английском и русском языках в двух подлинных экземплярах в день и год, установленный в Преамбуле.</p>	<p><b>IN WITNESS WHEREOF</b>, the Parties hereto have caused this Annex to be executed in Russian and in English in duplicate on the day indicated in the Preamble.</p>
<p><b>7. Банковские реквизиты Фонда.</b></p>	<p><b>7. Bank requisites of the Foundation</b></p>

Beneficiary  
Account  
Beneficiary Bank  
Address beneficiary bank  
SWIFT  
Account  
Intermediary bank  
SWIFT

International Foundation of Technology and Investment  
40703840816861092930  
Banque Societe Generale Vostok, Moscow  
2, Yakimanskaya nab., 6 floor, 119180, Moscow, Russia  
SOGERUMM  
00171352  
SG NEW YORK  
SOGEUS33

**ПОДПИСИ**

От Фонда:

Директор

  
Ю. И. Черчес

On behalf of The Foundation:

Director

  
Yury I. Chorches

**SIGNATURES**


От Партнера:

Президент

  
Charles B. Curtis

On behalf of the Partner:

President

  
Charles B. Curtis

## NUCLEAR THREAT INITIATIVE, INC. AWARD AGREEMENT

ORGANIZATION: Academy of Scientific Research and Technology ("Awardee")  
 PROJECT: Joint Training on Laboratory Biosafety and Biosecurity in Egypt  
 AWARD NO.: 2053  
 APPROVED AMOUNT: for up to \$ 69,192 ("Award")

1. This Award is for the specific purposes set forth in the written proposal to Nuclear Threat Initiative, Inc ("NTI") attached hereto as Exhibit "A" (for convenience of reference, such purposes hereinafter the "Project" and such proposal hereinafter the "Proposal"), and payments received by Awardee may be expended for no other purpose without the prior written consent of NTI. In addition, the Project budget attached to and included as a part of the Proposal (the "Project Budget") may not be modified or adjusted without the prior written consent of NTI. Consistent with the foregoing, all payments received by Awardee may be expended only for charitable, scientific, literary or educational purposes ("Charitable Purposes") within the meaning of Sections 501(c)(3) and 170(c)(2) of the Internal Revenue Code of 1986, as amended (the "Code"). Awardee shall return any funds not used for the specific Charitable Purposes set forth in the attached Proposal unless Awardee has obtained NTI's prior written approval of an alternative use of the funds.
2. Awardee agrees that none of the funds covered by this Award Agreement (with all exhibits and any special stipulations, hereinafter the "Agreement") shall be used to participate in, or intervene in any political campaign on behalf of (or in opposition to) any candidate for public office, to influence legislation, to carry on voter registration drives, to make grants to individuals or other organizations, or to undertake any nonexempt activity, when such use of the funds would be a taxable expenditure if made directly by NTI.
3. By checking the appropriate box below, the undersigned officer of Awardee hereby certifies that Awardee is (check applicable and strike out statements that do not apply):
  - Tax exempt under Code Section 501(c)(3) and "not a private foundation" within the meaning of Code Section 509(a), or in the absence of such a determination, Awardee is a state or any political subdivision thereof within the meaning of Code Section 170(c)(1), or a state college or university within the meaning of Code Section 511(a)(2)(B) (hereinafter referred to as a "Public Charity"). (Please provide a copy of any letter from the IRS determining this status.)
  - Tax exempt under Code Section 501(c)(3) and classified as a private foundation under the Code. (Please provide a copy of the letter from IRS determining this status.)
  - Not tax exempt under Code Section 501(c)(3).
4. If Awardee is currently tax exempt under Code Section 501(c)(3) or classified as a Public Charity under the Code, then in the event Awardee loses such tax exempt or Public Charity status, this Agreement shall be considered null and void and all unexpended Award funds shall be immediately returned to NTI.
5. Awardee agrees to immediately notify NTI, in writing, if: (i) Awardee's federal tax status is revoked or altered; (ii) Awardee has reasonable grounds to believe that its federal tax status may be revoked or altered; or (iii) Awardee has reason to believe that the Award cannot be or continue to be expended for the specific purposes set forth in the attached Proposal.
6. In order to ensure that there is no misunderstanding by the general public regarding NTI's involvement with the Project, NTI reserves the right to, in advance, review, comment on and otherwise approve any statements, announcements or releases proposed to be made by Awardee to the press or public regarding NTI's involvement with the Project. Awardee may, however, make reference to NTI's support of Awardee's work generally as Awardee executes the Project.
7. NTI reserves the right, prior to submission for publication, to review and comment upon any documents, manuscripts, papers, exhibits or other materials that might result from the Project. Awardee agrees to duly consider comments, suggestions or issues that NTI identifies as noteworthy or of significance. At NTI's election, NTI's support will be acknowledged in any such publication. Any such acknowledgment will indicate, "This (publication) has been

supported (in part) with funds from the Nuclear Threat Initiative. Its contents represent the views, findings and opinions of the authors, and are not necessarily those of the Nuclear Threat Initiative."

8. Awardee hereby grants and NTI hereby accepts a royalty-free, nonexclusive, irrevocable and perpetual license (with a right to sublicense) to reproduce, publish and otherwise use and authorize others to reproduce, publish and otherwise use, any materials resulting from the Project
9. Awardee shall cooperate with NTI in supplying any additional information or in complying with any laws, rules, regulations, or procedures which might be required by any governmental authority in order for NTI to comply with and establish the fact that it has observed all requirements of all laws, rules and regulations with respect to this Award
10. Awardee agrees to keep accurate and complete books and records of receipts and expenditures made in connection with the Project. Awardee will maintain such books and records in a manner that the receipts and expenditures of Award funds will be shown separately thereon. Awardee will keep records of receipts and expenditures of Award funds as well as copies of reports submitted to NTI and supporting documentation for at least four (4) years after the completion of use of Award funds, and will make the same available to NTI for inspection as reasonably required from the time of Awardee's acceptance of this Award through such period.
11. Both the quality of the work done and Awardee's progress toward achieving the goals of the Award will be reviewed by NTI. NTI may monitor and conduct formal evaluations of operations and progress under this Award, which may include visits from NTI personnel to observe Awardee's projects and programs and to review financial and other records and materials connected with activities financed by this Award, and Awardee agrees to timely cooperate and assist NTI with such monitoring and evaluation activities.
12. It is anticipated the Award will be paid in accordance with the disbursement schedule attached hereto as Exhibit "B". However, in the case of a multi-year or other Award payable in installments, the payment of each installment shall be additionally subject to a determination by NTI, in its sole and absolute discretion, that: (i) Awardee has timely provided the deliverables and services set forth in the attached Proposal; (ii) Awardee has timely delivered the report(s) requested by NTI in the attached guidelines; (iii) payments received from NTI have been used solely for the purposes for which they were authorized; (iv) additional payments shall be used solely for the purposes for which the Award was authorized; (v) Awardee has otherwise strictly complied with the terms and conditions of this Agreement; and (vi) there have been no material changes in Awardee's operations, staffing or funding which would adversely affect the objectives for which the Award was authorized; and (vii) the context in which the Project is to be executed has not been changed so substantially that the objectives for which the funds were authorized cannot be adequately realized.
13. Awardee is encouraged to submit intermittent updates of Project activities. These updates should be selective and succinct, while providing a sense of what the organization is accomplishing with the NTI Award.
14. In addition to the discretionary updates set forth in the foregoing section, Awardee shall provide more detailed reporting as described in Exhibit "C" hereto.
15. In the case of any violation by Awardee of any of the terms or conditions of this Award, including but not limited to not executing the Project in strict compliance with the Proposal, or in the event of any change in or challenge by the Internal Revenue Service of Awardee's federal tax status, NTI reserves the right in its absolute discretion to terminate the Award. NTI's determination will be final and will be binding and conclusive upon Awardee. Upon termination of this Award for any reason, NTI will withhold any further payment of Award funds and all unexpended Award funds and any portion of the Award funds which was not spent for the Project shall be immediately returned to NTI.
16. Awardee shall indemnify and hold NTI, its directors, officers, employees, consultants, representatives and agents harmless from and against all third party claims, liabilities, suits, demands, losses, judgments, fines, penalties, interest, expenses and costs (including, without limitation, reasonable accounting and attorneys' fees and disbursements) which result from any breach of Awardee's representations or warranties made in relation to this Agreement, the Proposal, or the Project, or from any breach of the terms of this Agreement, or from any negligent acts or omissions of Awardee, its directors, officers, employees, consultants, representatives and agents relating to, or in any way connected with, activities conducted pursuant to this Agreement.
17. Awardee understands that there is no commitment by NTI to supply any further support for Awardee. NTI considers each request and proposal on an individual basis, and this Award is not to be construed as establishing a precedent for further support.



18. This Agreement and the exhibits and any special stipulations attached hereto constitute the entire understanding of NTT and Awardee with respect to the subject matter hereof, and supersede all prior agreements and understandings, whether oral or written. This Agreement may not be amended or modified except in a writing signed by NTT. This Agreement shall be deemed to be made under, and in all respects shall be interpreted under and governed by, the laws of the District of Columbia, U.S.A.

19. The special stipulations contained on Exhibit "D" are hereby incorporated herein by reference.

The undersigned duly authorized official of Awardee accepts and agrees to, on behalf of Awardee, these terms and conditions, as of the date set forth below.

**AWARDEE:**

Academy of Scientific Research and Technology

By: Mohamed Dia Eldin Hassanein

Title: Head of Management office

Date: March, 16/2007

Exhibit "A"**Purpose**

The purpose of the workshop, Joint Training on Laboratory Biosafety and Biosecurity in Egypt, is to introduce the concept of laboratory biosecurity; to share experiences and perspectives among the participants; and to foster collaborations that will lay the foundations for improving laboratory biosecurity in Egypt. The effective implementation of laboratory biosecurity depends on cooperation among diverse communities, including scientists, policy makers, security engineers, and law enforcement officials. All of these professionals are critical to the implementation of pathogen security at a facility, and this workshop will seek to engage all of these stakeholders.

The three-day workshop will cover the principles of laboratory biosecurity and biosafety. The core material will comprise lectures on the rationale for biosecurity, an overview of risk assessment and risk management, and an introduction to the components (physical security, personnel security, transport security, material control & accountability, information security, and program management).

This workshop will include lectures on the fundamentals of both biosafety and biosecurity. There has been a growing recognition that there cannot be biosecurity without biosafety. Indeed, some biosecurity measures do overlap with existing biosafety measures. Biosecurity and biosafety differ fundamentally in that biosecurity deals with the *deliberate* attempts to acquire and release biological agents, while biosafety measures prevent the *accidental* release of biological organisms from the lab. Both biosecurity and biosafety will be included in the workshop.

**Background**

NTI proposed to partner with Sandia National Laboratories' Biological Weapons Nonproliferation Program (BWNPP) to conduct a national workshop on laboratory Biosecurity and Biosafety in Egypt. The NTI Board of Directors approved this proposal at the May 2006 meeting.

**Workshop**

To execute this proposed workshop in Egypt, Sandia National Labs assisted NTI in identifying The Academy of Scientific Research and Technology (ASRT) as the Egyptian institution to host the event. NTI will fund the ASRT to host the workshop and Sandia National Laboratories will develop the curriculum. Sandia National Laboratories will identify other funding to support its role in this project. The workshop, Joint Training on Laboratory Biosafety and Biosecurity in Egypt, will raise awareness of the threat of bioterrorism and the need for safe and secure handling of dangerous biological materials in legitimate bioscience facilities.

**Deliverables**

The Academy of Scientific Research and Technology will be responsible for organizing the logistical elements (accommodations, meals, meeting space) for the workshop and will be required to submit post-workshop Final Financial and Narrative Reports to NTL.

**Detailed Budget of Biosafety  
and Biosecurity Workshop, Egypt  
3-5 April 2007**

Item	Details of item	Total
Accommodation	100 persons x 4 days x 61\$	24400
Breakfast & Dinner	100 persons x 4 days x 22\$	8800
Lunch Box	220 persons x 3 days x 6\$	3960
Coffee Breaks	200 persons x 3 days x 2 times x 4.4\$	5280
Official Dinner (Nile Cruise)	220 persons x 26\$	5200
Buses	4 buses x 175\$	700
Stationary	(including bags)	3200
Rent of visual equipments	-----	1400
Transportation for people coming from outside of Cairo	100 persons x 8 8\$ in average	880
For printing certificates	170 persons x 2\$	340
Incentives for people working out of working hours		3500
10% for facing unexpected expenditure		5766
10% for any changing in the price		5766
<b>TOTAL</b>		<b>69192</b>

Exhibit "B"

## Tentative Disbursement Schedule

Subject to the terms and conditions of the Agreement, it is anticipated the Award will be disbursed as follows:

Disbursement Date	Instalment Amount
Upon signature of Agreement	\$57,660
Upon Receipt of Invoice for Contingent Funds Used	Up to \$11,532

Exhibit "C"

Nuclear Threat Initiative, Inc.  
Reporting Guidelines

At the end of each Award year and at such time as the Award funds are fully expended, NTI requires for our records an annual or final report, as appropriate, which will (i) describe in narrative fashion what was achieved with the Award funds; and (ii) provide a full financial accounting of the Award.

**I. Narrative Report**

Each narrative report should briefly (no more than five pages) summarize how the Award was used and the results which were achieved. The report will be used by NTI staff to evaluate and to provide an overview of your work for our Board of Directors. The following list, insofar as relevant to our Award to your organization, may provide guidance in the preparation of your reports:

- a. Did the Project achieve the objectives outlined in your organization's Proposal? If not, how did the results vary from these objectives? Explain any milestones that have been achieved. How do you view the future of the Project?
- b. What developments or implementations of solutions to the problems addressed by this Award have occurred because of this Project? What, if anything, has/is occurring in the field that has changed the climate surrounding the issue?
- c. Describe the tangible results of the project. What did the Project "produce"? (e.g. payment of salaries, print publications, meetings)
- d. Describe the Project's impact on the issues being addressed. What supporting information demonstrates the Project's impact?
- e. Submit copies of significant reports, books, or media productions that stem from your efforts in connection with the Award.
- f. For interim reports on multi-year Awards only: Describe the Project activities to be conducted in the next year and provide an updated budget for those activities as part of the financial report (see below). If you have previously submitted a Project Budget for the next Award year, what modifications, if any, do you expect to make to the Project Budget?

**II. Financial Report**

Each financial report should be as detailed as possible and include the following:

- a. A line item comparison of budgeted versus actual expenses as they relate *specifically to our Award*.
- b. A statement certifying that all Award funds were expended for the purposes of the Award. If the entire Award has not been expended, please explain proposed usage of the unexpended amount.
- c. An explanation of any variations from the Project Budget submitted with your organization's Proposal.
- d. A brief summary of any fundraising for the Project, including a description of any unexpected shortfalls or surpluses. Did this grant assist your organization in leveraging funds from other sources? If not, why not?

**III. Delivery of the Narrative and Financial Report**

The reports described above are due, with respect to annual reports, within thirty (30) days of the anniversary of this Agreement (see agreement date), and with respect to the final report, within sixty (60) days of the date on which the Award funds are fully expended. Such reports should be sent to:

Mr. Terence Taylor  
Nuclear Threat Initiative  
1747 Pennsylvania Avenue NW  
7th Floor  
Washington, DC 20006

Exhibit "D"

Special Stipulations

The following terms and conditions are hereby incorporated into the Agreement by reference:

Awardee agrees to: (i) control the process whereby any individual who may use this Award, or any portion thereof, for purposes of travel or attendance at a meeting or workshop is selected and (ii) supervise such individual in carrying out the purpose for which the Award was made

Awardee agrees to observe and conform to, and cause its subgrantees, if any, to so observe and conform, in all material respects, to all laws, rules, regulations, orders and requirements of governmental authorities relating to the Project, including, without limitation, the U.S. Export Administration Act, Arms Export Control Act, Trading With the Enemy Act, International Emergency Economic Powers Act, associated regulations and Executive Orders, and Internal Revenue Service rules and regulations. Awardee agrees to strictly comply with, and cause its subgrantees, if any, to strictly comply with, all U.S. export control and sanctions regulations (including, without limitation, the International Traffic in Arms Regulation at 22 CFR Parts 120-130, the Export Administration Regulation at 15 CFR Parts 730-774, and the Foreign Assets Control Regulations at 31 CFR 500-599) and acknowledges that, when applicable, it has the responsibility to obtain export licenses, or other authorization as may be required, with respect to activities undertaken in connection with the Project.

## NUCLEAR THREAT INITIATIVE, INC. AWARD AGREEMENT

ORGANIZATION: Al Quds University ("Awardee")  
 PROJECT: MECIDS Country Support  
 AWARD NO.: 2056  
 APPROVED AMOUNT: for up to \$138,300 ("Award")

1. This Award is for the specific purposes as described in Exhibit "A" (for convenience of reference, such purposes hereinafter the "Project"), and payments received by Awardee may be expended for no other purpose without the prior written consent of NTL. In addition, the Project budget attached to and included as a part of Exhibit "A" (the "Project Budget") may not be modified or adjusted without the prior written consent of NTL. Consistent with the foregoing, all payments received by Awardee may be expended only for charitable, scientific, literary or educational purposes ("Charitable Purposes") within the meaning of Sections 501(c)(3) and 170(c)(2) of the Internal Revenue Code of 1986, as amended (the "Code"). Awardee shall return any funds not used for the specific Charitable Purposes set forth in Exhibit "A" unless Awardee has obtained NTL's prior written approval of an alternative use of the funds.
2. Awardee agrees that none of the funds covered by this Award Agreement (with all exhibits and any special stipulations, hereinafter the "Agreement") shall be used to participate in, or intervene in any political campaign on behalf of (or in opposition to) any candidate for public office, to influence legislation, to carry on voter registration drives, to make grants to individuals or other organizations, or to undertake any nonexempt activity, when such use of the funds would be a taxable expenditure if made directly by NTL.
3. By checking the appropriate box below, the undersigned officer of Awardee hereby certifies that Awardee is (check applicable and strike out statements that do not apply):
  - Tax exempt under Code Section 501(c)(3) and "not a private foundation" within the meaning of Code Section 509(a), or in the absence of such a determination, Awardee is a state or any political subdivision thereof within the meaning of Code Section 170(c)(1), or a state college or university within the meaning of Code Section 511(a)(2)(B) (hereinafter referred to as a "Public Charity"). (Please provide a copy of any letter from the IRS determining this status.)
  - Tax exempt under Code Section 501(c)(3) and classified as a private foundation under the Code. (Please provide a copy of the letter from IRS determining this status.)
  - Not tax exempt under Code Section 501(c)(3).
4. If Awardee is currently tax exempt under Code Section 501(c)(3) or classified as a Public Charity under the Code, then in the event Awardee loses such tax exempt or Public Charity status, this Agreement shall be considered null and void and all unexpended Award funds shall be immediately returned to NTL.
5. Awardee agrees to immediately notify NTL, in writing, if: (i) Awardee's federal tax status is revoked or altered; (ii) Awardee has reasonable grounds to believe that its federal tax status may be revoked or altered; or (iii) Awardee has reason to believe that the Award cannot be or continue to be expended for the specific purposes set forth in Exhibit "A".
6. In order to ensure that there is no misunderstanding by the general public regarding NTL's involvement with the Project, NTL reserves the right to, in advance, review, comment on and otherwise approve any statements, announcements or releases proposed to be made by Awardee to the press or public regarding NTL's involvement with the Project. Awardee may, however, make reference to NTL's support of Awardee's work generally as Awardee executes the Project.
7. NTL reserves the right, prior to submission for publication, to review and comment upon any documents, manuscripts, papers, exhibits or other materials that might result from the Project. Awardee agrees to duly consider comments, suggestions or issues that NTL identifies as noteworthy or of significance. At NTL's election, NTL's support will be acknowledged in any such publication. Any such acknowledgment will indicate, "This (publication) has been supported (in part) with funds from the Nuclear Threat Initiative. Its contents represent the views, findings and opinions of the authors, and are not necessarily those of the Nuclear Threat Initiative."

8. Awardee hereby grants and NTI hereby accepts a royalty-free, nonexclusive, irrevocable and perpetual license (with a right to sublicense) to reproduce, publish and otherwise use and authorize others to reproduce, publish and otherwise use, any materials resulting from the Project.
9. Awardee shall cooperate with NTI in supplying any additional information or in complying with any laws, rules, regulations, or procedures which might be required by any governmental authority in order for NTI to comply with and establish the fact that it has observed all requirements of all laws, rules and regulations with respect to this Award
10. Awardee agrees to keep accurate and complete books and records of receipts and expenditures made in connection with the Project. Awardee will maintain such books and records in a manner that the receipts and expenditures of Award funds will be shown separately thereon. Awardee will keep records of receipts and expenditures of Award funds as well as copies of reports submitted to NTI and supporting documentation for at least four (4) years after the completion of use of Award funds, and will make the same available to NTI for inspection as reasonably required from the time of Awardee's acceptance of this Award through such period.
11. Both the quality of the work done and Awardee's progress toward achieving the goals of the Award will be reviewed by NTI. NTI may monitor and conduct formal evaluations of operations and progress under this Award, which may include visits from NTI personnel to observe Awardee's projects and programs and to review financial and other records and materials connected with activities financed by this Award, and Awardee agrees to timely cooperate and assist NTI with such monitoring and evaluation activities. [
12. It is anticipated the Award will be paid in accordance with the disbursement schedule attached hereto as Exhibit "B". However, in the case of a multi-year or other Award payable in installments, the payment of each installment shall be additionally subject to a determination by NTI, in its sole and absolute discretion, that: (i) Awardee has timely provided the deliverables and services set forth in the attached Proposal; (ii) Awardee has timely delivered the report(s) requested by NTI in the attached guidelines; (iii) payments received from NTI have been used solely for the purposes for which they were authorized; (iv) additional payments shall be used solely for the purposes for which the Award was authorized; (v) Awardee has otherwise strictly complied with the terms and conditions of this Agreement; and (vi) there have been no material changes in Awardee's operations, staffing or funding which would adversely affect the objectives for which the Award was authorized; and (vii) the context in which the Project is to be executed has not been changed so substantially that the objectives for which the funds were authorized cannot be adequately realized.
13. Awardee shall provide detailed reporting as described in Exhibit "C" hereto.
14. In the case of any violation by Awardee of any of the terms or conditions of this Award, including but not limited to not executing the Project in strict compliance with Exhibit "A", or in the event of any change in or challenge by the Internal Revenue Service of Awardee's federal tax status, NTI reserves the right in its absolute discretion to terminate the Award. NTI's determination will be final and will be binding and conclusive upon Awardee. Upon termination of this Award for any reason, NTI will withhold any further payment of Award funds and all unexpended Award funds and any portion of the Award funds which was not spent for the Project shall be immediately returned to NTI.
15. Awardee shall indemnify and hold NTI, its directors, officers, employees, consultants, representatives and agents harmless from and against all third party claims, liabilities, suits, demands, losses, judgments, fines, penalties, interest, expenses and costs (including, without limitation, reasonable accounting and attorneys' fees and disbursements) which result from any breach of Awardee's representations or warranties made in relation to this Agreement, the Project, or from any breach of the terms of this Agreement, or from any negligent acts or omissions of Awardee, its directors, officers, employees, consultants, representatives and agents relating to, or in any way connected with, activities conducted pursuant to this Agreement.
16. This Agreement and the exhibits and any special stipulations attached hereto constitute the entire understanding of NTI and Awardee with respect to the subject matter hereof, and supersede all prior agreements and understandings, whether oral or written. This Agreement may not be amended or modified except in a writing signed by NTI. This Agreement shall be deemed to be made under, and in all respects shall be interpreted under and governed by, the laws of the District of Columbia, U.S.A.
17. The special stipulations contained on Exhibit "D" are hereby incorporated herein by reference.



THE UNIVERSITY OF AL-QADISIYA  
INSTITUTIONAL INFORMATION SYSTEMS

NAME:

QUADRI

BY: PROF. HASAN DWEIK

H. Dweik

EXEC. VICE PRESIDENT



DATE: 5<sup>th</sup> AUG. 2007

(

H.D.

Exhibit "A"

## Project Description

**Background**

The governance of the Middle East Consortium on Infectious Disease Surveillance (MECIDS) is based upon a newly formed Executive Council composed of an Executive Chairperson and Executive Board, supported by national MECIDS Country Coordinators and a Secretariat.

The primary responsibility for day-to-day management of the program and its activities, determining the meeting agendas, holding the consortium accountable for deliverables, and planning the strategic direction for MECIDS will be driven by the Executive Council supported by a Secretariat. All MECIDS activities, including those described below, are determined by the MECIDS Executive Board. Should the MECIDS Executive Board decide to modify the budget or project activities, the budget and/or activities outlined in this Agreement will likewise be modified.

**MECIDS Country Support**

The purpose of this Award is to improve the early detection and response to pandemic influenza and other food- and water-borne diseases by increasing laboratory and epidemiological capacity within the MECIDS countries. Over the last four years, the laboratory capacity in Jordan, Israel and the Palestinian Authority has been increasing through NTI's financial support of MECIDS. This increased capacity has included the support of dedicated laboratory personnel for food- and water-borne disease surveillance, laboratory equipment and supplies for food- and water-borne diseases, and training opportunities for both laboratorians and other public health staff in applied epidemiology and disease investigations.

As the consortium has taken on the threat of avian and human influenza preparedness efforts, diagnostic efforts need to increase against these threats. Laboratory personnel and essential supplies for meeting the increased demands placed on a system with already inadequate resources will have to be met. In addition, an immediate need exists to build a rapid, real-time communications capacity among the various laboratories within each country or government, and across borders to the international secretariat.

Services: Country Coordinators

One or two professional staff will serve as points of contact for day-to-day MECIDS communications and planning needs, including:

- ❖ Data sharing
- ❖ Communications infrastructure development
- ❖ Providing assistance to immediate needs of the Secretariat regarding logistical arrangements for meetings, conferences, and other special events.

The Country Coordinator(s) will work closely with both the Executive Council members from their country or government as well as interact closely with other Country Coordinators. The Coordinator(s) will be required to attend meetings, including Executive Council meetings, training workshops and various other technical and scientific exercises and meetings.

The MECIDS Country Coordinator(s) will follow the direction of the MECIDS Executive Council. The Coordinator(s) will work towards the goals identified in the Business Plan, as agreed upon by the MECIDS Executive Board. The Coordinator(s) will be required to report to the Executive Council and Secretariat regularly or as determined by the Executive Board.

Training: Regional, National Meetings & Exercises

A Regional Training Session on laboratory pathogens may include 2-3 representatives from each partner, including the Secretariat. Funds allow for 10 people to attend a four-day training session at a regional location to be determined. At least one Country Coordinator from each partner country must be in attendance.

A Local Training Session on laboratory pathogens may include up to 10 representatives, including the Country Coordinator(s). Funds allow for 10 people to attend a four-day training session.

A National Influenza and Disease Surveillance Exercise will provide each MECIDS country with tools to identify and address challenges at the national levels related to planning, surveillance and response to public health emergencies. Pandemic influenza preparedness will be used as an illustrative example for this purpose. To achieve this goal, a national "tabletop" exercise will be developed, based on plausible scenarios, and conducted in individual MECIDS countries, with the view to conduct an exercise at the regional level.

Once the National Exercise has occurred, Awardee shall conduct a National Training Session on Surveillance and Disease Response Preparation. This training session will address lessons-learned from the national exercise and will produce a training syllabus

#### Procurement Method<sup>1</sup>

In order to obtain Project funds, Awardee is required to submit Procurement documents as designated below.

##### **Individual Consultant**

In order to procure funds for the Country Coordinator(s), Awardee is required to submit the following:

- ❖ Name, title and work address of individual(s) selected for Country Coordinator position
- ❖ Brief explanation of selection, including past experience with MECIDS (if applicable)
- ❖ If individual has not engaged in previous work with MECIDS, Awardee is required to provide evidence that a fair selection process has been undertaken to hire select individual(s)
- ❖ Country Coordinator(s) Curriculum Vitae
- ❖ If nominated Country Coordinator changes, Awardee must notify NTI and provide relevant details for selection of new Country Coordinator.

##### **Quality and Cost-based Selection (QCBS)**

In order to procure funds for Training, Awardee is required to submit the following:

- ❖ If it results in cost-savings, NTI may act as the QCBS Procurement agent.
- ❖ At least 3 price quotations from appropriate suppliers. Any variance (i.e. a sole provider) must be approved by NTI.
- ❖ Copies of the requests for quotations, which shall indicate the description and quantity of the specification of works, as well as desired delivery (or completion) time and place.

Awardee will be required to submit to NTI a description of the training to be held, including date, subject matter and potential attendees, as well as price quotations for travel and other meeting/training costs. Upon receipt of description and price quotations, NTI will either pay the costs directly or will disburse funds to Awardee for this purpose.

---

<sup>1</sup> Refer to "Project Budget".

Project Budget  
 date of [unclear] \$60,000 [unclear]

↑  
Project Budget

The Project Budget covers a period of 16 months. Awardee will identify specific dates in Interim and Final Reports. The Project shall be used only for work that directly supports MECIDS, as directed by the Executive Board.

Services	Procurement Method <sup>2</sup>	Quantity	Unit	Unit Rate	Total
Country Coordinator(s)	Individual Consultants	16	Months	\$3,750	\$60,000
					\$60,000

Training	Procurement Method	Quantity	Unit	Unit Rate	Total
Regional Training					
Laboratory pathogens training, 10 people, 4 days	Quality & Cost-Based Selection	1	Trainings	\$3,300	\$3,300
Local Training					
Enhanced Laboratory pathogens training, 10 people, 4 days	Quality & Cost-Based Selection	1	Trainings	\$10,000	\$10,000
National Influenza and Disease Surveillance Exercises	Quality & Cost-Based Selection	1	Trainings	\$15,000	\$15,000
National Training for Surveillance and Response Preparation	Quality & Cost-Based Selection	1	Trainings	\$50,000	\$50,000
					\$78,300

**Total: \$138,300**

<sup>2</sup> Refer to "Procurement Method" on page 5 of Agreement.

Exhibit "B"**Tentative Disbursement Schedule**

Subject to the terms and conditions of the Agreement, it is anticipated the Award will be disbursed as follows:

Services: Country Coordinators

<b>Tentative Disbursement Date</b>	<b>Installment Amount (USD)</b>
Upon receipt of Procurement documents and signed Agreement July 2007	\$20,000
Upon receipt of 1 <sup>st</sup> Interim Report (Financial & Narrative) November 2007	\$20,000
Upon receipt of 2 <sup>nd</sup> Interim Report (Financial & Narrative) March 2008	\$20,000

Training: Regional, Local Training & Exercise

<b>Tentative Disbursement Date</b>	<b>Installment Amount</b>
Upon receipt of QCBS documents	NTI will disburse allocated funds to Awardee; Or if cost-savings result NTI may provide funds directly to provider

Exhibit "C"Interim Reporting Requirements**Services**

Country Coordinator(s) will be required to submit Interim Financial and Narrative Reports. Interim Financial Reports should include a description of costs incurred during period of work, including timeframe (period of time for which the disbursement of funds covered), activities, travel, technical support and other MECIDS activities. Interim Narrative Reports should include a brief description of activities and work performed during this period.

Interim Reports will be due:

October 15, 2007

February 15, 2008

**Training**

If NTI pays costs directly, Awardee will be required to submit a report to NTI describing the outcome of the training session, including agenda, attendees and a summary of activities/lessons, no later than one month after session has taken place.

If NTI disburses funds to Awardee to cover the costs of training, Awardee will be required to submit invoices for payments made with funds. Upon completion of training session, Awardee will be required to submit a report describing the outcome of the session, including agenda, attendees and a summary of activities/lessons. Awardee will also be required to submit a training syllabus for each respective training session. These reports, including invoices, will be due to NTI no later than one month after session has taken place.

Final Reporting Requirements

At such time as the Award funds are fully expended, NTI requires for our records a final report, as appropriate, which will: (i) describe in narrative fashion what was achieved with the Award funds; and (ii) provide a full financial accounting of the Award.

**I. Narrative Report**

Each narrative report should briefly (no more than five pages) summarize how the Award was used and the results which were achieved. The report will be used by NTI staff to evaluate and to provide an overview of your work for our Board of Directors. The following list, insofar as relevant to our Award to your organization, may provide guidance in the preparation of your reports:

- a. Did the Project achieve the objectives outlined in your organization's Proposal? If not, how did the results vary from these objectives? Explain any milestones that have been achieved. How do you view the future of the Project?
- b. What developments or implementations of solutions to the problems addressed by this Award have occurred because of this Project? What, if anything, has/is occurring in the field that has changed the climate surrounding the issue?
- c. Describe the tangible results of the project. What did the Project "produce"? (e.g. payment of salaries, print publications, meetings)
- d. Describe the Project's impact on the issues being addressed. What supporting information demonstrates the Project's impact?
- e. Submit copies of significant reports, books, or media productions that stem from your efforts in connection with the Award.
- f. For interim reports on multi-year Awards only: Describe the Project activities to be conducted in the next year and provide an updated budget for those activities as part of the financial report (see below). If you have previously submitted a Project Budget for the next Award year, what modifications, if any, do you expect to make to the Project Budget?

**II. Financial Report**

Each financial report should be as detailed as possible and include the following:

- a. A line item comparison of budgeted versus actual expenses as they relate *specifically to our Award*.
- b. A statement certifying that all Award funds were expended for the purposes of the Award. If the entire Award has not been expended, please explain proposed usage of the unexpended amount.
- c. An explanation of any variations from the Project Budget submitted with your organization's Proposal.
- d. A brief summary of any fundraising for the Project, including a description of any unexpected shortfalls or surpluses. Did this grant assist your organization in leveraging funds from other sources? If not, why not?

**III. Delivery of the Narrative and Financial Report**

Interim and Final Reports should be sent to:

Terence Taylor  
NTI, Global Health and Security Initiative  
1747 Pennsylvania Avenue NW  
7th Floor  
Washington, DC 20006

Exhibit "D"

Special Stipulations

The following terms and conditions are hereby incorporated into the Agreement by reference:

Awardee agrees that the proceeds of the Grant may not be used to pay for Taxes levied by, or in the territory of, the Member Country on or in respect of Eligible Expenditures, or on their importation, manufacture, procurement or supply.

Awardee agrees to (i) control the process whereby any individual who may use this Award, or any portion thereof, for purposes of travel or attendance at a meeting or workshop is selected and (ii) supervise such individual in carrying out the purpose for which the Award was made.

Awardee agrees that all goods, works and services financed out of this Grant shall be used exclusively for the purposes of the Project

Awardee agrees that it shall not involve as participants in the Project or otherwise use any Award funds to enter into transactions with entities listed pursuant to the U.S. Foreign Assets Control Regulations (31 Code of Federal Regulations Parts 500-598) or relevant Executive Orders as ineligible to participate in transactions, directly or indirectly, with U.S. organizations and persons. NTI calls Awardee's attention to the list of entities published in the Weapons of Mass Destruction Trade Control Regulations (31 Code of Federal Regulations 539 and the list of Weapons of Mass Destruction Proliferators and Their Supporters published pursuant to Executive Order 13382; partial list provided as Exhibit "E"). Awardee understands that the list may change from time to time. Prohibited transactions with the parties listed pursuant to the Weapons of Mass Destruction Trade Control Regulations and subject to this limitation include, without limitation: (i) procuring any goods, technology or services, or entering into any agreement for the procurement of any goods, technology or services from the listed organizations; (ii) providing any assistance to or obligating funds for such purpose with listed organizations; or (iii) importing into the U.S. any goods, technology, or services produced or provided by listed organizations, any of entities described in the above regulations or executive order. For entities listed pursuant to Executive Order 13382 and certain Parts of the Foreign Assets Control Regulations (e.g., listed Foreign Terrorist Organizations) the prohibition covers all business transactions and funds transfers of any kind.



Exhibit "E"

## Selected Entities Subject to 31 Code of Federal Regulations Part 539 "WMD Trade Control Regulations" and Executive Order 13382

- AEROSPACE INDUSTRIES ORGANIZATION (a.k.a. SAZMANE SANAYE HAVA FAZA; a.k.a. "AIO"), Langarc Street, Nobonyad Square, Tehran, Iran [NPWMD]
- ATOMIC ENERGY ORGANIZATION OF IRAN (a.k.a. SAZEMAN-E ENERGY ATOMI), P.O. Box 14144-1339, End of North Karegar Avenue, Tehran, Iran [NPWMD]
- BANK SEPAH, Imam Khomeini Square P.O. Box 11364-9569, Tehran, Iran; all offices worldwide [NPWMD]
- BANK SEPAH INTERNATIONAL PLC, 5-7 Eastcheap, London EC3M 1JT, United Kingdom [NPWMD]
- BALTIC STATE TECHNICAL UNIVERSITY, wherever located, including 1/21, 1-ya Krasnoarmeiskaya Ul., 198005 St. Petersburg, Russia [63 FR 42089, July 30, 1998]
- BEIJING ALITE TECHNOLOGIES CO., LTD. (a.k.a. ALCO; a.k.a. BEIJING HAILI LIANHE KEJI YOUXIAN GONGSI), 12A Beisanhuan Zhong Road, P.O. Box 3042, Beijing, China; and all other locations worldwide [NPWMD]
- CHINA GREAT WALL INDUSTRY CORPORATION (a.k.a. CGWIC; a.k.a. ZHONGGUO CHANGCHENG GONGYE ZONGGONGSI), No. 30 Haidian Nanlu, Beijing, China; Moscow, Russia; and all other locations worldwide [NPWMD]
- CHINA NEW ERA GROUP (a.k.a. China Xinshidai Company; a.k.a. New Era Group; a.k.a. XSD, a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]
- CHINA NATIONAL PRECISION MACHINERY IMPORT/EXPORT CORPORATION (a.k.a. CHINA NATIONAL PRECISION MACHINERY I/E CORP.; a.k.a. CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION; a.k.a. CPMIEC; a.k.a. ZHONGGUO JINGMI JIXIE JINCHUKOU ZONGGONGSI), No. 30 Haidian Nanlu, Beijing, China; and all other locations worldwide [NPWMD]
- CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION (a.k.a. CPMIEC), wherever located [July 30, 2003]
- CHINA XINSHIDAI COMPANY (a.k.a. China New Era Group; a.k.a. New Era Group; a.k.a. XSD; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]
- CPMIEC (a.k.a. CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION), wherever located [July 30, 2003]
- D. MENDELEYEV UNIVERSITY OF CHEMICAL TECHNOLOGY OF RUSSIA, wherever located, including 9 Miusskaya Sq., Moscow 125047, Russia [64 FR 2935, January 8, 1999]
- DEFENSE INDUSTRIES ORGANIZATION (a.k.a. DEFENCE INDUSTRIES ORGANISATION; a.k.a. DIO; a.k.a. SASEMAN SANAJE DEFA; a.k.a. SAZEMANE SANAYE DEFA; a.k.a. "SASADJA"), P.O. Box 19585-777, Pasdaran Street, Entrance of Babaie Highway, Permanent Expo of Defence Industries Organization, Tehran, Iran [NPWMD]
- DERAKHSHANDEH, AHMAD, c/o BANK SEPAH, No. 33 Hormozan Building, Pirozan St., Sharak Ghods, Tehran, Iran; DOB 11 Aug 1956; POB Iran (individual) [NPWMD]
- ELECTRONICS INSTITUTE, P.O. Box 4470, Damascus, Syria [NPWMD]
- FAJR INDUSTRIES GROUP (a.k.a. FADJR INDUSTRIES GROUP; a.k.a. IFP; a.k.a. INDUSTRIAL FACTORIES OF PRECISION MACHINERY, a.k.a. INSTRUMENTATION FACTORIES OF PRECISION MACHINERY; a.k.a. INSTRUMENTATION FACTORY PLANT; a.k.a. MOJTAME SANTY AJZAE DAGHIGH; a.k.a. NASR INDUSTRIES GROUP), P.O. Box 1985-777, Tehran, Iran [NPWMD]
- FARAYAND TECHNIQUE (a.k.a. FARAYAND TECHNIC), End of North Karegar Avenue, Shomali, Tehran, Iran; P.O. Box 14155-1339, Tehran, Iran; Esfahan, Iran; Isfahan, Iran [NPWMD]

FEDERAL RESEARCH AND PRODUCTION COMPLEX ALTAY, Russia [69 FR 67617-18, November 18, 2004]

G.W. AEROSPACE, INC (a.k.a. GREAT WALL AEROSPACE, INC.), 21515 Hawthorne Blvd., Suite 670, Torrance, CA 90503; California Corporate Number C1458237 (United States) [NPWMD]

GLAVKOSMOS, wherever located, including 9 Krasnoprolctarskaya St., 103030 Moscow, Russia [63 FR 42089, July 30, 1998]

HESONG TRADING CORPORATION, Pyongyang, Korea, North [NPWMD]

HIGHER INSTITUTE OF APPLIED SCIENCE AND TECHNOLOGY (a.k.a. HIAST; a.k.a. INSTITUT DES SCIENCES APPLIQUEES ET DE TECHNOLOGIE; a.k.a. INSTITUT SUPERIEUR DES SCIENCES APPLIQUEES ET DE TECHNOLOGIE; a.k.a. ISAT; a.k.a. ISSAT), P.O. Box 31983, Barzeh, Damascus, Syria [NPWMD]

KALAYE ELECTRIC COMPANY (a.k.a. KALA ELECTRIC COMPANY), 33 Fifteenth (15th) Street, Seyed-Jamal-Eddin-Assad Abadi Avenue, Tehran, Iran [NPWMD]

KAVOSHYAR COMPANY (a.k.a. KAAVOSH YAAR; a.k.a. KAVOSHYAR), P.O. Box 19395-1834, Tehran, Iran; Vanaq Square, Corner of Shiraz Across No. 71, Molla Sadra Ave., Tehran, Iran; No. 86, 20th St., North Karegar Ave., Tehran, Iran [NPWMD]

KOHAS AG, Route des Arsenaux 15, Fribourg, FR 1700, Switzerland; C.R. No. CH-217.0.135.719-4 (Switzerland) [NPWMD]

KOREA COMPLEX EQUIPMENT IMPORT CORPORATION, Rakwondong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA INTERNATIONAL CHEMICAL JOINT VENTURE COMPANY (a.k.a. CHOSON INTERNATIONAL CHEMICALS JOINT OPERATION COMPANY; a.k.a. CHOSUN INTERNATIONAL CHEMICALS JOINT OPERATION COMPANY; a.k.a. INTERNATIONAL CHEMICAL JOINT VENTURE CORPORATION), Hamhung, South Hamgyong Province, Korea, North; Man gyongdae-kuyok, Pyongyang, Korea, North; Mangyungdae-gu, Pyongyang, Korea, North [NPWMD]

KOREA KWANGSONG TRADING CORPORATION, Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA MINING DEVELOPMENT TRADING CORPORATION (a.k.a. CHANGGWANG SINYONG CORPORATION; a.k.a. EXTERNAL TECHNOLOGY GENERAL CORPORATION; a.k.a. NORTH KOREAN MINING DEVELOPMENT TRADING CORPORATION; a.k.a. "KOMID"), Central District, Pyongyang, Korea, North [NPWMD]

KOREA PUGANG TRADING CORPORATION, Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONBONG GENERAL CORPORATION (a.k.a. KOREA YONBONG GENERAL CORPORATION; f.k.a. LYONGAKSAN GENERAL TRADING CORPORATION), Pot'onggang District, Pyongyang, Korea, North; Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONGWANG TRADING CORPORATION (a.k.a. KOREA RYENGWANG TRADING CORPORATION), Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONHA MACHINERY JOINT VENTURE CORPORATION (a.k.a. CHOSUN YUNHA MACHINERY JOINT OPERATION COMPANY; a.k.a. KOREA RYENHA MACHINERY J/V CORPORATION; a.k.a. RYONHA MACHINERY JOINT VENTURE CORPORATION), Central District, Pyongyang, Korea, North; Mangungdae-gu, Pyongyang, Korea, North; Mangyongdae District, Pyongyang, Korea, North [NPWMD]

LEILABADI, ALI HAJINIA (a.k.a. LAJLABADI, ALI HADJINIA), c/o MESBAH ENERGY COMPANY, Iran; DOB 19 Feb 1950; POB Tabriz, Iran; citizen Iran; nationality Iran; Passport E4710151 (Iran) issued 15 Oct 2000 expires 15 Oct 2005 (individual) [NPWMD]

LIMMT ECONOMIC AND TRADE COMPANY, LTD. (a.k.a. LIMMT (DALIAN FTZ) METALLURGY AND MINERALS CO., LTD., a.k.a. LIMMT (DALIAN FTZ) MINMETALS AND METALLURGY CO., LTD.; a.k.a. LIMMT (DALIAN) METALLURGY AND MINERALS CO., LTD.), 2501-2508 Yucxiu Mansion, No. 82 Xinkai Road, Dalian, Liaoning 116011, China; and all other locations worldwide [NPWMD]

MAI (a.k.a. MOSCOW AVIATION INSTITUTE), wherever located, including 4 Volokolamskoye Shosse, Moscow 125871, Russia [64 FR 2935, January 8, 1999]

MESBAH ENERGY COMPANY (a.k.a. "MEC"), 77 Armaghan Gharbi Street, Valiasr Blvc., Tehran, Iran [NPWMD]

MIZAN MACHINE MANUFACTURING GROUP (a.k.a. 3MG), P.O. Box 16595-365, Tehran, Iran [NPWMD]

MOSCOW AVIATION INSTITUTE (a.k.a. MAI), wherever located, including 4 Volokolamskoye Shosse, Moscow 125871, Russia [64 FR 2935, January 8, 1999]

NATIONAL STANDARDS AND CALIBRATION LABORATORY (a.k.a. NATIONAL CALIBRATION CENTRE, a.k.a. NSCL), P.O. Box 4470, Damascus, Syria [NPWMD]

NEW ERA GROUP (a.k.a. China New Era Group; a.k.a. China Xinshidai Company; a.k.a. Xinshidai; a.k.a. XSD) [69 FR 56260, September 20, 2004]

NOVIN ENERGY COMPANY (a.k.a. Eenergy Novin; a.k.a. Novcen Energy Company), End of North Karegar Avenue, Tehran, Iran [NPWMD]

PARS TRASH COMPANY (a.k.a. PARS TARASH; a.k.a. PARS TERASH; a.k.a. PARS TRASH), 33 Fifteenth (15th) Street, Seyed-Jamal-Eddin- Assad Abadi Avenue, Tehran, Iran [NPWMD]

PIONEER ENERGY INDUSTRIES COMPANY (a.k.a. PISHGAM ENERGY INDUSTRIES DEVELOPMENT; a.k.a. "PEI"), P.O. Box 81465-361, Isfahan, Iran [NPWMD]

QANNADI, MOHAMMAD (a.k.a. GHANNADI MARAGHEH, MOHAMMAD; a.k.a. GHANNADI, MOHAMMAD; a.k.a. QANNADI MARAGHEH, MOHAMMAD), c/o ATOMIC ENERGY ORGANIZATION OF IRAN, Iran; DOB 13 Oct 1952; POB Maragheh, Iran; citizen Iran; nationality Iran; Passport 20694 (Iran); alt. Passport A0003044 (Iran) (individual)[NPWMD]

SANAM INDUSTRIAL GROUP (a.k.a. Sanam Industries Group) Pasdaran Road 15, Tehran, Iran

SCIENTIFIC STUDIES AND RESEARCH CENTER (a.k.a. CENTRE D'ETUDES ET RECHERCHES, a.k.a. "SSRC"), P.O. Box 4470, Damascus, Syria [NPWMD]

SHAHID BAKERI INDUSTRIAL GROUP (a.k.a. "SBIG"), Tehran, Iran [NPWMD]

SHAHID HEMMAT INDUSTRIAL GROUP (a.k.a. "SHIG"), Damavand Tehran Highway, Tehran, Iran [NPWMD]

STEIGER, Jakob, c/o KOHAS AG, Fribourg, FR, Switzerland; DOB 27 Apr 1941; POB Altstatten, SG, Switzerland (individual) [NPWMD]

TANCHON COMMERCIAL BANK (f.k.a. CHANGGWANG CREDIT BANK; f.k.a. KOREA CHANGGWANG CREDIT BANK), Saemul 1-Dong Pyongchon District, Pyongyang, Korea, North [NPWMD]

TOSONG TECHNOLOGY TRADING CORPORATION, Pyongyang, Korea [NPWMD]

XINSHIDAI (a.k.a. China New Era Group; a.k.a. China Xinshidai Company; a.k.a. New Era Group; a.k.a. XSD) [69 FR 56260, September 20, 2004]

XSD (a.k.a. China New Era Group; a.k.a. China Xinshidai Company a.k.a. New Era Group; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]

YA MAHDI INDUSTRIES GROUP (a.k.a. Ya Mahdi Industrial Research Complex, a.k.a. Ya Mahdi Industrial Complex,  
a.k.a. "YMA") PO Box 19395-4797, Tehran, Iran

## NUCLEAR THREAT INITIATIVE, INC. AWARD AGREEMENT

ORGANIZATION: Jordanian Ministry of Health ("Awardee")  
 PROJECT: MECIDS Country Support  
 AWARD NO.: 2057  
 APPROVED AMOUNT: for up to \$138,300 ("Award") *Signed Agreement*

---

1. This Award is for the specific purposes as described in Exhibit "A" (for convenience of reference, such purposes hereinafter the "Project"), and payments received by Awardee may be expended for no other purpose without the prior written consent of NTI. In addition, the Project budget attached to and included as a part of Exhibit "A" (the "Project Budget") may not be modified or adjusted without the prior written consent of NTI. Consistent with the foregoing, all payments received by Awardee may be expended only for charitable, scientific, literary or educational purposes ("Charitable Purposes") within the meaning of Sections 501(c)(3) and 170(c)(2) of the Internal Revenue Code of 1986, as amended (the "Code"). Awardee shall return any funds not used for the specific Charitable Purposes set forth in Exhibit "A" unless Awardee has obtained NTI's prior written approval of an alternative use of the funds.
2. Awardee agrees that none of the funds covered by this Award Agreement (with all exhibits and any special stipulations, hereinafter the "Agreement") shall be used to participate in, or intervene in any political campaign on behalf of (or in opposition to) any candidate for public office, to influence legislation, to carry on voter registration drives, to make grants to individuals or other organizations, or to undertake any nonexempt activity, when such use of the funds would be a taxable expenditure if made directly by NTI.
3. By checking the appropriate box below, the undersigned officer of Awardee hereby certifies that Awardee is (check applicable and strike out statements that do not apply):
  - Tax exempt under Code Section 501(c)(3) and "not a private foundation" within the meaning of Code Section 509(a), or in the absence of such a determination, Awardee is a state or any political subdivision thereof within the meaning of Code Section 170(c)(1), or a state college or university within the meaning of Code Section 511(a)(2)(B) (hereinafter referred to as a "Public Charity"). (Please provide a copy of any letter from the IRS determining this status.)
  - Tax exempt under Code Section 501(c)(3) and classified as a private foundation under the Code. (Please provide a copy of the letter from IRS determining this status.)
  - Not* tax exempt under Code Section 501(c)(3).
4. If Awardee is currently tax exempt under Code Section 501(c)(3) or classified as a Public Charity under the Code, then in the event Awardee loses such tax exempt or Public Charity status, this Agreement shall be considered null and void and all unexpended Award funds shall be immediately returned to NTI.
5. Awardee agrees to immediately notify NTI, in writing, if: (i) Awardee's federal tax status is revoked or altered; (ii) Awardee has reasonable grounds to believe that its federal tax status may be revoked or altered; or (iii) Awardee has reason to believe that the Award cannot be or continue to be expended for the specific purposes set forth in Exhibit "A".
6. In order to ensure that there is no misunderstanding by the general public regarding NTI's involvement with the Project, NTI reserves the right to, in advance, review, comment on and otherwise approve any statements, announcements or releases proposed to be made by Awardee to the press or public regarding NTI's involvement with the Project. Awardee may, however, make reference to NTI's support of Awardee's work generally as Awardee executes the Project.
7. NTI reserves the right, prior to submission for publication, to review and comment upon any documents, manuscripts, papers, exhibits or other materials that might result from the Project. Awardee agrees to duly consider comments, suggestions or issues that NTI identifies as noteworthy or of significance. At NTI's election, NTI's support will be acknowledged in any such publication. Any such acknowledgment will indicate, "This (publication) has been supported (in part) with funds from the Nuclear Threat Initiative. Its contents represent the views, findings and opinions of the authors, and are not necessarily those of the Nuclear Threat Initiative."

8. Awardee hereby grants and NTI hereby accepts a royalty-free, nonexclusive, irrevocable and perpetual license (with a right to sublicense) to reproduce, publish and otherwise use and authorize others to reproduce, publish and otherwise use, any materials resulting from the Project.
9. Awardee shall cooperate with NTI in supplying any additional information or in complying with any laws, rules, regulations, or procedures which might be required by any governmental authority in order for NTI to comply with and establish the fact that it has observed all requirements of all laws, rules and regulations with respect to this Award.
10. Awardee agrees to keep accurate and complete books and records of receipts and expenditures made in connection with the Project. Awardee will maintain such books and records in a manner that the receipts and expenditures of Award funds will be shown separately thereon. Awardee will keep records of receipts and expenditures of Award funds as well as copies of reports submitted to NTI and supporting documentation for at least four (4) years after the completion of use of Award funds, and will make the same available to NTI for inspection as reasonably required from the time of Awardee's acceptance of this Award through such period.
11. Both the quality of the work done and Awardee's progress toward achieving the goals of the Award will be reviewed by NTI. NTI may monitor and conduct formal evaluations of operations and progress under this Award, which may include visits from NTI personnel to observe Awardee's projects and programs and to review financial and other records and materials connected with activities financed by this Award, and Awardee agrees to timely cooperate and assist NTI with such monitoring and evaluation activities. |
12. It is anticipated the Award will be paid in accordance with the disbursement schedule attached hereto as Exhibit "B". However, in the case of a multi-year or other Award payable in installments, the payment of each installment shall be additionally subject to a determination by NTI, in its sole and absolute discretion, that: (i) Awardee has timely provided the deliverables and services set forth in the attached Proposal; (ii) Awardee has timely delivered the report(s) requested by NTI in the attached guidelines; (iii) payments received from NTI have been used solely for the purposes for which they were authorized; (iv) additional payments shall be used solely for the purposes for which the Award was authorized; (v) Awardee has otherwise strictly complied with the terms and conditions of this Agreement; and (vi) there have been no material changes in Awardee's operations, staffing or funding which would adversely affect the objectives for which the Award was authorized; and (vii) the context in which the Project is to be executed has not been changed so substantially that the objectives for which the funds were authorized cannot be adequately realized.
13. Awardee shall provide detailed reporting as described in Exhibit "C" hereto.
14. In the case of any violation by Awardee of any of the terms or conditions of this Award, including but not limited to not executing the Project in strict compliance with Exhibit "A", or in the event of any change in or challenge by the Internal Revenue Service of Awardee's federal tax status, NTI reserves the right in its absolute discretion to terminate the Award. NTI's determination will be final and will be binding and conclusive upon Awardee. Upon termination of this Award for any reason, NTI will withhold any further payment of Award funds and all unexpended Award funds and any portion of the Award funds which was not spent for the Project shall be immediately returned to NTI.
15. Awardee shall indemnify and hold NTI, its directors, officers, employees, consultants, representatives and agents harmless from and against all third party claims, liabilities, suits, demands, losses, judgments, fines, penalties, interest, expenses and costs (including, without limitation, reasonable accounting and attorneys' fees and disbursements) which result from any breach of Awardee's representations or warranties made in relation to this Agreement, the Project, or from any breach of the terms of this Agreement, or from any negligent acts or omissions of Awardee, its directors, officers, employees, consultants, representatives and agents relating to, or in any way connected with, activities conducted pursuant to this Agreement.
16. This Agreement and the exhibits and any special stipulations attached hereto constitute the entire understanding of NTI and Awardee with respect to the subject matter hereof, and supersede all prior agreements and understandings, whether oral or written. This Agreement may not be amended or modified except in a writing signed by NTI. This Agreement shall be deemed to be made under, and in all respects shall be interpreted under and governed by, the laws of the District of Columbia, U.S.A.
17. The special stipulations contained on Exhibit "D" are hereby incorporated herein by reference.

08/12/2007 02:44 [TX/RX NO 9579] [002

The undersigned duly authorized official of Awardee accepts and agrees to, on behalf of Awardee, these terms and conditions, as of the date set forth below.

AWARDEE:

Jordanian Ministry of Health

By: Dr Adel Belbeisi

Title: Assistant Secretary General -  
For Primary Health Care -


Date: 9/8/2007 

Exhibit "A"

Project Description

Background

The governance of the Middle East Consortium on Infectious Disease Surveillance (MECIDS) is based upon a newly formed Executive Council composed of an Executive Chairperson and Executive Board, supported by national MECIDS Country Coordinators and a Secretariat.

The primary responsibility for day-to-day management of the program and its activities, determining the meeting agendas, holding the consortium accountable for deliverables, and planning the strategic direction for MECIDS will be driven by the Executive Council supported by a Secretariat. All MECIDS activities, including those described below, are determined by the MECIDS Executive Board. Should the MECIDS Executive Board decide to modify the budget or project activities, the budget and/or activities outlined in this Agreement will likewise be modified.

MECIDS Country Support

The purpose of this Award is to improve the early detection and response to pandemic influenza and other food- and water-borne diseases by increasing laboratory and epidemiological capacity within the MECIDS countries. Over the last four years, the laboratory capacity in Jordan, Israel and the Palestinian Authority has been increasing through NTI's financial support of MECIDS. This increased capacity has included the support of dedicated laboratory personnel for food- and water-borne disease surveillance, laboratory equipment and supplies for food- and water-borne diseases, and training opportunities for both laboratorians and other public health staff in applied epidemiology and disease investigations.

As the consortium has taken on the threat of avian and human influenza preparedness efforts, diagnostic efforts need to increase against these threats. Laboratory personnel and essential supplies for meeting the increased demands placed on a system with already inadequate resources will have to be met. In addition, an immediate need exists to build a rapid, real-time communications capacity among the various laboratories within each country or government, and across borders to the international secretariat.

Services: Country Coordinators

One or two professional staff will serve as points of contact for day-to-day MECIDS communications and planning needs, including:

- ❖ Data sharing
- ❖ Communications infrastructure development
- ❖ Providing assistance to immediate needs of the Secretariat regarding logistical arrangements for meetings, conferences, and other special events.

The Country Coordinator(s) will work closely with both the Executive Council members from their country or government as well as interact closely with other Country Coordinators. The Coordinator(s) will be required to attend meetings, including Executive Council meetings, training workshops and various other technical and scientific exercises and meetings.

The MECIDS Country Coordinator(s) will follow the direction of the MECIDS Executive Council. The Coordinator(s) will work towards the goals identified in the Business Plan, as agreed upon by the MECIDS Executive Board. The Coordinator(s) will be required to report to the Executive Council and Secretariat regularly or as determined by the Executive Board.

Training: Regional, National Meetings & Exercises

A Regional Training Session on laboratory pathogens may include 2-3 representatives from each partner, including the Secretariat. Funds allow for 10 people to attend a four-day training session at a regional location to be determined. At least one Country Coordinator from each partner country must be in attendance.

A Local Training Session on laboratory pathogens may include up to 10 representatives, including the Country Coordinator(s). Funds allow for 10 people to attend a four-day training session.



A National Influenza and Disease Surveillance Exercise will provide each MECIDS country with tools to identify and address challenges at the national levels related to planning, surveillance and response to public health emergencies. Pandemic influenza preparedness will be used as an illustrative example for this purpose. To achieve this goal, a national "tabletop" exercise will be developed, based on plausible scenarios, and conducted in individual MECIDS countries, with the view to conduct an exercise at the regional level.

Once the National Exercise has occurred, Awardee shall conduct a National Training Session on Surveillance and Disease Response Preparation. This training session will address lessons-learned from the national exercise and will produce a training syllabus.

#### Procurement Method<sup>1</sup>

In order to obtain Project funds, Awardee is required to submit Procurement documents as designated below.

##### **Individual Consultant**

In order to procure funds for the Country Coordinator(s), Awardee is required to submit the following:

- ❖ Name, title and work address of individual(s) selected for Country Coordinator position
- ❖ Brief explanation of selection, including past experience with MECIDS (if applicable)
- ❖ If individual has not engaged in previous work with MECIDS, Awardee is required to provide evidence that a fair selection process has been undertaken to hire select individual(s)
- ❖ Country Coordinator(s) Curriculum Vitae
- ❖ If nominated Country Coordinator changes, Awardee must notify NTI and provide relevant details for selection of new Country Coordinator.

##### **Quality and Cost-based Selection (QCBS)**

In order to procure funds for Training, Awardee is required to submit the following:

- ❖ If it results in cost-savings, NTI may act as the QCBS Procurement agent.
- ❖ At least 3 price quotations from appropriate suppliers. Any variance (i.e. a sole provider) must be approved by NTI.
- ❖ Copies of the requests for quotations, which shall indicate the description and quantity of the specification of works, as well as desired delivery (or completion) time and place.

Awardee will be required to submit to NTI a description of the training to be held, including date, subject matter and potential attendees, as well as price quotations for travel and other meeting/training costs. Upon receipt of description and price quotations, NTI will either pay the costs directly or will disburse funds to Awardee for this purpose.

---

<sup>1</sup> Refer to "Project Budget".

## Project Budget

The Project Budget covers a period of 16 months. Awardee will identify specific dates in Interim and Final Reports. The Project shall be used only for work that directly supports MECIDS, as directed by the Executive Board.

Services	Procurement Method <sup>2</sup>	Quantity	Unit	Unit Rate	Total
Country Coordinator(s)	Individual Consultants	16	Months	\$3,750	\$60,000
					\$60,000

Training	Procurement Method	Quantity	Unit	Unit Rate	Total
Regional Training					
Laboratory pathogens training, 10 people, 4 days	Quality & Cost-Based Selection	1	Trainings	\$3,300	\$3,300
Local Training					
Enhanced Laboratory pathogens training, 10 people, 4 days	Quality & Cost-Based Selection	1	Trainings	\$10,000	\$10,000
National Influenza and Disease Surveillance Exercises	Quality & Cost-Based Selection	1	Trainings	\$15,000	\$15,000
National Training for Surveillance and Response Preparation	Quality & Cost-Based Selection	1	Trainings	\$50,000	\$50,000
					\$78,300

**Total: \$138,300**

<sup>2</sup> Refer to "Procurement Method" on page 5 of Agreement.

Exhibit "B"**Tentative Disbursement Schedule**

Subject to the terms and conditions of the Agreement, it is anticipated the Award will be disbursed as follows:

Services: Country Coordinators

<b>Tentative Disbursement Date</b>	<b>Installment Amount (USD)</b>
Upon receipt of Procurement documents and signed Agreement July 2007	\$20,000
Upon receipt of 1 <sup>st</sup> Interim Report (Financial & Narrative) November 2007	\$20,000
Upon receipt of 2 <sup>nd</sup> Interim Report (Financial & Narrative) March 2008	\$20,000

Training: Regional, Local Training & Exercise

<b>Tentative Disbursement Date</b>	<b>Installment Amount</b>
Upon receipt of QCBS documents	NTI will disburse allocated funds to Awardee; Or if cost-savings result NTI may provide funds directly to provider

Exhibit "C"

Interim Reporting Requirements

Services

Country Coordinator(s) will be required to submit Interim Financial and Narrative Reports. Interim Financial Reports should include a description of costs incurred during period of work, including timeframe (period of time for which the disbursement of funds covered), activities, travel, technical support and other MECIDS activities. Interim Narrative Reports should include a brief description of activities and work performed during this period.

Interim Reports will be due:

October 15, 2007

February 15, 2008

Training

If NTI pays costs directly, Awardee will be required to submit a report to NTI describing the outcome of the training session, including agenda, attendees and a summary of activities/lessons, no later than one month after session has taken place.

If NTI disburses funds to Awardee to cover the costs of training, Awardee will be required to submit invoices for payments made with funds. Upon completion of training session, Awardee will be required to submit a report describing the outcome of the session, including agenda, attendees and a summary of activities/lessons. Awardee will also be required to submit a training syllabus for each respective training session. These reports, including invoices, will be due to NTI no later than one month after session has taken place.

Final Reporting Requirements

At such time as the Award funds are fully expended, NTI requires for our records a final report, as appropriate, which will: (i) describe in narrative fashion what was achieved with the Award funds; and (ii) provide a full financial accounting of the Award.

**I. Narrative Report**

Each narrative report should briefly (no more than five pages) summarize how the Award was used and the results which were achieved. The report will be used by NTI staff to evaluate and to provide an overview of your work for our Board of Directors. The following list, insofar as relevant to our Award to your organization, may provide guidance in the preparation of your reports:

- a. Did the Project achieve the objectives outlined in your organization's Proposal? If not, how did the results vary from these objectives? Explain any milestones that have been achieved. How do you view the future of the Project?
- b. What developments or implementations of solutions to the problems addressed by this Award have occurred because of this Project? What, if anything, has/is occurring in the field that has changed the climate surrounding the issue?
- c. Describe the tangible results of the project. What did the Project "produce"? (e.g. payment of salaries, print publications, meetings)
- d. Describe the Project's impact on the issues being addressed. What supporting information demonstrates the Project's impact?
- e. Submit copies of significant reports, books, or media productions that stem from your efforts in connection with the Award.
- f. For interim reports on multi-year Awards only: Describe the Project activities to be conducted in the next year and provide an updated budget for those activities as part of the financial report (see below). If you have previously submitted a Project Budget for the next Award year, what modifications, if any, do you expect to make to the Project Budget?

**II. Financial Report**

Each financial report should be as detailed as possible and include the following:

- a. A line item comparison of budgeted versus actual expenses as they relate *specifically to our Award*.
- b. A statement certifying that all Award funds were expended for the purposes of the Award. If the entire Award has not been expended, please explain proposed usage of the unexpended amount.
- c. An explanation of any variations from the Project Budget submitted with your organization's Proposal.
- d. A brief summary of any fundraising for the Project, including a description of any unexpected shortfalls or surpluses. Did this grant assist your organization in leveraging funds from other sources? If not, why not?

**III. Delivery of the Narrative and Financial Report**

Interim and Final Reports should be sent to:

Terence Taylor  
NTI, Global Health and Security Initiative  
1747 Pennsylvania Avenue NW  
7th Floor  
Washington, DC 20006

Exhibit "D"

Special Stipulations

The following terms and conditions are hereby incorporated into the Agreement by reference:

Awardee agrees that the proceeds of the Grant may not be used to pay for Taxes levied by, or in the territory of, the Member Country on or in respect of Eligible Expenditures, or on their importation, manufacture, procurement or supply.

Awardee agrees to: (i) control the process whereby any individual who may use this Award, or any portion thereof, for purposes of travel or attendance at a meeting or workshop is selected and (ii) supervise such individual in carrying out the purpose for which the Award was made

Awardee agrees that all goods, works and services financed out of this Grant shall be used exclusively for the purposes of the Project

Awardee agrees that it shall not involve as participants in the Project or otherwise use any Award funds to enter into transactions with entities listed pursuant to the U.S. Foreign Assets Control Regulations (31 Code of Federal Regulations Parts 500-598) or relevant Executive Orders as ineligible to participate in transactions, directly or indirectly, with U.S. organizations and persons. NTI calls Awardee's attention to the list of entities published in the Weapons of Mass Destruction Trade Control Regulations (31 Code of Federal Regulations 539 and the list of Weapons of Mass Destruction Proliferators and Their Supporters published pursuant to Executive Order 13382; partial list provided as Exhibit "E"). Awardee understands that the list may change from time to time. Prohibited transactions with the parties listed pursuant to the Weapons of Mass Destruction Trade Control Regulations and subject to this limitation include, without limitation: (i) procuring any goods, technology or services, or entering into any agreement for the procurement of any goods, technology or services from the listed organizations; (ii) providing any assistance to or obligating funds for such purpose with listed organizations; or (iii) importing into the U.S. any goods, technology, or services produced or provided by listed organizations, any of entities described in the above regulations or executive order. For entities listed pursuant to Executive Order 13382 and certain Parts of the Foreign Assets Control Regulations (e.g., listed Foreign Terrorist Organizations) the prohibition covers all business transactions and funds transfers of any kind.

Exhibit "E"

## Selected Entities Subject to 31 Code of Federal Regulations Part 539 "WMD Trade Control Regulations" and Executive Order 13382

AEROSPACE INDUSTRIES ORGANIZATION (a.k.a. SAZMANE SANAYE HAVA FAZA; a.k.a. "AIO"), Langare Street, Nobonyad Square, Tehran, Iran [NPWMD]

ATOMIC ENERGY ORGANIZATION OF IRAN (a.k.a. SAZEMAN-E ENERGY ATOMI), P.O. Box 14144-1339, End of North Karegar Avenue, Tehran, Iran [NPWMD]

BANK SEPAH, Imam Khomeini Square P.O. Box 11364-9569, Tehran, Iran; all offices worldwide [NPWMD]

BANK SEPAH INTERNATIONAL PLC, 5-7 Eastcheap, London EC3M 1JT, United Kingdom [NPWMD]

BALTIC STATE TECHNICAL UNIVERSITY, wherever located, including 1/21, 1- ya Krasnoarmeiskaya Ul., 198005 St. Petersburg, Russia [63 FR 42089, July 30, 1998]

BEIJING ALITE TECHNOLOGIES CO., LTD. (a.k.a. ALCO; a.k.a. BEIJING HAILI LIANHE KEJI YOUXIAN GONGSI), 12A Beisanhuan Zhong Road, P.O. Box 3042, Beijing, China; and all other locations worldwide [NPWMD]

CHINA GREAT WALL INDUSTRY CORPORATION (a.k.a. CGWIC; a.k.a. ZHONGGUO CHANGCHENG GONGYE ZONGGONGSI), No. 30 Haidian Nanlu, Beijing, China; Moscow, Russia; and all other locations worldwide [NPWMD]

CHINA NEW ERA GROUP (a.k.a. China Xinshidai Company; a.k.a. New Era Group; a.k.a. XSD; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]

CHINA NATIONAL PRECISION MACHINERY IMPORT/EXPORT CORPORATION (a.k.a. CHINA NATIONAL PRECISION MACHINERY I/E CORP.; a.k.a. CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION; a.k.a. CPMIEC; a.k.a. ZHONGGUO JINGMI JIXIE JINCHUKOU ZONGGONGSI), No. 30 Haidian Nanlu, Beijing, China; and all other locations worldwide [NPWMD]

CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION (a.k.a. CPMIEC), wherever located [July 30, 2003]

CHINA XINSHIDAI COMPANY (a.k.a. China New Era Group; a.k.a. New Era Group; a.k.a. XSD; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]

CPMIEC (a.k.a. CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION), wherever located [July 30, 2003]

D. MENDELEYEV UNIVERSITY OF CHEMICAL TECHNOLOGY OF RUSSIA, wherever located, including 9 Miusskaya Sq., Moscow 125047, Russia [64 FR 2935, January 8, 1999]

DEFENSE INDUSTRIES ORGANIZATION (a.k.a. DEFENCE INDUSTRIES ORGANISATION; a.k.a. DIO; a.k.a. SASEMAN SANAJE DEFA; a.k.a. SAZEMANE SANAYE DEFA; a.k.a. "SASADJA"), P.O. Box 19585-777, Pasdaran Street, Entrance of Babaie Highway, Permanent Expo of Defence Industries Organization, Tehran, Iran [NPWMD]

DERAKHSHANDEH, AHMAD, c/o BANK SEPAH, No. 33 Hormozan Building, Pirozan St., Sharak Ghods, Tehran, Iran; DOB 11 Aug 1956; POB Iran (individual) [NPWMD]

ELECTRONICS INSTITUTE, P.O. Box 4470, Damascus, Syria [NPWMD]

FAJR INDUSTRIES GROUP (a.k.a. FADJR INDUSTRIES GROUP; a.k.a. IFP; a.k.a. INDUSTRIAL FACTORIES OF PRECISION MACHINERY; a.k.a. INSTRUMENTATION FACTORIES OF PRECISION MACHINERY; a.k.a. INSTRUMENTATION FACTORY PLANT; a.k.a. MOJTAME SANTY AJZAE DAGHIGH; a.k.a. NASR INDUSTRIES GROUP), P.O. Box 1985-777, Tehran, Iran [NPWMD]

FARAYAND TECHNIQUE (a.k.a. FARAYAND TECHNIC), End of North Karegar Avenue, Shomali, Tehran, Iran; P.O. Box 14155-1339, Tehran, Iran; Esfahan, Iran; Isfahan, Iran [NPWMD]

FEDERAL RESEARCH AND PRODUCTION COMPLEX ALTAY, Russia [69 FR 67617-18, November 18, 2004]

G.W AEROSPACE, INC (a.k.a. GREAT WALL AEROSPACE, INC.), 21515 Hawthorne Blvd., Suite 670, Torrance, CA 90503, California Corporate Number C1458237 (United States) [NPWMD]

GLAVKOSMOS, wherever located, including 9 Krasnoprolctarskaya St., 103030 Moscow, Russia [63 FR 42089, July 30, 1998]

IIESONG TRADING CORPORATION, Pyongyang, Korea, North [NPWMD]

HIGHER INSTITUTE OF APPLIED SCIENCE AND TECHNOLOGY (a.k.a. HIAST; a.k.a. INSTITUT DES SCIENCES APPLIQUEES ET DE TECHNOLOGIE; a.k.a. INSTITUT SUPERIEUR DES SCIENCES APPLIQUEES ET DE TECHNOLOGIE; a.k.a. ISAT; a.k.a. ISSAT), P.O. Box 31983, Barzeh, Damascus, Syria [NPWMD]

KALAYE ELECTRIC COMPANY (a.k.a. KALA ELECTRIC COMPANY), 33 Fifteenth (15th) Street, Seyed Jamal Eddin-Assad Abadi Avenue, Tehran, Iran [NPWMD]

KAVOSHYAR COMPANY (a.k.a. KAAVOSH YAAR; a.k.a. KAVOSHYAR), P.O. Box 19395-1834, Tehran, Iran; Vanaq Square, Corner of Shiraz Across No. 71, Molla Sadra Ave., Tehran, Iran; No. 86, 20th St., North Kargar Ave., Tehran, Iran [NPWMD]

KOHAS AG, Route des Arsenaux 15, Fribourg, FR 1700, Switzerland; C.R. No. CH-217.0.135.719-4 (Switzerland) [NPWMD]

KOREA COMPLEX EQUIPMENT IMPORT CORPORATION, Rakwondong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA INTERNATIONAL CHEMICAL JOINT VENTURE COMPANY (a.k.a. CHOSUN INTERNATIONAL CHEMICALS JOINT OPERATION COMPANY; a.k.a. CHOSUN INTERNATIONAL CHEMICALS JOINT OPERATION COMPANY; a.k.a. INTERNATIONAL CHEMICAL JOINT VENTURE CORPORATION), Hamhung, South Hamgyong Province, Korea, North; Man gyongdae-kuyok, Pyongyang, Korea, North; Mangyungdae-gu, Pyongyang, Korea, North [NPWMD]

KOREA KWANGSONG TRADING CORPORATION, Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA MINING DEVELOPMENT TRADING CORPORATION (a.k.a. CHANGGWANG SINYONG CORPORATION; a.k.a. EXTERNAL TECHNOLOGY GENERAL CORPORATION; a.k.a. NORTH KOREAN MINING DEVELOPMENT TRADING CORPORATION; a.k.a. "KOMID"), Central District, Pyongyang, Korea, North [NPWMD]

KOREA PUGANG TRADING CORPORATION, Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONBONG GENERAL CORPORATION (a.k.a. KOREA YONBONG GENERAL CORPORATION; f.k.a. LYONGAKSAN GENERAL TRADING CORPORATION), Pot'onggang District, Pyongyang, Korea, North; Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONGWANG TRADING CORPORATION (a.k.a. KOREA RYENGWANG TRADING CORPORATION), Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONHA MACHINERY JOINT VENTURE CORPORATION (a.k.a. CHOSUN YUNHA MACHINERY JOINT OPERATION COMPANY; a.k.a. KOREA RYENHA MACHINERY J/V CORPORATION; a.k.a. RYONHA MACHINERY JOINT VENTURE CORPORATION), Central District, Pyongyang, Korea, North; Mangungdae-gu, Pyongyang, Korea, North; Mangyongdae District, Pyongyang, Korea, North [NPWMD]

LEILABADI, ALI HAJINIA (a.k.a. LAILABADI, ALI HADJINIA), c/o MESBAH ENERGY COMPANY, Iran; DOB 19 Feb 1950; POB Tabriz, Iran; citizen Iran; nationality Iran; Passport E4710151 (Iran) issued 15 Oct 2000 expires 15 Oct 2005 (individual) [NPWMD]



LIMMT ECONOMIC AND TRADE COMPANY, LTD (a.k.a. LIMMT (DALIAN FTZ) METALLURGY AND MINERALS CO., LTD.; a.k.a. LIMMT (DALIAN FTZ) MINMETALS AND METALLURGY CO., LTD.; a.k.a. LIMMT (DALIAN) METALLURGY AND MINERALS CO., LTD.), 2501-2508 Yuxiu Mansion, No. 82 Xinkai Road, Dalian, Liaoning 116011, China; and all other locations worldwide [NPWMD]

MAI (a.k.a. MOSCOW AVIATION INSTITUTE), wherever located, including 4 Volokolamskoye Shosse, Moscow 125871, Russia [64 FR 2935, January 8, 1999]

MESBAH ENERGY COMPANY (a.k.a. "MEC"), 77 Armaghan Gharbi Street, Valiasr Blve., Tehran, Iran [NPWMD]

MIZAN MACHINE MANUFACTURING GROUP (a.k.a. 3MG), P.O. Box 16595-365, Tehran, Iran [NPWMD]

MOSCOW AVIATION INSTITUTE (a.k.a. MAI), wherever located, including 4 Volokolamskoye Shosse, Moscow 125871, Russia [64 FR 2935, January 8, 1999]

NATIONAL STANDARDS AND CALIBRATION LABORATORY (a.k.a. NATIONAL CALIBRATION CENTRE; a.k.a. NSCL), P.O. Box 4470, Damascus, Syria [NPWMD]

NEW ERA GROUP (a.k.a. China New Era Group; a.k.a. China Xinshidai Company; a.k.a. Xinshidai; a.k.a. XSD) [69 FR 56260, September 20, 2004]

NOVIN ENERGY COMPANY (a.k.a. Energy Novin; a.k.a. Noveen Energy Company), End of North Karegar Avenue, Tehran, Iran [NPWMD]

PARS TRASH COMPANY (a.k.a. PARS TARASH; a.k.a. PARS TERASH; a.k.a. PARS TRASH), 33 Fifteenth (15th) Street, Seyed-Jamal-Eddin- Assad Abadi Avenue, Tehran, Iran [NPWMD]

PIONEER ENERGY INDUSTRIES COMPANY (a.k.a. PISHGAM ENERGY INDUSTRIES DEVELOPMENT; a.k.a. "PET"), P.O. Box 81465-361, Isfahan, Iran [NPWMD]

QANNADI, MOHAMMAD (a.k.a. GHANNADI MARAGHEH, MOHAMMAD; a.k.a. GHANNADI, MOHAMMAD; a.k.a. QANNADI MARAGHEH, MOHAMMAD), c/o ATOMIC ENERGY ORGANIZATION OF IRAN, Iran; DOB 13 Oct 1952; POB Maragheh, Iran; citizen Iran; nationality Iran; Passport 20694 (Iran); alt. Passport A0003044 (Iran) (individual)[NPWMD]

SANAM INDUSTRIAL GROUP (a.k.a. Sanam Industries Group) Pasdaran Road 15, Tehran, Iran

SCIENTIFIC STUDIES AND RESEARCH CENTER (a.k.a. CENTRE D'ETUDES ET RECHERCHES; a.k.a. "SSRC"), P.O. Box 4470, Damascus, Syria [NPWMD]

SHAHID BAKERI INDUSTRIAL GROUP (a.k.a. "SBIG"), Tehran, Iran [NPWMD]

SHAHID HEMMAT INDUSTRIAL GROUP (a.k.a. "SHIG"), Damavand Tehran Highway, Tehran, Iran [NPWMD]

STEIGER, Jakob, c/o KOHAS AG, Fribourg, FR, Switzerland; DOB 27 Apr 1941; POB Altstatten, SG, Switzerland (individual) [NPWMD]

TANCHON COMMERCIAL BANK (f.k.a. CHANGGWANG CREDIT BANK; f.k.a. KOREA CHANGGWANG CREDIT BANK), Saemul 1-Dong Pyongchon District, Pyongyang, Korea, North [NPWMD]

TOSONG TECHNOLOGY TRADING CORPORATION, Pyongyang, Korea [NPWMD]

XINSHIDAI (a.k.a. China New Era Group; a.k.a. China Xinshidai Company; a.k.a. New Era Group; a.k.a. XSD) [69 FR 56260, September 20, 2004]

XSD (a.k.a. China New Era Group; a.k.a. China Xinshidai Company a.k.a. New Era Group; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]

YA MAHDI INDUSTRIES GROUP (a.k.a. Ya Mahdi Industrial Research Complex; a.k.a. Ya Mahdi Industrial Complex;  
a.k.a. "YMA") PO Box 19395-4797, Tehran, Iran

003 [TX/RX NO 9579] [TX/RX NO 9579] [TX/RX NO 9579] [TX/RX NO 9579] [TX/RX NO 9579]

Form **W-8EXP**  
(Rev. December 2007)

**Certificate of Foreign Government or Other Foreign Organization for United States Tax Withholding**  
(For use by foreign governments, international organizations, foreign central banks of issue, foreign tax-exempt organizations, foreign private foundations, and governments of U.S. possessions.)  
▶ Section references are to the Internal Revenue Code. ▶ See separate instructions.  
▶ Give this form to the withholding agent or payer. Do not send to the IRS.

OMB No. 1545-1621

Department of the Treasury  
Internal Revenue Service

- Do not use this form for:
- Any foreign government or other foreign organization that is not claiming the applicability of section(s) 115(2), 501(c), 892, 895, or 1443(b).
  - A beneficial owner entity claiming foreign status or treaty benefits.
  - A foreign partnership or a foreign trust.
  - A person claiming an exemption from U.S. withholding on income effectively connected with the conduct of a trade or business in the United States.
  - A person acting as an intermediary.
- Instead, use Form:
- W-8BEN or W-8ECI
  - W-8BEN
  - W-8BEN or W-8BTI
  - W-BECI
  - W-6IMY

**Part I Identification of Beneficial Owner (See instructions.)**

1 Name of organization Ministry of Health 2 Country of incorporation or organization JORDAN

3 Type of entity:  Foreign government  International organization  Foreign central bank of issue not wholly owned by the foreign sovereign  Foreign tax-exempt organization  Foreign private foundation

4 Permanent address (street, apt. or suite no., or rural route). Do not use a P.O. box.  
Abdulhamed Sharaf Street - Shmaisani No 93  
City or town, state or province, include postal code where appropriate. Country (do not abbreviate) JORDAN

5 Mailing address (if different from above)  
AMMAN - JORDAN - 11194  
City or town, state or province, include postal or ZIP code where appropriate. Country (do not abbreviate)

6 U.S. taxpayer identification number, if required (see instructions) 7 Foreign tax identifying number, if any (optional)

8 Reference number(s) (see instructions)

**Part II Qualification Statement**

- 9 For a foreign government:
- I certify that the entity identified in Part I is a foreign government within the meaning of section 892 and the payments are within the scope of the exemption granted by section 892.  
Check box 9b or box 9c, whichever applies:
  - The entity identified in Part I is an integral part of the government of JORDAN.
  - The entity identified in Part I is a controlled entity of the government of .....
- 10 For an international organization:
- I certify that:
    - The entity identified in Part I is an international organization within the meaning of section 7701(a)(18) and
    - The payments are within the scope of the exemption granted by section 892.
- 11 For a foreign central bank of issue (not wholly owned by the foreign sovereign):
- I certify that:
    - The entity identified in Part I is a foreign central bank of issue,
    - The entity identified in Part I does not hold obligations or bank deposits to which this form relates for use in connection with the conduct of a commercial banking function or other commercial activity, and
    - The payments are within the scope of the exemption granted by section 895.

(Part II and required certification continued on page 2)

For Paperwork Reduction Act Notice, see separate instructions.

OMB No. 1545-1621

Form **W-8EXP** (Rev. 11-2000)

**Part II** Qualification Statement (continued)

12 For a foreign tax-exempt organization, including foreign private foundations:

If any of the income to which this certification relates constitutes income includible under section 512 in computing the entity's unrelated business taxable income, attach a statement identifying the amounts.

Check either box 12a or box 12b:

- a  I certify that the entity identified in Part I has been issued a determination letter by the IRS dated ..... that is currently in effect and that concludes that it is an exempt organization described in section 501(c).
- b  I have attached to this form an opinion from U.S. counsel concluding that the entity identified in Part I is described in section 501(c).

For section 501(c)(3) organizations only, check either box 12c or box 12d:

- c  If the determination letter or opinion of counsel concludes that the entity identified in Part I is described in section 501(c)(3), I certify that the organization is not a private foundation described in section 509. I have attached an affidavit of the organization setting forth sufficient facts for the IRS to determine that the organization is not a private foundation because it meets one of the exceptions described in section 509(a)(1), (2), (3), or (4).
  - d  If the determination letter or opinion of counsel concludes that the entity identified in Part I is described in section 501(c)(2), I certify that the organization is a private foundation described in section 509.
- 13 For a government of a U.S. possession:
- I certify that the entity identified in Part I is a government of a possession of the United States, or is a political subdivision thereof, and is claiming the exemption granted by section 115(2).

**Part III** Certification

Under penalties of perjury, I declare that I have examined the information on this form and to the best of my knowledge and belief it is true, correct, and complete. I further certify under penalties of perjury that:

- The organization for which I am signing is the beneficial owner of the income to which this form relates.
- The beneficial owner is not a U.S. person.
- For a beneficial owner that is a controlled entity of a foreign sovereign (other than a central bank of issue wholly owned by a foreign sovereign), the beneficial owner is not engaged in commercial activities within or outside the United States, and
- For a beneficial owner that is a central bank of issue wholly owned by a foreign sovereign, the beneficial owner is not engaged in commercial activities within the United States.

Furthermore, I authorize this form to be provided to any withholding agent that has control, receipt, or custody of the income of which I am the beneficial owner or any withholding agent that can disburse or make payments of the income of which I am the beneficial owner.

Sign Here

Signature of authorized official

9/8/2007  
Date (MM-DD-YYYY)

Ministry of Health  
Asst. Sec. Gen.  
Capacity in which acting



## NUCLEAR THREAT INITIATIVE, INC. AWARD AGREEMENT

ORGANIZATION: Tel Aviv University ("Awardee") represented by Professor Daniel Cohen, Head, Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine (MECIDS Project Leader in Israel)

PROJECT: MECIDS Country Support

AWARD NO.: 2058

APPROVED AMOUNT: for up to \$138,300 ("Award")

---

1. This Award is for the specific purposes as described in Exhibit "A" (for convenience of reference, such purposes hereinafter the "Project"), and payments received by Awardee may be expended for no other purpose without the prior written consent of NTI. In addition, the Project budget attached to and included as a part of Exhibit "A" (the "Project Budget") may not be modified or adjusted without the prior written consent of NTI. Consistent with the foregoing, all payments received by Awardee may be expended only for charitable, scientific, literary or educational purposes ("Charitable Purposes") within the meaning of Sections 501(c)(3) and 170(c)(2) of the Internal Revenue Code of 1986, as amended (the "Code"). Awardee shall return any funds not used for the specific Charitable Purposes set forth in Exhibit "A" unless Awardee has obtained NTI's prior written approval of an alternative use of the funds.
2. Awardee agrees that none of the funds covered by this Award Agreement (with all exhibits and any special stipulations, hereinafter the "Agreement") shall be used to participate in, or intervene in any political campaign on behalf of (or in opposition to) any candidate for public office, to influence legislation, to carry on voter registration drives, to make grants to individuals or other organizations, or to undertake any nonexempt activity, when such use of the funds would be a taxable expenditure if made directly by NTI.
3. By checking the appropriate box below, the undersigned officer of Awardee hereby certifies that Awardee is (check applicable and strike out statements that do not apply):
  - Tax exempt under Code Section 501(c)(3) and "not a private foundation" within the meaning of Code Section 509(a), or in the absence of such a determination, Awardee is a state or any political subdivision thereof within the meaning of Code Section 170(c)(1), or a state college or university within the meaning of Code Section 511(a)(2)(B) (hereinafter referred to as a "Public Charity"). (Please provide a copy of any letter from the IRS determining this status.)
  - Tax exempt under Code Section 501(c)(3) and classified as a private foundation under the Code. (Please provide a copy of the letter from IRS determining this status.)
  - Not tax exempt under Code Section 501(c)(3).
4. If Awardee is currently tax exempt under Code Section 501(c)(3) or classified as a Public Charity under the Code, then in the event Awardee loses such tax exempt or Public Charity status, this Agreement shall be considered null and void and all unexpended Award funds shall be immediately returned to NTI.
5. Awardee agrees to immediately notify NTI, in writing, if: (i) Awardee's federal tax status is revoked or altered; (ii) Awardee has reasonable grounds to believe that its federal tax status may be revoked or altered; or (iii) Awardee has reason to believe that the Award cannot be or continue to be expended for the specific purposes set forth in Exhibit "A".
6. In order to ensure that there is no misunderstanding by the general public regarding NTI's involvement with the Project, NTI reserves the right to, in advance, review, comment on and otherwise approve any statements, announcements or releases proposed to be made by Awardee to the press or public regarding NTI's involvement with the Project. Awardee may, however, make reference to NTI's support of Awardee's work generally as Awardee executes the Project.
7. NTI reserves the right, prior to submission for publication, to review and comment upon any documents, manuscripts, papers, exhibits or other materials that might result from the Project. Awardee agrees to duly consider comments, suggestions or issues that NTI identifies as noteworthy or of significance and which will be received within 30 days. At NTI's election, NTI's support will be acknowledged in any such publication. Any such acknowledgment will indicate, "This (publication) has been supported (in part) with funds from the Nuclear Threat Initiative. Its contents

represent the views, findings and opinions of the authors, and are not necessarily those of the Nuclear Threat Initiative."

8. Awardee hereby grants and NTI hereby accepts a royalty-free, nonexclusive, irrevocable and perpetual license (with a right to sublicense) to reproduce, publish and otherwise use and authorize others to reproduce, publish and otherwise use, any materials resulting from the Project. These materials may be published after their content has been approved by Awardee. Awardee will receive the adequate professional and scientific credit.
9. Awardee shall cooperate with NTI in supplying any additional information or in complying with any laws, rules, regulations, or procedures which might be required by any governmental authority in order for NTI to comply with and establish the fact that it has observed all requirements of all laws, rules and regulations with respect to this Award.
10. Awardee agrees to keep accurate and complete books and records of receipts and expenditures made in connection with the Project. Awardee will maintain such books and records in a manner that the receipts and expenditures of Award funds will be shown separately thereon. Awardee will keep records of receipts and expenditures of Award funds as well as copies of reports submitted to NTI and supporting documentation for at least four (4) years after the completion of use of Award funds, and will make the same available to NTI for inspection as reasonably required from the time of Awardee's acceptance of this Award through such period.
11. Both the quality of the work done and Awardee's progress toward achieving the goals of the Award will be reviewed by NTI. NTI may monitor and conduct formal evaluations of operations and progress under this Award, which may include visits from NTI personnel to observe Awardee's projects and programs and to review financial and other records and materials connected with activities financed by this Award, and Awardee agrees to timely cooperate and assist NTI with such monitoring and evaluation activities.
12. It is anticipated the Award will be paid in accordance with the disbursement schedule attached hereto as Exhibit "B". However, in the case of a multi-year or other Award payable in installments, the payment of each installment shall be additionally subject to a determination by NTI, in its sole and absolute discretion, that: (i) Awardee has timely provided the deliverables and services set forth in the attached Proposal; (ii) Awardee has timely delivered the report(s) requested by NTI in the attached guidelines; (iii) payments received from NTI have been used solely for the purposes for which they were authorized; (iv) additional payments shall be used solely for the purposes for which the Award was authorized; (v) Awardee has otherwise strictly complied with the terms and conditions of this Agreement; and (vi) there have been no material changes in Awardee's operations, staffing or funding which would adversely affect the objectives for which the Award was authorized; and (vii) the context in which the Project is to be executed has not been changed so substantially that the objectives for which the funds were authorized cannot be adequately realized.
13. Awardee shall provide detailed reporting as described in Exhibit "C" hereto.
14. In the case of any violation by Awardee of any of the terms or conditions of this Award, including but not limited to not executing the Project in strict compliance with Exhibit "A", or in the event of any change in or challenge by the Internal Revenue Service of Awardee's federal tax status, NTI reserves the right in its absolute discretion to terminate the Award. NTI's determination will be final and will be binding and conclusive upon Awardee. Upon termination of this Award for any reason, NTI will withhold any further payment of Award funds and all unexpended Award funds and any portion of the Award funds which was not spent for the Project shall be immediately returned to NTI. Notwithstanding the aforesaid, NTI will not undertake to terminate the Award unless prior written notice of the violation has been given to the University and the violation has not been remedied within 30 days of such notice.
15. Awardee shall indemnify and hold NTI, its directors, officers, employees, consultants, representatives and agents harmless from and against all third party claims, liabilities, suits, demands, losses, judgments, fines, penalties, interest, expenses and costs (including, without limitation, reasonable accounting and attorneys' fees and disbursements) which result from any breach of legal liability of Awardee's representations or warranties made in relation to this Agreement, the Project, or from any breach of the terms of this Agreement, or from any negligent acts or omissions of Awardee, its directors, officers, employees, consultants, representatives and agents relating to, or in any way connected with, activities conducted pursuant to this Agreement.
16. This Agreement and the exhibits and any special stipulations attached hereto constitute the entire understanding of NTI and Awardee with respect to the subject matter hereof, and supersede all prior agreements and understandings, whether oral or written. This Agreement may not be amended or modified except in a writing signed by NTI. This Agreement shall be deemed to be made under, and in all respects shall be interpreted under and governed by, the laws of the District of Columbia, U.S.A.

17. The special stipulations contained on exhibit "D" are hereby incorporated herein by reference.

The undersigned duly authorized official of Awardee accepts and agrees to, on behalf of Awardee, these terms and conditions, as of the date set forth below.

**AWARDEE:**

Tel Aviv University

By: \_\_\_\_\_



LEA PAIS  
DIRECTOR  
RESEARCH SECURITY

Title: \_\_\_\_\_

22 JAN 2008

Amit Streit  
Vice Director General  
of Finance

Date: \_\_\_\_\_

**GRANTOR:**

Nuclear Threat Initiative

By: Craig B. Cantor

Title: COO & President

Date: March 20, 2008

Exhibit "A"

Project Description

Background

The governance of the Middle East Consortium on Infectious Disease Surveillance (MECIDS) is based upon a newly formed Executive Council composed of an Executive Chairperson and Executive Board, supported by national MECIDS Country Coordinators and a Secretariat.

The primary responsibility for day-to-day management of the program and its activities, determining the meeting agendas, holding the consortium accountable for deliverables, and planning the strategic direction for MECIDS will be driven by the Executive Council supported by a Secretariat. All MECIDS activities, including those described below, are determined by the MECIDS Executive Board. Should the MECIDS Executive Board decide to modify the budget or project activities, the budget and/or activities outlined in this Agreement will likewise be modified.

MECIDS Country Support

The purpose of this Award is to improve the early detection and response to pandemic influenza and other food- and water-borne diseases by increasing laboratory and epidemiological capacity within the MECIDS countries. Over the last four years, the laboratory capacity in Jordan, Israel and the Palestinian Authority has been increasing through NTT's financial support of MECIDS. This increased capacity has included the support of dedicated laboratory personnel for food- and water-borne disease surveillance, laboratory equipment and supplies for food- and water-borne diseases, and training opportunities for both laboratorians and other public health staff in applied epidemiology and disease investigations.

As the consortium has taken on the threat of avian and human influenza preparedness efforts, diagnostic efforts need to increase against these threats. Laboratory personnel and essential supplies for meeting the increased demands placed on a system with already inadequate resources will have to be met. In addition, an immediate need exists to build a rapid, real-time communications capacity among the various laboratories within each country or government, and across borders to the international secretariat.

Services: Country Coordinators

One or two professional staff will serve as points of contact for day-to-day MECIDS communications and planning needs, including:

- ❖ Data sharing
- ❖ Communications infrastructure development
- ❖ Providing assistance to immediate needs of the Secretariat regarding logistical arrangements for meetings, conferences, and other special events.

The Country Coordinator(s) will work closely with both the Executive Council members from their country or government as well as interact closely with other Country Coordinators. The Coordinator(s) will be required to attend meetings, including Executive Council meetings, training workshops and various other technical and scientific exercises and meetings.

The MECIDS Country Coordinator(s) will follow the direction of the MECIDS Executive Council. The Coordinator(s) will work towards the goals identified in the Business Plan, as agreed upon by the MECIDS Executive Board. The Coordinator(s) will be required to report to the Executive Council and Secretariat regularly or as determined by the Executive Board.

Training: Regional, National Meetings & Exercises

A Regional Training Session on laboratory pathogens may include 2-3 representatives from each partner, including the Secretariat. Funds allow for 10 people to attend a four-day training session at a regional location to be determined. At least one Country Coordinator from each partner country must be in attendance.

A Local Training Session on laboratory pathogens may include up to 10 representatives, including the Country Coordinator(s). Funds allow for 10 people to attend a four-day training session.



A National Influenza and Disease Surveillance Exercise will provide each MECIDS country with tools to identify and address challenges at the national levels related to planning, surveillance and response to public health emergencies. Pandemic influenza preparedness will be used as an illustrative example for this purpose. To achieve this goal, a national "tabletop" exercise will be developed, based on plausible scenarios, and conducted in individual MECIDS countries, with the view to conduct an exercise at the regional level.

Once the National Exercise has occurred, Awardee shall conduct a National Training Session on Surveillance and Disease Response Preparation. This training session will address lessons-learned from the national exercise and will produce a training syllabus.

#### Procurement Method<sup>1</sup>

In order to obtain Project funds, Awardee is required to submit Procurement documents as designated below.

#### **Individual Consultant**

In order to procure funds for the Country Coordinator(s), Awardee is required to submit the following:

- ❖ Name, title and work address of individual(s) selected for Country Coordinator position
- ❖ Brief explanation of selection, including past experience with MECIDS (if applicable)
- ❖ If individual has not engaged in previous work with MECIDS, Awardee is required to provide evidence that a fair selection process has been undertaken to hire select individual(s)
- ❖ Country Coordinator(s) Curriculum Vitae
- ❖ If nominated Country Coordinator changes, Awardee must notify NTI and provide relevant details for selection of new Country Coordinator.

#### **Quality and Cost-based Selection (QCBS)**

In order to procure funds for Training, Awardee is required to submit the following:

- ❖ If it results in cost-savings, NTI may act as the QCBS Procurement agent.
- ❖ At least 3 price quotations from appropriate suppliers. Any variance (i.e. a sole provider) must be approved by NTI.
- ❖ Copies of the requests for quotations, which shall indicate the description and quantity of the specification of works, as well as desired delivery (or completion) time and place.

Training costs may include staff/personnel, conference rooms, supplies, communication, transportation, accommodation and food for participants, international travel (for selected people who will undergo training abroad), and other miscellaneous costs related to coordination of the Training sessions.

Awardee will be required to submit to NTI a description of the training to be held, including date, subject matter and potential attendees, as well as price quotations for travel and other meeting/training costs. Upon receipt of description and price quotations, NTI will either pay the costs directly or will disburse funds to Awardee for this purpose.

---

<sup>1</sup> Refer to "Project Budget".

Project Budget

The Project Budget covers a period of 16 months. Awardee will identify specific dates in Interim and Final Reports. The Project shall be used only for work that directly supports MECIDS, as directed by the Executive Board. The Project Budget shall not be used for the salary of the project leader, Dr Daniel Cohen.

Services	Procurement Method <sup>2</sup>	Quantity	Unit	Unit Rate	Total
Country Coordinator(s)	Individual Consultants	16	Months	\$3,750	\$60,000
					\$60,000

Training	Procurement Method	Quantity	Unit	Unit Rate	Total
Regional Training					
Laboratory pathogens training, 10 people, 4 days	Quality & Cost-Based Selection	1	Trainings	\$3,300	\$3,300
Local Training					
Enhanced Laboratory pathogens training, 10 people, 4 days	Quality & Cost-Based Selection	1	Trainings	\$10,000	\$10,000
National Influenza and Disease Surveillance Exercises	Quality & Cost-Based Selection	1	Trainings	\$15,000	\$15,000
National Training for Surveillance and Response Preparation	Quality & Cost-Based Selection	1	Trainings	\$50,000	\$50,000
					\$78,300

**Total: \$138,300**

<sup>2</sup> Refer to "Procurement Method" on page 5 of Agreement.

Exhibit "B"**Tentative Disbursement Schedule**

Subject to the terms and conditions of the Agreement, it is anticipated the Award will be disbursed as follows:

Services: Country Coordinators

<b>Tentative Disbursement Date</b>	<b>Installment Amount (USD)</b>
Upon receipt of Procurement documents and signed Agreement July 2007	\$20,000
Upon receipt of 1 <sup>st</sup> Interim Report (Financial & Narrative) November 2007	\$20,000
Upon receipt of 2 <sup>nd</sup> Interim Report (Financial & Narrative) March 2008	\$20,000

Training: Regional, Local Training & Exercise

<b>Tentative Disbursement Date</b>	<b>Installment Amount</b>
Upon receipt of QCBS documents	NTI will disburse allocated funds to Awardee; Or if cost-savings result NTI may provide funds directly to provider

Exhibit "C"Interim Reporting Requirements**Services**

Country Coordinator(s) will be required to submit Interim Financial and Narrative Reports. Interim Financial Reports should include a description of costs incurred during period of work, including timeframe (period of time for which the disbursement of funds covered), activities, travel, technical support and other MECIDS activities. Interim Narrative Reports should include a brief description of activities and work performed during this period.

Interim Reports will be due:

October 15, 2007 } Superseded by ext. letter  
February 15, 2008 }

**Training**

If NTI pays costs directly, Awardee will be required to submit a report to NTI describing the outcome of the training session, including agenda, attendees and a summary of activities/lessons, no later than one month after session has taken place.

If NTI disburses funds to Awardee to cover the costs of training, Awardee will be required to submit invoices for payments made with funds. Upon completion of training session, Awardee will be required to submit a report describing the outcome of the session, including agenda, attendees and a summary of activities/lessons. Awardee will also be required to submit a training syllabus for each respective training session. These reports, including invoices, will be due to NTI no later than one month after session has taken place.

Final Reporting Requirements

At such time as the Award funds are fully expended, NTI requires for our records a final report, as appropriate, which will: (i) describe in narrative fashion what was achieved with the Award funds; and (ii) provide a full financial accounting of the Award.

**I. Narrative Report**

Each narrative report should briefly (no more than five pages) summarize how the Award was used and the results which were achieved. The report will be used by NTI staff to evaluate and to provide an overview of your work for our Board of Directors. The following list, insofar as relevant to our Award to your organization, may provide guidance in the preparation of your reports:

- a. Did the Project achieve the objectives outlined in your organization's Proposal? If not, how did the results vary from these objectives? Explain any milestones that have been achieved. How do you view the future of the Project?
- b. What developments or implementations of solutions to the problems addressed by this Award have occurred because of this Project? What, if anything, has/is occurring in the field that has changed the climate surrounding the issue?
- c. Describe the tangible results of the project. What did the Project "produce"? (e.g. payment of salaries, print publications, meetings)
- d. Describe the Project's impact on the issues being addressed. What supporting information demonstrates the Project's impact?
- e. Submit copies of significant reports, books, or media productions that stem from your efforts in connection with the Award.
- f. For interim reports on multi-year Awards only: Describe the Project activities to be conducted in the next year and provide an updated budget for those activities as part of the financial report (see below). If you have previously submitted a Project Budget for the next Award year, what modifications, if any, do you expect to make to the Project Budget?

**II. Financial Report**

Each financial report should be as detailed as possible and include the following:

- a. A line item comparison of budgeted versus actual expenses as they relate *specifically to our Award*
- b. A statement certifying that all Award funds were expended for the purposes of the Award. If the entire Award has not been expended, please explain proposed usage of the unexpended amount.
- c. An explanation of any variations from the Project Budget submitted with your organization's Proposal
- d. A brief summary of any fundraising for the Project, including a description of any unexpected shortfalls or surpluses. Did this grant assist your organization in leveraging funds from other sources? If not, why not?

**III. Delivery of the Narrative and Financial Report**

Interim and Final Reports should be sent to:

Terence Taylor  
NTI, Global Health and Security Initiative  
1747 Pennsylvania Avenue NW  
7th Floor  
Washington, DC 20006

Exhibit "D"

Special Stipulations

The following terms and conditions are hereby incorporated into the Agreement by reference:

Awardee agrees that the proceeds of the Grant may not be used to pay for Taxes levied by, or in the territory of, the Member Country on or in respect of Eligible Expenditures, or on their importation, manufacture, procurement or supply

Awardee agrees to: (i) control the process whereby any individual who may use this Award, or any portion thereof, for purposes of travel or attendance at a meeting or workshop is selected and (ii) supervise such individual in carrying out the purpose for which the Award was made.

Awardee agrees that all goods, works and services financed out of this Grant shall be used exclusively for the purposes of the Project

Awardee agrees that it shall not involve as participants in the Project or otherwise use any Award funds to enter into transactions with entities listed pursuant to the U.S. Foreign Assets Control Regulations (31 Code of Federal Regulations Parts 500-598) or relevant Executive Orders as ineligible to participate in transactions, directly or indirectly, with U.S. organizations and persons. NTI calls Awardee's attention to the list of entities published in the Weapons of Mass Destruction Trade Control Regulations (31 Code of Federal Regulations 539 and the list of Weapons of Mass Destruction Proliferators and Their Supporters published pursuant to Executive Order 13382; partial list provided as Exhibit "E"). Awardee understands that the list may change from time to time. Prohibited transactions with the parties listed pursuant to the Weapons of Mass Destruction Trade Control Regulations and subject to this limitation include, without limitation: (i) procuring any goods, technology or services, or entering into any agreement for the procurement of any goods, technology or services from the listed organizations; (ii) providing any assistance to or obligating funds for such purpose with listed organizations; or (iii) importing into the U.S. any goods, technology, or services produced or provided by listed organizations, any of entities described in the above regulations or executive order. For entities listed pursuant to Executive Order 13382 and certain Parts of the Foreign Assets Control Regulations (e.g., listed Foreign Terrorist Organizations) the prohibition covers all business transactions and funds transfers of any kind.

Exhibit "E"

**Selected Entities Subject to 31 Code of Federal Regulations Part 539 "WMD Trade Control Regulations" and Executive Order 13382**

AEROSPACE INDUSTRIES ORGANIZATION (a.k.a. SAZMANE SANAYE HAVA FAZA; a.k.a. "AIO"), Langare Street, Nobonyad Square, Tehran, Iran [NPWMD]

ATOMIC ENERGY ORGANIZATION OF IRAN (a.k.a. SAZEMAN-E ENERGY ATOMI), P.O. Box 14144-1339, End of North Karegar Avenue, Tehran, Iran [NPWMD]

BANK SEPAH, Imam Khomeini Square P.O. Box 11364-9569, Tehran, Iran; all offices worldwide [NPWMD]

BANK SEPAH INTERNATIONAL PLC, 5-7 Eastcheap, London EC3M 1JT, United Kingdom [NPWMD]

BALTIC STATE TECHNICAL UNIVERSITY, wherever located, including 1/21, 1-ya Krasnoarmeiskaya Ul., 198005 St. Petersburg, Russia [63 FR 42089, July 30, 1998]

BEIJING ALITE TECHNOLOGIES CO., LTD. (a.k.a. ALCO; a.k.a. BEIJING HAILI LIANHE KEJI YOUXIAN GONGSI), 12A Beisanhuan Zhong Road, P.O. Box 3042, Beijing, China; and all other locations worldwide [NPWMD]

CHINA GREAT WALL INDUSTRY CORPORATION (a.k.a. CGWIC; a.k.a. ZHONGGUO CHANGCHENG GONGYE ZONGGONGSI), No. 30 Haidian Nanlu, Beijing, China; Moscow, Russia; and all other locations worldwide [NPWMD]

CHINA NEW ERA GROUP (a.k.a. China Xinshidai Company; a.k.a. New Era Group; a.k.a. XSD; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]

CHINA NATIONAL PRECISION MACHINERY IMPORT/EXPORT CORPORATION (a.k.a. CHINA NATIONAL PRECISION MACHINERY I/E CORP.; a.k.a. CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION; a.k.a. CPMIEC; a.k.a. ZHONGGUO JINGMI JIXIE JINCHUKOU ZONGGONGSI), No. 30 Haidian Nanlu, Beijing, China; and all other locations worldwide [NPWMD]

CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION (a.k.a. CPMIEC), wherever located [July 30, 2003]

CHINA XINSHIDAI COMPANY (a.k.a. China New Era Group; a.k.a. New Era Group; a.k.a. XSD; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]

CPMIEC (a.k.a. CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION), wherever located [July 30, 2003]

D. MENDELEYEV UNIVERSITY OF CHEMICAL TECHNOLOGY OF RUSSIA, wherever located, including 9 Miusskaya Sq., Moscow 125047, Russia [64 FR 2935, January 8, 1999]

DEFENSE INDUSTRIES ORGANIZATION (a.k.a. DEFENCE INDUSTRIES ORGANISATION; a.k.a. DIO; a.k.a. SASEMAN SANAJE DEFA; a.k.a. SAZEMANE SANAYE DEFA; a.k.a. "SASADJA"), P.O. Box 19585-777, Pasdaran Street, Entrance of Babaie Highway, Permanent Expo of Defence Industries Organization, Tehran, Iran [NPWMD]

DERAKHSHANDEH, AHMAD, c/o BANK SEPAH, No. 33 Hormozan Building, Pirozan St., Sharak Ghods, Tehran, Iran; DOB 11 Aug 1956; POB Iran (individual) [NPWMD]

ELECTRONICS INSTITUTE, P.O. Box 4470, Damascus, Syria [NPWMD]

FAJR INDUSTRIES GROUP (a.k.a. FADJR INDUSTRIES GROUP; a.k.a. IFP; a.k.a. INDUSTRIAL FACTORIES OF PRECISION MACHINERY; a.k.a. INSTRUMENTATION FACTORIES OF PRECISION MACHINERY; a.k.a. INSTRUMENTATION FACTORY PLANT; a.k.a. MOJTAME SANTY AJZAE DAGHIGH; a.k.a. NASR INDUSTRIES GROUP), P.O. Box 1985-777, Tehran, Iran [NPWMD]

FARAYAND TECHNIQUE (a.k.a. FARAYAND TECHNIC), End of North Karegar Avenue, Shomali, Tehran, Iran; P.O. Box 14155-1339, Tehran, Iran; Esfahan, Iran; Isfahan, Iran [NPWMD]

FEDERAL RESEARCH AND PRODUCTION COMPLEX ALTAY, Russia [69 FR 67617-18, November 18, 2004]

G W. AEROSPACE, INC (a.k.a. GREAT WALL AEROSPACE, INC ), 21515 Hawthorne Blvd., Suite 670, Torrance, CA 90503; California Corporate Number C1458237 (United States) [NPWMD]

GLAVKOSMOS, wherever located, including 9 Krasno proletarskaya St., 103030 Moscow, Russia [63 FR 42089, July 30, 1998]

HESONG TRADING CORPORATION, Pyongyang, Korea, North [NPWMD]

HIGHER INSTITUTE OF APPLIED SCIENCE AND TECHNOLOGY (a.k.a. HIAST; a.k.a. INSTITUT DES SCIENCES APPLIQUEES ET DE TECHNOLOGIE; a.k.a. INSTITUT SUPERIEUR DES SCIENCES APPLIQUEES ET DE TECHNOLOGIE; a.k.a. ISAT; a.k.a. ISSAT), P.O. Box 31983, Barzeh, Damascus, Syria [NPWMD]

KALAYE ELECTRIC COMPANY (a.k.a. KALA ELECTRIC COMPANY), 33 Fifteenth (15th) Street, Seyed-Jamal-Eddin-Assad Abadi Avenue, Tehran, Iran [NPWMD]

KAVOSHYAR COMPANY (a.k.a. KAAVOSH YAAR; a.k.a. KAVOSHYAR), P.O. Box 19395-1834, Tehran, Iran; Vanaq Square, Corner of Shiraz Across No. 71, Molla Sadra Ave , Tehran, Iran; No. 86, 20th St., North Karegar Ave , Tehran, Iran [NPWMD]

KOHAS AG, Route des Arsenaux 15, Fribourg, FR 1700, Switzerland; C.R. No. CH-217.0.135.719-4 (Switzerland) [NPWMD]

KOREA COMPLEX EQUIPMENT IMPORT CORPORATION, Rakwondong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA INTERNATIONAL CHEMICAL JOINT VENTURE COMPANY (a.k.a. CHOSUN INTERNATIONAL CHEMICALS JOINT OPERATION COMPANY; a.k.a. CHOSUN INTERNATIONAL CHEMICALS JOINT OPERATION COMPANY; a.k.a. INTERNATIONAL CHEMICAL JOINT VENTURE CORPORATION), Hamhung, South Hamgyong Province, Korea, North; Man gyongdae-kuyok, Pyongyang, Korea, North; Mangyungdae-gu, Pyongyang, Korea, North [NPWMD]

KOREA KWANGSONG TRADING CORPORATION, Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA MINING DEVELOPMENT TRADING CORPORATION (a.k.a. CHANGGWANG SINYONG CORPORATION; a.k.a. EXTERNAL TECHNOLOGY GENERAL CORPORATION; a.k.a. NORTH KOREAN MINING DEVELOPMENT TRADING CORPORATION; a.k.a. "KOMID"), Central District, Pyongyang, Korea, North [NPWMD]

KOREA PUGANG TRADING CORPORATION, Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONBONG GENERAL CORPORATION (a.k.a. KOREA YONBONG GENERAL CORPORATION; f.k.a. LYONGAKSAN GENERAL TRADING CORPORATION), Pot'onggang District, Pyongyang, Korea, North; Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONGWANG TRADING CORPORATION (a.k.a. KOREA RYENGWANG TRADING CORPORATION), Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONHA MACHINERY JOINT VENTURE CORPORATION (a.k.a. CHOSUN YUNHA MACHINERY JOINT OPERATION COMPANY; a.k.a. KOREA RYENHA MACHINERY J/V CORPORATION; a.k.a. RYONHA MACHINERY JOINT VENTURE CORPORATION), Central District, Pyongyang, Korea, North; Mangyongdae-gu, Pyongyang, Korea, North; Mangyongdae District, Pyongyang, Korea, North [NPWMD]

LEILABADI, ALI HAJINIA (a.k.a. LAILABADI, ALI HADJINIA), c/o MESBAH ENERGY COMPANY, Iran; DOB 19 Feb 1950; POB Tabriz, Iran; citizen Iran; nationality Iran; Passport E4710151 (Iran) issued 15 Oct 2000 expires 15 Oct 2005 (individual) [NPWMD]



LIMMT ECONOMIC AND TRADE COMPANY, LTD. (a.k.a. LIMMT (DALIAN FTZ) METALLURGY AND MINERALS CO., LTD.; a.k.a. LIMMT (DALIAN FTZ) MINMETALS AND METALLURGY CO., LTD.; a.k.a. LIMMT (DALIAN) METALLURGY AND MINERALS CO., LTD.), 2501-2508 Yuexiu Manston, No. 82 Xinkai Road, Dalian, Liaoning 116011, China; and all other locations worldwide [NPWMD]

MAI (a.k.a. MOSCOW AVIATION INSTITUTE), wherever located, including 4 Volokolamskoye Shosse, Moscow 125871, Russia [64 FR 2935, January 8, 1999]

MESBAH ENERGY COMPANY (a.k.a. "MEC"), 77 Armaghan Gharbi Street, Valiasr Blve., Tehran, Iran [NPWMD]

MIZAN MACHINE MANUFACTURING GROUP (a.k.a. 3MG), P.O. Box 16595-365, Tehran, Iran [NPWMD]

MOSCOW AVIATION INSTITUTE (a.k.a. MAI), wherever located, including 4 Volokolamskoye Shosse, Moscow 125871, Russia [64 FR 2935, January 8, 1999]

NATIONAL STANDARDS AND CALIBRATION LABORATORY (a.k.a. NATIONAL CALIBRATION CENTRE; a.k.a. NSCL), P.O. Box 4470, Damascus, Syria [NPWMD]

NEW ERA GROUP (a.k.a. China New Era Group; a.k.a. China Xinshidai Company; a.k.a. Xinshidai; a.k.a. XSD) [69 FR 56260, September 20, 2004]

NOVIN ENERGY COMPANY (a.k.a. Energy Novin; a.k.a. Noveen Energy Company), End of North Karegar Avenue, Tehran, Iran [NPWMD]

PARS TRASH COMPANY (a.k.a. PARS TARASH; a.k.a. PARS TERASH; a.k.a. PARS TRASH), 33 Fifteenth (15th) Street, Seyed-Jamal-Eddin- Assad Abadi Avenue, Tehran, Iran [NPWMD]

PIONEER ENERGY INDUSTRIES COMPANY (a.k.a. PISHGAM ENERGY INDUSTRIES DEVELOPMENT; a.k.a. "PEP"), P.O. Box 81465-361, Isfahan, Iran [NPWMD]

QANNADI, MOHAMMAD (a.k.a. GHANNADI MARAGHEH, MOHAMMAD; a.k.a. GHANNADI, MOHAMMAD; a.k.a. QANNADI MARAGHEH, MOHAMMAD), c/o ATOMIC ENERGY ORGANIZATION OF IRAN, Iran; DOB 13 Oct 1952; POB Maragheh, Iran; citizen Iran; nationality Iran; Passport 20694 (Iran); alt. Passport A0003044 (Iran) (individual)[NPWMD]

SANAM INDUSTRIAL GROUP (a.k.a. Sanam Industries Group) Pasdaran Road 15, Tehran, Iran

SCIENTIFIC STUDIES AND RESEARCH CENTER (a.k.a. CENTRE D'ETUDES ET RECHERCHES; a.k.a. "SSRC"), P.O. Box 4470, Damascus, Syria [NPWMD]

SHAHID BAKERI INDUSTRIAL GROUP (a.k.a. "SBIG"), Tehran, Iran [NPWMD]

SHAHID HEMMAT INDUSTRIAL GROUP (a.k.a. "SHIG"), Damavand Tehran Highway, Tehran, Iran [NPWMD]

STEIGER, Jakob, c/o KOHAS AG, Fribourg, FR, Switzerland; DOB 27 Apr 1941; POB Altstatten, SG, Switzerland (individual) [NPWMD]

TANCHON COMMERCIAL BANK (f.k.a. CHANGGWANG CREDIT BANK; f.k.a. KOREA CHANGGWANG CREDIT BANK), Saemul 1-Dong Pyongchon District, Pyongyang, Korea, North [NPWMD]

TOSONG TECHNOLOGY TRADING CORPORATION, Pyongyang, Korea [NPWMD]

XINSHIDAI (a.k.a. China New Era Group; a.k.a. China Xinshidai Company; a.k.a. New Era Group; a.k.a. XSD) [69 FR 56260, September 20, 2004]

XSD (a.k.a. China New Era Group; a.k.a. China Xinshidai Company a.k.a. New Era Group; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]

YA MAHDI INDUSTRIES GROUP (a.k.a Ya Mahdi Industrial Research Complex; a.k.a. Ya Mahdi Industrial Complex;  
a k.a. "YMA") PO Box 19395-4797, Tehran, Iran



May 15, 2008

- Ted Turner  
Executive Director
- Gay Niles  
Executive Director
- Charles E. Carrin  
President  
Chief Operating Officer
- Dr. George A. Baker  
Director of World Economy  
and International Relations
- U.S. Senator Peter V. Domenici  
(R-New Mexico)
- Susan F. Greenhouse  
The Foundation for the Americas
- Ambassador Ralf H. J. Jansen  
Ambassador General  
Chief Executive Officer
- General Eugene F. Habiger  
USAF (Ret.)  
Former Commander in Chief  
US Central Command
- DR. J. Frank III  
Executive Director  
Tetras
- Tom LaBanche  
Executive Director  
National Assembly
- U.S. Senator Robert C. Byrd  
(West Virginia)
- Dr. Jessica T. Matthews  
Executive Director for  
International Affairs
- Judge E. Mark O'Connell  
International Court of Justice
- Dr. William Perry  
Executive Director  
U.S. Secretary of Defense
- Dr. Nabil Sadeh  
Special Advisor to the  
U.S. Secretary of Defense
- Professor Amartya Sen  
Executive Director  
Professor of Economics and Philosophy  
Harvard University
- R. Alan Ponder  
Senior Director  
Office of Health, USAID
- Professor Jishi Yang  
Fudan University  
Chinese Academy of Sciences

Dr. Moc Ko Oo  
Mekong Basin Disease Surveillance Network (MBDS)  
MBDS Coordinator

Re: NTI Award No. 2060

Dear Dr. Moc:

We have approved your request for an Award in the amount of \$30,000 to assist MBDS in the deployment of Rapid Response Teams to Myanmar in order to provide support following the recent cyclone. The end date of this Award is June 3, 2008.

NTI funds shall be used for transportation to and from Myanmar, communication and translators. In the case of any violation by Awardee of any of the terms or conditions of this Award, including but not limited to not executing the Project in strict compliance with the Proposal, NTI reserves the right in its absolute discretion to terminate the Award. Upon termination of this Award for any reason, NTI will withhold any further payment of Award funds and all unexpended Award funds and any portion of the Award funds which was not spent for the Project shall be immediately returned to NTI.

Awardee shall indemnify and hold NTI, its directors, officers, employees, consultants, representatives and agents harmless from and against all third party claims, liabilities, suits, demands, losses, judgments, fines, penalties, interest, expenses and costs (including, without limitation, reasonable accounting and attorneys' fees and disbursements) which result from any breach of Awardee's representations or warranties made in relation to this Agreement, the Proposal, or the Project, or from any breach of the terms of this Agreement, or from any negligent acts or omissions of Awardee, its directors, officers, employees, consultants, representatives and agents relating to, or in any way connected with, activities conducted pursuant to this Agreement.

747 Pennsylvania Ave., NW  
7th Floor  
Washington, D.C. 20006  
202 296 2300  
202 296 2400  
www.nti.org

A charitable organization working to reduce the global burden  
from malaria, dengue and other mosquito-borne diseases

Dr Moe  
May 15, 2008  
Page 2

Pursuant to the U.S. Government's Office of Foreign Assets Control regulations, these funds may not be exported, directly or indirectly, to the Government of Myanmar. All financial transactions must occur outside of Myanmar, in Thailand.

Final financial and narrative reports concerning this Award will be due within 60 days of the end of the grant period (no later than August 2, 2008).

Please sign and return the duplicate copy of this letter to acknowledge your agreement to the conditions for this Award.


We look forward to the continued relationship between MRDS and NTL.

Sincerely,




Charles B. Curtis  
*President and Chief Operating Officer*

Enclosure

  
\_\_\_\_\_  
Acknowledgement of conditions for Award  
Dr. Moe Ko Oo

## MEMORANDUM

TO: CHARLES B CURTIS  
FROM: LOUISE GRESHAM  
THRU: JOAN ROHLFING   
CHARLOTTE ATKINSON  
TERRENCE TAYLOR  
CC: BROOKE ANDERSON  
SUBJECT: REQUEST FOR FUNDING TO MBDS FOR RAPID RESPONSE TEAMS TO MYANMAR  
DATE: 5/15/2008

---

**Purpose:** To provide \$30,000 to the Mekong Basin Disease Surveillance Network (MBDS) to assist in the deployment of Rapid Response Teams (RRTs) to Myanmar. The current situation in post-cyclone Myanmar is dire. Oxfam estimates that 1.5 million people in Myanmar are on the brink of a "massive public health catastrophe" and the necessary aid is not being delivered due to the military junta's refusal of western aid. The junta is finally allowing Thai aid into the country and members of MBDS have been able to enter the country to provide support. Fears of cholera, as well as mosquito-borne diseases such as malaria and dengue fever, which are endemic to the area, have heightened.

The teams will be departing Thailand on Friday, May 16 and will be traveling to and from Myanmar for roughly two weeks. NTI funds will go directly to MBDS, which has its Secretariat stationed in Bangkok, in order to support the deployment of the RRTs. These funds will be used to support teams that will be crossing the border into Myanmar but all transactions will take place in Thailand. No funding will be delivered to Myanmar. MK Technologies has reviewed this work plan and has given us the go-ahead pursuant to the Office of Foreign Assets Control (OFAC) "Burmese Sanctions Regulations, 31 C.F.R. Part 537" (attached), dated May 9, 2008, which states that "Certain financial transactions in support of humanitarian [...] activities in Burma (Myanmar) [are] authorized" "for a period of 120 days".

NTI funds will be used for the following:

- Transportation to/from Myanmar
- Communication (phone, radio, etc)
- Translators

**Relevance to NTP's mission:**

The creation of regional disease surveillance networks is an essential tool for combating biological threats. NTP's Global Health and Security Initiative has been supporting the work of MBDS since 2005. As a result of the NTI-funded Regional Tabletop Simulation Exercise that took place in Cambodia in March 2007, MBDS developed a comprehensive six-year plan. One component of this plan, which NTI is currently supporting, is to train and mobilize Rapid Response Teams to help

reduce the spread and impact of infectious disease outbreaks, whether naturally occurring or intentionally caused.

We will explore whether Google funds can be used for this grant

Approve Charles Cantor

Disapprove \_\_\_\_\_

May 15, 2008

Pursuant to the authority vested in the President of NTI pursuant a board resolution approved on April 30, 2001, I hereby authorize and approve a small grant of \$30,000 for the Mekong Basin Disease Surveillance Network (MBDS) to assist in the deployment of Rapid Response Teams (RRTs) consistent with the six year plan developed out of NTI's recent tabletop exercises. The development and deployment of RRTs will further strengthen the ability of MBDS to respond to outbreaks of infectious diseases, whether naturally occurring or terrorist induced.

A handwritten signature in black ink, reading "Charles B. Curtis". The signature is written in a cursive style and is underlined.

Charles B. Curtis  
President and Chief Operating Officer

## NUCLEAR THREAT INITIATIVE, INC. AWARD AGREEMENT

**ORGANIZATION:** Institute of Peace and Conflict Studies ("Awardee")  
**PROJECT:** WMD Project Funding  
**AWARD NO.:** ~~XXXX~~ 5041  
**APPROVED AMOUNT:** Up to \$184,000 ("Award")  
**EFFECTIVE DATE:** Upon receipt of executed Award Agreement by Awardee

1. This Award is for the specific purpose of supporting the Institute's activities and programming related to Weapons of Mass Destruction (WMD) in South Asia, as more fully described on the written proposal attached hereto as Exhibit "A" (for convenience of reference, such purposes hereinafter the "Project" and such proposal hereinafter the "Proposal"), and payments received by Awardee may be expended for no other purpose without the prior written consent of Nuclear Threat Initiative, Inc. (NTI). In addition, the Project budget attached to the Proposal (the "Project Budget") may not be materially modified or adjusted without the prior written consent of NTI. Consistent with the foregoing, all payments received by Awardee may be expended only for charitable, scientific, literary or educational purposes ("Charitable Purposes") within the meaning of Sections 501(c)(3) and 170(c)(2) of the Internal Revenue Code of 1986, as amended (the "Code"). Awardee shall return any funds not used for the specific Charitable Purposes set forth in the attached Proposal unless Awardee has obtained NTI's prior written approval of an alternative use of the funds. The project shall be completed on or before March 2, 2009, unless Awardee requests and receives approval from NTI for an extension.
2. Awardee agrees that none of the funds covered by this Award Agreement (with all exhibits and any special stipulations, hereinafter the "Agreement") shall be used to participate in, or intervene in any political campaign on behalf of (or in opposition to) any candidate for public office, to influence legislation, to carry on voter registration drives, to make grants to individuals or other organizations, or to undertake any nonexempt activity, when such use of the funds would be a taxable expenditure if made directly by NTI.
3. The undersigned officer of Awardee hereby certifies that Awardee is: (i) an independent, non-profit and non-governmental charitable organization for collaborative research, networking and interaction on strategic and international issues pertaining to South Asia and (ii) tax-exempt under the laws of India.
4. Awardee agrees to immediately notify NTI, in writing, if Awardee has reason to believe that the Award cannot be or continue to be expended for the specific purposes set forth in the attached Proposal.
5. In order to ensure that there is no misunderstanding by the general public regarding NTI's involvement with the Project, NTI reserves the right to, in advance, review, comment on and otherwise approve any statements, announcements or news releases proposed to be made by Awardee to the press or public regarding NTI's involvement with the Project. Awardee may, however, make reference to NTI's support of Awardee's work generally as Awardee executes the Project. If Awardee chooses to acknowledge NTI's support for the WMD Module, any such acknowledgment will indicate, "This website has been supported with funds from the Nuclear Threat Initiative. Its contents represent the views, findings and opinions of the authors, and are not necessarily those of the Nuclear Threat Initiative."
6. Awardee will have editorial control and responsibility over data and actual information contained in the WMD Module on the Awardee's website, as well as other printed publications developed with NTI support.
7. Awardee hereby grants and NTI hereby accepts a royalty-free, nonexclusive, irrevocable and perpetual license to reproduce, publish and otherwise use (including, without limitation, on NTI's own website) original works appearing on the WMD Module on or before November 30, 2008 which are created by or otherwise proprietary to Awardee. Awardee and NTI agree the following language shall be placed at the conclusion of any Awardee content posted on the NTI website: "The provision of material herein is a free service published for the Nuclear Threat Initiative, which is dedicated to assisting and supporting activities which strengthen global security by reducing the risk of use, and preventing the spread of nuclear, biological and chemical weapons. The material hereunder is produced independently by the Institute of Peace and Conflict Studies, New Delhi, India. Any views, findings or opinions contained herein reflect the views, findings and opinions of the authors, and are not necessarily those of the Nuclear Threat Initiative."



8. Awardee shall cooperate with NTI in supplying any additional information or in complying with any laws, rules, regulations, or procedures which might be required by any governmental authority in order for NTI to comply with and establish the fact that it has observed all requirements of all laws, rules and regulations with respect to this Award.
9. Awardee agrees to keep accurate and complete books and records of receipts and expenditures made in connection with the Project. Awardee will maintain such books and records in a manner that the receipts and expenditures of Award funds will be shown separately thereon. Awardee will keep records of receipts and expenditures of Award funds as well as copies of reports submitted to NTI and supporting documentation for at least four (4) years after the completion of use of Award funds, and will make the same available to NTI for inspection as reasonably required from the time of Awardee's acceptance of this Award through such period.
10. Both the quality of the work done and Awardee's progress toward achieving the goals of the Award will be reviewed by NTI. NTI may monitor and conduct formal evaluations of operations and progress under this Award, which may include visits from NTI personnel to observe Awardee's projects and programs and to review financial and other records and materials connected with activities financed by this Award, and Awardee agrees to timely cooperate and assist NTI with such monitoring and evaluation activities.
11. It is anticipated the Award will be paid in accordance with the disbursement schedule attached hereto as Exhibit "B".
12. Awardee is encouraged to submit intermittent updates of Project activities. These updates should be selective and succinct, while providing a sense of what the organization is accomplishing with the NTI Award.
13. In addition to the discretionary updates set forth in the foregoing section, Awardee shall provide more detailed reporting as described in Exhibit "C" hereto.
14. In the case of any violation by Awardee of any of the terms or conditions of this Award, including but not limited to not executing the Project in strict compliance with the Proposal, NTI reserves the right in its absolute discretion to terminate the Award. NTI's determination will be final and will be binding and conclusive upon Awardee. Upon termination of this Award for any reason, NTI will withhold any further payment of Award funds and all unexpended Award funds and any portion of the Award funds which was not spent for the Project shall be immediately returned to NTI.
15. Awardee shall indemnify and hold NTI, its directors, officers, employees, consultants, representatives and agents harmless from and against all third party claims, liabilities, suits, demands, losses, judgments, fines, penalties, interest, expenses and costs (including, without limitation, reasonable accounting and attorneys' fees and disbursements) which result from any breach of Awardee's representations or warranties made in relation to this Agreement, the Proposal, or the Project, or from any breach of the terms of this Agreement, or from any negligent acts or omissions of Awardee, its directors, officers, employees, consultants, representatives and agents relating to, or in any way connected with, activities conducted pursuant to this Agreement.
16. Awardee understands that there is no commitment by NTI to supply any further support for Awardee. NTI considers each request and proposal on an individual basis, and this Award is not to be construed as establishing a precedent for further support.
17. Awardee agrees to: (i) control the process whereby any individual who may use this Award, or any portion thereof, for purposes of travel or attendance at a meeting or workshop is selected and (ii) supervise such individual in carrying out the purpose for which the Award was made.
18. Awardee agrees to comply in all material respects with the requirements of all laws, rules, regulations and orders of any governmental authority relating to the Award or the Project, including, without limitation, Internal Revenue Service rules and regulations pertaining to charitable organizations and grants to foreign organizations.
19. Awardee agrees that it shall not involve as participants in the Project or otherwise use any part of the Award to enter into transactions with entities listed pursuant to the U.S. Foreign Assets Control Regulations (31 Code of Federal Regulations Parts 500-598) as ineligible to participate in transactions, directly or indirectly, with U.S. organizations and persons. NTI calls Awardee's attention to the list of entities published in the Weapons of Mass Destruction Trade

Control Regulations (31 Code of Federal Regulations 539; current list attached hereto as Exhibit "D"). Awardee understands that the list may change from time to time. Prohibited transactions with the parties listed pursuant to the Weapons of Mass Destruction Trade Control Regulations and subject to this limitation include, without limitation: (i) procuring any goods, technology or services, or entering into any agreement for the procurement of any goods, technology or services from listed organizations; (ii) providing any assistance to or obligating funds for such purpose with listed organizations; or (iii) importing into the U.S. any goods, technology, or services produced or provided by listed organizations, any of the entities described in the above regulations or executive order. For entities listed pursuant to certain other Parts of the Foreign Assets Control Regulations (e.g., listed Foreign Terrorist Organizations) the prohibition covers all business transactions and funds transfers of any kind.


20. This Agreement and the exhibits attached hereto constitute the entire understanding of NTI and Awardee with respect to the subject matter hereof, and supersede all prior agreements and understandings, whether oral or written. This Agreement may not be amended or modified except in a writing signed by NTI. This Agreement shall be deemed to be made under, and in all respects shall be interpreted under and governed by, the laws of the District of Columbia, U.S.A.

The undersigned duly authorized official of Awardee accepts and agrees to, on behalf of Awardee, these terms and conditions, as of the date set forth below (the "Effective Date").

AWARDEE:

Institute of Peace and Conflict Studies

By:

  
Maj. Gen Dipankar Banerjee (Retd.)

Title: Director

Date:

2 Feb 07

Exhibit "A"

**Project Title:** WMD Project Funding  
**Program Area:** International Program  
**Recipient:** Institute of Peace and Conflict Studies, New Delhi

**Description:** This award is provided to support WMD related programs at the New Delhi based Institute of Peace and Conflict Studies. In particular, NTI funding will contribute to projects in the following five areas:

- 1) **Nuclear Materials Security:** IPCS will work to raise awareness of the threat of nuclear terrorism among elite as well as general public audiences, as well as the importance of achieving greater Indian participation in mechanisms for nuclear materials security;
- 2) **Fissile Material Cutoff Treaty (FMCT):** IPCS will work to build awareness and support for Indian engagement in Fissile Material Cutoff Treaty (FMCT) negotiations;
- 3) **WMD Web Module:** IPCS will continue to build and support the Institute's highly successful web module on WMD issues;
- 4) **Indo-US Nuclear Deal:** IPCS will produce analysis and host public discussions related to ongoing issues associated with the Indo-US nuclear deal; and finally,
- 5) **Supporting Global Standards for Biosafety and security:** IPCS will support NTI's biological security and safety agenda and help extend the International Council of the Life Sciences into India.

**Background:** The US-India nuclear deal has created a much greater need in India for information and informed experts on nuclear threats and proliferation challenges. It has also created a window of opportunity, as well as a responsibility, for the Indian government to become more engaged in the global proliferation system, for example through supporting efforts to negotiate a FMCT, and by demonstrating that it can secure its own nuclear materials to the highest global standards. But the debate in India surrounding its participation in the nuclear deal suggests that there is a great need for better, more accurate information regarding existing practices within the international nonproliferation system (for example, the IAEA safeguards process) as well as a need for more non-governmental capacity to contribute to the debate.

With the funds provided by this proposal, the Institute would help build this capacity and information base, and raise awareness of these issues among elite audiences (policymakers, media, and academia) through hosting a series of workshops and conferences around issues associated with the FMCT, materials security issues in India, and through the production of publications on these topics for its website. Unlike the US, where many NGOs work on security and nonproliferation issues, there are only a handful of such organizations in India, and the Institute is one of the only NGOs that is fully independent of the government of India, yet maintains credibility as a serious, non-partisan entity.

This award will also in part support the continuation of a web module on WMD issues that IPCS created with a small grant from NTI three years ago. The web module is up and running, and has significantly increased traffic to the IPCS website, which is one of the most visited websites on security in the region. IPCS estimates that they are now receiving more than one million hits per month. This represents a more than ten-fold increase since our last grant to IPCS two years ago (when the average hits per month were approximately 90,000).

The IPCS web module on WMD has a heavy regional focus. It expresses views from a South Asian, versus an American perspective, and it draws heavily on research and news reporting and analysis from non-US sources, especially from South Asia, China and Central Asia. In addition, it contains several features not available on the NTI website such as a monthly press digest, quarterly bibliography and links to relevant IPCS reviews, debates

and publications. By strengthening the information, news and research dissemination capacity in the region through this web module, NTI is helping to raise public awareness in Asia.

The Institute has also established a biological security component in its programming which we believe has the potential to serve as a platform for NTI's Global Health and Security Initiative in India. Director Emeritus of the Institute is a former Director of Public Health of the Indian State of Madhya Pradesh, and as such, brings a unique understanding of the importance of strengthening global public health systems in addressing bioterrorism. In particular NTI believes that the Institute provides a good base for supporting our biological security agenda and helping to extend the work of the International Council of the Life Sciences into India

**Activities:** Activities planned to advance these focus areas over the two year grant period are listed below with a brief description of the nature of tasks proposed under each:

- **Seminars/Discussion/Conferences** to engage the policy, academic, media and public to generate awareness on WMD issues in the areas listed above;
- **Regional Meetings** – up to three per year in major metropolitan areas of India on major issues related to WMD threat reduction. These meetings will help address a major weakness in India – that of the absence of institutions and experts (outside of the capital city of Delhi) on all major issues related to WMD threats. Regional meetings would be developed in partnership with leading local institutions to help build awareness. Initial meetings will be held in:
  - Bangalore – The National Institute of Advanced Studies
  - Chennai – Madras University
  - Kolkata – Jadavpur University Political Science Department
  - Jammu – Jammu University
  - To assure coordination with other NTI projects, IPCS will consult NTI regarding additional meeting locations before finalizing the venues.
- **Media workshops.** There continues to be a great lack of awareness even of factual information on nuclear and WMD issues among the media, even among those reporting on these issues. IPCS will conduct two workshops per year on major topics, led by some of India's leading experts. In addition, IPCS will work on developing press and media packages around a variety of WMD issues, as well as other web-based training tools for raising the level of media understanding and reporting on WMD issues.
- **Mentoring Young Scholars**
- **Online Training Modules and Tutorials**
- **Publications on the web**
  - Articles
  - Special Reports

**Project Budget****WMD Project Funding**

<b>Program Activity</b>	<b>USD for one year</b>
1. Project Officer salary and support	\$ 8,000
2. Seminar / Discussions / Conferences	\$12,000
3. Publications support and honoraria	\$ 8,000
4. Regional meetings	\$15,000
5. Workshops	\$19,000
6. Website / Online Tutorial / Learning Modules	\$15,000
7. Office expenses, such as: rent, communication, telephone, office supplies, stationary	\$15,000
<b>Total</b>	<b>\$92,000</b>

Exhibit "B"

Tentative Disbursement Schedule

Subject to the terms and conditions of the Agreement, it is anticipated the Award will be disbursed as follows:

Tentative Disbursement Date	Tentative Installment Amount
March 1, 2007	\$92,000
March 3, 2008	\$92,000

**Exhibit "C"****Nuclear Threat Initiative, Inc.  
Reporting Guidelines**

At the end of each Award year and at such time as the Award funds are fully expended, NTI requires for its records an annual or final report, as appropriate, which will: (i) describe in narrative fashion what was achieved with the Award funds; and (ii) provide a full financial accounting of the Award.

**I. Narrative Report**

Each narrative report should briefly (no more than five pages) summarize how the Award was used and the results which were achieved. The report will be used by NTI staff to evaluate and to provide an overview of your work for our Board of Directors. The following list, insofar as relevant to our Award to your organization, may provide guidance in the preparation of your reports:

- a. Did the Project achieve the objectives outlined in your organization's Proposal? If not, how did the results vary from these objectives? Explain any milestones that have been achieved. How do you view the future of the Project?
- b. What developments or implementations of solutions to the problems addressed by this Award have occurred because of this Project? What, if anything, has/is occurring in the field that has changed the climate surrounding the issue?
- c. Describe the tangible results of the project. What did the Project "produce"? (e.g. payment of salaries, print publications, meetings)
- d. Describe the Project's impact on the issues being addressed. What supporting information demonstrates the Project's impact?
- e. Submit copies of significant reports, books, articles or media productions that stem from your efforts in connection with the Award.
- f. For interim reports on multi-year Awards only: Describe the Project activities to be conducted in the next year and provide an updated budget for those activities as part of the financial report (see below). If you have previously submitted a Project Budget for the next Award year, what modifications, if any, do you expect to make to the Project Budget?

**II. Financial Report**

Each financial report should be detailed as possible and include the following: (See the attached Sample Financial Report)

- a. A line item comparison of budgeted versus actual expenses as they relate *specifically to our Award*.
- b. A statement certifying that all Award funds were expended for the purposes of the Award. If the entire Award has not been expended, please explain proposed usage of the unexpended amount.
- c. An explanation of any variations from the Project Budget submitted with your organization's Proposal.
- d. A brief summary of any fundraising for the Project, including a description of any unexpected shortfalls or surpluses. Did this grant assist your organization in leveraging funds from other sources? If not, why not?

**III. Delivery of the Narrative and Financial Report**

The reports described above are due, with respect to annual reports, within thirty (30) days of the anniversary of the Effective Date, and with respect to the final report, within sixty (60) days of the date on which the Award funds are fully expended. Such reports should be sent to:

Joan Rohlfing  
Senior Vice President for Programs and Operations  
Nuclear Threat Initiative, Inc.  
1747 Pennsylvania Avenue, NW 7th Floor  
Washington, DC 20006  
USA

Exhibit "D"Selected Entities Subject to 31 Code of Federal Regulations Part 539  
"WMD Trade Control Regulations" and Executive Order 13382

AEROSPACE INDUSTRIES ORGANIZATION (a.k.a. SAZMANE SANAYE HAVA FAZA; a.k.a. "AIO"), Langare Street, Nobonyad Square, Tehran, Iran [NPWMD]

ATOMIC ENERGY ORGANIZATION OF IRAN (a.k.a. SAZEMAN-E ENERGY ATOMI), P.O. Box 14144-1339, End of North Karegar Avenue, Tehran, Iran [NPWMD]

BALTIC STATE TECHNICAL UNIVERSITY, wherever located, including 1/21, 1- ya Krasnoarmeiskaya Ul., 198005 St. Petersburg, Russia [63 FR 42089, July 30, 1998]

BEIJING ALITE TECHNOLOGIES CO., LTD. (a.k.a. ALCO; a.k.a. BEIJING HAILI LIANHE KEJI YOUXIAN GONGSI), 12A Beisanhuan Zhong Road, P.O. Box 3042, Beijing, China, and all other locations worldwide [NPWMD]

CHINA GREAT WALL INDUSTRY CORPORATION (a.k.a. CGWIC; a.k.a. ZHONGGUO CHANGCHENG GONGYE ZONGGONGSI), No. 30 Haidian Nanlu, Beijing, China; Moscow, Russia; and all other locations worldwide [NPWMD]

CHINA NEW ERA GROUP (a.k.a. China Xinshidai Company; a.k.a. New Era Group; a.k.a. XSD; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]

CHINA NATIONAL PRECISION MACHINERY IMPORT/EXPORT CORPORATION (a.k.a. CHINA NATIONAL PRECISION MACHINERY I/E CORP.; a.k.a. CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION; a.k.a. CPMIEC; a.k.a. ZHONGGUO JINGMI JIXIE JINCHUKOU ZONGGONGSI), No. 30 Haidian Nanlu, Beijing, China; and all other locations worldwide [NPWMD]

CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION (a.k.a. CPMIEC), wherever located, including 3/F, Minxing Building No. 190, 817 (North) Road, Fuzhou City, Fujian Province, China [July 30, 2003]

CHINA XINSHIDAI COMPANY (a.k.a. China New Era Group; a.k.a. New Era Group; a.k.a. XSD; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]

CPMIEC (a.k.a. CHINA PRECISION MACHINERY IMPORT/EXPORT CORPORATION), wherever located, including 3/F, Minxing Building No. 190, 817 (North) Road, Fuzhou City, Fujian Province, China [July 30, 2003]

D. MENDELEYEV UNIVERSITY OF CHEMICAL TECHNOLOGY OF RUSSIA, wherever located, including 9 Miusskaya Sq., Moscow 125047, Russia [64 FR 2935, January 8, 1999]

FEDERAL RESEARCH AND PRODUCTION COMPLEX ALTAY, Russia [69 FR 67617-18, November 18, 2004]

G.W. AEROSPACE, INC. (a.k.a. GREAT WALL AEROSPACE, INC.), 21515 Hawthorne Blvd., Suite 670, Torrance, CA 90503; California Corporate Number C1458237 (United States) [NPWMD]

GREAT WALL AIRLINES COMPANY LIMITED (a.k.a. GREAT WALL AIRLINES; a.k.a. CHANGCHENG HANGKONG), 1600 Century Road, Shanghai 200122, China; C.R. No. 001144 (China) Issued 20 Oct 2005, expires 19 Oct. 2035 [NPWMD]

GLAVKOSMOS, wherever located, including 9 Krasno proletarskaya St., 103030 Moscow, Russia [63 FR 42089, July 30, 1998]

HESONG TRADING CORPORATION, Pyongyang, Korea, North [NPWMD]

KOHAS AG, Route des Arsenaux 15, Fribourg, FR 1700, Switzerland; C.R. No. CH-217.0.135.719-4 (Switzerland) [NPWMD]

KOREA COMPLEX EQUIPMENT IMPORT CORPORATION, Rakwondong, Pothonggang District, Pyongyang, Korea, North [NPWMD]



Exhibit "D" continued

KOREA INTERNATIONAL CHEMICAL JOINT VENTURE COMPANY (a.k.a. CHOSUN INTERNATIONAL CHEMICALS JOINT OPERATION COMPANY; a.k.a. CHOSUN INTERNATIONAL CHEMICALS JOINT OPERATION COMPANY; a.k.a. INTERNATIONAL CHEMICAL JOINT VENTURE CORPORATION), Hamhung, South Hamgyong Province, Korea, North; Man gyongdae-kuyok, Pyongyang, Korea, North; Mangyungdae-gu, Pyongyang, Korea, North [NPWMD]

KOREA KWANGSONG TRADING CORPORATION, Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA MINING DEVELOPMENT TRADING CORPORATION (a.k.a. CHANGGWANG SINYONG CORPORATION; a.k.a. EXTERNAL TECHNOLOGY GENERAL CORPORATION; a.k.a. NORTH KOREAN MINING DEVELOPMENT TRADING CORPORATION; a.k.a. "KOMID"), Central District, Pyongyang, Korea, North [NPWMD]

KOREA PUGANG TRADING CORPORATION, Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONBONG GENERAL CORPORATION (a.k.a. KOREA YONBONG GENERAL CORPORATION; f.k.a. LYONGAKSAN GENERAL TRADING CORPORATION), Pot'onggang District, Pyongyang, Korea, North; Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONGWANG TRADING CORPORATION (a.k.a. KOREA RYENGWANG TRADING CORPORATION), Rakwon-dong, Pothonggang District, Pyongyang, Korea, North [NPWMD]

KOREA RYONHA MACHINERY JOINT VENTURE CORPORATION (a.k.a. CHOSUN YUNHA MACHINERY JOINT OPERATION COMPANY; a.k.a. KOREA RYENHA MACHINERY J/V CORPORATION; a.k.a. RYONHA MACHINERY JOINT VENTURE CORPORATION), Central District, Pyongyang, Korea, North; Mangyungdae-gu, Pyongyang, Korea, North; Mangyongdae District, Pyongyang, Korea, North [NPWMD]

LIMMT ECONOMIC AND TRADE COMPANY, LTD. (a.k.a. LIMMT (DALIAN FTZ) METALLURGY AND MINERALS CO., LTD.; a.k.a. LIMMT (DALIAN FTZ) MINMETALS AND METALLURGY CO., LTD.; a.k.a. LIMMT (DALIAN) METALLURGY AND MINERALS CO., LTD.), 2501-2508 Yuexiu Mansion, No. 82 Xinkai Road, Dalian, Liaoning 116011, China; and all other locations worldwide [NPWMD]

MAI (a.k.a. MOSCOW AVIATION INSTITUTE), wherever located, including 4 Volokolamskoye Shosse, Moscow 125871, Russia [64 FR 2935, January 8, 1999]

MESBAH ENERGY COMPANY (a.k.a. "MEC"), 77 Armaghan Gharbi Street, Valiasr Blvc., Tehran, Iran [NPWMD]

MOSCOW AVIATION INSTITUTE (a.k.a. MAI), wherever located, including 4 Volokolamskoye Shosse, Moscow 125871, Russia [64 FR 2935, January 8, 1999]

NEW ERA GROUP (a.k.a. China New Era Group; a.k.a. China Xinshidai Company; a.k.a. Xinshidai; a.k.a. XSD) [69 FR 56260, September 20, 2004]

NOVIN ENERGY COMPANY (a.k.a. Energy Novin; a.k.a. Noveen Energy Company), End of North Karegar Avenue, Tehran, Iran [NPWMD]

SANAM INDUSTRIAL GROUP (a.k.a. Sanam Industries Group) Pasdaran Road 15, Tchrn, Iran

SCIENTIFIC STUDIES AND RESEARCH CENTER (a.k.a. CENTRE D'ETUDES ET RECHERCHES; a.k.a. "SSRC"), P.O. Box 4470, Damascus, Syria [NPWMD]

SHAHID BAKERI INDUSTRIAL GROUP (a.k.a. "SBIG"), Tehran, Iran [NPWMD]

Exhibit "D" continued

SHAHID HEMMAT INDUSTRIAL GROUP, Damavand Tehran Highway, Tehran, Iran (a.k.a. "SHIG") [NPWMD]

STEIGER, Jakob, c/o KOHAS AG, Fribourg, FR, Switzerland; DOB 27 Apr 1941; POB Altstätten, SG, Switzerland (individual) [NPWMD]

TANCHON COMMERCIAL BANK (f.k.a. CHANGGWANG CREDIT BANK; f.k.a. KOREA CHANGGWANG CREDIT BANK), Saemul 1-Dong Pyongchon District, Pyongyang, Korea, North [NPWMD]

TOSONG TECHNOLOGY TRADING CORPORATION, Pyongyang, Korea [NPWMD]

XINSHIDAI (a.k.a. China New Era Group; a.k.a. China Xinshidai Company; a.k.a. New Era Group; a.k.a. XSD) [69 FR 56260, September 20, 2004]

XSD (a.k.a. China New Era Group; a.k.a. China Xinshidai Company a.k.a. New Era Group; a.k.a. Xinshidai) [69 FR 56260, September 20, 2004]

YA MAHDI INDUSTRIES GROUP (a.k.a. Ya Mahdi Industrial Research Complex; a.k.a. Ya Mahdi Industrial Complex; a.k.a. "YMA") PO Box 19395-4797, Tehran, Iran

# Nuclear Threat Initiative, Inc.

Financial Statements  
June 30, 2008 and 2007

McGladrey & Pullen  
Certified Public Accountants

## Contents

---

<b>Independent Auditor's Report</b>	1
<b>Financial Statements</b>	
Statements of Financial Position	2
Statements of Activities	3
Statement of Functional Expenses - 2008	4
Statement of Functional Expenses - 2007	5
Statements of Cash Flows	6
<b>Notes to Financial Statements</b>	7 - 15

---

# McGladrey & Pullen

Certified Public Accountants

## Independent Auditor's Report

To the Board of Directors  
Nuclear Threat Initiative, Inc.  
Washington, D.C.

We have audited the accompanying statements of financial position of the Nuclear Threat Initiative, Inc. (NTI) as of June 30, 2008 and 2007, and the related statements of activities, functional expenses and cash flows for the years then ended. These financial statements are the responsibility of NTI's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Nuclear Threat Initiative, Inc. as of June 30, 2008 and 2007, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

*McGladrey & Pullen, LLP*

Vienna, Virginia  
October 14, 2008

**Nuclear Threat Initiative, Inc.**

**Statements of Financial Position  
June 30, 2008 and 2007**

<b>Assets</b>	<b>2008</b>	<b>2007</b>
Cash and Cash Equivalents	\$ 7,502,574	\$ 7,488,041
Investments (Note 3)	6,354,784	6,487,400
Promises to Give, net (Note 4)	3,660,000	5,953,293
Receivables	8,312	3,046
Prepaid Expenses and Other Assets	287,529	215,517
Property and Equipment, net (Note 5)	140,468	178,014
	<u>\$ 17,953,667</u>	<u>\$ 20,325,311</u>
<b>Liabilities and Net Assets</b>		
<b>Liabilities</b>		
Accounts payable and accrued expenses	\$ 779,566	\$ 291,276
Grants payable (Note 6)	661,645	1,400,414
Deferred rent	96,872	145,331
	<u>1,538,083</u>	<u>1,837,021</u>
Commitments (Notes 8 and 9)		
<b>Net Assets:</b>		
Unrestricted	9,180,890	11,991,934
Temporarily restricted (Note 7)	7,234,694	6,496,356
	<u>16,415,584</u>	<u>18,488,290</u>
	<u>\$ 17,953,667</u>	<u>\$ 20,325,311</u>

See Notes to Financial Statements.

**Nuclear Threat Initiative, Inc.**

**Statements of Activities  
Years Ended June 30, 2008 and 2007**

	2008			2007		
	Unrestricted	Temporarily Restricted (Note 7)	Total	Unrestricted	Temporarily Restricted (Note 7)	Total
<b>Support and revenue:</b>						
Contributions	\$ 4,103,376	\$ 6,174,283	\$ 10,277,659	\$ 9,130,958	\$ 3,290,151	\$ 12,421,109
Investment income (Note 3)	930,089	-	930,089	1,021,113	-	1,021,113
Other (loss)	-	-	-	(3,553)	-	(3,553)
Net assets released from restrictions	5,435,945	(5,435,945)	-	3,846,809	(3,846,809)	-
<b>Total support and revenue</b>	<b>10,469,410</b>	<b>738,338</b>	<b>11,207,748</b>	<b>13,995,327</b>	<b>(556,658)</b>	<b>13,438,669</b>
<b>Expenses:</b>						
Program	10,774,263	-	10,774,263	12,679,957	-	12,679,957
Management and governance	1,765,456	-	1,765,456	1,667,628	-	1,667,628
Fundraising	740,735	-	740,735	655,585	-	655,585
<b>Total expenses</b>	<b>13,280,454</b>	<b>-</b>	<b>13,280,454</b>	<b>15,003,170</b>	<b>-</b>	<b>15,003,170</b>
<b>Change in net assets</b>	<b>(2,811,044)</b>	<b>738,338</b>	<b>(2,072,706)</b>	<b>(1,007,843)</b>	<b>(556,658)</b>	<b>(1,564,501)</b>
<b>Net assets:</b>						
Beginning	11,991,934	6,496,356	18,488,290	12,999,777	7,053,014	20,052,791
Ending	<b>\$ 9,180,890</b>	<b>\$ 7,234,694</b>	<b>\$ 16,415,584</b>	<b>\$ 11,991,934</b>	<b>\$ 6,496,356</b>	<b>\$ 18,488,290</b>

See Notes to Financial Statements.

**Nuclear Threat Initiative, Inc.**

**Statement of Functional Expenses  
Year Ended June 30, 2008**

	Program	Management and Governance	Fundraising	Total
Employee costs	\$ 2,989,693	\$ 914,006	\$ 500,370	\$ 4,404,069
Contracts	2,394,714	-	-	2,394,714
Grants, contributions and gifts	2,230,429	-	-	2,230,429
Professional services	886,271	377,818	68,858	1,332,947
Travel	966,558	217,560	31,812	1,215,930
Occupancy	494,293	110,658	44,399	649,350
Telecommunications	245,098	17,118	20,816	283,032
Conferences and meetings	229,319	49,073	1,478	279,870
Printing and publication	90,648	2,119	30,556	123,323
Depreciation and amortization	55,669	18,529	7,435	81,633
Insurance	41,220	14,225	5,054	60,499
Supplies	42,844	12,657	3,819	59,320
Postage and shipping	21,574	5,487	21,547	48,608
Furniture, equipment rental and maintenance	22,098	7,482	2,930	32,510
Foreign exchange loss	29,782	-	-	29,782
Advertising	866	-	-	866
Miscellaneous	33,187	18,724	1,661	53,572
<b>Total expenses</b>	<b>\$ 10,774,263</b>	<b>\$ 1,765,456</b>	<b>\$ 740,735</b>	<b>\$ 13,280,454</b>

See Notes to Financial Statements.



Nuclear Threat Initiative, Inc.

Statement of Functional Expenses  
Year Ended June 30, 2007

	Program	Management And Governance	Fundraising	Total
Employee costs	\$ 3,104,228	\$ 977,022	\$ 349,386	\$ 4,430,636
Contracts	1,780,575	-	-	1,780,575
Grants, contributions and gifts	5,288,064	-	-	5,288,064
Professional services	770,928	178,345	105,966	1,055,239
Travel	563,424	193,857	70,940	828,221
Occupancy	501,700	131,748	51,917	685,365
Telecommunications	226,936	24,575	24,603	276,114
Conferences and meetings	65,312	44,037	6,651	116,000
Printing and publication	103,806	29,825	8,772	142,403
Depreciation and amortization	64,286	25,327	9,980	99,593
Insurance	49,198	16,953	6,764	72,915
Supplies	42,890	17,992	6,177	67,059
Postage and shipping	49,152	8,343	10,572	68,067
Furniture, equipment rental and maintenance	20,848	7,814	2,921	31,583
Foreign exchange loss	13,004	-	-	13,004
Advertising	2,092	-	-	2,092
Miscellaneous	33,514	11,790	936	46,240
<b>Total expenses</b>	<b>\$ 12,679,957</b>	<b>\$ 1,667,628</b>	<b>\$ 655,585</b>	<b>\$ 15,003,170</b>

See Notes to Financial Statements.

**Nuclear Threat Initiative, Inc.**

**Statements of Cash Flows  
Years Ended June 30, 2008 and 2007**

	2008	2007
<b>Cash Flows from Operating Activities</b>		
Change in net assets	\$ (2,072,706)	\$ (1,564,501)
Adjustments to reconcile change in net assets to net cash (used in) operating activities:		
Depreciation and amortization	81,633	99,593
Loss on property and equipment disposal	-	3,553
Unrealized loss (gain) on investments	24,486	(469,590)
Realized (gain) on investments	(752,785)	-
Donated stock	(3,560,641)	(3,500,784)
Changes in assets and liabilities:		
(Increase) decrease in:		
Promises to give	2,293,293	(804,781)
Receivables	(5,266)	1,140
Prepaid expenses and other assets	(72,012)	(40,739)
Increase (decrease) in:		
Accounts payable and accrued expenses	493,442	97,006
Grants payable	(738,769)	185,780
Deferred rent	(48,459)	129,464
<b>Net cash (used in) operating activities</b>	<b>(4,357,784)</b>	<b>(5,863,859)</b>
<b>Cash Flows from Investing Activities</b>		
Proceeds from sales of investments	4,421,556	-
Purchase of property and equipment	(44,087)	(177,627)
Proceeds from sale of property and equipment	-	202
<b>Net cash provided by (used in) investing activities</b>	<b>4,377,469</b>	<b>(177,425)</b>
<b>Cash Flows from Financing Activities</b>		
Principal payments on capital lease obligations	(5,152)	(4,572)
<b>Net cash (used in) financing activities</b>	<b>(5,152)</b>	<b>(4,572)</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>14,533</b>	<b>(6,045,856)</b>
<b>Cash and Cash Equivalents</b>		
Beginning	7,488,041	13,533,897
Ending	<b>\$ 7,502,574</b>	<b>\$ 7,488,041</b>
<b>Supplemental Disclosures of Cash Flow Information</b>		
Cash payments for interest	<b>\$ 1,100</b>	<b>\$ 1,680</b>
<b>Supplemental Schedule of Noncash Investing and Financing Activities</b>		
Donated stock	<b>\$ 3,560,641</b>	<b>\$ 3,500,784</b>

See Notes to Financial Statements.

**Nuclear Threat Initiative, Inc.**

**Notes to Financial Statements**

---

**Note 1. Nature of Activities and Significant Accounting Policies**

Nature of activities: Nuclear Threat Initiative, Inc. (NTI) is a not-for-profit organization whose mission is to strengthen global security by reducing the risk of use and preventing the spread of nuclear and other weapons of mass destruction and to work to build the trust, transparency, and security which are preconditions to the ultimate fulfillment of the Nonproliferation Treaty's goals and ambitions. NTI is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code.

Summary of significant accounting policies:

Basis of accounting: The accompanying financial statements have been prepared on the accrual basis of accounting, whereby revenue is recognized when earned and expenses are recognized when incurred.

Basis of presentation: The financial statements are prepared in accordance with the Financial Accounting Standards Board (FASB) Statement of Financial Accounting Standards (SFAS) No. 117, *Financial Statements of Not-for-Profit Organizations*. Under SFAS No. 117, NTI must provide a statement of financial position, a statement of activities, and a statement of cash flows. NTI must classify its net assets, revenues, expenses, gains, and losses based on the existence or absence of donor-imposed restrictions, into one of three classes of net assets—permanently restricted, temporarily restricted, and unrestricted. NTI held no permanently restricted net assets at June 30, 2008 and 2007.

Contributions and receivables: In accordance with SFAS No. 116, *Accounting for Contributions Received and Contributions Made*, contributions received and unconditional promises to give are measured at their fair values and are reported as an increase in net assets. Fair value is calculated as the present value of the estimated future cash flows using discount rates approximating the rate of return on U.S. government securities with similar maturities. Management reviews all outstanding promises on a monthly basis, and determines an allowance for doubtful promises based on historical experience applied to an aging of promises. Promises are written off when deemed uncollectible. There is no provision for doubtful promises based on management's evaluation of the collection of promises at June 30, 2008 and 2007. Conditional promises to give are recognized in income when the conditions imposed by the donor have been substantially met.

NTI reports gifts of cash and other assets as restricted support if they are received with donor stipulations that limit the use of the donated assets to particular programs or activities, or if they are designated as support for future periods. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporary restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions. Donor-restricted contributions whose restrictions are met in the same reporting period are reported as unrestricted support.

In accordance with SFAS No. 116 and SFAS No. 136, *Transfers of Assets to a Not-For-Profit Organization or Charitable Trust That Raises or Holds Contributions for Others*, NTI reports gifts of cash and other assets received from a donor and specified by the donor to be used on behalf of another entity, the beneficiary, as a liability to the specified beneficiary concurrent with the recognition of the assets received.

Donated assets and services: Donated investments and other noncash donations are recorded as contributions at their estimated fair values at the date of the donation. Donated professional services (which include accounting services) are reflected in the statement of activities at their fair value.

Functional allocation of expenses: The costs of providing the various programs, fund-raising, and management and governance activities have been summarized on a functional basis in the statement of activities. NTI allocates expenses to various activities based on the percentage ratio of time spent by the employees on specific activities. Accordingly, certain costs have been allocated between program expenses, fundraising expenses, and management and governance expenses as shown in the statement of functional expenses.

**Nuclear Threat Initiative, Inc.**

**Notes to Financial Statements**

---

**Note 1. Nature of Activities and Significant Accounting Policies (Continued)**

Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents: Cash and cash equivalents are defined as currency on hand, demand deposits with banks or financial institutions, and other amounts that have the general characteristics of demand deposits. Cash and cash equivalents are carried at cost, which approximates market value. For the purpose of the statements of cash flows, cash includes all cash held in bank accounts at June 30, 2008 and 2007.

Investments: Investments are reported at fair value, as determined by quoted market prices, in the statement of financial position. Investment income or loss (including realized and unrealized gains and losses on investments, interest, and dividends) is included in the statement of activities as increases or decreases in unrestricted net assets unless the income or loss is restricted by the donor or the law. There was no such restricted income or loss as of June 30, 2008 and 2007. Purchases and sales of investments are recorded on the trade date.

Foreign Exchange: NTI leases office space in Moscow under a contract that is denominated in Russian Rubles (RUB). The contract determines a floor on the USD/RUB foreign exchange rate. NTI recognizes a foreign exchange loss under this contract in accordance with the provisions of SFAS 52, *Foreign Currency Translation*, which requires that all elements of the financial statements are translated using a current foreign exchange rate.

Concentration of credit and market risk: Financial instruments that potentially expose NTI to concentrations of credit and market risk consist primarily of cash equivalents and investments. NTI maintains its cash balances at three high-quality financial institutions and credit exposure is limited at any one institution. NTI has not experienced losses in the accounts, and believes it is not exposed to any significant credit risk on cash and cash equivalents.

NTI holds donations in the form of company stock (Berkshire Hathaway A and B shares at June 30, 2008 and 2007) and mutual funds. Such investments are exposed to various risks such as market and credit. Due to the level of risk associated with such investments, and the volatility of such investments, it is at least reasonably possible that changes in risk in the near term could materially affect investment balances and the amounts reported in the financial statements.

Property and equipment: Property and equipment are carried at cost. Depreciation is calculated on straight-line basis over the estimated useful lives of the related assets. Property and equipment are depreciated over the life of the D.C. office lease or over five years, whichever is shorter. Leasehold improvements are amortized straight line over the three-year remaining life of the lease term. In 2008, NTI calculated depreciation expense for all new acquisitions using five year life expectation for furniture, fixtures, and equipment and three year life expectation for computers. NTI capitalizes all property and equipment with a cost of \$500 or more.

Landlord allowance: As an incentive for entering into a lease extension in FY 2006, NTI received a "Refurbishment Cash Allowance" of \$124,870 from the landlord to be applied toward the hard costs of permanent leasehold improvements undertaken by NTI during the period preceding the lease extension date of April 26<sup>th</sup>, 2006. The value of this allowance payment is amortized over the three-year remaining life of the lease. As of June 30, 2008, \$60,748 was included in deferred rent on the statement of financial position as unamortized landlord allowance.

**Nuclear Threat Initiative, Inc.**

**Notes to Financial Statements**

---

**Note 1. Nature of Activities and Significant Accounting Policies (Continued)**

Impairment of long-lived assets: NTI accounts for the valuation of long-lived assets under Statement of Financial Accounting Standards (SFAS) No. 144, *Accounting for the Impairment or Disposal of Long-Lived Assets*. SFAS No. 144 requires that long-lived assets and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

Grants payable: NTI awards grants that are payable over multiple years. The total grant is expensed upon the acceptance by the grantee of the grant agreement in the year accepted. The grants are disbursed over the period established in the grant agreement.

Grants payable within one year are recorded at net realizable value. Grants payable in future years are recorded at the present value of their estimated future cash flows using discount rates approximating the rate of return on U.S. government securities with similar maturities as required by SFAS 116.

At June 30, 2008 and 2007, all grants payable were due within one year. As such no discount was recorded.

Income taxes: NTI is a not-for-profit corporation as described in Section 501(c)(3) of the Internal Revenue Code whose revenue is derived from contributions. NTI is qualified, commencing July 1, 2003, as a public charity under Sections 509(a)(1) and 170(b)(1)(a)(vi) of the Code. NTI is not subject to federal or state income taxes.

Accounting and financial reporting developments: In September 2006, the FASB issued SFAS No. 157, *Fair Value Measurements*. SFAS No. 157 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurement. This statement is effective for fiscal year beginning after November 15, 2007, which is the fiscal year ended June 30, 2009, for NTI. Adoption of SFAS No. 157 is not expected to have a material impact on NTI's financial position, activities or cash flows.

In May 2008, the FASB issued SFAS No. 162, *The Hierarchy of Generally Accepted Accounting Principles* (SFAS No. 162). SFAS No. 162 identifies the sources of accounting principles and the framework for selecting the principles to be used in the preparation of financial statements of nongovernmental entities that are presented in accordance with US GAAP. SFAS No. 162 will be effective 60 days following the U.S. Securities and Exchange Commission's approval of the Public Company Accounting Oversight Board amendments to AU Section 411, *The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles*. Adoption of SFAS No. 162 is not expected to have a material impact on NTI's financial position, activities or cash flows.

In July 2006, the FASB issued Interpretation No. 48, *Accounting for Uncertainty in Income Taxes – an interpretation of FASB Statement No. 109* (FIN 48). FIN 48 clarifies the accounting for uncertainty in income tax recognized in an enterprise's financial statements in accordance with SFAS No. 109, *Accounting for Income Taxes*. FIN 48 is effective for fiscal years beginning after December 15, 2007, which is the fiscal year ended June 30, 2009, for NTI. Adoption of FIN 48 is not expected to have a material impact on NTI's financial position, activities or cash flows.

## Nuclear Threat Initiative, Inc.

### Notes to Financial Statements

---

#### Note 2. Conditional Pledges

The Susan Thompson Buffett Foundation has pledged to NTI seven million dollars a year for the calendar years 2005-2009. Revenue is recorded as cash or stock is received due to the condition made by the Susan Thompson Buffett Foundation. A significant portion of NTI's contribution revenue consists of donations from the Susan Thompson Buffett Foundation.

NTI has also received a conditional pledge from the World Bank totaling \$976,899. In accordance with its policy, NTI recognized \$252,580 and \$47,420 of this contribution during the years ended June 30, 2008 and 2007, respectively.

#### Note 3. Investments

NTI investments consist of readily marketable securities of donated Berkshire Hathaway Stock. Investments totaled \$6,354,784 and \$6,487,400 at June 30, 2008 and 2007, respectively.

Investment income for the years ended June 30, 2008 and 2007, consists of the following:

	2008	2007
Interest and dividend income	\$ 201,790	\$ 551,523
Realized gain	752,785	-
Unrealized (loss) gain	(24,486)	469,590
	<u>\$ 930,089</u>	<u>\$ 1,021,113</u>

#### Note 4. Promises to Give

Promises to give are due through fiscal year 2009. All promises to give with payments due in future periods are recorded as temporarily restricted contributions in accordance with Statement of Accounting Standards (SFAS) No. 116, *Accounting for Contributions Received and Contributions Made*.

Promises to give at June 30, 2008 and 2007, consist of the following:

	2008	2007
Within one year	\$ 3,660,000	\$ 4,159,790
One to three years	-	2,000,000
	<u>3,660,000</u>	<u>6,159,790</u>
Less: Discount to net present value	-	(206,497)
	<u>\$ 3,660,000</u>	<u>\$ 5,953,293</u>

**Nuclear Threat Initiative, Inc.**

**Notes to Financial Statements**

**Note 5. Property and Equipment**

Property and equipment and accumulated depreciation are as follows at June 30, 2008 and 2007:

	Estimated Lives	2008			
		Cost	Accumulated Depreciation	Net	Depreciation Expense
Office furniture and equipment	3-5 years	\$ 572,546	\$ 502,580	\$ 69,966	\$ 33,258
Leasehold improvements	3-5 years	229,922	164,777	65,145	43,429
Leased equipment	4 years	19,784	14,427	5,357	4,946
		<u>\$ 822,252</u>	<u>\$ 681,784</u>	<u>\$ 140,468</u>	<u>\$ 81,633</u>

	Estimated Lives	2007			
		Cost	Accumulated Depreciation	Net	Depreciation Expense
Office furniture and equipment	3-5 years	\$ 563,085	\$ 503,950	\$ 59,135	\$ 64,715
Leasehold improvements	3-5 years	229,922	121,347	108,575	29,527
Leased equipment	4 years	19,784	9,480	10,304	4,946
Developed software	4 years	-	-	-	405
		<u>\$ 812,791</u>	<u>\$ 634,777</u>	<u>\$ 178,014</u>	<u>\$ 99,593</u>

**Note 6. Grants Payable**

Grants payable totaled \$661,645 and \$1,400,414 at June 30, 2008 and 2007, respectively. All grants payable are due within one year.

**Note 7. Temporarily Restricted Net Assets**

Temporarily restricted net assets include donor restricted funds, which are only available for program activities, or general support designated for future years. Temporarily restricted net assets were released from restrictions during the years ended June 30, 2008 and 2007, due to the time restriction ending or the purpose restriction being accomplished.

**Nuclear Threat Initiative, Inc.**

**Notes to Financial Statements**

**Note 7. Temporarily Restricted Net Assets (Continued)**

Temporarily restricted net assets at June 30, 2008 and 2007, are:

	Balance June 30, 2007	Additions	Releases	Balance June 30, 2008
Google Foundation	\$ -	\$ 2,500,000	\$ 195,411	\$ 2,304,589
Fred Iseman	2,268,752	-	218,752	2,050,000
MacArthur Foundation	-	1,750,000	357,964	1,392,036
Norwegian Royal Ministry of Foreign Affairs	-	800,188	30	800,158
Bill and Melinda Gates Foundation	918,062	89,516	645,755	361,823
Statens Karnkraftinspektion	200,000	2,134	-	202,134
Carnegie Corporation	-	500,209	404,485	95,724
Rockefeller Foundation	-	112,000	93,770	18,230
Dona and Jim Fuller	10,000	-	-	10,000
Turner Charitable Remainder Unitrust #4	1,896,752	-	1,896,752	-
The Russell Family Foundation	1,000,000	-	1,000,000	-
Saga Foundation	100,000	-	100,000	-
World Bank	47,420	252,580	300,000	-
UK Foreign Commonwealth Office	45,370	40,156	85,526	-
Edlow International	10,000	-	10,000	-
Toledo Community Foundation	-	127,500	127,500	-
	<u>\$ 6,496,356</u>	<u>\$ 6,174,283</u>	<u>\$ 5,435,945</u>	<u>\$ 7,234,694</u>

	Balance June 30, 2006	Additions	Releases	Balance June 30, 2007
Fred Iseman	\$ -	\$ 3,000,000	\$ 731,248	\$ 2,268,752
Turner Charitable Remainder Unitrust #4	2,729,616	270,384	1,103,248	1,896,752
The Russell Family Foundation	1,889,997	110,003	1,000,000	1,000,000
Bill and Melinda Gates Foundation	1,475,598	30,000	587,536	918,062
Statens Karnkraftinspektion	-	200,000	-	200,000
Saga Foundation	-	100,000	-	100,000
World Bank	-	47,420	-	47,420
UK Foreign Commonwealth Office	-	45,370	-	45,370
Edlow International	18,900	1,100	10,000	10,000
Dona and Jim Fuller	10,000	-	-	10,000
Better World Fund	928,903	113,874	1,042,777	-
	<u>\$ 7,053,014</u>	<u>\$ 3,918,151</u>	<u>\$ 4,474,809</u>	<u>\$ 6,496,356</u>



**Nuclear Threat Initiative, Inc.**

**Notes to Financial Statements**

**Note 8. Capital Leases**

NTI leases certain office equipment under the provisions of a capital lease. The terms of the capital lease provide for monthly payments of \$521 through fiscal year 2010.

The future minimum lease payments under capital lease remaining are as follows:

Years Ending June 30,	
2009	\$ 6,252
2010	521
	<u>6,773</u>
Less the amount representing interest	(451)
	<u>\$ 6,322</u>

**Note 9. Lease Commitments**

NTI leases office space, an apartment, and equipment under non-cancelable operating leases in Moscow, Russia, and Washington, D.C. These leases expire in fiscal year 2010. The Washington, D.C. office lease contains annual rate escalations per square foot occupied. These escalating future payments are recorded as rent expense on a straight-line basis. A deferred rent amount was recognized for the difference between straight-line rent expense and actual payments.

The future minimum lease payments under these leases are as follows:

Years Ending June 30,	Moscow				Total
	D.C. Office Space	Office Space	Apartment	Equipment	
2009	\$ 551,873	\$ 153,255	\$ 41,484	\$ 1,452	\$ 748,064
2010	279,938	76,628	-	726	357,292
	<u>\$ 831,811</u>	<u>\$ 229,883</u>	<u>\$ 41,484</u>	<u>\$ 2,178</u>	<u>\$ 1,105,356</u>

Subsequent to year end, NTI terminated its lease for office space in Moscow. If not terminated, this lease would have expired during fiscal year 2010. Terminating the lease reduces future minimum lease payments for the Moscow office space to \$63,856 and \$0 in the years ending June 30, 2009 and 2010, respectively. NTI will continue its operations in Russia from a new location.

Rent expenses recognized on a straight-line basis were as follows for the years ended June 30, 2008 and 2007:

	2008	2007
Occupancy	\$ 680,559	\$ 685,365
Other	1,536	1,485
	<u>\$ 682,095</u>	<u>\$ 686,850</u>

**Nuclear Threat Initiative, Inc.**

**Notes to Financial Statements**

---

**Note 10. Pension Benefits**

NTI provides a defined contribution plan, which is a qualified plan under Section 401(k) of the Internal Revenue Code (the Code). Employees must be at least 18 years old to be eligible to participate. Participants may elect to defer (Elected Deferral) up to 100% of their total compensation, not to exceed annual dollar limits set by the Internal Revenue Service (\$15,500 in 2008; \$20,500 for employees 50 years and older). NTI matches 150% of the first 4% of annual taxable earnings deferred and contributed to the plan by participants. NTI has made an additional contribution to the plan in the amount of 4% of a participant's total compensation (Non-Elective Deferral). For Elected Deferrals and Non-Elective Deferrals a participant's compensation is the total remuneration received during the plan year excluding any amount in excess of the annual dollar limit set by IRS (\$230,000 in 2008). NTI's contributions on behalf of participating employees were \$325,039 and \$315,607 for the years ended June 30, 2008 and 2007, respectively.

**Note 11. Related Parties**

Contributions: R.E. Turner, Co-Chairman of NTI's Board of Directors, made a \$4,000,000 pledge during the fiscal year ended June 30, 2005. This pledge was fully received as of June 30, 2008.

Awards and contributions to related organizations: Certain members of NTI's Board of Directors, officers, and immediate family members are also directors, officers of awardees organizations. According to NTI's conflict of interest policy, the review and final approval of awards and contributions excludes anyone who has a recognizable conflict of interest.

Total amounts awarded to these organizations for the years ended June 30, 2008 and 2007, are as follows:

	2008	2007
Monterey Institute of International Studies	\$ 650,000	\$ 650,000
International Council for the Life Sciences	397,150	-
Center for Strategic and International Studies	196,166	670,000
Belfer Center for Science and International Affairs	75,000	-
Carnegie Endowment for International Peace	50,000	-
Council on Foreign Relations	-	(1,644)
	<u>\$ 1,368,316</u>	<u>\$ 1,318,356</u>

Professional fees to related parties: Immediate family members of NTI's Board of Directors provide professional services for NTI. According to NTI's conflict of interest policy, the review and final approval of such services excludes anyone who has a recognizable conflict of interest.

Total amounts paid for such services for the years ended June 30, 2008 and 2007, are as follows:

	2008	2007
Davis, Pickren & Seydel	\$ 38,904	\$ 77,581

**Nuclear Threat Initiative, Inc.**

**Notes to Financial Statements**

---

**Note 12. Donated Services by Related Organizations**

Avalon Financial Advisors LLC, a related organization, has provided in-kind tax services in the amount of \$38,400 and \$36,800 for the years ended June 30, 2008 and 2007, respectively.

Coca Cola Enterprises, a related organization, has provided in-kind donations in the amount of \$4,870 and \$4,338 for the years ended June 30, 2008 and 2007, respectively.

Form **8868**  
(Rev. April 2008)  
Department of the Treasury  
Internal Revenue Service

### Application for Extension of Time To File an Exempt Organization Return

OMB No 1545-1709

▶ File a separate application for each return

- If you are filing for an Automatic 3-Month Extension, complete only Part I and check this box
  - If you are filing for an Additional (Not Automatic) 3-Month Extension, complete only Part II (on page 2 of this form)
- Do not complete Part II unless you have already been granted an automatic 3-month extension on a previously filed Form 8868**

**Part I Automatic 3-Month Extension of Time.** Only submit original (no copies needed).

A corporation required to file Form 990-T and requesting an automatic 6-month extension—check this box and complete Part I only

All other corporations (including 1120-C filers), partnerships, REMICs, and trusts must use Form 7004 to request an extension of time to file income tax returns.

**Electronic Filing (e-file).** Generally, you can electronically file Form 8868 if you want a 3-month automatic extension of time to file one of the returns noted below (6 months for a corporation required to file Form 990-T). However, you cannot file Form 8868 electronically if (1) you want the additional (not automatic) 3-month extension or (2) you file Forms 990-BL, 6069, or 8870, group returns, or a composite or consolidated Form 990-T. Instead, you must submit the fully completed and signed page 2 (Part II) of Form 8868. For more details on the electronic filing of this form, visit [www.irs.gov/efile](http://www.irs.gov/efile) and click on e-file for Charities & Nonprofits

Type or print  File by the due date for filing your return. See instructions	Name of Exempt Organization <b>Nuclear Threat Initiative, Inc.</b>	Employer identification number <b>52-2289435</b>
	Number, street, and room or suite no. If a P.O. box, see instructions. <b>1747 Pennsylvania Ave, Suite 700</b>	
	City, town or post office, state, and ZIP code. For a foreign address, see instructions. <b>Washington, DC 20006</b>	

Check type of return to be filed (file a separate application for each return):

- |   |   |                                    |
|---|---|------------------------------------|
| <input type="checkbox"/> Form 990               | <input type="checkbox"/> Form 990-T (corporation)                 | <input type="checkbox"/> Form 4720 |
| <input type="checkbox"/> Form 990-BL            | <input type="checkbox"/> Form 990-T (sec. 401(a) or 408(a) trust) | <input type="checkbox"/> Form 5227 |
| <input type="checkbox"/> Form 990-EZ            | <input type="checkbox"/> Form 990-T (trust other than above)      | <input type="checkbox"/> Form 6069 |
| <input checked="" type="checkbox"/> Form 990-PF | <input type="checkbox"/> Form 1041-A                              | <input type="checkbox"/> Form 8870 |

• The books are in the care of ▶ Ms. Charlotte Atkinson

Telephone No. ▶ (202) 454-7736 FAX No. ▶ (202) 296-4811

- If the organization does not have an office or place of business in the United States, check this box
- If this is for a Group Return, enter the organization's four digit Group Exemption Number (GEN) \_\_\_\_\_ . If this is for the whole group, check this box  . If it is for part of the group, check this box  and attach a list with the names and EINs of all members the extension will cover.

1 I request an automatic 3-month (6 months for a corporation required to file Form 990-T) extension of time until February 16, 2009, to file the exempt organization return for the organization named above. The extension is for the organization's return for:

▶  calendar year 20\_\_\_\_ or

▶  tax year beginning July 1, 2007, and ending June 30, 2008

2 If this tax year is for less than 12 months, check reason:  Initial return  Final return  Change in accounting period

3a If this application is for Form 990-BL, 990-PF, 990-T, 4720, or 6069, enter the tentative tax, less any nonrefundable credits. See instructions.	3a \$
b If this application is for Form 990-PF or 990-T, enter any refundable credits and estimated tax payments made. Include any prior year overpayment allowed as a credit.	3b \$
c <b>Balance Due.</b> Subtract line 3b from line 3a. Include your payment with this form, or, if required, deposit with FTD coupon or, if required, by using EFTPS (Electronic Federal Tax Payment System). See instructions.	3c \$ <u>0.00</u>

Caution. If you are going to make an electronic fund withdrawal with this Form 8868, see Form 8453-EO and Form 8879-EO for payment instructions.

For Privacy Act and Paperwork Reduction Act Notice, see Instructions.

Form **8868** (Rev. 4-2008)

BKA